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Different strategies for pharmacological
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Background: Thromboprophylaxis can reduce the risk of venous thromboembolism (VTE) during lower-
limb immobilisation, but it is unclear whether or not this translates into meaningful health benefit, justifies
the risk of bleeding or is cost-effective. Risk assessment models (RAMs) could select higher-risk individuals
for thromboprophylaxis.
Objectives: To determine the clinical effectiveness and cost-effectiveness of different strategies for
providing thromboprophylaxis to people with lower-limb immobilisation caused by injury and to identify
priorities for future research.
Data sources: Ten electronic databases and research registers (MEDLINE, EMBASE, Cochrane Database
of Systematic Reviews, Database of Abstracts of Review of Effects, the Cochrane Central Register of
Controlled Trials, Health Technology Assessment database, NHS Economic Evaluation Database, Science
Citation Index Expanded, ClinicalTrials.gov and the International Clinical Trials Registry Platform) were
searched from inception to May 2017, and this was supplemented by hand-searching reference lists and
contacting experts in the field.
Review methods: Systematic reviews were undertaken to determine the effectiveness of pharmacological
thromboprophylaxis in lower-limb immobilisation and to identify any study of risk factors or RAMs for VTE
in lower-limb immobilisation. Study quality was assessed using appropriate tools. A network meta-analysis
was undertaken for each outcome in the effectiveness review and the results of risk-prediction studies were
presented descriptively. A modified Delphi survey was undertaken to identify risk predictors supported by
expert consensus. Decision-analytic modelling was used to estimate the incremental cost per quality-adjusted
life-year (QALY) gained of different thromboprophylaxis strategies from the perspectives of the NHS and
Personal Social Services.
Results: Data from 6857 participants across 13 trials were included in the meta-analysis. Thromboprophylaxis
with low-molecular-weight heparin reduced the risk of any VTE [odds ratio (OR) 0.52, 95% credible interval
(CrI) 0.37 to 0.71], clinically detected deep-vein thrombosis (DVT) (OR 0.40, 95% CrI 0.12 to 0.99) and
pulmonary embolism (PE) (OR 0.17, 95% CrI 0.01 to 0.88). Thromboprophylaxis with fondaparinux (Arixtra®,
Aspen Pharma Trading Ltd, Dublin, Ireland) reduced the risk of any VTE (OR 0.13, 95% CrI 0.05 to 0.30)
and clinically detected DVT (OR 0.10, 95% CrI 0.01 to 0.94), but the effect on PE was inconclusive (OR 0.47,
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95% CrI 0.01 to 9.54). Estimates of the risk of major bleeding with thromboprophylaxis were inconclusive
owing to the small numbers of events. Fifteen studies of risk factors were identified, but only age (ORs 1.05 to
3.48), and injury type were consistently associated with VTE. Six studies of RAMs were identified, but only two
reported prognostic accuracy data for VTE, based on small numbers of patients. Expert consensus was achieved
for 13 risk predictors in lower-limb immobilisation due to injury. Modelling showed that thromboprophylaxis
for all is effective (0.015 QALY gain, 95% CrI 0.004 to 0.029 QALYs) with a cost-effectiveness of £13,524 per
QALY, compared with thromboprophylaxis for none. If risk-based strategies are included, it is potentially more
cost-effective to limit thromboprophylaxis to patients with a Leiden thrombosis risk in plaster (cast) [L-TRiP(cast)]
score of ≥ 9 (£20,000 per QALY threshold) or ≥ 8 (£30,000 per QALY threshold). An optimal threshold on the
L-TRiP(cast) receiver operating characteristic curve would have sensitivity of 84–89% and specificity of 46–55%.
Limitations: Estimates of RAM prognostic accuracy are based on weak evidence. People at risk of bleeding
were excluded from trials and, by implication, from modelling.
Conclusions: Thromboprophylaxis for lower-limb immobilisation due to injury is clinically effective and
cost-effective compared with no thromboprophylaxis. Risk-based thromboprophylaxis is potentially optimal
but the prognostic accuracy of existing RAMs is uncertain.
Future work: Research is required to determine whether or not an appropriate RAM can accurately select
higher-risk patients for thromboprophylaxis.
Study registration: This study is registered as PROSPERO CRD42017058688.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Chronic thromboembolic pulmonary hypertension Persistent increased blood pressure in the arteries
supplying the lungs, which is caused by pulmonary embolism and results in long-term shortness of breath
and fatigue.
Cost-effectiveness acceptability curve A way of illustrating cost-effectiveness results by plotting the
probability that the intervention is cost-effective (y-axis) against the maximum that society is willing to pay
for an improvement in health (x-axis).
Cost-effectiveness plane A way of illustrating cost-effectiveness results by plotting the mean incremental
cost and effectiveness on a four-quadrant graph. Interventions that are more costly and more effective fall
in the north-east quadrant.
Deep-vein thrombosis A blood clot that develops within a deep vein in the body, usually in the leg.
Incremental cost-effectiveness ratio The difference in the mean costs in the population of interest
divided by the differences in the mean outcomes in the population of interest.
L-TRiP(cast)–N A strategy of giving thromboprophyalxis to patients with a L-TRiP(cast) score of N or
above.
Post-thrombotic syndrome Pain, swelling, itching, skin discolouration and leg ulcers occurring after a
deep-vein thrombosis, caused by damage to the valves in the leg veins that prevent backflow of blood.
Predictor Throughout this report, ‘predictor’ is used to refer to any clinical, laboratory or demographic
characteristic. The term ‘predictor’ encompasses other similar terms, such as prognostic factor, covariate
and variable.
Prophylaxis A measure taken to prevent a disease.
Pulmonary embolism A blood clot that breaks off from the deep veins and travels around the circulation
to block the pulmonary arteries (arteries in the lung). Most deaths arising from deep-vein thrombosis are
caused by pulmonary embolism.
Quality-adjusted life-year A measure of the benefit of health care that combines the impact of both the
expected length of life and quality of life.
Risk assessment models In this report, defined as a combination of at least two predictors within a
statistical model that is used to predict an individual’s risk of outcome, for example venous thromboembolism.
Other terms also related to risk assessment models may include prognostic model, prediction models, clinical
decision rules and clinical prediction guides. The term ‘risk assessment model’ is used in this report to
encompass all of these terms; therefore, all are considered to refer to the same thing.
Thromboprophylaxis A measure taken to reduce the risk of thrombosis.
Vein thrombosis A condition in which a blood clot (thrombus) forms in a vein.
Venous thromboembolism The blocking of a blood vessel by a blood clot dislodged from its site of
origin. It includes both deep-vein thrombosis and pulmonary embolism.
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AF atrial fibrillation
AUC area under the curve
BMI body mass index
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iliofemoral deep-vein thrombosis
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curve
CG clinical guideline
CI confidence interval
CrI credible interval
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Plain English summary
People who have their leg immobilised in a plaster cast or brace following an injury are at risk ofdeveloping a blood clot. Sometimes the clot can break up and lodge in the lungs, which can make the
person seriously ill. Drugs that thin the blood (anticoagulants) can reduce the risk of blood clots, but they
carry a small risk of serious bleeding. This study analysed all published trials of anticoagulants for people
with leg immobilisation and found that, without treatment, there was a 1–2% risk of a serious blood clot.
This risk was roughly halved by using anticoagulant treatment. These estimates were used in a simulation
model of patient treatment and it was found that the benefit of anticoagulants in reducing blood clots
(in terms of length and quality of life) outweighed the risks of bleeding.
Next, all published studies of risk assessment tools were analysed. Risk assessment tools can be used to
predict who is most likely to get a blood clot. There were only a few studies and they had significant
weaknesses. The risk assessment tools in the simulation model were evaluated and it was found that the
most cost-effective approach was to use a risk assessment tool to select approximately half of the patients
for treatment (those at higher risk), while not treating those at lower risk. Treating only the higher-risk
patients would be a cost-effective use of NHS resources, compared with treating nobody. Treating
everybody, compared with just treating higher-risk patients, would improve outcomes for some patients
but would not be a cost-effective use of NHS resources.
This study suggests that anticoagulant drugs are an effective and potentially cost-effective way of preventing
blood clots in people with leg immobilisation due to injury. Research is needed to determine whether or not
risk assessment tools can accurately predict who needs anticoagulant drugs and who does not.
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Scientific summary
Background
People with lower-limb immobilisation following an injury are at risk of venous thromboembolism (VTE),
including symptomatic and asymptomatic deep-vein thrombosis (DVT) and pulmonary embolism (PE).
Preventative treatment with anticoagulant drugs (thromboprophylaxis) has the potential to reduce the risk
of VTE, but it is not clear if this translates into a meaningful health benefit for patients, justifies the risk of
treatment-related bleeding or is cost-effective. Risk assessment models (RAMs) could improve the ratio of
benefit to risk and benefit to cost, but the evidence to support RAMs for lower-limb immobilisation has
not been robustly evaluated.
Objectives
The aims were to determine the clinical effectiveness and cost-effectiveness of different strategies for
providing thromboprophylaxis to people with lower-limb immobilisation due to injury and to identify
priorities for future research. Specifically:
l To undertake systematic reviews and, if appropriate, a meta-analysis to (1) estimate the effectiveness of
thromboprophylaxis for preventing VTE outcomes, (2) identify individual risk factors associated with VTE
risk and (3) identify RAMs that predict the risk of VTE and to estimate the accuracy of these models.
l To undertake a modified Delphi survey of expert opinion regarding risk factors and RAMs for VTE in
lower-limb immobilisation, augmenting the limited data anticipated from reviews 2 and 3 above.
l To develop an economic model to estimate the clinical effectiveness of different strategies for providing
thromboprophylaxis [in terms of adverse outcomes avoided or incurred by treatment, and quality-adjusted
life-years (QALYs)], the cost-effectiveness of different strategies (in terms of the incremental cost per
QALY gained by each strategy compared with the next most effective strategy on the efficiency frontier)
and the expected value of information provided by further primary research.
Methods
Systematic reviews were undertaken in accordance with the general principles recommended in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A range of
bibliographic sources was searched, comprising MEDLINE, EMBASE, Cochrane Database of Systematic
Reviews, Database of Abstracts of Review of Effects, Cochrane Central Register of Controlled Trials, Health
Technology Assessment database, NHS Economic Evaluation Database, Science Citation Index Expanded,
ClinicalTrials.gov and the International Clinical Trials Registry Platform, from inception to April/May 2017.
Searches were supplemented by hand-searching reference lists, undertaking citation searches, contacting
key experts and carrying out systematic keyword searches of the internet.
For the effectiveness review, controlled trials were selected that reported VTE or bleeding outcomes in
people requiring temporary lower-limb immobilisation following an injury who received pharmacological
thromboprophylaxis or control/no treatment. For the risk-prediction reviews, any study that reported and
analysed risk factors or RAMs for VTE outcomes in a cohort of people requiring temporary lower-limb
immobilisation following an injury was selected. Methodological quality was assessed using a revised
Cochrane Risk of Bias tool for randomised trials for the effectiveness review, the Risk Of Bias In Non-randomized
Studies of Interventions (ROBINS-I) tool for the risk factor prediction review and a generic list of important
methodological features for the review of RAMs.
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A network meta-analysis (NMA) was undertaken for each outcome in the effectiveness review. A fixed-effects
model was used to estimate the effects of different thromboprophylaxis regimes relative to control in the
available studies and a random-effects model was used to allow for heterogeneity in the effects of interventions
between studies. The results of risk-prediction studies were presented descriptively.
A modified Delphi survey of experts in haematology, emergency medicine and orthopaedics was
undertaken to identify risk factors for VTE in lower-limb immobilisation that expert consensus suggested
could be incorporated in a RAM. This involved two rounds of elicitation of expert opinion via an online
survey, followed by a facilitated round-table discussion.
A de novo decision-analytic model was created to simulate the management of a cohort of people with
lower-limb immobilisation due to injury in accordance with strategies including thromboprophylaxis for all,
thromboprophylaxis for none and risk-based thromboprophylaxis using a RAM. Costs were estimated from
the perspective of the UK NHS and Personal Social Services. A decision tree was used to model rates of
prophylaxis, VTE events and major bleeds in the first 6 months. A Markov model with a lifetime horizon
was used to extrapolate costs and QALY losses associated with chronic complications following VTE or
bleeding events. The model was populated with data from the effectiveness and risk-prediction reviews
and additional model inputs were sourced from the published literature. Costs and QALYs were discounted
to their net 2018 value at 3.5%. Probabilistic sensitivity analysis, deterministic sensitivity analysis and
expected value-of-information analysis were used to explore and quantify decision uncertainty.
Results
Effectiveness of thromboprophylaxis
Data from 6857 participants across 13 randomised controlled trials (RCTs) were included: 11 comparing
low-molecular-weight heparin (LMWH) with no thromboprophylaxis, one comparing fondaparinux (Arixtra®,
Aspen Pharma Trading Ltd, Dublin, Ireland) or LMWH with no thromboprophylaxis and one comparing
fondaparinux with LMWH. A risk of bias was present in all studies, with 10 raising some concerns and three
rated as being at a high risk of bias, principally attributable to outcome assessment in three open-label
studies. LMWH and fondaparinux were analysed as separate nodes in the NMA and each was compared
with control treatment, which included aspirin, placebo and no treatment.
The rate of any VTE in the control group ranged from 1.8% to 40.4% (median 12.2%). LMWH [odds ratio
(OR) 0.52, 95% credible interval (CrI) 0.37 to 0.71] and fondaparinux (OR 0.13, 95% CrI 0.05 to 0.30) both
reduced the risk of any VTE compared with no thromboprophylaxis. Clinically detected (symptomatic) DVTs
were reported in 11 out of 13 trials, with control event rates ranging from 0.0% to 5.5% (median 0.7%).
LMWH (OR 0.40, 95% CrI 0.12 to 0.99) and fondaparinux (OR 0.10, 95% CrI 0.01 to 0.94) both reduced
the risk of clinically detected DVT compared with control. The rate of PE in the control group was 0.0% in
eight trials and ranged from 0.7% to 2.1% in the other four trials. LMWH (OR 0.17, 95% CrI 0.01 to 0.88)
reduced the risk of PE compared with control, whereas results were inconclusive for fondaparinux (OR 0.47,
95% CrI 0.01 to 9.54). Only four major bleeding events were reported across the studies; therefore, estimates
of the risk of bleeding with thromboprophylaxis were inconclusive. In all analyses, evidence of heterogeneity
suggested that the true effects may vary according to study characteristics, but network metaregressions
showed no reliable evidence of effect modification from key covariates.
Individual risk predictors for venous thromboembolism
Fifteen studies were included (five RCTs, three prospective observational cohort or cross-sectional studies,
one case–control study and six retrospective cohort studies), reporting data from 80,678 participants.
Overall, studies were rated as being at a moderate or serious risk of bias. The only factors consistently
identified as being associated with the risk of VTE were age (ORs ranging from 1.05 to 3.48), and injury type
(severe traumatic injuries and fractures associated with VTE).
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Other potential risk factors were not examined or showed inconsistent associations with VTE across the
studies or no association with VTE.
Risk assessment models
Six studies were included (three prospective observational cohort studies, two case–control studies and
one unclear design), reporting data from 16,893 participants. Overall, the risk of bias was rated as being
high or unclear for the criteria assessed. Validation data were very limited, with only two studies reporting
estimates of sensitivity and specificity. Receiving operating characteristic (ROC) analysis for the Leiden
thrombosis risk in plaster (cast) [L-TRiP(cast)] score showed sensitivity of 92.6% and specificity of 39.7%
using a threshold score of ≥ 8.
Expert consensus
Consensus was achieved for 13 risk predictors in lower-limb immobilisation due to injury: age, body mass
index (BMI), thrombophilia, pregnancy/puerperium, active cancer, surgery in the preceding 3 months, prior
VTE, exogenous oestrogen/hormone therapy, lower-limb paralysis, superficial thrombophlebitis, Achilles
tendon rupture, rigid immobilisation and an above-knee cast.
Decision-analytic modelling
The decision-analytic modelling suggested that the combined risk of non-fatal intracranial bleeding or
death from VTE or bleeding after lower-limb immobilisation due to injury was around 1 in 4000, regardless
of thromboprophylaxis use. The effectiveness of thromboprophylaxis was therefore mainly determined by
the relative effects of non-fatal VTE and non-intracranial major bleeding. Thromboprophylaxis compared
with no thromboprophylaxis produced a mean QALY gain of 0.015 per patient (95% CrI 0.004 to 0.029)
in the probabilistic sensitivity analysis, suggesting that the overall benefits outweigh the risks. The mean
incremental cost was £203 (95% CrI £172 to £245) and the incremental cost-effectiveness ratio (ICER),
based on the mean costs and QALYs, was £13,524, with a 76% probability of thromboprophylaxis being
cost-effective compared with no treatment at the £20,000 per QALY threshold.
If risk-based strategies for providing thromboprophylaxis are included in the analysis, the optimal strategy
would be to use the L-TRiP(cast) score with a threshold of ≥ 9 (sensitivity 80.8%, specificity 60.8%) if
£20,000 per QALY is used and with a threshold of ≥ 8 (sensitivity 92.6%, specificity 39.7%) if £30,000 per
QALY is used. Analyses to determine the optimal balance of sensitivity and specificity using the L-TRiP(cast)
ROC curve showed that, at £20,000 per QALY, the incremental net monetary benefit is maximised for a
sensitivity of 84% and a specificity of 55%, whereas, at £30,000 per QALY, the incremental net monetary
benefit is maximised for a sensitivity of 89% and a specificity of 46%.
The expected value of perfect information (EVPI) was £4.12 per patient treated; therefore, over 5 years,
assuming that 70,000 patients have lower-limb immobilisation every year across the English NHS, the
overall discounted population EVPI is £1.3M. The most important parameters for decision uncertainty are
the utility value for post-thrombotic syndrome, the efficacy of thromboprophylaxis in reducing VTE, the
probability of post-thrombotic syndrome for patients with distal DVT and the utility decrement associated
with taking thromboprophylaxis. Sensitivity analysis showed that a strategy of treating all patients would
be most cost-effective if the prognostic accuracy of the RAM were lower (i.e. assuming a lower area under
the ROC curve).
Sensitivity analyses suggested that using a direct oral anticoagulant (DOAC) for thromboprophylaxis, assuming
equivalent effectiveness to LMWH, shifted the optimal strategy from L-TRiP(cast)-9 to L-TRiP(cast)-8 at the
£20,000 per QALY threshold and to treat all at the £30,000 per QALY threshold. Using fondaparinux resulted
in L-TRiP(cast)-8 being the optimal strategy at both the £20,000 per QALY and £30,000 per QALY thresholds.
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Discussion
Thromboprophylaxis with LMWH approximately halves the risk of any VTE in people with temporary
lower-limb immobilisation following an injury and has similar effects on other VTE outcomes. Fondaparinux
appears to have a greater effect based on evidence from two trials. The effect of thromboprophylaxis on
major bleeding is uncertain as a result of the very low event rate.
The only risk factors for VTE consistently identified in studies of lower-limb immobilisation are age, BMI
and type of injury. A number of RAMs have been developed for predicting VTE risk in this patient group,
but validation has been very limited and so estimates of prognostic accuracy are very uncertain. Expert
consensus identified 13 potential predictors for VTE that are also commonly incorporated in RAMs, but
other variables included in the RAMs were not supported by expert consensus.
The evidence for thromboprophylaxis with LMWH is reasonably strong but is limited by heterogeneity
between studies and exclusion of patients known to be at risk of VTE or bleeding. The evidence base for
risk prediction, using either individual predictors or a RAM, is weak and based on studies with significant
methodological limitations and relatively small numbers of participants with lower-limb immobilisation.
Decision-analytic modelling showed that the combined risk of death (from VTE or bleeding) and non-fatal
intracranial bleeding would be very low, regardless of the approach used, but the QALYs gained by using
thromboprophylaxis to prevent VTE and their sequelae outweighed the QALYs associated with bleeding
and administering thromboprophylaxis.
Thromboprophylaxis for all patients is probably cost-effective compared with thromboprophylaxis for
none, with an ICER of £13,524, which is lower than the National Institute for Health and Care Excellence
(NICE) threshold of £20,000 per QALY, and a 76% probability of being cost-effective at the £20,000 per
QALY threshold. If risk-based thromboprophylaxis is considered alongside thromboprophylaxis for all
and thromboprophylaxis for none, then providing thromboprophylaxis on the basis of a L-TRiP(cast) score
of ≥ 8 is the optimal strategy if the threshold for willingness to pay is £20,000 per QALY, and providing
thromboprophylaxis on the basis of a L-TRiP(cast) score of ≥ 9 is the optimal strategy if the threshold for
willingness to pay is £30,000 per QALY. Assuming that a RAM has a ROC curve similar to L-TRiP(cast), the
optimal balance of sensitivity and specificity for a RAM appears to be 84–89% and 46–55%, respectively.
The decision-analytic modelling was able to draw on reasonably robust effectiveness data for
thromboprophylaxis and data sources for other parameters that have been used in previous models of VTE
management. The main limitation of the model related to the weakness of estimates of RAM sensitivity
and specificity. This uncertainty could not be addressed in a probabilistic sensitivity analysis, but a
deterministic sensitivity analysis suggested that RAM prognostic accuracy is a potentially important
determinant of cost-effectiveness.
There are also important limitations relating to the generalisability of findings to other drugs. The estimates
of effectiveness of thromboprophylaxis were based on trials of LMWH and, to a lesser extent, fondaparinux,
both of which are administered by injection. The patient representatives suggested that this was a significant
barrier to use and that thromboprophylaxis with a DOAC would be preferable. However, we found no
relevant trials of these agents, so modelling used potentially favourable assumptions that DOACs are as
effective as LMWH but can be delivered at lower cost to determine their cost-effectiveness.
Trials of thromboprophylaxis excluded important patient groups, particularly those at an increased risk of
bleeding. It was assumed that the modelling population had a risk of bleeding similar to that of the general
population and so these findings should not be applied to those at a higher risk. The trials were also limited
to people with full immobilisation rather than including those with removable splints or splints that allowed
some movement. Therefore, these findings should not be applied to this wider group, for whom the benefits
of thromboprophylaxis are unknown.
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Conclusions
Thromboprophylaxis for lower-limb immobilisation due to injury appears to be clinically effective and
cost-effective. Risk-based thromboprophylaxis using a RAM with 84–89% sensitivity and 46–55%
specificity for predicting VTE is a potentially optimal strategy that would cost £6M and gain 891 QALYs
per year across the English NHS compared with no thromboprophylaxis. Compared with this, providing
thromboprophylaxis for all would cost an additional £8.2M per year and gain an additional 160 QALYs.
Future work
Research is required to determine whether or not an appropriate RAM can accurately select higher-risk
patients for thromboprophylaxis. However, given the evidence of effectiveness for thromboprophylaxis,
this probably needs to be an implementation study rather than the scientifically ideal design of a prognostic
accuracy study of untreated patients. Research is also required to determine the effectiveness of DOACs in
lower-limb immobilisation and the effectiveness of thromboprophylaxis for incomplete (removable or flexible)
immobilisation. Efficient designs are likely to be required to deliver the large numbers of participants required
to estimate key outcomes with acceptable precision.
The patient and public representatives identified substantial potential for shared decision-making in risk
assessment and delivery of thromboprophylaxis for lower-limb immobilisation, but this requires clear
communication of the potential risks and benefits. Research is required to develop methods of and tools
for communicating the risks and benefits to patients and involving patients in decision-making.
Study registration
This study is registered as PROSPERO CRD42017058688.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Venous thromboembolism (VTE) is a condition in which a blood clot (a thrombus) forms in a vein.
It predominantly occurs in the large veins of the legs and causes a deep-vein thrombosis (DVT). When
part or all of the thrombus dislodges from its site of origin, it can travel to the lungs and disrupt or block
the blood flow in a pulmonary artery, causing a pulmonary embolism (PE).1 VTE encompasses a range of
clinical presentations. Thrombosis in the venous circulation may be asymptomatic (no clinical symptoms),
whether a DVT or a PE, or symptomatic (clinically apparent e.g. DVT may cause leg pain or swelling,
whereas PE may lead to sudden death or cause symptoms such as breathlessness or chest pain).2
If patients survive the acute episode of VTE, they may go on to develop long-term problems. Post-thrombotic
syndrome (PTS) can occur if DVT causes damage to the valves in the leg veins that prevent backflow of
blood, resulting in pain, swelling, itching, discolouration of the skin and, in some cases, an ulcer on the leg.
Chronic thromboembolic pulmonary hypertension (CTEPH) can occur if a PE blocks blood flow to the lungs
and increases the blood pressure in the arteries supplying the lungs, resulting in chronic shortness of breath
and fatigue.
Despite modern advances in care, both asymptomatic and symptomatic VTE are still associated with
significant morbidity and mortality.3,4 In the past decade, VTE has resulted in more deaths than prostate
cancer, breast cancer, road traffic accidents and acquired immune deficiency syndrome combined.5 It is
the second most common cause of vascular death after heart attack.6 In 2005, the total cost (comprising
direct and indirect costs) to the UK for the management of VTE was estimated at approximately £640M.6
Temporary immobilisation of lower-limb injury is an important cause of potentially preventable VTE.
In this context, injury is defined as physical trauma caused by an external force (e.g. a fall or a direct blow),
abnormal movement (e.g. twisting or overstretching) or normal movement applied to a weakened limb
structure (e.g. rupture of an inflamed tendon). Immobilisation is defined as involving a temporary splint,
cast or boot that prevents movement in the knee and/or ankle joint. It is temporary insofar as it is applied
after the injury and then removed when the injury has healed. For the purposes of this report, removable
splints that are used only at times of activity during healing and hinged splints or bandages that allow joint
movement while they are in place are not included.
Case reports, observational cohort studies and randomised controlled trials (RCTs) suggest that patients
with lower-limb immobilisation due to injury have a significant risk of VTE, morbidity and death.7–16 A
typical type one emergency department (ED) is likely to see, immobilise and discharge around 360 patients
per year with lower-limb injury, with an overall subsequent VTE rate approaching 2%.16–18 There are
currently 194 type one EDs in the English NHS that generate a relevant annual patient population of just
under 70,000 patients. The exclusion of type two EDs, minor injury units and walk-in centres, probably
renders this an underestimate of the population. The incidence of VTE in ambulatory trauma patients with
lower-limb immobilisation is ≈11%. However, this rate can vary from 2% to 30%, depending on the type
of injury and the immobilisation used.19 Although the majority of these events will be asymptomatic distal
DVT, there is a small risk of clot propagation, potentially leading to fatal PE19 in 20–30% of patients
receiving no prophylaxis,14 reducing to 0.3–2.0% in those with prophylaxis.20
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Description of the technology under assessment
Thromboprophylaxis, both mechanical [e.g. antiembolism stockings or VTE compression devices (not the
subject of this report, as plaster cast immobilisation precludes the application of devices to support the
calf muscle pump and/or stimulate blood flow in the leg)] and pharmacological, has been the routine
standard of care after lower-limb immobilisation. The main goal of administering thromboprophylaxis is to
prevent PE and DVT and their sequelae. Pharmacological thromboprophylaxis in patients with lower-limb
immobilisation due to injury has been principally studied using subcutaneous low-molecular-weight
heparin (LMWH). Several different agents are available [e.g. dalteparin (Fragmin®, Pfizer Inc., New York
City, NY, USA), enoxaparin (Clexane®, Sanofi Genzyme, Cambridge, MA, USA) and tinzaparin (Innohep®,
Leo Pharma A/S, Copenhagen, Denmark)]21 and equivalent doses are used for hospital inpatients, extended
spectrum groups (e.g. post-operative orthopaedic cases) and pregnant patients. LMWH is well tolerated in
these groups and has clear acceptability to staff and patients, given its widespread utilisation across the
NHS. LMWH has some limitations. As an injection-only agent, it causes a degree of pain and discomfort,
which are poorly tolerated by some. It also requires administration; therefore, patients unhappy to
self-inject, or elderly patients, often require expensive and time-consuming additional district nursing
support to facilitate home medication. Finally, there are associated complications with LMWH, principally
bleeding and, rarely, heparin-induced thrombocytopenia.
Aspirin use has also been studied in this patient group, albeit with limited evidence of efficacy.22,23
The attractions and benefits of aspirin include familiarity and availability, cost and a clearly understood
side-effect profile. Despite this, the National Institute for Health and Care Excellence (NICE) guidelines
on VTE (clinical guideline number 9224 and NICE guideline number 891) do not consider aspirin or other
antiplatelet agents to be appropriate for VTE prophylaxis. In addition, aspirin is not indicated as a treatment
for VTE prophylaxis in lower-limb immobilisation.21,25,26
Fondaparinux (Arixtra®, Aspen Pharma Trading Ltd, Dublin, Ireland) is a synthetic pentasaccharide
antithrombotic that inactivates factor X (Xa) and results in a strong inhibition of thrombin generation and
clot formation without affecting thrombin or platelets. It is administered subcutaneously and has similar
limitations to LMWH. However, it is not widely used in the UK for VTE prophylaxis.
Finally, direct oral anticoagulant (DOAC) medications [e.g. apixaban (Eliquis®, Bristol-Myers Squibb Company,
New York City, NY, USA), dabigatran etexilate (Pradaxa®, Boehringer Ingelheim GmbH, Ingelheim am Rhein,
Germany) and rivaroxaban (Xarelto®, Bayer AG, Leverkusen, Germany)] are of increasing interest to clinicians
and offer an option for thromboprophylaxis. DOACs present an attractive option based on applicable
evidence from extrapolated orthopaedic surgical thromboprophylaxis trials, in addition to their inherent
acceptability and practicality.27–29 Oral anticoagulant prophylaxis regimens can be taken orally once or twice
daily, have no additional specific contraindications to LMWH, are convenient and reliable, and appear
acceptable to staff and patients. However, they are currently more expensive and are associated with more
limited clinical experience than heparin products; furthermore, the management of bleeding complications
may be challenging, given the lack of an agent to reverse DOACs’ anticoagulant effect.30
Preventative treatment with anticoagulant drugs (thromboprophylaxis) could reduce the risk of VTE, but these
drugs carry risks of adverse events, in particular an increased risk of intracranial or gastrointestinal (GI) bleeding.
Thromboprophylaxis can be justified only if the benefits of reducing VTE outweigh the risks of bleeding and
other side effects. Furthermore, the considerable expense of providing thromboprophylaxis to all patients with
lower-limb immobilisation can be justified only if this treatment delivers meaningful improvements in health at
an acceptable cost. The risk to benefit and cost to benefit ratios of thromboprophylaxis could be improved if
patients were selected for treatment on the basis of risk factors for VTE, but this requires accurate and usable
risk assessment methods.
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A number of risk assessment models (RAMs) have been developed to select patients with lower-limb cast
immobilisation due to injury for thromboprophylaxis.17,31–33 These models aim to target high-risk patients
who stand to gain maximal health benefit on treatment and avoid treatment in low-risk groups. However,
the methodology for deriving and validating these RAMs is often poorly described, limited in validity or
based on expert consensus only.17,31–33
In general, risk prediction tools use clinical information from a patient’s history and examination to identify
those with an increased risk of VTE who could be selected for thromboprophylaxis. Existing risk prediction
rules use either a flow chart or a checklist to guide the user through risk assessment and lead him or her
to a decision regarding thromboprophylaxis. Tools may take the form of rules that simply categorise
patients by whether or not they need thromboprophylaxis, or scores that estimate the risk of VTE but leave
the decision to provide thromboprophylaxis in the hands of the user. The tools may be paper based or
electronic. The latter can potentially facilitate more complex risk assessment based on weighting of risk
factors, if appropriate data are available to support such weighting.
Current service provision
Extended spectrum thromboprophylaxis for outpatients immobilised in plaster following lower-limb injury
continues to generate international debate. There is substantial variation in both the use of thromboprophylaxis
and the use of RAMs. Although VTE events are potentially preventable with prophylaxis, international guidance
offers conflicting advice, from no intervention, to pragmatic shared decision-making, all the way to routine
chemical thromboprophylaxis.17,34,35
In many European countries, thromboprophylaxis is routine,35 whereas, in North America, recent guidelines
interpret the literature as too weak to justify intervention, and actively discourage thromboprophylaxis.34
Current UK guidance from NICE recommends that clinicians consider pharmacological VTE prophylaxis
with LMWH or fondaparinux for people with lower-limb immobilisation whose risk of VTE outweighs their
risk of bleeding, but does not provide guidance on how these risks can be determined.24 This may foster
clinical uncertainty and has led to a UK position of variable practice, using variable drug regimens throughout
the NHS, with limited understanding of the safety, efficacy or cost-effectiveness of local protocols. Since 2015,
there has been a move towards using the DOACs for this indication, despite the lack of applicable research
or licence, based on convenience and cost implications. Personal correspondence from the Royal College of
Emergency Medicine (RCEM) Clinical Studies Group suggests that DOAC drugs are currently being used
for this indication in at least four NHS trusts (Catherine Roberts, Lancashire Teaching Hospitals, 2018, personal
communication).
In the UK, risk assessment strategies in current use include the Plymouth VTE risk assessment tool (derived
by expert consensus),31 the Guidelines in Emergency Medicine Network (GEMNet) guidance (produced in
2012 for RCEM, following a rapid review of the applicable literature and expert consensus)17 and several
expert-derived pathways supported by the British Orthopaedic Association Standards for Trauma.33
However, uptake of these RAMs seems to be poor as a result of equipoise/uncertainty, and many centres
utilising these tools have pragmatically amended them without published supporting evidence.
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Chapter 2 Research questions
Rationale for the study
Venous thromboembolism is a documented global health burden.4,5 Preventative treatment with anticoagulant
drugs (thromboprophylaxis) has the potential to reduce the risk of symptomatic or asymptomatic VTE in
patients with lower-limb immobilisation due to injury; however, it is not clear whether or not this translates
into meaningful health benefit for patients, justifies the risk of treatment-related adverse events (in particular,
an increased risk of intracranial or GI bleeding) or is cost-effective. Risk assessment strategies could improve
the ratios of benefit to risk and benefit to cost, but the evidence to support VTE RAMs for lower-limb
immobilisation has not been robustly evaluated.
International guidelines have made clear recommendations for research in this area. Previous NICE
clinical guidelines (CG92)24 made a specific recommendation of research into the clinical effectiveness and
cost-effectiveness of pharmacological prophylaxis for reducing the risk of VTE in patients with lower-limb
plaster casts, which this research proposal was designed to address. The 2012 American College of
Chest Physicians guidance contains a grade 2C recommendation (i.e. weak recommendation, low- or
very-low-quality evidence) on the topic and highlights the extensive list of exclusion criteria from previous
research.34 In addition, the RCEM guidelines17 and several additional review papers published in specialist
journals have called for further research to address the equipoise.13,36
Primary research could reduce uncertainty around decision-making, but carries substantial risks of failure.
A large pragmatic trial could estimate the benefits and harms of thromboprophylaxis and determine
whether or not it is effective, but the low rates of symptomatic VTE events and bleeding events mean that
a very large sample would be required. Furthermore, it may not be ethical to randomise patients to no
treatment if convincing evidence of the effectiveness of thromboprophylaxis already exists. It is also not
clear whether or not a risk-based approach might be better than thromboprophylaxis for all, and, if it is,
what RAM should be used. A cohort study could be used to derive or validate a RAM but it is not clear
whether or not participants in such a study should receive thromboprophylaxis or how a RAM should
weigh the relative benefits of optimising sensitivity and specificity when there is inevitably a trade-off
between these parameters.
In these circumstances, an evidence synthesis project, involving systematic review, meta-analysis, elicitation
of expert consensus, decision-analytic modelling and value-of-information analysis, provides a relatively
quick and inexpensive way of drawing together all of the existing evidence in a rational and explicit manner,
exploring the trade-off between treatment harms and benefits, and between sensitivity and specificity in risk
assessment, estimating the cost-effectiveness of different strategies and the cost-effectiveness of different
options for future primary research.
Overall aims and objectives of assessment
The overall aim was to determine the clinical effectiveness and cost-effectiveness of different strategies for
providing thromboprophylaxis to people with lower-limb immobilisation due to injury and identify priorities
for future research. More specifically, the objectives were as follows:
1. To undertake systematic reviews and meta-analysis (when appropriate) to (1) assess the effectiveness of
pharmacological thromboprophylaxis for preventing any VTE, clinically detected (symptomatic) DVT,
clinically relevant (symptomatic, proximal or extensive) DVT, PE and asymptomatic DVT in people with
lower-limb immobilisation due to injury; (2) identify individual risk factors associated with VTE risk in
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patients with temporary lower-limb immobilisation due to injury; and (3) identify RAMs that predict
the risk of VTE in people with lower-limb immobilisation due to injury and estimate the accuracy of
these models.
2. To undertake a modified Delphi survey of expert opinion to augment reviews 2 and 3 above, on the
assumption that the available evidence will be very limited and expert opinion will be required to
identify risk factors and RAMs for VTE in lower-limb immobilisation due to injury.
3. To develop an economic model to estimate the (i) clinical effectiveness of thromboprophylaxis, in terms
of overall adverse outcomes avoided or incurred by treatment and quality-adjusted life-years (QALYs);
(ii) cost-effectiveness of different strategies for providing thromboprophylaxis (including thromboprophylaxis
for all, thromboprophylaxis for none and risk-based strategies), in terms of the incremental cost per QALY
gained by each strategy compared with the next most effective strategy on the efficiency frontier; and
(iii) expected value of information provided by further primary research and to determine the optimal
direction of future research.
RESEARCH QUESTIONS
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Chapter 3 Assessment of clinical effectiveness
A series of systematic reviews of the literature and (network) meta-analysis (when appropriate) wereundertaken to (1) assess the effectiveness of pharmacological thromboprophylaxis for preventing VTE,
(2) identify individual risk factors associated with VTE risk and (3) identify RAMs for the prediction of VTE
risk in people with temporary lower-limb immobilisation due to injury.
All reviews of the evidence were undertaken in accordance with the general principles recommended
in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement37 and were
registered on the PROSPERO international prospective register of systematic reviews (CRD42017058688).38
The full protocol is available on the project web page [URL: www.journalslibrary.nihr.ac.uk/programmes/
hta/1518706/#/ (accessed 3 December 2018)].
Review of pharmacological thromboprophylaxis for preventing
venous thromboembolism
Objective
The objective was to assess the effectiveness of pharmacological thromboprophylaxis for preventing any
VTE, clinically detected (symptomatic) DVT, clinically relevant (symptomatic, proximal or extensive) DVT,
PE and asymptomatic DVT in patients with temporary lower-limb immobilisation due to injury. In this
study, proximal DVT is defined as disease at or above the level of the popliteal trifurcation. Distal DVT is
defined as disease below the popliteal trifurcation, confined to the calf veins (e.g. peroneal, posterior,
anterior tibial and muscular veins).
Methods of reviewing effectiveness
Identification of studies
Studies were identified by searching the following electronic databases and research registers:
l Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily, MEDLINE and Versions(R) (OvidSP), 1946 to April 2017.
l EMBASE (OvidSP), 1974 to April 2017.
l Cochrane Database of Systematic Reviews (Wiley Online Library), 1996 to April 2017.
l Database of Abstracts of Review of Effects (Wiley Online Library), 1995 to March 2015.
l Cochrane Central Register of Controlled Trials (Wiley Online Library), 1898 to April 2017.
l Health Technology Assessment (HTA) database (Wiley Online Library), 1995 to April 2017.
l NHS Economic Evaluation Database NHS EED (Wiley Online Library), 1995 to March 2015.
l Science Citation Index Expanded (Web of Science), 1900 to April 2017.
l ClinicalTrials.gov (US National Institutes of Health), 2000 to April 2017.
l International Clinical Trials Registry Platform (World Health Organization), 1990 to April 2017.
The search strategy used free text and thesaurus terms and combined synonyms relating to the condition
(i.e. VTE in people with lower-limb immobilisation) with synonyms relating to the interventions (e.g. LMWH,
aspirin and oral anticoagulants). No language restrictions were used. However, as the search strategy of the
current review updated the search strategy of an existing review on LMWH,15 searches were limited by date
from 2013 (the last search date from the earlier review) to April 2017 for this intervention. For the other
interventions, the search strategy was amended to include terms for aspirin and oral anticoagulants and
searched from inception to April 2017. Further details of the search strategy can be found in Appendix 1.
Searches were supplemented by hand-searching the reference lists of all relevant studies (including existing
systematic reviews), performing a citation search of relevant articles, contacting key experts in the field and
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undertaking systematic keyword searches of the internet using the Google search engine (Google Inc.,
Mountain View, CA, USA).
All identified citations from the electronic searches and other resources were imported into and managed
using EndNote bibliographic software version X8 [Clarivate Analytics (formerly Thomson Reuters),
Philadelphia, PA, USA].
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles
were examined for inclusion by one reviewer (AP) and any citations that clearly did not meet the inclusion
criteria (e.g. non-human, unrelated to VTE) were excluded. Second, all abstracts and full-text articles were
examined independently by two reviewers (AP and DH). When necessary, non-English-language studies
were translated using Google Translate (Google Inc., Mountain View, CA, USA) to facilitate study selection
and subsequent data extraction. Any disagreements in the selection process were resolved through
discussion or, if necessary, arbitration by a third reviewer (SG), and articles were included by consensus.
Studies were considered eligible for inclusion if they met the following criteria: (1) study design – RCTs
and controlled clinical trials; (2) population – adults (aged > 16 years) requiring temporary immobilisation
(e.g. leg cast or brace in an ambulatory setting) for an isolated lower-limb injury; (3) interventions –
chemical thromboprophylaxis with LMWH (e.g. dalteparin, enoxaparin, tinzaparin), fondaparinux or oral
anticoagulants (e.g. apixaban, dabigatran etexilate, rivaroxaban); (4) comparators – these included placebo,
no treatment, aspirin or alternative treatment (although the original protocol considered aspirin to be an
option for VTE prophylaxis, NICE guidelines on venous thromboembolism (CG92)24 do not consider aspirin
or other antiplatelet agents to be appropriate for VTE prophylaxis; in addition, aspirin is not indicated
as a treatment for VTE prophylaxis in lower-limb immobilisation);21,25,26 and (5) outcomes – these included
symptomatic or asymptomatic DVT, PE, major bleeding or mortality. Exclusion criteria for selection included
studies that had not been designed as experimental studies (e.g. cohort studies and case–control studies),
studies that had involved hospital inpatient care or any patient requiring hospital admission of > 5 days
and studies in which patients received mechanical thromboprophylaxis or underwent ambulant
orthopaedic surgery (e.g. arthroscopy, arthroscopic surgery).
Data abstraction and quality assessment strategy
Data relating to study design, methodological quality and outcomes were extracted by one reviewer (AP)
into a standardised data extraction form and independently checked for accuracy by a second reviewer
(DH). Any discrepancies were resolved through discussion or, if necessary, arbitration by a third reviewer
(SG), and articles were included by consensus. If required, authors of primary studies were contacted to
obtain additional data, clarify uncertainties and/or confirm data that had been extracted. When multiple
publications of the same study were identified, data were extracted and reported as a single study.
The methodological quality of each included study was evaluated using a revised Cochrane Risk of Bias
tool for randomised trials (RoB 2.0).39 The original tool40 was updated because of questionable inter-rater
agreement, subjectivity in assigning risk-of-bias judgements and bias judgements assigned at the trial level.41–44
In general, RoB 2.0 redefined the potential for bias to five domains: (1) bias arising from the randomisation
process, (2) bias as a result of deviations from intended interventions, (3) bias as a result of missing outcome
data, (4) bias in the measurement of the outcome and (5) bias in the selection of the reported result. To limit
subjectivity in assigning bias judgements, the RoB 2.0 tool provides detailed guidance and contains decision
algorithms. An overall judgement of bias was assigned as ‘low risk’ if all domains were judged as being at
a low risk of bias, a judgement of bias was assigned as ‘high risk’ if at least one domain was judged to be
at a high risk of bias (or if the study had some concerns for multiple domains in a way that substantially lowers
confidence in the result) and as ‘some concerns’ if some concerns of bias were noted in at least one domain.39
The methodological quality of each included study was independently evaluated by two reviewers (AP and DH).
Any discrepancies were resolved through discussion or, if necessary, the involvement of a third reviewer (SG).
Blinding of the quality assessor to author, institution or journal was not considered necessary.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Methods of data synthesis and analysis
The extracted data and quality assessment variables were presented for each included study, both in
structured tables and as a narrative description. For each outcome of interest, a network meta-analysis
(NMA) was performed to allow a simultaneous comparison between interventions using all available studies.
The data were the number of events out of the number of patients randomised to each intervention, which
were assumed to arise from an underlying binomial distribution. The probabilities of an event for each
intervention were modelled using a logistic model to estimate odds ratios (ORs). The control intervention
was defined as placebo, no treatment or aspirin, and the reference intervention defined in the NMA was
the control intervention. Aspirin was grouped with placebo and no treatment on the basis that aspirin
is not indicated as a treatment for VTE prophylaxis in lower-limb immobilisation21,25 and NICE guidelines
on VTE (CG9224 and NG891) do not consider aspirin or other antiplatelet agents to be appropriate for VTE
prophylaxis. It was planned to analyse different types of thromboprophylaxis drugs as separate interventions
(i.e. LMWH, DOACs and fondaparinux) in the NMA on the basis of having different mechanisms of action
and, therefore, potentially different effects.
The analysis was implemented using a Markov chain Monte Carlo simulation using WinBUGS software
version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).45 A fixed-effect model was used to estimate the
effects of LMWH and fondaparinux relative to control in the available studies, namely a conditional
inference. In addition, a random-effects model was used to allow for heterogeneity in the effects of
interventions between studies and to estimate whether or not the interventions can have an effect in
future studies. The random-effects model was the primary analysis. The baseline log odds in each study
were given normally distributed prior distributions with mean 0 and variance 1000, namely N(0, 1000).
The log-odds ratios for LMWH and fondaparinux versus control were given normally distributed prior
distributions with a mean of 0 and variance of 1000, namely N(0, 1000). The between-study standard
deviation (SD) was given a half-normal prior distribution with a mean of 0 and precision of 1.82, namely
HN(0, 0.5495); this prior distribution was chosen to have, a priori, 95% of the study-specific odds ratios
lie within a factor of 5 from the median odds ratio for each comparison. Convergence of the Markov
chains to their stationary distributions was assessed using the Gelman–Rubin convergence statistic.46
For all outcomes other than major bleeding, convergence occurred within 30,000 iterations of the Markov
chain and within 100,000 samples for major bleeding; a burn-in of 100,000 iterations was used in all
analyses. There was some evidence of high autocorrelation between successive iterations of the Markov
chain; parameters were estimated after retaining every 10th sample of the Markov chain to limit the
number of unnecessary runs of the decision model that are informed by the results of the NMA. Results
were presented using ORs, 95% credible intervals (CrIs) and the 95% predictive intervals47 for the OR in a
randomly chosen study relative to the control, and the probability of each intervention being the best.48
It was planned to assess the following potential treatment effect modifiers in a series of meta-regressions:
(1) population characteristics (e.g. proportion who were male, baseline risk of VTE), (2) type of injury (i.e.
fractures, Achilles tendon rupture, other soft-tissue injury), (3) treatment of injury (surgical vs. conservative,
above- vs. below-knee immobilisation), (4) thromboprophylactic agent used and (5) duration of
thromboprophylaxis.
Results
Quantity and quality of research available
The literature searches identified 1105 citations. Of these, 13 studies (all RCTs) met the inclusion criteria.23,49–60
A flow chart describing the process of identifying relevant literature can be found in Figure 1. A total of
23 full-text articles were excluded as they did not meet all of the prespecified inclusion criteria. The majority
of the articles were excluded primarily on the basis of inappropriate study design (i.e. non-randomised
controlled trial or controlled clinical trial), wrong target population (i.e. not isolated lower-limb injury requiring
temporary immobilisation) or unsuitable publication type (i.e. reviews, commentaries, editorials or multiple
publications of the same study). A full list of excluded studies with reasons for exclusion is presented in
Appendix 2.
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Description of included studies (design and participant characteristics)
The design and participant characteristics of the 13 included studies23,49–60 that evaluated the effectiveness
of pharmacological thromboprophylaxis for preventing VTE in ambulatory trauma patients with temporary
lower-limb immobilisation are summarised in Table 1.
All studies were published between 1993 and 2017. In total, 6857 patients were included and randomised
across 10 countries (i.e. Canada,50,58 China,60 Denmark,51,56 France,57 Germany,23,52,53,57 Italy,57 the
Netherlands,49,57,59 Russia,57 Spain57 and Sweden54,55) to receive either intervention or control treatment.
LMWH injections were the primary intervention, using variable agents (i.e. certoparin,52 dalteparin,50,54,55,58
nadroparin,49,53,57,59 reviparin23,56 and tinzaparin51) and dosing regimes (e.g. administered once daily without
Records identified through
database searching
(n = 1074)
Additional records identified through other
sources including pre-2013 studies identified
from an existing systematic review, meeting
review inclusion criteria
(n = 31)
Full-text articles
(references) assessed
for eligibility
(n = 36)
Records screened by title
(n = 1105)
Excluded by title
(n = 891) 
Excluded by abstract
(n = 178)
Full-text articles included
(n = 13, studies) 
Records screened
by abstract
(n = 214)
Full-text articles excluded,
with reasons
(n = 23)
• Population not isolated to
   lower-limb injury
   requiring temporary
   immobilisation, n = 1
• Not a RCT or controlled 
   clinical trial, n = 6
• Review/comment/editorial,
   n = 10
• Abstract/duplicate/
   substudy of an included
   full-text paper, n = 6
Studies included in
quantitative synthesis
(meta-analysis)
(n = 13, studies)
In
cl
u
d
e
d
E
li
g
ib
il
it
y
S
cr
e
e
n
in
g
Id
e
n
ti
fi
ca
ti
o
n
FIGURE 1 Study flow chart (adapted):37 review of pharmacological thromboprophylaxis for preventing VTE. © 2009
Moher et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and
source are credited.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
TABLE 1 Summary of design and participant characteristics: review of pharmacological thromboprophylaxis for preventing VTE
Authors,
year
Country
(sites) Design Population Exclusion criteria (main)
Time between injury and
recruitment/immobilisation
duration (mean)
Prophylaxis before
randomisation Intervention Comparator
Outcome measure
(primary)
Goel et al.,
200950
Canada (NR) RCT, DB
a
l Adults (aged 18–75 years;
mean age, 41 years; male: 62%)
l Fractures below knee
l Surgically treated
l Outpatients
l n= 305
History of VTE, foot
fractures, contraindications
to surgery, anticoagulant
medication, platelet counts
of < 100, elevated serum
creatinine of > 200 µmol/l
l Within 48 hours
l Immobilisation duration:
14 days
b
No LMWH (dalteparin:
5000 IU/day for 14 days,
administered by s.c.
injection; compliance:
> 95%)
Matching placebo for
14 days (compliance
with injections: > 95%)
Incidence of DVT
determined by bilateral
venography at end of
treatment
Jørgensen
et al., 200251
Denmark
(three
centres)
RCT, OL
a
l Adults (aged > 18 years;
mean age 48 years; male: 57%)
l Fracture or soft-tissue injury
l Conservative treatment or
surgically treated
l Outpatients
l n= 300
Pregnancy, allergy to
heparin or contrast media,
renal or liver impairment,
uncontrolled hypertension,
bleeding disorders, recent
GI bleeding, inability to
perform self-injection
l NR
l Immobilisation duration:
5.5 weeks
No LMWH (tinzaparin:
3500 IU/day for duration
of cast immobilisation,
administered by s.c.
injection; compliance: NR)
No treatment Incidence of DVT
determined by
unilateral venography
after plaster cast
removal
Kock et al.,
199552
Germany
(NR)
RCT, OL l Adults (aged 18–75 years;
mean age 34 years; male: 61%)
l Fracture or soft-tissue injury
l Conservative treatment
l Outpatients
l n= 428
Previous DVT, pregnancy,
clotting disorders or
anticoagulant medication,
bleeding, chronic venous
insufficiency,
contraindication to
heparin, surgical treatment
l NR
l Immobilisation duration:
17 days
b
No LMWH [certoparin
(Mono-Embolex®,
Novartis International AG,
Basel, Switzerland):
3000 IU/day for duration
of cast immobilisation,
administered by s.c.
injection; compliance: NR]
No treatment Incidence of DVT
determined by duplex
sonography and
confirmed by
phlebography after
plaster cast removal
Kujath et al.,
199353
Germany
(one hospital)
RCT, OL l Patients aged > 16 years
(mean age 34 years; male: 58%)
l Fracture or soft-tissue injury
l Conservative treatment
l Outpatients
l n= 306
Known thrombopathy,
oral anticoagulation, recent
brain or GI bleeding, acute
pancreatitis, inflammatory
heart disease
l NR
l Immobilisation duration:
15.7 days
b
No LMWH [nadroparin
(Fraxiparine®, Sanofi SA,
Paris, France): 2850 IU/
day for duration of
cast immobilisation,
administered by s.c.
injection; compliance: NR]
No treatment Incidence of DVT
determined by
compression
ultrasonography and
phlebography (positive
findings only) after
plaster cast removal
Lapidus et al.,
200755
Sweden
(one centre)
RCT, DB
a
l Adults (aged 18–75 years;
mean age 40 years; male: 79%)
l Soft-tissue injury (Achilles tendon
rupture)
l Surgically treated
l Outpatients
l n= 105
Anticoagulant medication,
contrast media allergy,
kidney disorder, VTE in
preceding 3 months,
surgery in preceding
month, malignancy,
bleeding disorder,
pregnancy, high-dose
aspirin or platelet
inhibitors
l Within 72 hours of injury
l Immobilisation duration:
43 days
b
No LMWH (dalteparin:
5000 IU/day for 6 weeks,
administered by s.c.
injection; compliance: NR)
Matching placebo for
6 weeks (compliance
with injections: NR)
Incidence of DVT
determined by
unilateral duplex
sonography and
confirmed by
phlebography
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TABLE 1 Summary of design and participant characteristics: review of pharmacological thromboprophylaxis for preventing VTE (continued )
Authors,
year
Country
(sites) Design Population Exclusion criteria (main)
Time between injury and
recruitment/immobilisation
duration (mean)
Prophylaxis before
randomisation Intervention Comparator
Outcome measure
(primary)
Lapidus et al.,
200754
Sweden
(one centre)
RCT, DB
a
l Adults (aged 18–75 years;
mean age 48 years; male: 46%)
l Fracture of the ankle
l Surgically treated
l Outpatients
l n= 272
Anticoagulant medication,
allergy to contrast media,
renal disorders (including
transplant), VTE in
preceding 3 months,
surgery in preceding
month, malignancy,
bleeding disorder,
pregnancy, high-dose
aspirin or platelet
inhibitors, multitrauma
l Within 72 hours of injury
l Immobilisation duration:
44 days
b
Yes, all patients
received 1 week of
initial treatment with
dalteparin (5000
IU/day) before
randomisation
LMWH (dalteparin:
5000 IU/day for 5 weeks,
administered by s.c.
injection; compliance:
94.6%)
Matching placebo for
5 weeks (compliance
with injections:
94.6%)
Incidence of DVT
confirmed by unilateral
phlebography after
cast removal or
compression
ultrasonography if the
phlebography failed
Lassen et al.,
200256
Denmark
(six hospitals)
RCT, DB
a
l Adults (aged > 18 years;
median age 47 years;
male: 52%)
l Fracture or rupture of the
Achilles tendon
l Conservative treatment or
surgically treated
l Outpatient (in most cases)
l n= 440
Current VTE, hypertension,
cerebral aneurysm, CVA in
preceding 3 weeks, active
GI ulcer, bleeding disorder,
previous heparin use,
contraindication to heparin
or contrast allergy,
venography, kidney
disorder, MI in the
preceding 3 months,
multiple myeloma,
pregnancy, body weight of
< 35 kg, history of drug or
alcohol abuse
l Within 4 days of injury
l Immobilisation duration:
44 days
b
Yes, approximately
one-third of
participants in each
group received other
LMWH for up to
4 days before
randomisation
LMWH [reviparin
(Clivarin®, Abbott
Laboratories, Lake Bluff,
IL, USA): 1750 IU/day
for the duration of
cast immobilisation,
administered by s.c.
injection; compliance:
approximately 100%]
Matching placebo for
the duration of cast
immobilisation
(compliance with
injections:
approximately 100%)
Incidence of DVT
determined by
unilateral venography
after plaster cast
removal (or earlier if
clinical symptoms of
thrombosis suspected)
Selby et al.,
201558
Canada
(13 hospitals)
RCT, DB
a
l Patients aged > 16 years
(mean age 49 years; male: 52%)
l Fractures
l Surgically treated
l Outpatients
l n= 265
Major trauma, other
anticoagulant use, allergy
to LMWH, pregnancy,
active cancer, previous
VTE, hypercoagulable
state, active bleeding
or bleeding disorder,
intracranial bleeding in
preceding 4 weeks,
vascular injury needing
repair
l Within 72 hours of injury
l Immobilisation duration:
43 days
b
No LMWH (dalteparin:
5000 IU/day for 14 days,
administered by s.c.
injection; compliance:
90%)
Matching placebo for
14 days (compliance
with injections: 92%)
Symptomatic VTE
within 3 months
after surgery or
asymptomatic proximal
DVT determined by
bilateral Doppler
ultrasonography at
end of treatment
van Adrichem
et al., 201759
The
Netherlands
(eight
hospitals)
RCT, OL
a
l Adults (aged > 18 years;
mean age 46 years; male: 49.9%)
l Fracture or soft-tissue injury
l Conservative treatment or
surgically treated
l Outpatients
l n= 1519
History of VTE,
contraindications to
LMWH therapy,
pregnancy, current use of
anticoagulant therapy for
other indications (use of
antiplatelet drugs was
allowed)
l NR
l Immobilisation duration:
4.9 weeks
b
No LMWH [nadroparin:
2850 IU/day or
dalteparin (2500 IU/day
for < 100 kg or 5000
IU/day for > 100 kg)
for the duration of
cast immobilisation,
administered by s.c.
injection; compliance:
87%]
No treatment Incidence of
symptomatic VTE
within 3 months after
the procedure. DVT
determined by
abnormal compression
ultrasonography
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Authors,
year
Country
(sites) Design Population Exclusion criteria (main)
Time between injury and
recruitment/immobilisation
duration (mean)
Prophylaxis before
randomisation Intervention Comparator
Outcome measure
(primary)
Zheng et al.,
201660
China (three
hospitals)
RCT, DB
a
l Adults (aged > 18 years; mean
age 47.8 years; male: 62.3%)
l Fracture of the ankle or foot
l Surgically treated
l Outpatients
l n= 814
Multiple fractures; history
of VTE; a tibial, fibular,
femoral or hip fracture
that required operative
treatment or had casts
or splints; history of
thromboembolic event;
anticoagulation; active
cancer; or known
hypercoagulability and
pilon fractures
l Mean 3.3 days
l Immobilisation
duration: NR
No LMWH (NR but given
once daily for 14 days,
administered by s.c.
injection; compliance: NR)
Matching placebo for
14 days (compliance
with injections: NR)
Incidence of VTE.
DVT determined by
bilateral Doppler
ultrasonography
Gehling et al.,
199823
Germany
(one hospital)
RCT l Patients aged > 16 years
(mean age 36 years; male: 49%)
l Fracture or soft-tissue injury
l Management approach unclear
(but majority appear to have
been surgically treated)
l Outpatients
l n= 287
Patients aged < 40 years
without lower-limb
injury and risk factors,
contraindication to LMWH
or aspirin anticoagulation,
thrombocytopenia,
pregnancy, kidney
damage, apoplectic insult,
haemorrhagic diathesis,
gastric ulcer, hypertension,
acute thrombosis
l NR
l Immobilisation
duration: NR
NR LMWH (reviparin:
1750 IU/day, administered
by s.c. injection;
compliance: NR)
Aspirin (1000mg/day,
administered orally;
compliance: NR)
Incidence of DVT
determined by duplex
sonography (all) or
phlebography (if
thrombosis suspected)
Bruntink et al.,
201749 (three-
arm study)
The
Netherlands
(seven
hospitals)
RCT, SB
a
l Adults (aged > 18 years;
mean age 47 years; male: 42%)
l Fracture of the ankle or foot
l Conservative treatment
l Outpatients
l n= 467
History of VTE,
hypersensitivity to
nadroparin or
fondaparinux,
anticoagulation,
hypercoagulability,
bleeding tendency/disorder
(including previous or
active bleeding from the
digestive tract), pregnancy
or lactation, ‘active’
malignancy, severe hepatic
or renal impairment,
retinopathy, haemorrhagic
stroke, major surgery in
the preceding 2 months,
severe hypertension
l Within 72 hours of injury
l Immobilisation duration:
39.5 days
b
No LMWH (nadroparin:
2850 IU/day for the
duration of cast
immobilisation,
administered by s.c.
injection; compliance:
approximately 100%)
1. Fondaparinux
(2.5mg/day for the
duration of cast
immobilisation,
administered by
s.c. injection;
compliance:
approximately
100%)
2. No treatment
Incidence of DVT
determined by duplex
sonography after the
removal of the cast
(or earlier if thrombosis
was suspected)
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TABLE 1 Summary of design and participant characteristics: review of pharmacological thromboprophylaxis for preventing VTE (continued )
Authors,
year
Country
(sites) Design Population Exclusion criteria (main)
Time between injury and
recruitment/immobilisation
duration (mean)
Prophylaxis before
randomisation Intervention Comparator
Outcome measure
(primary)
Samama
et al., 201357
France,
Russia, the
Netherlands,
Spain,
Germany and
Italy (93
centres)
RCT, OL
a
l Adults (aged > 18 years; mean
age 46 years; male: 46.6%)
l Fracture or soft-tissue injury
l Conservative treatment
l Outpatients
l n= 1349
Antithrombotic therapy;
bleeding tendency/
disorder; peptic ulcer
disease; haemorrhagic
stroke, brain, spinal or
ophthalmological surgery
(in the preceding
12 months); severe head
injury in the preceding
3 months; uncontrolled
arterial hypertension;
severe hepatic impairment;
body weight of < 50 kg;
contraindication to
anticoagulant therapy;
pregnancy/lactation or
not using a reliable
contraceptive method
l Within 72 hours of injury
l Immobilisation duration:
33.7 days
b
No LMWH (nadroparin:
2850 IU/day for the
duration of cast
immobilisation,
administered by s.c.
injection; compliance: NR)
Fondaparinux
(2.5mg/day for the
duration of cast
immobilisation,
administered
by s.c. injection;
compliance: NR)
Incidence of VTE.
Compression
ultrasonography
and/or venography
performed for
suspected DVT after
cast removal
CVA, cerebrovascular accident; DB, double blind; MI, myocardial infarction; NR, not reported; OL, open label; SB, single blind; s.c, subcutaneous.
a Blinded outcome assessment.
b Means were calculated from the reported group means of intervention and comparator arms.
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dose adjustment for bodyweight), but two studies used fondaparinux.49,57 One study used aspirin as a
control group treatment,23 with others using placebo injections or nothing dependent on design.50–56,58–60
In general, most studies excluded patients at highest risk of VTE, namely those with active cancer,49,54,55,58,60
previous VTE49,50,52–56,58–60 or first-degree family history of VTE.59,60
Five identified studies used open-label methodology with subjective screening outcomes (duplex
sonography or phlebography on cast removal).51–53,57,59 Six studies used double blinding within the
design.50,54–56,58,60 The single largest study had symptomatic VTE only as an identified primary outcome,
confirmed with imaging.59 Although all studies included adult patients with an isolated lower-limb injury
requiring temporary immobilisation, there was wide variation in terms of injury type. Five studies focused
on patients with fractures,49,50,54,58,60 one focused on Achilles tendon ruptures55 and the remaining seven
studies included patients with mixed pathology.23,51–53,56,57,59 Depending on the type of injury, the
management of lower-limb injury included conservative treatment,49,52,53,57 surgical management50,54,55,58,60
or both.51,56,59 In eight studies,49,50,54–58,60 patients were recruited within 4 days of injury, whereas, in the
remaining studies,23,51–53,59 the time to recruitment was not stated. The duration of immobilisation ranged
from 14 days50 to 44 days.54,56 In two studies, all54 or some (approximately one-third)56 patients first
received prophylaxis prior to randomisation; these studies were included, as any final impact on outcome
would be likely to take the form of a reduction in VTE outcome events. In addition, the results of these
trials remain relevant to the study question in the light of current regimes, suggesting that prophylaxis
continue for the duration of immobilisation (usually 4–6 weeks). The sample sizes of the included studies
ranged from 10555 to 151959 patients, with the mean age of participants ranging from 34 years52,53 to
49 years.58 The number of male participants ranged from 42%58 to 79%.55
Quality characteristics
The overall methodological quality of the 13 included studies is summarised in Figure 2 and Table 2.
Overall, risk of bias was present in all studies. Ten studies raised some concerns of bias.49–51,54–60 The
potential sources of bias most frequently identified included concerns about the randomisation process
(allocation concealment was not reported in nine studies),23,50–56,60 blinding (open-label design)23,49,51–53,57,59
and analyses intentions (only one study provided sufficient information on the selection of the reported
result).59 A high risk of bias was noted in three studies.23,52,53 High risk of bias was principally attributable to
outcome assessment; in three open-label studies,23,52,53 outcome assessment was performed on all patients
with routine screening compression ultrasonography and phlebography for confirmation of positive
findings. Finally, all of the included studies were conducted outside the UK, making generalisability of the
findings to the UK setting uncertain.
Bias arising from randomisation process
Bias due to deviations from
intended interventions
Bias due to missing outcome data
Bias in measurement of outcome
Bias in selection of reported result
0 10 20 30 40 50 60 70 80 90 100
Risk of bias
Proportion fulfilled (%)
Low
Some concerns
High
FIGURE 2 Risk-of-bias assessment graph:39 review authors’ judgements about each methodological quality item
across all included studies – review of pharmacological thromboprophylaxis for preventing VTE.
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Quantitative data synthesis
Details of the results of the primary studies are provided in Appendix 3. All 13 studies reported outcomes
for any VTE, PE and major bleeding. The rate of any VTE in the control group ranged from 1.8% to 40.4%
with a median of 12.2%. The rate of PE in the control group was zero in eight studies and ranged from
0.7% to 2.1% in the other four. There was only one bleeding event across all the control groups. Clinically
relevant (proximal or symptomatic) DVTs were reported in 10 out of 13 studies, with control event rates
ranging from 0.0% to 6.4% (median 1.5%). Clinically detected (symptomatic) DVTs were reported in all
13 studies, with control event rates ranging from 0.0% to 5.5% (median 0.7%). Any proximal or distal
asymptomatic DVTs were reported in 10 out of 13 studies, with control event rates ranging from 1.6% to
25.7% (median 6.9%). Asymptomatic proximal DVTs were reported in 8 out of 13 studies, with control
event rates ranging from 0.0% to 6.4% (median 0.7%). Asymptomatic distal DVTs were reported in 8 out
of 13 studies, with control event rates ranging from 0.8% to 16.0% (median 3.0%).
TABLE 2 Risk-of-bias assessment summary:39 review authors’ judgements about each methodological quality item
for each included study – review of pharmacological thromboprophylaxis for preventing VTE
Study
authors,
year
Area of potential bias
Overalla
Randomisation
process
Deviations
from intended
interventions
Missing
outcome data
Measurement
of the outcome
Selection of the
reported result
Goel et al.,
200950
Some concerns Low Low Low Some concerns Some concerns
Jørgensen
et al., 200251
Some concerns Some concerns Low Low Some concerns Some concerns
Kock et al.,
199552
Some concerns Some concerns Low High Some concerns High
Kujath et al.,
199353
Some concerns Some concerns Some concerns High Some concerns High
Lapidus
et al., 200755
Some concerns Low Low Low Some concerns Some concerns
Lapidus
et al., 200754
Some concerns Low Low Low Some concerns Some concerns
Lassen et al.,
200256
Some concerns Low Low Low Some concerns Some concerns
Selby et al.,
201558
Low Low Low Low Some concerns Some concerns
van
Adrichem
et al., 201759
Low Some concerns Low Low Low Some concerns
Zheng et al.,
201660
Some concerns Low Some concerns Low Some concerns Some concerns
Gehling
et al., 199823
Some concerns Some concerns Some concerns High Some concerns High
Bruntink
et al., 201749
Low Some concerns Low Low Some concerns Some concerns
Samama
et al., 201357
Low Some concerns Low Low Some concerns Some concerns
Note
Overall, risk-of-bias judgement (equal to the most severe level of bias found in any domain) was as follows: (1) being at a
low risk of bias – the study is judged to be at a low risk of bias for all domains for this result; (2) some concerns – the study
is judged to have some concerns of bias in at least one domain for this result; and (3) being at a high risk of bias – the
study is judged to be at a high risk of bias in at least one domain for this result or have some concerns for multiple
domains in a way that substantially lowers confidence in the result.
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A NMA was undertaken to compare the effectiveness of two alternative forms of thromboprophylaxis
(i.e. LMWH or fondaparinux) with no thromboprophylaxis (i.e. aspirin, placebo or no treatment). Figure 3
presents the network of evidence. All 13 studies were included in the analysis and provided information on
at least one of the outcomes being analysed. Eleven of the studies compared LMWH thromboprophylaxis
with no thromboprophylaxis, one three-arm study compared LMWH with fondaparinux with no
thromboprophylaxis, and one study compared LMWH with fondaparinux. A summary of the key results of
fixed-effect and random-effects NMA are provided in Table 3.
Clinically detected deep-vein thrombosis (symptomatic)
Data were available from all 13 studies.23,49–60 The risk of clinically detected DVT (symptomatic) was lower
in adult outpatients with lower-limb immobilisation who received LMWH (OR 0.40, 95% CrI 0.12 to 0.99)
and fondaparinux (OR 0.10, 95% CrI 0.01 to 0.94) than those in the control group. Fondaparinux is likely
to be the most effective treatment (probability of being the most effective = 0.91). However, the heterogeneity
in treatment effects between studies suggests that the true effects may vary depending on study
characteristics (between-study SD 0.55, 95% CrI 0.03 to 1.59).
Asymptomatic deep-vein thrombosis (proximal segment)
Data were available from eight studies.23,50–52,55,57,58,60 The risk of asymptomatic DVT (proximal segment) was
lower in adult outpatients with lower-limb immobilisation who received LMWH (OR 0.21, 95% CrI 0.04
to 0.82) than those in adults in the control group. A similar effect was found for fondaparinux, although
the results were inconclusive (OR 0.28, 95% CrI 0.02 to 3.42). The heterogeneity in treatment effects
between studies suggests that the true effects may vary depending on study characteristics (between-study
SD 0.42, 95% CrI 0.02 to 1.44).
Asymptomatic deep-vein thrombosis (distal)
Data were available from eight studies.23,50–52,56–58,60 The risk of asymptomatic DVT (distal) was lower in
adult outpatients with lower-limb immobilisation who received fondaparinux (OR 0.11, 95% CrI 0.03
to 0.35) than in those in the control group; fondaparinux is likely to be the most effective treatment
(probability of being the most effective = 1.00). There was insufficient evidence of an effect of LMWH
(OR 0.69, 95% CrI 0.43 to 1.12) compared with control, although the effect favoured treatment with
LMWH. There was evidence of mild to moderate heterogeneity between studies, suggesting that the true
effects may vary depending on study characteristics (between-study SD 0.20, 95% CrI 0.01 to 0.83).
Asymptomatic deep-vein thrombosis (all)
Data were available from 10 studies.23,49–52,54,56–58,60 The risk of asymptomatic DVT (all) was lower in adult
outpatients with lower-limb immobilisation who received LMWH (OR 0.57, 95% CrI 0.39 to 0.82) and
fondaparinux (OR 0.14, 95% CrI 0.05 to 0.31) than in those in the control group. Fondaparinux is likely
to be the most effective treatment (probability of being the most effective = 1.00). There was evidence of
mild to moderate heterogeneity in treatment effects between studies, suggesting that the true effects may
vary depending on study characteristics (between-study SD 0.17, 95% CrI 0.01 to 0.70).
Pulmonary embolism
Data were available from all 13 studies.23,49–60 The risk of PE was lower in adult outpatients with lower-limb
immobilisation who received LMWH (OR 0.17, 95% CrI 0.01 to 0.88) than in those in the control group.
A reduction in risk was also found for fondaparinux, although the results were inconclusive (OR 0.47,
95% CrI 0.01 to 9.54). The heterogeneity in treatment effects between studies suggests that the true
effects may vary depending on study characteristics (between-study SD 0.81, 95% CrI 0.05 to 2.04).
Major bleeding
Data were available from all 13 studies,23,49–60 but, with only four events across all the studies, estimates of
the effects of LMWH (OR 1.45, 95% CrI 0.08 to 32.17) and fondaparinux on the risk of major bleeding
were inconclusive. Control had the highest probability of being the best treatment (probability of being the
best = 0.59). The between-study SD was 0.50 (95% CrI 0.02 to 1.64).
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Control
(e.g. placebo, no
treatment or aspirin)
Any VTE: 12 studies
Clinically relevant DVT: 9 studies
Clinically detected DVT (symptomatic): 10 studies
Asymptomatic DVT (all): 9 studies
Asymptomatic proximal DVT: 7 studies
Asymptomatic distal DVT: 7 studies
PE: 12 studies
Major bleeding: 12 studies
LMWH
(e.g. dalteparin,
enoxaparin, tinzaparin)
Fondaparinux
Any VTE: 1 study
Clinically relevant DVT: 0 studies
Clinically detected DVT (symptomatic): 1 study
Asymptomatic DVT (all): 1 study
Asymptomatic proximal DVT: 0 studies
Asymptomatic distal DVT: 0 studies
PE: 1 study
Major bleeding: 1 study
Any VTE: 2 studies
Clinically relevant DVT: 1 study
Clinically detected DVT (symptomatic): 2 studies
Asymptomatic DVT (all): 2 studies
Asymptomatic proximal DVT: 1 study
Asymptomatic distal DVT: 1 study
PE: 2 studies
Major bleeding: 2 studies
FIGURE 3 Network diagram of different pharmacological thromboprophylaxis interventions vs. no thromboprophylaxis for preventing VTE. The nodes are the interventions.
The numbers against each outcome represent the number of times that each pair of interventions has been compared. There was one multiarm study comparing LMWH vs.
fondaparinux vs. control. Diagrams for specific outcomes depend on the number of studies that provide data and the number of non-zero event studies; not all outcomes
involve feedback loops.
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TABLE 3 Results of fixed-effect and random-effects NMAs of different pharmacological thromboprophylaxis
interventions vs. no thromboprophylaxis
Treatment
NMA, OR (95% CrI)
Probability of
being bestFixed effect Random effects OR (95% PrI)
Clinically detected DVT (symptomatic)
LMWH 0.45 (0.22 to 0.89) 0.40 (0.12 to 0.99) 0.41 (0.05 to 2.31) 0.09
Fondaparinux 0.11 (0.01 to 0.60) 0.10 (0.01 to 0.94) 0.10 (0.00 to 1.46) 0.91
None – – – 0.00
Asymptomatic DVT (proximal segment)
LMWH 0.22 (0.05 to 0.71) 0.21 (0.04 to 0.82) 0.21 (0.02 to 1.34) 0.63
Fondaparinux 0.29 (0.03 to 2.35) 0.28 (0.02 to 3.42) 0.28 (0.01 to 4.49) 0.36
None – – – 0.01
Asymptomatic DVT (distal)
LMWH 0.69 (0.47 to 1.01) 0.69 (0.43 to 1.12) 0.69 (0.29 to 1.62) 0.00
Fondaparinux 0.11 (0.04 to 0.27) 0.11 (0.03 to 0.35) 0.11 (0.03 to 0.42) 1.00
None – – – 0.00
Asymptomatic DVT (all)
LMWH 0.57 (0.42 to 0.77) 0.57 (0.39 to 0.82) 0.57 (0.28 to 1.12) 0.00
Fondaparinux 0.14 (0.07 to 0.27) 0.14 (0.05 to 0.31) 0.14 (0.05 to 0.38) 1.00
None – – – 0.00
PE
LMWH 0.30 (0.07 to 0.96) 0.17 (0.01 to 0.88) 0.18 (0.00 to 1.79) 0.74
Fondaparinux 0.64 (0.05 to 7.26) 0.47 (0.01 to 9.54) 0.48 (0.01 to 17.53) 0.25
None – – – 0.01
Major bleeding
LMWH 1.60 (0.14 to 25.67) 1.45 (0.08 to 32.17) 1.46 (0.06 to 42.87) 0.37
Fondaparinux 14,380 (0.48 to 9.9 × 1014) 8422 (0.32 to 1.3 × 1014) 8421 (0.29 to 1.3 × 1014) 0.03
None – – – 0.59
Clinically relevant DVTa
LMWH 0.43 (0.22 to 0.79) 0.40 (0.16 to 0.85) 0.40 (0.07 to 1.76) 0.22
Fondaparinux 0.25 (0.07 to 0.82) 0.23 (0.03 to 1.36) 0.23 (0.02 to 2.11) 0.77
None – – – 0.01
Any VTE
LMWH 0.53 (0.41 to 0.67) 0.52 (0.37 to 0.71) 0.52 (0.23 to 1.12) 0.00
Fondaparinux 0.14 (0.07 to 0.25) 0.13 (0.05 to 0.30) 0.13 (0.04 to 0.39) 1.00
None – – – 0.00
PrI, predictive interval.
a Clinically relevant DVT was defined as the cumulative figure of any symptomatic or asymptomatic proximal DVT.
DOI: 10.3310/hta23630 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 63
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Clinically relevant deep-vein thrombosis
Data were available from 10 studies.23,50–52,55,57,58,60 The risk of clinically relevant DVT was lower in adult
outpatients with lower-limb immobilisation who received LMWH (OR 0.40, 95% CrI 0.16 to 0.85) than in
those in the control group. The risk was also lower in patients treated with fondaparinux, although the
results were inconclusive (OR 0.23, 95% CrI 0.03 to 1.36). The heterogeneity in treatment effects between
studies suggests that the true effects may vary depending on study characteristics (between-study SD 0.45,
95% CrI 0.02 to 1.39).
Any venous thromboembolism
Data were available from all 13 studies.23,49–60 The risk of any VTE was lower in adult outpatients with
lower-limb immobilisation who received LMWH (OR 0.52, 95% CrI 0.37 to 0.71) and fondaparinux
(OR 0.13, 95% CrI 0.05 to 0.30) than in those not receiving thromboprophylaxis. Fondaparinux is likely
to be the most effective treatment (probability of being the most effective = 1.00). There was mild to
moderate heterogeneity in treatment effects between studies. Although the results suggest that the true
effects may vary depending on study characteristics, the predictive distribution still favoured fondaparinux
relative to control (between-study SD 0.23, 95% CrI 0.01 to 0.75).
There were few reported adverse effects in the treated patients. Minor bleeding event rates varied from
0.0% to 10.5% in the LMWH intervention groups, 0.0% to 1.5% in the fondaparinux intervention groups
and 0.0% to 6.8% in the control groups. In the largest RCT to date,59 the most common adverse event
(of infection) occurred at a similar rate in the intervention and control groups (1.6% vs. 2.0%, respectively).
When assessed in the trials, compliance appeared good, with only a single open-label study49 recording pain
on injection, which was seen in 1.4% of participants in the intervention group. In studies monitoring for
the incidence of heparin-induced thrombocytopaenia, no cases were found.58 No deaths in any study were
deemed attributable to either VTE or the use of an intervention.
The results of the network meta-regressions are detailed in Appendix 4. A network meta-regression of
population characteristics (e.g. proportion of males, baseline risk of VTE), type of injury (i.e. fractures,
Achilles tendon rupture, other soft-tissue injury), treatment of injury (surgical vs. conservative, above- vs.
below-knee immobilisation) and the duration of thromboprophylaxis was undertaken for each available
outcome. This showed that no covariate improved model fitted and, therefore, explained the variation in
treatment effects.
The effect of the type of thromboprophylactic agent used (i.e. dalteparin, tinzaparin, certoparin, nadroparin,
reviparin) was assessed using a separate NMA. This suggested that there were differences in the effects of
the type of thromboprophylactic agent used, including between the different types of LMWH, with certoparin
having the highest probability of having the greatest effect on any VTE. However, this finding was based on
the effect of certoparin being used in one study,52 so it is not possible to draw any reliable conclusions.
Summary of key findings
l Thromboprophylaxis with LMWH approximately halves the risk of any VTE. The effects on different
types of VTE are variable and uncertain (in accordance with random error), but all are consistent with a
halving of risk.
l Thromboprophylaxis with fondaparinux appears to have a greater effect on the risk of VTE and a
greater probability than LMWH of being the more clinically effective, but estimates for fondaparinux are
based on only two trials.
l Major bleeding is very uncommon; therefore, the effect of thromboprophylaxis on major bleeding in
this group is uncertain.
l Meta-regression did not identify any reliable evidence of effect modification by key covariates.
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Review of individual risk factors associated with venous
thromboembolic risk
Objectives
To identify individual, patient identifiable risk factors associated with VTE risk in patients with temporary
lower-limb immobilisation due to injury.
Methods of reviewing effectiveness
Identification of studies
Studies were identified by searching the following electronic databases and research registers:
l Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily, MEDLINE and Versions(R) (via OvidSP), 1946 to May 2017.
l EMBASE (via OvidSP), 1974 to May 2017.
l Cochrane Database of Systematic Reviews (via Wiley Online Library), 1996 to May 2017.
l Database of Abstracts of Review of Effects (via Wiley Online Library), 1995 to March 2015.
l Cochrane Central Register of Controlled Trials (via Wiley Online Library), 1898 to May 2017.
l HTA database (via Wiley Online Library), 1995 to May 2017.
l NHS EED (via Wiley Online Library), 1995 to March 2015.
l Science Citation Index Expanded (via Web of Science), 1900 to May 2017.
l ClinicalTrials.gov (via US National Institutes of Health), 2000 to May 2017.
l International Clinical Trials Registry Platform (via World Health Organization), 1990 to May 2017.
The search strategy used free-text and thesaurus terms and combined synonyms relating to the condition
(i.e. VTE in people with lower-limb immobilisation) with risk factor assessment or risk prediction modelling
terms (used in the searches of MEDLINE, The Cochrane Library and EMBASE only). No language or date
restrictions were used on any database. Further details on the search strategy can be found in Appendix 5.
Searches were supplemented by hand-searching the reference lists of all relevant studies (including existing
systematic reviews), performing a citation search of relevant articles, contacting key experts in the field and
undertaking systematic keyword searches of the internet using the Google search engine.
All identified citations from the electronic searches and other resources were imported into and managed
using EndNote bibliographic software.
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were
examined for inclusion by one reviewer (AP) and any citations that clearly did not meet the inclusion criteria
(e.g. non-human, unrelated to VTE) were excluded. Second, all abstracts and full-text articles were then
examined independently by two reviewers (AP and DH). When necessary, non-English-language studies
were translated using Google Translate to facilitate study selection and subsequent data extraction. Any
disagreements in the selection process were resolved through discussion or, if necessary, arbitration by a
third reviewer (SG), and articles were included by consensus.
Studies were considered eligible for inclusion if they met the following criteria: (1) any study design
that included a measurement of VTE patient outcome, (2) a study population of adults (aged > 16 years)
requiring temporary immobilisation (e.g. leg cast or brace in an ambulatory setting) for an isolated
lower-limb injury, (3) any studies that reported and analysed data on individual risk factors associated
with DVT or PE. Exclusion criteria for the selection included studies that involved hospital inpatient care
or any patient requiring hospital admission for > 5 days, or studies that involved patients undergoing
ambulant orthopaedic surgery (e.g. arthroscopy, arthroscopic surgery).
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Data abstraction and quality assessment strategy
Data relating to study design, methodological quality and outcomes were extracted by one reviewer (AP)
into a standardised data extraction form and independently checked for accuracy by a second reviewer
(DH). Any discrepancies were resolved through discussion to achieve agreement. When differences were
unresolved, the opinion of a third reviewer (SG) was sought. When multiple publications of the same study
were identified, data were extracted and reported as a single study.
The methodological quality of each included study was assessed using the Risk Of Bias In Non-randomized
Studies – of Interventions tool (ROBINS-I) [formerly called A Cochrane Risk of Bias Assessment Tool for
Non-Randomized Studies of Interventions (ACROBAT-NRSI)].61 The tool is based on the original Cochrane
Risk of Bias tool for randomised studies40 and also builds on related tools, such as the quality assessment
of diagnostic accuracy studies (QUADAS-2).62
The ROBINS-I61 tool provides a detailed framework for assessment and judgement of risk-of-bias domains that
may arise in three phases: (1) at pre-intervention, bias arising from confounding and selection of participants
into the study; (2) at intervention, bias in measurement of interventions; and (3) at post-intervention, bias due
to deviations from intended interventions, missing data, measurement of outcomes and selection of reported
results. Each domain is rated as being at low, moderate, serious or critical risk of bias. A low risk of bias
indicates that the study is comparable to a well-performed randomised trial in the domain being evaluated.
A moderate risk of bias indicates that the study is sound for a non-randomised study but is not comparable to
a well-performed randomised trial. A serious risk of bias indicates the presence of important problems in the
domain and a critical risk of bias indicates that the study is too problematic to provide any useful evidence
on the intervention effects. If insufficient information is provided to determine the risk of bias of a certain
domain, the domain is marked as having no information. In general, the overall risk of bias of each study
was determined to be equal to that of the most severe level of bias found in any domain.
All studies were analysed using ROBINS-I,61 regardless of whether or not the original study design included
randomisation to other exposures, thus ensuring that risk of bias was assessed specifically for the comparisons
of interest to this review. It is important to note that the quality assessment reflects how well a specific result
evaluated the association of interest to this review, regardless of the objectives of the original study.
Methods of data synthesis and analysis
Venous thromboembolism was considered to comprise any subsequent recorded diagnosis of DVT or PE,
or death attributable to either pathology. No attempt was made to distinguish between anatomical location,
thrombus burden or clinical sequelae of VTE for this project, in accordance with the definitions of hospital-
acquired thrombosis produced by NHS England.63 Individual risk factors highlighted through regression,
OR analysis or parametric testing as significantly associated with an increased or decreased likelihood of
subsequent VTE were extracted. In particular, each paper was scrutinised for evidence of individual risk
factors, especially those highlighted within current risk stratification tools,17,31–33 and their predictive
performance was recorded, when available. Other risk factors demonstrating an association with VTE in the
context of individual studies were also reported. A meta-analysis was not possible owing to significant levels
of heterogeneity between studies, variable reporting items and the high risk of attributable bias. Descriptive
statistics and thematic analysis were used to synthesise risk factors acting in a reproducible fashion across
studies. Thematic analysis took an inductive/semantic form, using familiarisation and coding directed by
data content. Consistent risk factor themes were then highlighted in ordinal fashion. All analyses were
conducted using Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA).
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Results
Quantity and quality of research available
The literature searches identified 4771 citations. Of these, 15 studies9,11,23,50,52,53,60,64–71 met the inclusion
criteria. Figure 4 presents a flow chart describing the process of identifying relevant literature. Sixty full-text
articles were excluded as they did not meet all the prespecified inclusion criteria. The majority of the
articles were excluded primarily on the basis of an inappropriate target population (not isolated lower-limb
injury requiring temporary immobilisation), no data or analysis of risk factors associated with VTE, or an
unsuitable publication type (i.e. reviews, commentaries, editorials or abstracts of excluded/included full-text
papers). More specifically, two potentially relevant papers72,73 were excluded as they included a specific
elective surgical population who were not considered to meet the inclusion criterion of lower-limb injury.
A potentially relevant prospective observational cohort study74 was excluded, based on the authors’
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FIGURE 4 Study flow chart (adapted):37 review of individual risk factors associated with VTE risk. © 2009 Moher et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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conclusion of a low event rate precluding any subsequent analysis for predictors of VTE. Finally, a
case–control study32 specifically seeking to derive a decision rule for the cohort of interest was excluded,
based on the creation of this rule from a generic thrombosis cohort rather than a subgroup of patients
with temporary lower-limb immobilisation. A full list of excluded studies with reasons for exclusion is
presented in Appendix 6.
Description of included studies (design and patient characteristics)
The design and patient characteristics of the 15 included studies9,11,23,50,52,53,60,64–71 that provided data on
individual patient identifiable risk factors associated with VTE risk in ambulatory trauma patients with
temporary immobilisation following lower-limb injury is summarised in Table 4.
All studies were published between 1993 and 2017 (five were RCTs with conservative arms,23,50,52,53,60
three were prospective observational cohort or cross-sectional studies,65,67,69 one was a case–control study70
and six were retrospective cohort studies)9,11,64,66,68,71 and conducted in 10 countries (Australia,11,64,65
Canada,9,50 China,60 Denmark,71 France,69 Germany,23,52,53 Iran,67 the Netherlands,70 the UK66 and the
USA).68 Most of the studies (n = 11) were entirely outpatient based,11,23,50,52,53,60,64–67,69 whereas the
remaining studies9,68,70,71 included patients with a short-duration inpatient stay to facilitate day-case
surgery. In total, data were collated on 80,678 patients with a subsequent reported outcome of VTE
positive or negative following temporary lower-limb immobilisation. The incidence of VTE across the
studies with interpretable outcome data (79,202 patients) ranged from 0.22%66 to 23.5%9 (median
4.8%), mean age ranged from 33.8 years52 to 52.6 years71 and the proportion of male patients ranged
from 45.8%65 to 86.1%,9 with a median across those studies with reported data of 56.3%.
The duration of follow-up varied between studies. Ten studies reported follow-up over a period of at least
3 months9,50,60,64–66,68–71 and one study followed up patients for up to 14 days.67 Although four studies
failed to record the duration of follow-up,11,23,52,53 two of these appeared to report follow-up only for the
duration of the plaster cast, which averaged at 15.7 days53 and 17 days.52 Eight studies collected data on
risk factors prospectively via physician assessment or questionnaire,23,50,52,53,60,65,69,70 whereas six studies
collected these data through clinical records, electronic patient notes or registries.9,11,64,66,68,71 One study did
not report the methodology for this aspect of data collection.67 Analysis and methodology of VTE diagnosis
subsequent to immobilisation varied markedly across studies and included prospective screening in all
patients following plaster cast removal (seven studies),23,50,52,53,60,65,67 adjudicated diagnostic evaluation in
those with symptoms (two studies)69,70 and retrospective identification of VTE through the interrogation of
clinical records/health databases (six studies).9,11,64,66,68,71 A single study66 looked only at the subsequent
diagnosis of PE as an outcome, with reduced prevalence as expected. The association of individual risk
factors with subsequent VTE was highlighted through regression analyses (nine studies),11,50,60,64,66,68–71
non-parametric tests (two studies)9,65 and descriptive statistics (four studies).23,52,53,67
Quality characteristics
The overall methodological quality of the 15 included studies is summarised in Figure 5 and Table 5.
All studies were deemed to be at overall moderate (seven studies)23,50,52,53,60,68,71 or serious (eight
studies)9,11,64–67,69,70 risk of bias, using the ROBINS-I61 framework for assessment and judgement. Studies
scoring a serious risk of bias did so predominantly on the selection of participants into the study, perhaps
highlighting the issue with retrospective observational work into VTE outcomes; patients deemed to be
at high risk in these cohorts are often treated with thromboprophylaxis (as highlighted in Table 4), or
managed in a different manner from other patients. If this is not highlighted within a prospective analysis
plan, a false low event rate is seen and risk is marginalised.
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TABLE 4 Summary of design and patient characteristics: review of individual risk factors associated with VTE risk
Study authors,
year; country Design, setting Inclusion criteria (main)
Patients, sex, age
(years) Incidence of VTE Prophylaxis Duration of follow-up
Risk factor
ascertainment
Outcome
ascertainment
Statistical
analysis
Gehling et al.,
1998; Germany23
l Design: prospective
open-label RCT
l Setting: outpatient
Age > 16 years with
lower-limb injury requiring
immobilisation with plaster
or bandages (and at least
one risk factor for VTE)
l n = 287
l 50.5% male
l Mean age: 36.3 years
a
l LMWH group: 6.3%
l Aspirin group: 4.8%
NR NR Physician assessment
(prospective)
Clinical assessment,
screening sonography
and confirmation
phlebography
NR (appears
descriptive)
Goel et al.,
2009; Canada50
l Design: prospective
double-blind RCT
l Setting: outpatient
Adults aged 18–75 years
with unilateral displaced
fractures below the knee
requiring operative
intervention
l n = 238
l 62% male
l Mean age: 40.5 years
a
LMWH group: 8.7%
Control group: 12.6%
No prophylaxis
prior to
randomisation
Minimum of 3 months
following surgery or until
the fracture had united
Physician assessment
(prospective)
Clinical assessment
and bilateral lower-leg
venography for all
patients
Univariate and
multivariate
logistic regression
Kock et al.,
1995; Germany52
l Design: prospective
open-label RCT
l Setting: outpatient
Adults aged 18–65 years
undergoing conservative
treatment for below-knee
injury with cylinder or
below-knee cast
l n = 339
l 61% male
l Mean age: 33.8 years
a
LMWH group: 0.0%
Control group: 4.3%
No prophylaxis
prior to
randomisation
NR (however, duration of
casting: LMWH group,
15.2 days; control group,
18.8 days)
Physician assessment
(prospective)
Clinical assessment,
screening sonography
and confirmation
phlebography
NR (appears
descriptive)
Kujath et al.,
1993; Germany53
l Design: prospective
open-label RCT
l Setting: outpatient
Aged > 16 years
undergoing conservative
treatment for lower-limb
injury with below-knee
plaster applied for
> 7 days
l n = 253
l 58% male
l Mean age: 34.3 years
a
LMWH group: 4.8%
Control group: 16.5%
No prophylaxis
prior to
randomisation
NR (however, duration of
casting: LMWH group,
15.6 days; control group,
15.8 days)
Physician assessment
(prospective)
Compression
ultrasonography by
two examiners
and confirmation
phlebography
NR (appears
descriptive)
Zheng et al.,
2016; China60
l Design: prospective
double-blind RCT
l Setting: outpatient
Adults aged > 18 years
with any fracture of the
lower limb requiring
operative treatment
l n = 814
l 62.3% male
l Mean age: 47.8 years
LMWH group: 1.5%
Control group: 3.2%
No prophylaxis
prior to
randomisation
3 months Physician assessment
(prospective)
Blinded bilateral
Doppler compression
ultrasonography
Logistic regression
Riou et al., 2007;
France69
l Design: prospective
cohort study
l Setting: outpatient
Aged > 18 years with
isolated lower-limb
injury (below the knee)
managed conservatively
(immobilisation duration
of > 7 days)
l n = 2761
l 51% male
l Mean age: 40 years
6.4% Antithrombotic
prophylaxis was
given to 61% of
patients
3 months Physician assessment
(prospective)
Adjudication
committee
Logistic regression
with propensity
score analysis
Hanslow et al.,
2006; Australia64
l Design: retrospective
cohort study
l Setting: outpatient
Patients who had an
operative intervention to
the foot or ankle
l n = 602
l 52% male
l Mean age: 42.9 years
5.3% Antithrombotic
prophylaxis was
given to 31% of
patients
4.4 months Collected from
clinical records
(retrospectively)
Case note search,
including hospital
reattendance and
diagnostic imaging
Logistic regression
Jameson et al.,
2014; UK66
l Design: retrospective
cohort study
l Setting: outpatient
Patients with isolated
unilateral closed ankle
fracture, managed
conservatively
l n = 14,777
l 47% male
l Mean age: 46.4 years
0.22% (PE only) No data
recorded
3 months NR, assumed to be
collected from
clinical records
(retrospective)
Inpatient mortality or
coded diagnosis of PE
within 90 days of
injury
Logistic regression
continued
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TABLE 4 Summary of design and patient characteristics: review of individual risk factors associated with VTE risk (continued )
Study authors,
year; country Design, setting Inclusion criteria (main)
Patients, sex, age
(years) Incidence of VTE Prophylaxis Duration of follow-up
Risk factor
ascertainment
Outcome
ascertainment
Statistical
analysis
Makhdom et al.,
2013; Canada9
l Design: retrospective
cohort study
l Setting: outpatient
until surgery,
short day-case
stay thereafter
All patients undergoing
Achilles tendon repair
l n = 115
l 86.1% male
l Mean age: 41 years
23.5% No peri- or
post-operative
prophylaxis
3 months Collected from
electronic medical
record system
(retrospectively)
Case note search,
including hospital
reattendance and
diagnostic imaging
Non-parametric
testing using
Fisher’s exact test
Meek and Tong,
2012; Australia11
l Design: retrospective
cohort study
l Setting: outpatient
Aged > 18 years with acute
lower-limb injury requiring
temporary immobilisation
(ED discharge within
24 hours of presentation)
l n = 1231
l 56.3% male
l Mean age: 37 years
2.9% No prophylaxis
(excluded if
received at any
dose)
NR Electronic notes
screened for
eligibility by one
investigator
(retrospective)
Case note search,
including hospital
reattendance and
diagnostic imaging
Logistic regression
Patel et al.,
2012; USA68
l Design: retrospective
cohort study
l Setting: mostly
outpatient, some with
short inpatient stays
(of < 3 days)
All patients who had
Achilles tendon rupture
l n= 1172
l Sex: NR
l Mean age: 45 years
0.77% Nil routine,
assumed to be
none provided
3 months Collected from
electronic medical
record system
(retrospective)
Case note search,
including hospital
reattendance and
diagnostic imaging
Logistic regression
Wahlsten et al.,
2015; Denmark71
l Design: retrospective
cohort study
l Setting: inpatient
or outpatient
Aged > 18 years
undergoing an operative
procedure for a fracture of
the foot, ankle, tibia or
patella
l n = 57,619
l 51.4% male
l Mean age: 52.6 years
a
1.0% Routine
perioperative
prophylaxis
with nil post
operative
prophylaxis
180 days Collected from five
different cross-linked
registries
(retrospective)
Case note search,
including hospital
reattendance and
diagnostic imaging
Multivariate Cox
regression
van Adrichem
et al., 2014; the
Netherlands70
l Design: case–control
study
l Setting: mostly
outpatient, some with
short inpatient stays
(of < 3 days)
l Aged 18–70 years with
a first VTE identified
at an anticoagulation
clinic (cases)
l Control group identified
by random dialling
method (matched for
sex and age)
l n = 10,567
b
l Sex: NR
l Mean age: NR
NR No data
recorded
3 months Participant
completed
questionnaire
(prospective
collection)
Case note search,
including hospital
reattendance and
diagnostic imaging
Logistic regression
Ho and Omari,
2017; Australia65
l Design: cross-
sectional study
l Setting: outpatient
Aged > 18 years with
fracture to foot/ankle with
conservative management
l n = 72
l 45.8% male
l Mean age: NR
(median: 38 years)
11.0% Nil routine,
assumed to be
none provided
6 months Questionnaire
(unclear if physician
or patient completed)
Prospective
compression
ultrasonography
Parametric and
non-parametric
testing with
bootstrapping
Manafi Rasi
et al., 2013;
Iran67
l Design: cross-
sectional study
l Setting: outpatient
Aged > 15 years with
stable foot/ankle fracture
or grade 3 sprain
(non-surgical treatment)
l n = 95
l 77.9% male
l Mean age: 38 years
3.0% NR 7–14 days NR Compression
ultrasonography by
two independent
examiners
NR (appears
descriptive)
NR, not reported.
a Data calculated based on mean of means.
b Sample included 4418 cases and 6149 controls (of these, only 227 cases and 76 controls had lower-extremity injuries).
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Narrative data synthesis
Age was the most consistent individual risk prediction factor, highlighted across 11 studies.9,11,50,52,53,60,65,68–71
ORs reported for age varied from 1.0560 to 3.48,11 with limited estimates of precision. Meta-analysis was not
undertaken owing to limitations in the data reported and concerns about the heterogeneous nature of the
study populations. Injury type was the second most highlighted risk factor across six studies,11,50,52,53,69,70 all
using multivariate logistic regression to suggest that severe traumatic injuries and fractures (when compared
with soft-tissue injuries) were independently associated with VTE. Body mass index (BMI) was the third most
consistent individual risk highlighted, noted as independently predictive of VTE across four studies,53,60,70,71
with ORs ranging from 1.20160 to 17.2.70 Other risk factors were highlighted in fewer than four studies.
Despite being present within several currently used risk stratification tools, pregnancy, recent hospital
admission and preceding immobility prior to injury failed to demonstrate an independent association with
VTE in any of the selected studies. Individual risk factors currently used within risk stratification tools and
their association with VTE across all studies are shown in Table 6.
Other potential risk factors associated with subsequent development of VTE after lower-limb immobilisation
included recent air travel (one study),64 coagulopathy and peripheral arterial disease (one study).71 A single
paper67 looked at the cumulative incidence of risk factors per patient and reported the presence of three or
more factors to be significantly associated with the development of VTE. Methodology of reporting individual
variables to have no association with subsequent VTE was inconsistent and heterogeneous. Six studies
reported no association between sex and VTE in this cohort,11,50,52,65,66,70 five studies reported no association
between exogenous oestrogen use and VTE9,50,52,53,65 and six studies reported no association between
smoking and subsequent VTE.9,50,52,65,69,71 Several papers produced conflicting results; six studies reported
no association between raised BMI and subsequent risk of VTE9,50,52,65,68,69 and one study reported no
association of VTE with increasing age.66 These other identified risk factors and all negative associations are
reported in Table 7.
Bias due to confounding
Bias in selection of participants into study
Bias in measurement of interventions
Bias due to deviations from
intended interventions
Bias due to missing data
Bias in measurement of outcomes
Bias in selection of the reported result
0 10 20 30 40 50 60 70 80 90 100
Risk
Proportion fulfilled (%)
Low
Moderate
Serious
FIGURE 5 ROBINS-I61 risk-of-bias assessment graph: review authors’ judgements about each methodological quality
item across all included studies – review of individual risk factors associated with VTE risk.
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TABLE 5 ROBINS-I48 risk-of-bias assessment summary: review authors’ judgements about each methodological quality item for each included study – review of individual risk
factors associated with VTE risk
Study authors, year
Cause/area of bias
OverallaConfounding
Selection of
participants
into the study
Classification/
measurement
of interventions
Deviations
from intended
interventions Missing data
Measurement
of outcomes
Selection of the
reported result
Gehling et al., 199823 Low Low Moderate Moderate Moderate Moderate Moderate Moderate
Goel et al., 200950 Low Low Low Low Low Low Moderate Moderate
Kock et al., 199552 Low Low Moderate Moderate Low Moderate Moderate Moderate
Kujath et al., 199353 Low Low Moderate Moderate Moderate Moderate Moderate Moderate
Zheng et al., 201660 Low Moderate Low Low Moderate Low Moderate Moderate
Riou et al., 200769 Moderate Moderate Moderate Serious Moderate Moderate Moderate Serious
Hanslow et al., 200664 Moderate Moderate Moderate Serious Moderate Moderate Moderate Serious
Jameson et al., 201466 Moderate Serious Moderate Serious Moderate Moderate Moderate Serious
Makhdom et al., 20139 Serious Serious Moderate Moderate Moderate Moderate Moderate Serious
Meek and Tong, 201211 Moderate Serious Moderate Moderate Moderate Moderate Moderate Serious
Patel et al., 201268 Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate
Wahlsten et al., 201571 Moderate Moderate Moderate Moderate Moderate Moderate Moderate Moderate
van Adrichem et al., 201470 Moderate Serious Serious Serious Moderate Moderate Moderate Serious
Ho and Omari, 201765 Serious Serious Moderate Moderate Serious Moderate Moderate Serious
Manafi Rasi et al., 201367 Serious Moderate Moderate Moderate Moderate Moderate Moderate Serious
a Overall risk-of-bias judgement (equal to the most severe level of bias found in any domain) was: (1) low risk of bias – the study is comparable to a well-performed randomised trial;
(2) moderate risk of bias – the study is sound for a non-randomised study but not comparable to a rigorous randomised trial; (3) serious risk of bias – the study has some important
problems; or (4) critical risk of bias – the study is too problematic to provide any useful evidence on the effects of intervention.
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TABLE 6 Individual risk factors and their reported strength of association with developing VTE
Study
authors, year
Risk factors associated with developing VTE
Permanent (present before episode of lower-limb immobilisation) Transient (during injured period)
Age BMI
Active
cancer Pregnancy Smoking Varicosities
Prior or family
history of VTE
Significant
comorbidity
Known
thrombophilia
Exogenous
oestrogen
therapy
Recent hospital
admission or
surgery
Preceding
immobility
Injury
type
Immobilisation
type
Weight-bearing
status
Using an end point of asymptomatic VTE, detected by routine screening
Gehling et al.,
199823
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Goel et al.,
200950
PSAR
a
NSAR
a
NSAR
a
N/A NSAR
a
N/A N/A NSAR
a
NSAR
a
NSAR
a
N/A N/A PSAR
a
N/A N/A
Kock et al.,
199552
PSAR
b
NSAR
b
N/A N/A NSAR
b
NSAR
b
N/A N/A N/A NSAR
b
N/A N/A PSAR
b
PSAR
b
N/A
Kujath et al.,
199353
PSAR
c
PSAR
c
N/A N/A N/A PSAR
c
N/A N/A N/A N/A N/A N/A PSAR
c
N/A N/A
Zheng et al.,
201660
PSAR
d
PSAR
d
N/A N/A N/A N/A N/A NSAR
d
N/A N/A N/A N/A N/A NSAR
d
N/A
Ho and Omari,
201765
PSAR
e
NSAR
e
N/A N/A NSAR
e
N/A NSAR
e
N/A N/A NSAR
e
N/A N/A N/A NSAR
e
NSAR
e
Manafi Rasi
et al., 201367
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Using an end point of symptomatic VTE, detected by clinical follow-up and targeted investigation
Riou et al.,
200769
PSAR
f
NSAR
f
N/A N/A NSAR
f
NSAR
f
NSAR
f
NSAR
f
N/A NSAR
f
N/A N/A PSAR
f
PSAR
f
PSAR
f
Hanslow et al.,
200664
N/A N/A N/A N/A N/A N/A PSAR
g
PSAR
g
N/A N/A N/A N/A N/A PSAR
g
PSAR
g
Jameson et al.,
201466
NSAR
h
N/A N/A N/A N/A N/A N/A PSAR
h
N/A N/A N/A N/A N/A N/A N/A
Makhdom
et al., 20139
PSAR
i
NSAR
i
N/A N/A NSAR
i
N/A N/A NSAR
i
N/A NSAR
i
N/A N/A N/A N/A N/A
Meek and
Tong, 201211
PSAR
j
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A PSAR
j
NSAR
j
N/A
Patel et al.,
201268
PSAR
k
NSAR
k
N/A N/A N/A N/A NSAR
k
NSAR
k
N/A N/A N/A N/A N/A N/A N/A
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TABLE 6 Individual risk factors and their reported strength of association with developing VTE (continued )
Study
authors, year
Risk factors associated with developing VTE
Permanent (present before episode of lower-limb immobilisation) Transient (during injured period)
Age BMI
Active
cancer Pregnancy Smoking Varicosities
Prior or family
history of VTE
Significant
comorbidity
Known
thrombophilia
Exogenous
oestrogen
therapy
Recent hospital
admission or
surgery
Preceding
immobility
Injury
type
Immobilisation
type
Weight-bearing
status
Wahlsten et al.,
201571
PSAR
l
PSAR
l
PSAR
l
N/A NSAR
l
N/A PSAR
l
N/A N/A PSAR
l
N/A N/A N/A N/A N/A
van Adrichem
et al., 201470
PSAR
m
PSAR
m
N/A N/A N/A N/A N/A N/A PSAR
m
PSAR
m
N/A N/A PSAR
m
N/A N/A
CI, confidence interval; HR, hazard ratio; N/A, no attempt to report or analyse in the published manuscript; NSAR, no significant association reported; PSAR, positive significant association reported.
a Multivariate logistic regression: p= 0.001 for age, p= 0.009 for injury type; otherwise reported as showing no association for the relevant prespecified variables.
b Descriptive statistics: comparison of percentages only, with Fisher’s exact test. It is notable that no patients in the LMWH group had a VTE event.
c Descriptive statistics: comparison of percentages only.
d Binary logistic regression analysis: noting OR 1.050 (95% CI 1.014 to 1.088; p = 0.007) for advancing age and OR 1.201 (95% CI 1.034 to 1.395; p = 0.016) for high BMI, with no evidence of association between comorbidity, immobilisation
type or sex and outcome of VTE detected.
e Direct comparison of percentages using Fisher’s exact test, or continuous variables using independent t-test. p = 0.011 for age, other identified risk factors all failing to reach predefined significance level. It is notable that the size of the analysed
group was 35 patients only.
f Logistic regression technique described, suggesting the following associations: OR 3.14 (95% CI 2.27 to 4.33) for age > 50 years, OR 2.70 (95% CI 1.66 to 4.38) for rigid immobilisation, OR 4.11 (95% CI 1.72 to 9.86) for non-weight-bearing
and OR 1.88 (95% CI 1.34 to 2.62) for severe injury.
g Descriptive statistics, with p-values presented for direct comparisons without mention of a statistical test. Significant comorbidity, prior VTE and weight-bearing status were noted to be associated with VTE development (p= 0.04, 0.02 and 0.003).
Logistic regression also performed, highlighting plaster immobilisation as an independent predictor of risk (no OR presented).
h Logistic regression analysis using univariate and multivariable analysis. OR 11.97 (95% CI 5.14 to 27.87; p< 0.001) reported for a Charlson score of ≥ 1. No significant association of age with subsequent PE on univariate or multivariate analysis.
i Fisher’s exact test used to compare categorical variable. Higher proportional rate of VTE for patients aged > 40 years (p = 0.0026). No significant association seen regarding VTE and categorised BMI, comorbidity and exogenous oestrogen use.
j Multivariable logistic regression: OR 3.48 (95% CI 1.11 to 10.89) for age and OR 0.16 (95% CI 0.03 to 0.80) for soft-tissue injury compared with Achilles repair. No association seen between VTE development and sex, immobilisation type or
length of stay.
k Categorical variables assessed using Fisher’s exact test; age > 40 years deemed to be associated with higher risk (p = 0.016). No association with BMI, comorbidity or prior VTE and no presentation of significant ORs on further multivariable
analysis.
l Multivariable cox regression: HR 1.13 for age, HR 4.15 for exogenous oestrogens, HR 6.27 (95% CI 4.18 to 9.40) for prior VTE, HR 1.65 (95% CI 1.12 to 2.42) for active cancer and HR 2.68 (95% CI 1.66 to 4.33) for increased BMI.
m Adjusted ORs reported following binary logistic regression: OR 12.7 (95% CI 6.6 to 24.6) for traumatic indication (vs. non-traumatic), OR 18.2 (95% CI 6.2 to 53.4) for oral contraceptive use, OR 17.2 (95% CI 5.4 to 55.2) for obesity and OR
23.0 (95% CI 11.5 to 44.6) for known thrombophilia.
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TABLE 7 Other identified individual risk factors and their association with developing VTE
Study authors, year
Other risk factors shown to be associated
with VTE
Risk factors shown to have no
association with VTE Other key findings/author conclusions
Gehling et al., 199823 NR Unable to demonstrate association between
cumulative risk factors and thrombosis
Non-relevant
Goel et al., 200950 NR l Sex
l Comorbidities
l BMI
Given the overall number of fractures, it is difficult to
define a specific type as increasing the risk for DVT, but
those fractures of the tibial plateau did display a tendency
towards higher rates of DVT in the study
Kock et al., 199552 NR l Sex
l Exogenous oestrogen
l BMI
Treatment procedures involving less immobilisation should
be used whenever possible
Kujath et al., 199353 NR l Smoking
l Prior VTE
l Exogenous oestrogen
The patients who did not develop a thrombosis had an
average of 1.24 risk factors, whereas the patients with
thrombosis had an average of 1.96 risk factors. The
patients who suffered a thrombosis despite prophylaxis
had 2.7 risk factors
Zheng et al., 201660 NR NR The study was not statistically powered to properly cull out
any additional potential risk factors that might affect VTE
incidence in this population
Riou et al., 200769 Non-weight-bearing status (OR 4.11, 95% CI
1.72 to 9.86)
No association seen on multivariate
regression with:
l VTE development and cancer
l Exogenous oestrogen and comorbidity
Owing to a very low incidence of certain variables (e.g.
cancer, severe diseases and hormonal treatment), the
power of the study was not sufficient to identify their roles
as potential risk factors. Because the incidence of obesity
was not high in the study population, the results may not
apply to morbidly obese patients
Hanslow et al., 200664 l Air travel (multivariate logistic regression)
l History of rheumatoid arthritis (multivariate
logistic regression)
Tourniquet use and mode of anaesthesia
for those undergoing operative intervention
The incidence of thromboembolic disease after foot
and ankle surgery could be higher than that previously
reported, particularly if a patient has certain risk factors
Jameson et al., 201466 Charlson score of ≥ 1 gives OR 11.97 (95% CI
5.14 to 27.87; p < 0.001)
l Age
l Sex
Comorbidities elevate the risk of PE and these data can be
utilised by clinicians when considering whether or not to
prescribe LMWH for VTE prophylaxis with the attendant
risks of the therapy itself borne in mind
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TABLE 7 Other identified individual risk factors and their association with developing VTE (continued )
Study authors, year
Other risk factors shown to be associated
with VTE
Risk factors shown to have no
association with VTE Other key findings/author conclusions
Makhdom et al., 20139 NR l Smoking
l BMI
l Exogenous oestrogen use
l Steroid use
Patient education is necessary regarding anticipated
complications, and early mobilisation should be advocated,
especially for patients aged > 40 years
Meek and Tong, 201211 Achilles tendon rupture (descriptive) l Sex
l Soft-tissue injury
l Method of immobilisation
l ED length of stay
l Surgical intervention
Increasing age and a diagnosis of Achilles tendon rupture
appeared to increase the risk of VTE
Patel et al., 201268 NR l Age
l Comorbidity
l Previous VTE
l BMI
l Operative intervention
Congestive heart failure, history of DVT or PE, and obesity
might be risk factors, but perhaps the study did not have
an adequate number of patients to show this difference
Wahlsten et al., 201571 l Coagulopathy (HR 2.47, 95% CI 1.1 to 5.7)
l Peripheral arterial disease (HR 2.34, 95% CI
1.2 to 4.6)
l Non-steroidal anti-inflammatory drugs use
(HR 1.3, 95% CI 1.1 to 1.6)
l Smoking
l Statin therapy and use of ACE inhibitor
medications appeared to convey a
protective effect, with HRs of 0.8 and
0.6, respectively
Patients with risk factors, especially previous DVT or PE,
use of oral contraceptives and mobid obesity, have an
increased risk of DVT/PE that exceeds the risk of DVT/PE in
healthy patients undergoing total hip or knee replacement
van Adrichem et al., 201470 The presence of two or more acquired or
genetic risk factors in patients with below-knee
cast immobilisation produced an OR of 43.4
(95% CI 13.4 to 141.0)
Sex Patients with below-knee cast immobilisation have a
substantially increased risk of venous thrombosis, namely a
56-fold increased risk, compared with patients with no
cast, corresponding to an estimated incidence of 1% in the
first 3 months after cast application
Ho and Omari, 201765 Subsequent presentation with symptoms
suggestive of DVT (p = 0.006)
l Sex
l BMI
l Type of injury
l Type of immobilisation
l Weight-bearing status
l Smoking
l Exogenous oestrogen use
l Family history of VTE
This pilot study unveiled limitations and logistical issues to
be addressed in the future. Notably, the limitations include
the small number of patients and the low adherence to
attending ultrasonography assessment
Manafi Rasi et al., 201367 Cumulative number of risk factors: presence of
≥ 3 risk factors reported as being significantly
associated with VTE development (p = 0.01)
NR The incidence of DVT significantly increased in the
presence of ≥ 3 risk factors (p = 0.01)
ACE, angiotensin-converting enzyme; CI, confidence interval; HR, hazard ratio; NR, not reported or analysed.
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Summary of key findings
l Increasing age and injury severity were the most consistent risk factors associated with the development
of VTE in patients with lower-limb injury and temporary immobilisation.
l Many clinical features considered to be risk factors for VTE were not examined or associated with VTE
in the studies.
l All studies included in the review were deemed to be at moderate or serious risk of bias.
l The evidence base for tailored risk prediction in people with lower-limb immobilisation due to injury is
very weak.
Review of risk assessment models for predicting venous
thromboembolic risk
Objective
The objective was to identify RAMs that predict the risk of VTE in ambulatory trauma patients with
temporary immobilisation following lower-limb injury.
Methods of reviewing effectiveness
Identification of studies
Studies were identified by searching the following electronic databases and research registers:
l Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily, MEDLINE and Versions(R) (via OvidSP), 1946 to May 2017.
l EMBASE (via OvidSP), 1974 to May 2017.
l Cochrane Database of Systematic Reviews (via Wiley Online Library), 1996 to May 2017.
l Database of Abstracts of Review of Effects (via Wiley Online Library), 1995 to March 2015.
l Cochrane Central Register of Controlled Trials (via Wiley Online Library), 1898 to May 2017.
l HTA database (via Wiley Online Library), 1995 to May 2017.
l NHS EED (via Wiley Online Library), 1995 to March 2015.
l Science Citation Index Expanded (via Web of Science), 1900 to May 2017.
l ClinicalTrials.gov (via US National Institutes of Health), 2000 to May 2017.
l International Clinical Trials Registry Platform (via Word Health Organization), 1990 to May 2017.
The search strategy used free text and thesaurus terms and combined synonyms relating to the condition
(i.e. VTE in people with lower-limb immobilisation) with risk factor assessment or risk prediction modelling
terms (used in the searches of MEDLINE, The Cochrane Library and EMBASE only). No language or date
restrictions were used on any database. Further details on the search strategy can be found in Appendix 5.
Searches were supplemented by hand-searching the reference lists of all relevant studies (including existing
systematic reviews), performing a citation search of relevant articles, contacting key experts in the field and
undertaking systematic keyword searches of the World Wide Web using the Google search engine.
All identified citations from the electronic searches and other resources were imported into and managed
using EndNote bibliographic software.
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were
examined for inclusion by one reviewer (AP) and any citations that clearly did not meet the inclusion
criteria (e.g. non-human, unrelated to VTE) were excluded. Second, all abstracts and full-text articles were
then examined independently by two reviewers (AP and DH). When necessary, non-English-language
studies were translated using Google Translate to facilitate study selection and subsequent data extraction.
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Any disagreements in the selection process were resolved through discussion or, if necessary, arbitration
by a third reviewer (SG), and articles were included by consensus.
Studies were considered eligible for inclusion if they met the following criteria: (1) any study design that
included a measurement of VTE patient outcome, (2) studies that recruited adults (aged > 16 years) who
required temporary immobilisation (e.g. leg cast or brace in an ambulatory setting) for an isolated lower-
limb injury and (3) any studies that reported any validation, or estimates of utility and performance of VTE
risk assessment models for people with lower-limb cast immobilisation.
Data abstraction and quality assessment strategy
Data relating to study design, methodological quality and outcomes were extracted by one reviewer (AP)
into a standardised data extraction form and independently checked for accuracy by a second reviewer
(DH). Any discrepancies were resolved through discussion or, if necessary, arbitration by a third reviewer
(SG) and included by consensus. When multiple publications of the same study were identified, data were
extracted and reported as a single study.
There are no validated (or widely agreed on) tools for the assessment of prognosis research studies
and there is little empirical evidence to support the importance of particular study features affecting
the reliability of findings, including the avoidance of bias.75 For this review, a generic list of important
methodological features recommended by Altman76 and Moons et al.77 for prediction modelling studies
was deemed to be the most appropriate (i.e. useful) to assess the internal validity of the included studies.
In general, five domains were considered important for assessing biases sufficiently large to distort the
findings of prognosis research. These included (1) participant selection, (2) predictor assessment, (3) outcome
assessment, (4) sample size and missing data and (5) statistical analysis. An overall judgement of bias was
assigned as ‘low risk’ if all domains were judged as low risk, as ‘high risk’ if at least one domain was judged
to be at high risk and as ‘unclear risk’ if an unclear risk of bias was noted in at least one domain and it
was ‘low risk’ for all other domains. The methodological quality of each included study was independently
evaluated by two reviewers (AP and DH). Any discrepancies were resolved through discussion or, if necessary,
through the involvement of a third reviewer (SG). Blinding of the quality assessor to author, institution or
journal was not considered necessary.
Methods of data synthesis and analysis
Venous thromboembolism was considered to comprise any subsequent recorded diagnosis of DVT,
PE or death attributable to either pathology. No attempt was made to distinguish between anatomical
location, thrombus burden or clinical sequelae of VTE for this project, in accordance with the definitions
of hospital-acquired thrombosis produced by NHS England.63 A narrative review of all identified scoring
systems was performed, to compare design characteristics with thresholds for prophylaxis. Estimates of
sensitivity, specificity, predictive values or likelihood ratios were directly extracted from validation studies or
retrospectively calculated using available baseline data when applicable. All analyses were conducted using
Microsoft Excel 2010.
Results
Quantity and quality of research available
The literature searches identified 4771 citations. In total, only six studies32,78–82 met the inclusion criteria.
Of these, one paper32 focused on prediction model development with external validation in independent
data. The remaining papers focused on external model validation without model updating.78–82 A flow
chart describing the process of identifying relevant literature is given in Figure 6. A total of 69 full-text
articles were excluded as they did not meet all of the prespecified inclusion criteria. The majority of the
articles were excluded on the basis of inappropriate target population (i.e. not isolated lower-limb injury
requiring temporary immobilisation), having no relevant RAMs or outcome evaluations and being an
unsuitable publication type (i.e. reviews, commentaries, editorial or abstracts of included full-text papers).
A full list of excluded studies with reasons for exclusion is presented in Appendix 7.
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Description of included studies (design and patient characteristics)
Study characteristics are described in Table 8. Two case–control studies32,82 and four observational
studies78–81 that described the evaluation of seven RAMs were found. A single study32 presented data on
derivation and validation; this study used a generic thrombosis database (including all acute thrombosis
patients seen in an outpatient clinic matched with partner controls) to derive a new rule, rather than a
relevant cohort of patients with temporary lower-limb immobilisation. All other papers looked to provide
measures of external validation or implementation metrics regarding previously derived scores, with no
description of the initial derivation methodology.
Records identified through
database searching
(n = 4703)
Additional records identified
through other sources
(n = 68)
Full-text articles
(references) assessed
for eligibility
(n = 75)
Records screened by title
(n = 4771)
Excluded by title
(n = 4379) 
Excluded by abstract
(n = 317)
Full-text articles included
(n = 6, studies)
Records screened by
abstract
(n = 392)
Full-text articles excluded,
with reasons
(n = 69)
• Population not isolated
   lower-limb injury
   requiring temporary
   immobilisation, n = 13
• No prognostic/risk
   assessment model, n = 37
• Review/comment/editorial,
   n = 8
• No outcome evaluation
   of risk assessment model,
   n = 9
• Abstract of an included
   full-text paper, n = 1
• Not available, n = 1
Studies included in
qualitative synthesis
(n = 6, studies)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 0, studies)
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FIGURE 6 Study flow chart (adapted):37 review of RAMs that predict the risk of VTE. © 2009 Moher et al. This is an
open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are
credited.
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TABLE 8 Summary of key characteristics of RAM studies that predict the risk of VTE
Authors,
year Study objective/type Source of data
Recruitment
method Study dates
Setting,
country Eligibility criteria
Study
population
Nemeth
et al.,
201532
l Develop and validate
a clinical prediction
score for VTE after
cast immobilisation
of the lower leg
l Prediction model
development with
external validation in
independent data
Case–control
study
Consecutive
recruitment
1 March 1999
to 31 August
2004
Six clinics, the
Netherlands
Patients aged 18–70 years
with a first DVT, PE or both.
Control group consisted of
partners of participating
patients or individuals
identified via random digit
dialling (controls were
frequency matched to
cases with respect to sex
and age). Information on
thromboprophylaxis use
during plaster cast
immobilisation was missing
l Derivation:
n = 10,564
a
l Validation
1: n= 1307
a
l Validation 2:
n = 4205
a
Watson
et al.,
201682
l Evaluate the
performance
of VTE RAMs for
lower-limb cast
immobilisation
l External model
validation without
model updating
Case–control
study
Consecutive
recruitment
1 November
2010 to
31 May 2011
Single centre
(fracture clinic),
Wales
Patients aged 19–75 years
with lower-limb casts who
developed symptomatic VTE
(confirmed by Doppler
ultrasonography, CT pulmonary
angiography or a pulmonary
V/Q scan within 5 months of
application of cast). Control
group consisted of patients
(case matched to age, sex and
injury) who were treated with
casts during the same date
range, but did not develop
symptomatic VTE. Routine
thromboprophylaxis
was not used
Validation:
n = 42
Saragas
et al.,
201781
l Evaluate a thrombosis
risk assessment form
on incidence of VTE
in an external
population
l External model
validation without
updating
Prospective cohort
study without
control
Consecutive
recruitment
March 2014 to
April 2015
NR, South
Africa
All patients aged > 18 years
who underwent foot and
ankle surgery requiring the
combination of below-knee
immobilisation in a cast and
non-weight bearing for
≥ 4 weeks. Patients who were
already on anticoagulants or
had previously had a DVT
were excluded
Validation:
n = 142
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Outcome to be
predicted
Candidate
predictors
Sample size
(events) Missing data
Model
development
Model
performance
Model
evaluation
Results (key
comparisons)
l Accuracy in
diagnosing VTE
(DVT or PE was
confirmed by
Doppler
ultrasonography,
a V/Q scan,
angiography or
a spiral CT scan)
after cast
immobilisation
of the lower
extremity
l Outcome
assessment
blinding NR
l 54 candidate
predictors
(mix of
environmental
risk factors,
genetic risk
factors and
biomarkers)
l Predictor
assessment at
presentation
to clinic
l 4446 patients
with first VTE
(plaster cast
subpopulation,
n= 194 cases)
l The number
of events per
variable
(candidate
predictor):
82.3 (4446/54)
Multiple
imputation
was used
to complete
missing predictor
values
Modelling method:
logistic regression
Predictor selection:
full model
(32 predictors),
forward selection
procedure, and if
p≤ 0.25 in the
univariate analysis of
all participants or a
well-established
association with VTE
Restricted model
(11 predictors)
and clinical model
(14 environmental
predictors) also
developed. Based
on the regression
coefficients in the
clinical logistic
regression model,
L-TRiP(cast) score
developed for plaster
cast patients
Shrinkage of predictor
weight or regression
coefficient: NR
l Discrimination:
an AUC
(c-statistic) was
calculated by
means of a
ROC curve
analysis, based
on the
predictions
from the
multiple
logistic
regression
models
l Calibration: NR
l Classification
measures:
the sensitivity,
specificity,
positive and
negative
predictive
values, and
positive and
negative
likelihood
ratios were
calculated
Internal
validation:
test set for
derivation
and two
separate
validation
data sets
Comparison of
sensitivity, specificity,
positive and negative
predictive values,
and positive and
negative likelihood
ratios
l Accuracy of each
RAM in assessing
a patient’s VTE
risk after cast
immobilisation
of the lower
extremity
l Outcome
assessment
blinding NR
l Validation:
2 models
(Roberts et al.17
and Keenan
et al.31).
Completion
of a risk
assessment
form on
demographics,
patient history
and clinical
examination
l Predictor
assessment in
retrospect (i.e.
retrospective
review of
individual
patient
hospital and
GP notes)
21 symptomatic
VTE cases
NR Modelling method:
NA
Predictor selection:
Roberts et al.17
11 predictor variables
(environmental
factors with a
well-established
association with
the occurrence
of VTE in the
literature); Keenan
et al.31 14 predictor
variables (no details
provided)
Shrinkage of predictor
weight or regression
coefficient: NA
Discrimination,
calibration,
classification
measures: NR
No
recalibration;
no adjustment
or update
Comparison of
sensitivity, specificity
and positive and
negative predictive
values
l Development
of a clinically
evident DVT,
as confirmed by
compression
ultrasonography
or a V/Q lung
scan in the case
of PE
l Outcome
assessment
blinding NR
l Validation:
1 model.
Completion
of a risk
assessment
form on
demographics,
patient history
and clinical
examination
l Predictor
assessment
before surgery
Three DVT cases
(2.1%)
NR Modelling method:
NA
Predictor selection:
36 risk factors
(no details provided
on how these were
selected/derived)
Shrinkage of predictor
weight or regression
coefficient: NA
Discrimination,
calibration,
classification
measures: NR
No
recalibration;
no
adjustment
or update
Incidence of VTE
following
prophylactic
anticoagulation for
4–6 weeks, namely
until non-weight
bearing or cast
removal, whichever
came first (non-
comparative study)
continued
DOI: 10.3310/hta23630 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 63
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
TABLE 8 Summary of key characteristics of RAM studies that predict the risk of VTE (continued )
Authors,
year Study objective/type Source of data
Recruitment
method Study dates
Setting,
country Eligibility criteria
Study
population
Haque
et al.,
201680
l Evaluate a risk scoring
system on incidence
of VTE in an external
population
l External model
validation without
updating
Prospective cohort
study without
control
Consecutive
recruitment
NR Single centre,
UK
Patients aged ≥ 18 years
with isolated foot and
ankle fractures who were
treated non-operatively and
immobilised in a plaster cast
(weight bearing as well as
non-weight bearing) and
managed as outpatients.
Patients were excluded if
they had a known bleeding
disorder, renal disorder,
multiple injury/polytrauma,
complex pilon fracture or if
they had a known allergy
to LMWH (minimum of
6 months following injury)
Validation:
n= 150
Giannadakis
et al.,
200079
l Evaluate risk of
thrombosis using a
checklist on incidence
of DVT in an
external population
l External model
validation without
updating
Prospective cohort
study without
control
NR March 1994 to
March 1996
Single centre,
Germany
Selected patients (aged
> 16 years) with minor lower-
limb injuries and at low
risk of DVT, who required
cast immobilising and
did not receive medical
thromboprophylaxis,
were included. Patients
who required medical
thromboprophylaxis were
excluded
Validation:
n= 178
Eingartner
et al., 199578
l Evaluate risk of
thrombosis using a
patient questionnaire
and a scoring system
on incidence of
thrombosis in an
external population
l External model
validation without
updating
NR NR July 1993 to
February 1994
Single centre,
Germany
Outpatients with an
immobilising cast of a
lower-limb after an injury
Validation:
n= 305
AUC, area under the curve; CT, computerised tomography; CTPA, computerised tomography pulmonary angiography; GP, general practitioner;
L-TRIP(cast), Leiden Thrombosis Risk in Plaster(cast); NA, not applicable; NR, not reported; ROC, receiver operating characteristic; V/Q, ventilation/perfusion.
a Derivation: cases, n= 4446 with first VTE; control, n= 6118 (plaster cast subpopulation: cases, n = 194; control, n = 36); validation 1 – the THE-VTE study83
(a two-centre population-based case–control study from the Netherlands and UK, study dates, March 2003 to December 2008) n= 784 with first VTE,
control, n = 523 (plaster cast subpopulation: cases, n = 32; control, n= 7); the Milan study84 (a single-centre population-based case–control study from
Italy, study dates December 1993 to December 2010) n= 2117 with first VTE, control, n = 2088 (plaster cast subpopulation: cases, n = 143; control, n = 8).
Outcome to be
predicted
Candidate
predictors
Sample size
(events) Missing data
Model
development
Model
performance
Model
evaluation
Results (key
comparisons)
l Risk of VTEs
(hospital records
searched for
radiological
reports of
ultrasonography
and CTPA for
symptomatic
VTEs during
the period
of plaster cast
immobilisation)
l Outcome
assessment
blinding NR
l Validation:
1 model.
Patient-
completed
questionnaire
on
demographics,
patient history
and clinical
examination
l Predictor
assessment at
presentation to
fracture clinic
Three symptomatic
VTE (two distal
DVT’s and one PE)
cases (2.0%)
NR Modelling method:
NA
Predictor selection:
14 predictor variables
(consensus selection
of predictors from
NICE guidelines24
and GEMNet,17 which
focuses on patients
managed as
outpatients, with an
arbitrary cut-off
point)
Shrinkage of
predictor weight or
regression coefficient:
NA
Discrimination,
calibration,
classification
measures: NR
No
recalibration;
no adjustment
or update
Incidence of VTE in
those considered to
be at high risk, namely
with a score of ≥ 3
(non-comparative
study)
l Risk of DVT
(a clinical
examination and a
colour-coded
duplex sonography
were performed
after the removal
of the cast for
detection of DVT
of the lower limb.
A phlebography
was performed
when thrombosis
was suspected)
l Outcome
assessment
blinding NR
l Validation:
1 model.
Completion
of a risk
assessment
form on
demographics,
patient history
and clinical
examination
l Predictor
assessment at
presentation to
trauma clinic
Two DVT cases
(1.1%)
NR Modelling method:
NA
Predictor selection:
12 predictor variables
(no details provided
on how these were
selected/derived)
Shrinkage of
predictor weight
or regression
coefficient: NA
Discrimination,
calibration,
classification
measures: NR
No
recalibration;
no adjustment
or update
Incidence of
thrombosis in
low-risk patients
who received no
thromboprophylaxis,
namely no risk
factors (non-
comparative study)
l Risk of
thrombosis
l Outcome
assessment
blinding NR
l Validation:
1 model.
Patient-
completed
questionnaire
on
demographics,
patient history
and clinical
examination
l Predictor
assessment at
presentation
to clinic
No VTE events NR Modelling method:
NA
Predictor selection:
nine predictor
variables (no details
provided on how
these were selected/
derived)
Shrinkage of
predictor weight or
regression coefficient:
NA
Discrimination,
calibration,
classification
measures: NR
No
recalibration;
no adjustment
or update
Incidence of
thrombosis (non-
comparative study)
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The seven identified RAMs varied in design, structure, output and threshold for prophylaxis. Several scores
were dichotomous, with others providing ordinal measure of risk. Design characteristics and threshold
levels for each RAM are presented for comparison in Table 9. The majority of RAMs focused solely on the
estimate of thromboembolic risk; a single method featured characteristics designed to balance the risk
of bleeding with thromboprophylaxis.17 The individual predictors and their weighting varied markedly
between RAMs. Variables (and their definitions) for each RAM are presented for comparison in Table 10.
Quality characteristics
The overall methodological quality of the six included studies is summarised in Figure 7 and Table 11.
The majority of studies were deemed to be at high risk of bias,32,78,79,81,82 based primarily on participant
selection; all reviewed studies attempted validation of proposed decision rules in heterogeneous cohorts,
with pragmatic observational follow-up only. Outcomes were also non-standardised and varied by site in
terms of description and inclusion.
Both case–control studies32,82 had specific and notable limitations in methodology. The larger study, by
Nemeth et al.,32 used three distinct generic thrombosis data sets to derive and validate the proposed RAM.
As such, the tool is derived from a group of patients with unprovoked or hospital-acquired VTE and has
limited potential generalisability to the cohort of interest in this study. The authors looked at a subgroup of
patients with temporary lower-limb immobilisation within the study data, finding only a small proportion in
whom to attempt validation (230 patients, 2% of the original derivation data set). The smaller study, by
Watson et al.,82 derived case–control data using an equal measure of appropriate patients with thrombosis
following cast immobilisation, alongside a separate cohort of those without. As such, the prevalence
of thrombosis within this study cohort was 50%. This is 20 times the estimated prevalence within the
literature and, therefore, renders their estimates of predictive value at high risk of error.
Narrative data synthesis
The study by Nemeth et al.32 derived and validated a clinical risk score for plaster cast patients: the Leiden
thrombosis risk in plaster (cast) [L-TRiP(cast)] score. In this study,32 data from a large population-based
case–control study of approximately 10,000 patients (4446 consecutive patients with a first episode of
venous thrombosis and 6118 controls) were used in developing the model (included in patients with
TABLE 9 Summary of design characteristics and threshold levels of identified RAMs
Risk
assessment
model
Acronym/
descriptor Derivation Design
Incorporation
of bleeding
risk?
Number of
variables
Threshold
(suggested
cut-off point)
Attempted
validation?
Roberts et al.17 The GEMNet
guideline
EC Dichotomous Yes 11 N/A Yes
Keenan et al.31 The Plymouth
Rule
EC Ordinal No 14 > 2 Yes
Nemeth et al.32 The L-TRiP(cast)
score
Regression Ordinal No 14 > 8 Yes
Saragas et al.81 The modified
Caprini score
EC Ordinal No 36 > 1 No
Eingartner
et al.78
N/A EC Ordinal No 9 > 1 No
Haque et al.80 N/A EC Ordinal No 14 > 2 No
Giannadakis
et al.79
N/A EC Dichotomous No 12 N/A No
EC, expert consensus; GEMNet, Guidelines in Emergency Medicine Network; L-TRIP(cast), Leiden Thrombosis Risk in Plaster
(cast); N/A, not applicable.
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TABLE 10 Summary of predictor variables included in studies of RAMs that predict the risk of VTE
Variable
Study authors, year
Nemeth et al., 201532
L-TRiP(cast)
Watson et al., 201682
Saragas et al., 201781 Haque et al., 201680 Giannadakis et al., 200079 Eingartner et al., 199578Keenan et al., 200931 Roberts et al., 201317
Brief details of RAMs VTE risk scoring model for
thromboprophylaxis in
patients after cast
immobilisation of the lower
extremity (14 clinical
predictor variables)
VTE risk scoring model
for thromboprophylaxis
in patients after
lower-limb cast/boot
immobilisation
[14 clinical predictor
variables (patient
completed)]
VTE risk assessment for
thromboprophylaxis in
ambulatory trauma patients
requiring temporary
lower-limb plaster cast
immobilisation after acute
severe injury (11 clinical
predictor variables)
Thrombosis risk factor
assessment in foot and
ankle surgery patients
requiring below-knee
cast immobilisation and
non-weight bearing for
≥ 4 weeks (36 predictor
variables)
VTE risk scoring model
for thromboprophylaxis
in patients requiring lower-
limb immobilisation [14
clinical predictor variables
(patient completed)]
Checklist for pharmacological
thromboprophylaxis for
outpatients who required
cast immobilisation after
lower-limb injury (12 clinical
predictor variables)
VTE risk scoring system for
thromboprophylaxis in
patient with lower-limb
immobilisation [9 clinical
predictor variables
(patient completed)]
Predictor variables included in RAMs
Age Yes (≥ 35 and < 55 years;
≥ 55 years)
Yes (≥ 60 years) Yes (> 60 years) Yes (≥ 41 years) Yes (≥ 60 years) Yes (> 40 years) Yes (> 60 years)
Sex Yes (male sex) – – – – – –
Overweight/obese Yes (BMI of ≥ 25 kg/m2 and
< 35 kg/m2; ≥ 35 kg/m2)
Yes (very overweight,
BMI of ≥ 30 kg/m2)
Yes (BMI of ≥ 30 kg/m2) Yes (BMI of > 25 kg/m2) Yes (BMI of ≥ 30 kg/m2) Yes (Broca Index of > 20%) Yes (overweight, > 100 kg)
Cancer Yes (within previous 5 years) Yes (active) Yes (active) Yes (malignancy present
or previous)
Yes (active or cancer
treatment including
tamoxifen and raloxifen)
Yes (malignancies) Yes (ongoing malignancy)
Pregnancy or
puerperium
Yes Yes Yes Yes (including history of
unexplained stillborn
infant, recurrent
spontaneous abortion,
premature birth with
toxaemia or growth-
restricted infant)
Yes – –
Smoking – – Yes (active) – – Yes (> 20 cigarettes per day) Yes (active)
Varicosities Yes (superficial vein
thrombosis)
Yes (varicose veins) Yes (extensive varicosities) Yes (varicose veins, large) Yes (varicose veins) Yes (varicose veins) Yes (varicose veins even
after varicose vein surgery)
Prior or family history
of VTE
Yes [family history
(first-degree relative)]
Yes [family history
(brother, sister, father,
mother) or personal
history of DVT/PE]
Yes (personal history or
first-degree relative)
Yes (personal history of
DVT/PE, family history of
thrombosis)
Yes [personal or family
history (brother, sister,
father, mother, child) of
blood clot in leg or lung]
Yes (personal history of previous
thrombosis/PE, family history of
thrombosis/PE)
Yes (personal history of
previous DVT/PE)
continued
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TABLE 10 Summary of predictor variables included in studies of RAMs that predict the risk of VTE (continued )
Variable
Study authors, year
Nemeth et al., 201532
L-TRiP(cast)
Watson et al., 201682
Saragas et al., 201781 Haque et al., 201680 Giannadakis et al., 200079 Eingartner et al., 199578Keenan et al., 200931 Roberts et al., 201317
Significant
comorbidity
Yes (rheumatoid arthritis,
chronic kidney disease,
COPD, multiple sclerosis)
Yes (heart disease, lung
disease, bowel disease,
hormone disease or
other long-term medical
condition requiring
treatment)
Yes (any serious medical
comorbidity including
cardiac failure, COPD,
chronic renal failure or
inflammatory bowel
disease)
Yes (history of
inflammatory bowel
disease, acute MI, CHF for
< 1 month, COPD, stroke
with lower-extremity
weakness for < 1 month)
Yes (active heart, lung,
bowel or joint disease)
Yes (diabetes mellitus, CHD) Yes (history of
cardiovascular disease,
including arterial
hypertension)
Known
thrombophilia
– – Yes Yes (positive factor V
Leiden, positive
prothrombin G20210 A,
other congenital or
acquired thrombophilia)
Yes (thrombophilia
associated with increased
risk of blood clots)
Exogenous
oestrogen therapy
Yes (oral contraceptives) Yes (oral contraceptive
pill or HRT)
Yes [hormone therapy
(combined oral
contraceptive pill/HRT/
tamoxifen)]
Yes (oral contraceptives or
HRT)
Yes (on HRT or taking
oestrogen-containing
contraceptive)
Yes (contraception use) Yes (oral contraceptives)
Hospital admission
or surgery
Yes (hospital admission or
surgery within the previous
3 months)
Yes (abdominal surgery
in previous 6 weeks)
Yes (any recent hospital
admission/major surgery)
Yes (minor surgery
planned, major surgery
< 1 month previously,
major surgery > 45 minutes
previously, arthroscopic
surgery, elective major
lower-extremity
arthroplasty)
Yes (hospital admission
within the previous
6 weeks, including lower-
limb surgery)
– Yes (lower-limb, pelvic or
lower-abdominal surgery
over the previous 6 months)
Preceding immobility Yes (bedridden within
previous 3 months)
Yes (unable to walk
before accident/injury)
– Yes [medical patient
currently at bed rest,
patient confined to bed
(> 72 hours)]
– – –
Injury type – Yes (Achilles tendon
rupture)
– Yes [hip, pelvis or leg
fracture of < 1 month,
acute spinal-cord injury
(paralysis) of < 1 month]
Yes (Achilles tendon
rupture)
Yes (soft-tissue injury of
higher than grade 1)
–
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Variable
Study authors, year
Nemeth et al., 201532
L-TRiP(cast)
Watson et al., 201682
Saragas et al., 201781 Haque et al., 201680 Giannadakis et al., 200079 Eingartner et al., 199578Keenan et al., 200931 Roberts et al., 201317
Immobilisation type Yes (plaster cast: complete
leg, circular knee cast –
ankle free, foot, lower leg)
– – Yes (immobilising plaster
cast for < 1 month)
Yes (plaster cast extending
above the knee)
Yes (thigh bandage) –
Pneumonia Yes – – Yes (serious lung disease
including pneumonia
< 1 month)
– – –
Travel – – – – Yes [continuous travel of
≥ 3 hours (road, rail or air
travel) in the previous
4 weeks or needing to travel
while wearing plaster cast]
– –
Swollen legs – – – Yes (current) – – –
Sepsis – – – Yes (occurred < 1 month
previously)
– – –
Central venous
access
– – – Yes – – –
Antiphospholipid
antibodies
– – – Yes (positive lupus
anticoagulant, elevated
anticardiolipin antibodies)
– – –
Multiple trauma – – – Yes (multiple trauma
occurring < 1 month
previously)
– – –
CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HRT, hormone replacement therapy; MI, myocardial infarction.
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disease and many other confounding factors). After minimising the variables in an attempt to produce a
clinical (14 environmental predictor variables) and pragmatic rule (11 predictor variables), the authors
validated this rule in two subsequent VTE case–control data sets.
Watson et al.82 assessed the diagnostic accuracy of five RAMs (only two of these, the GEMNet model17
and the Plymouth model,31 were specific to patients with lower-limb trauma and cast immobilisation)
in a case–control study of 42 patients with lower-limb immobilisation following injury (21 cases and
21 controls). The reported sensitivity and specificity of the GEMNet model (85.7% and 47.6%, respectively)
did not seem to be compatible with the numbers of cases and controls, so contact was made with the
authors for clarification. They identified an error in the sensitivity, which should have been reported as
4.76%, and provided the raw numbers for both RAMs, which were used to calculate all diagnostic
parameters and confidence intervals (CIs).
0 10 20 30 40 50 60 70 80 90 100
Risk
Participant selection
Predictor assessment
Outcome assessment
Sample size and missing data
Statistical analysis
Proportion fulfilled (%)
Low
Unclear
High
FIGURE 7 Risk-of-bias assessment graph:76,77 review authors’ judgements about each methodological quality item
across all included studies in the review of RAMs that predict the risk of VTE.
TABLE 11 Risk-of-bias assessment summary:76,77 review authors’ judgements about each methodological quality
item for each included study in the review of RAMs that predict the risk of VTE
Study author, year
Participant
selection
Predictor
assessment
Outcome
assessment
Sample size and
missing data
Statistical
analysis Overalla
Nemeth et al., 201532 High Unclear Unclear Low Low High
Watson et al., 201682 High High Unclear Unclear Low High
Saragas et al., 201781 High Unclear Unclear Unclear Unclear High
Haque et al., 201680 Low Unclear Unclear Unclear Unclear Unclear
Giannadakis et al., 200079 High Unclear Unclear Unclear Unclear High
Eingartner et al., 199578 High Unclear Unclear Unclear Unclear High
a Overall risk-of-bias judgement (equal to the most severe level of bias found in any domain) was judged as: (1) low risk of
bias – the study is judged to be at low risk of bias for all domains for this result, (2) high risk of bias – the study is judged
to be at high risk of bias in at least one domain for this result, (3) unclear – the study is judged to have unclear risk of bias
in at least one domain for this result.
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Prognostic accuracy measures for the three scores evaluated in these two studies are presented in
Table 12. Sensitivity ranged from 57.1% to 92.6% across the RAMs and specificity ranged from 4.76%
to 60.8%. The L-TRiP(cast) data are displayed in this table using thresholds denoting optimal performance
and to allow direct comparison with other validated scores. The estimates of positive and negative
predictive value for the L-TRiP(cast) score were modelled using an appropriately low prevalence of VTE,
whereas the estimates for the GEMNet and Plymouth models used the artificial 50% prevalence from the
case–control study. This explains the relatively high positive predictive values and the relatively low negative
predictive values for these scores.
The area under the curve (AUC) for the L-TRiP(cast) score ranged from 0.77 (95% CI 0.66 to 0.87) in the
derivation cohort to 0.77 (95% CI 0.58 to 0.96) and 0.95 (95% CI 0.91 to 0.99) in the two subsequent
validation cohorts.
In addition to these rules, four additional models were identified (Saragas et al.,81 Haque et al.,80 Giannadakis
et al.79 and Eingartner et al.78). No measures of external validation of these RAMs were found. All were
found as single-centre small-scale implementation studies, revealing no further additional information on
performance, utility or reliability.
Summary of key findings
l A number of RAMs have been developed using a variety of methods and based on a variety of predictor
variables.
l External validation studies have weak designs and limited generalisability, so estimates of prognostic
accuracy are very uncertain.
l The limited data available suggest that the L-TRiP(cast) score with a cut-off point of 8 can achieve
reasonable sensitivity for predicting VTE without an excessive loss of specificity.
Identifying key variables to assess thromboembolic risk: a Delphi
consensus exercise
Objectives
The systematic reviews revealed a lack of evidence relating to individual risk predictors and RAMs for VTE
in lower-limb immobilisation due to trauma. Therefore, expert consensus methods were used to identify
potential risk factors for VTE and expert consensus was sought on which were considered to be the most
useful predictors. The aim was to bring together topic experts from haematology, orthopaedics and
emergency medicine and achieve consensus through serial rounds and facilitated discussion. The results of
this Delphi exercise would then be compared with current risk prediction models and consensus opinion
on clinical engagement, utility and acceptability to patients would be gauged. Delphi methodology has
been previously described85–87 and used throughout health services research for similar indications.88,89
Methods
Delphi methodology
A three-round Delphi study was conducted between August 2017 and April 2018 using a panel of
international topic experts, identified from the published literature and national clinical research network
(injuries and emergency theme).
Expertise was ascribed using two criteria: (1) evidence of experience in relevant guideline or risk
assessment tool design and (2) routine clinical experience with the relevant patient cohort and topic of
interest. These criteria were selected to allow disclosure of unpublished methodology deriving existing
rules, confer practicality of any rule and to ensure broad dissemination and uptake of consensus findings.
Experts were identified through national bodies, relevant literature and local thrombosis committee groups.
DOI: 10.3310/hta23630 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 63
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
TABLE 12 Diagnostic performance of the L-TRiP(cast), GEMNet and Plymouth RAMs
Author RAM
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
Positive predictive
value, % (95% CI)
Negative predictive
value, % (95% CI)
Likelihood
ratio positive
(95% CI)
Likelihood
ratio negative
(95% CI)
Percentage receiving
thromboprophylaxis
(95% CI)
Roberts et al.17 GEMNet 85.7 (62.6 to
96.2)
4.76
(0.2 to 25.9)
47.4
(31.3 to 64.0)
25.0
(1.3 to 78.1)
0.90
(0.73 to 1.10)
3.00
(0.16 to 55.31)
90.5
(76.5 to 96.9)
Keenan et al.31 Plymouth 57.1
(33.4 to 77.4)
52.4
(30.3 to 73.6)
54.5
(32.7 to 74.9)
55.0
(32.0 to 76.2)
1.20
(0.67 to 2.15)
0.81
(0.46 to 1.46)
52.4
(36.6 to 67.7)
Nemeth et al.32 L-TRiP(cast) with a
cut-off point of ≥ 8
92.6 39.7 3.8 99.5 1.5 0.2 87.8
L-TRiP(cast) with a
cut-off point of ≥ 9
80.8 60.8 5.0 99.2 2.1 0.3 74.7
Note
None of the studies reported measures of precision and we were unable to calculate a 95% CI for any of the L-TRiP(cast) parameters.
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National bodies included The British Orthopaedic Association, The Royal College of Emergency Medicine
and The Clinical Research Network Injuries and Emergencies Specialty group. Additional national or
international societies were not approached for independent representation owing to time constraints and
workload. All individuals approached agreed to participate and provided written informed consent. Experts
were entirely independent of the core review team (n = 11), local colleagues independent of the review
work (n = 3) and members of the core review team (n = 6).
The open first round of the classical Delphi approach was replaced with a systematic literature review to
identify possible VTE predictors, as previously described. Round 1 of the Delphi study was then delivered
via a web-based platform using SmartSurvey Ltd (Tewkesbury, UK)90 through a subscribed account. All
potential individual predictor variables identified through the previous systematic review of existing decision
rules and the wider literature on risk prediction in the relevant cohort were presented to participants as
potential candidate predictors. Participants were then asked to rate the strength of the VTE prediction risk
for each variable using a four-point Likert scale, with the option to record uncertainty. Their replies were
collated into quantitative and qualitative output for each individual question. An opportunity to identify
new relevant predictor variables was provided and participants were encouraged to identify missing themes.
New candidate variables were proposed, and those failing to achieve consensus in round 1 of the Delphi
exercise were carried forward to a second round. Participants were presented with these variables together
with a summary of the panel results from round 1, when applicable. Participants were asked to complete
the same Likert scale as before, with the advantage of having additional insight into comments and
quantitative results revealed by the rest of the group.
At the end of round 2 of the Delphi exercise, all variables were carried forward to a facilitated round-table
discussion where consensus results and comments were provided to all participants. Data were collated
and analysed to calculate frequencies, mean and range of scores.
Data synthesis and analysis
Criteria for inclusion in the decision rule were defined by a variable identified as a moderate or strong
predictor by consensus between two, three or more respondents. Variables identified as uncertain or
not or weakly predicting VTE risk by consensus between two, three or more respondents were likewise
excluded from the exercise. Quantitative data from rounds 1 and 2 were presented to participants as
bar charts with percentages. All analyses were conducted using Microsoft Excel 2010.
Results
Expert engagement
Twenty participants were identified to participate in the study. All (100%) completed round 1;
19 participants (95.0%) completed round 2. Ten participants (50.0%) contributed to the final facilitated
round-table discussion. A list of participants and the clinical scope of the Delphi panel is provided in
Appendix 8.
Systematic review and identification of candidate predictors
Trial flow results from the relevant systematic reviews prior to the Delphi exercise have been previously
described (see Review of individual risk factors associated with venous thromboembolic risk and Review
of risk assessment models for predicting venous thromboembolic risk). Thirty-five individual candidate
predictors were identified and included for dissemination in round 1. Predictors were subdivided into risks
related to injury/immobilisation and generic thrombosis risks. Initial proposed candidate predictors are
shown in Table 13, which also shows the results of subsequent Delphi rounds.
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TABLE 13 Summary of results from rounds 1 and 2 of the Delphi consensus exercise
Consensus as predictor Consensus as non-predictor No consensus
Additional suggested
variables
Delphi consensus exercise: round 1 results
Thrombophilia Smoker Age Non-weight-bearing
status
Prior VTE Hepatitis Intravenous drug use Partial weight-bearing
status
Surgery in the preceding
3 months
Dehydration Hospital admission in the
preceding 3 months
Significant soft-tissue
injury
BMI of > 30 kg/m2 Sex Pneumonia Baseline D-dimer level
Above-knee plaster cast Antipsychotic drug use Exogenous oestrogen/
hormone therapy
Pregnant/puerperium Extensive varicosities Preceding immobility
Active cancer Non-type O blood Superficial thrombophlebitis
Aircast® boot (DJO, LLC,
Dallas, TX, USA)
Ankle fracture/dislocationa
Complete ligament rupture
(non-Achilles tendon)
Family history of VTE
(first-degree relative)
Red cell distribution width Significant injury in the
preceding 3 months
Factor 8 activity Significant medical
comorbidity
Factor 11 activity Lower-limb paralysis
von Willebrand factor antigen
levels
Achilles tendon rupture
Comminuted injury
Rigid immobilisation in plaster
Delphi consensus exercise: round 2 results
Age Hospital admission within the
preceding 3 months
Intravenous drug use
Exogenous oestrogen/
hormone therapy
Baseline D-dimer level Significant injury in the
preceding 3 months
Lower-limb paralysis Pneumonia Significant medical
comorbidity
Superficial thrombophlebitis Partial weight-bearing status Preceding immobility
Achilles tendon rupture Significant soft-tissue injury Comminuted injury
Rigid immobilisation in
plaster
Non-weight-bearing status
Family history of VTE
(first-degree relative)
a Further to discussion at the end of round 1, this variable was removed based on agreement that this degree of severity
would usually merit inpatient admission and prescription of routine thromboprophylaxis.
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Round 1 results
Seven variables were identified as predictive of VTE risk by consensus criteria during round 1. Thirteen
variables were identified as not predictive of VTE by consensus criteria and excluded from the exercise.
No consensus was achieved on 15 variables; 14 predictors were carried forward to the second round,
with moderated peer feedback and tabular display. A single variable was excluded from the exercise after
collated comments, group discussion and feedback regarding the lack of primary suitability for inclusion.
Four new variables were suggested during the round 1 exercise and these were also carried forward.
All candidate predictors and their round 1 results are presented in Table 13.
Round 2 results
In the second round, consensus was achieved on six further variables as predictive of VTE risk. Five
variables were identified on reflection as not predictive of VTE risk by consensus criteria and these were
excluded from the exercise. No consensus remained for 7 of the 17 variables carried forward from round 1.
No further risk predictors were suggested by participants during round 2. Candidate variables taken
forward and their round 2 results are presented in Table 13.
Variables failing to achieve consensus
Of the seven variables failing to achieve consensus, two failed because of a dichotomous split with clear
unresolvable disagreement by experts (intravenous drug use and comminuted fracture). The other five
variables appeared to be categorised as weakly to moderately predictive by all, but fell short of agreed
criteria for inclusion. Further rounds were deemed unlikely to generate further consensus at this stage and
the trial team proposed a move to the facilitated round-table discussion to achieve consensus.
Facilitated round-table discussion
There was general round-table agreement about all variables for which consensus had been achieved by
the Delphi exercise. A specific point was made by the group regarding the inclusion of several variables
depicting the degree of immobilisation of the calf pump, and whether or not this should become a single
ordinal variable. A single variable (active intravenous drug use) on which the group did not reach consensus
was discussed in further detail, with the majority of the round table proposing that the variable be refined
or this entire cohort of patients be excluded based on safety concerns. Several discussion points followed
regarding the need for strict inclusion criteria when applying any decision rule, with particular regard to the
type of immobilisation in this group. The final agreed variables considered to be predictors of VTE risk via the
Delphi expert consensus were eight generic VTE risk predictors (i.e. thrombophilia, pregnancy/puerperium,
active cancer, surgery in the preceding 3 months, prior VTE, exogenous oestrogen/hormone therapy,
lower-limb paralysis and superficial thrombophlebitis), two patient demographics (i.e. age and BMI) and
three variables specific to lower-limb immobilisation or injury (i.e. Achilles tendon rupture, rigid immobilisation
and above-knee cast).
Table 14 compares the expert consensus variables to those included in the RAMs. Most of the expert
consensus variables were included in one or more of the RAMs but the RAMs also included many variables
that were not supported by expert consensus.
Originally, it was planned to use the expert consensus methods to refine existing RAMs or construct up to
five new RAMs from the selected risk factors, and then produce a consensus estimate of sensitivity and
specificity for each RAM that would allow the exploration of the trade-off between sensitivity and specificity
in decision-analytic modelling. It was decided not to proceed with this for the following reasons:
l The difficulty of achieving consensus on individual risk factors (which was felt to be unsurprising given
the limited available evidence) suggested that it would not be possible to achieve the necessary
consensus on the content and structure required to refine an existing RAM or construct a new RAM.
l The receiver operating characteristic (ROC) analysis of the L-TRiP(cast) score published by Nemeth et al.32
(identified in the systematic review of RAMs) provided an estimate of the trade-off between sensitivity
and specificity that could be used in decision-analytic modelling, and would be more credible and
usable than expert-derived estimates of sensitivity and specificity for expert-derived RAMs.
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TABLE 14 Summary of predictor variables included in studies of RAMs, with comparison with the Delphi consensus exercise
Variable
RAM
L-TRiP(cast)32 Plymouth31 GEMNet17 Saragas et al.81 Haque et al.80
Giannadakis
et al.79
Eingartner
et al.78 Delphi
Predictor variables included in risk assessment models
Age Yes (≥ 35 and ≥ 55 years) Yes (≥ 60 years) Yes (> 60 years) Yes (≥ 41 years) Yes (≥ 60 years) Yes (> 40 years) Yes (> 60 years) Yes (> 60 years)
Sex Yes (male sex) – – – – – – No
Overweight/obese Yes (BMI of ≥ 25 kg/m2
and ≥ 35 kg/m2)
Yes (BMI of ≥ 30 kg/m2) Yes (BMI of ≥ 30 kg/m2) Yes (BMI of > 25 kg/m2) Yes (BMI of ≥ 30 kg/m2) Yes (Broca Index
of > 20%)
Yes (overweight,
> 100 kg)
Yes (BMI of
> 30 kg/m2)
Cancer Yes (within previous
5 years)
Yes (active) Yes (active) Yes (malignancy present or
previous)
Yes (active or cancer
treatment)
Yes (malignancies) Yes (ongoing
malignancy)
Yes (active)
Pregnancy or
puerperium
Yes Yes Yes Yes Yes – – Yes
Smoking – – Yes (active) – – Yes (> 20
cigarettes per day)
Yes (active) No
Varicosities – Yes (varicose veins) Yes (extensive varicosities) Yes (varicose veins, large) Yes (varicose veins) Yes (varicose
veins)
Yes (varicose
veins even after
surgery)
No
Superficial
thrombophlebitis
Yes (superficial vein
thrombosis)
– – – – – – Yes
Prior or family history
of VTE
Yes [family history
(first-degree relative)]
Yes [family history
(brother, sister, father,
mother) or personal
history of DVT/PE]
Yes (personal history or
first-degree relative)
Yes (personal history of
DVT/PE, family history of
thrombosis)
Yes [personal or family
history (brother, sister,
father, mother, child) of
blood clot in leg or lung]
Yes (personal
history of previous
thrombosis/PE,
family history of
thrombosis/PE)
Yes (personal
history of
previous DVT/PE)
Yes (prior VTE
only)
Significant comorbidity Yes (rheumatoid arthritis,
chronic kidney disease,
COPD, multiple sclerosis)
Yes (heart disease, lung
disease, bowel disease,
hormone disease or
other long-term medical
condition requiring
treatment)
Yes (any serious medical
comorbidity, including
cardiac failure, COPD,
chronic renal failure or
inflammatory bowel
disease)
Yes [history of inflammatory
bowel disease, acute MI,
CHF (diagnosed < 1 month
previously), COPD, stroke
with lower-extremity
weakness < 1 month]
Yes (active heart, lung,
bowel or joint disease)
Yes (diabetes
mellitus, CHD)
Yes (history of
cardiovascular
disease, including
arterial
hypertension)
No
Known thrombophilia – – Yes Yes (positive factor
V Leiden, positive
prothrombin G20210 A,
other congenital or
acquired thrombophilia)
Yes (thrombophilia
associated with increased
risk of blood clots)
– – Yes
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Variable
RAM
L-TRiP(cast)32 Plymouth31 GEMNet17 Saragas et al.81 Haque et al.80
Giannadakis
et al.79
Eingartner
et al.78 Delphi
Exogenous oestrogen
therapy
Yes (oral contraceptives) Yes (oral contraceptive pill
or HRT)
Yes [hormone therapy
(combined oral
contraceptive pill/HRT/
tamoxifen)]
Yes (oral contraceptives or
HRT)
Yes (on HRT or taking
oestrogen-containing
contraceptive)
Yes
(contraception
use)
Yes (oral
contraceptives)
Yes (exogenous
oestrogen or
hormone therapy)
Hospital admission or
surgery
Yes (hospital admission
or surgery within the
previous 3 months)
Yes (abdominal surgery in
last 6 weeks)
Yes (any recent hospital
admission/major surgery)
Yes [minor surgery planned,
major surgery (occurring
< 1 month previously),
major surgery (occurring
> 45 minutes previously)
arthroscopic surgery,
elective major lower-
extremity arthroplasty]
Yes (hospital admission
within the previous
6 weeks, including
lower-limb surgery)
– Yes (lower limb,
pelvic or lower-
abdominal
surgery over
the previous
6 months)
Yes (surgery in
the preceding
3 months only)
Preceding immobility Yes (bedridden within
previous 3 months)
Yes (unable to walk
before accident/injury)
– Yes [medical patient
currently at bed rest,
patient confined to bed
(> 72 hours)]
– – – No
Injury type – Yes (Achilles tendon
rupture)
– Yes [hip, pelvis or leg
fracture (occurring
< 1 month previously),
acute spinal-cord injury
(paralysis) < 1 month]
Yes (Achilles tendon
rupture)
Yes (soft-tissue
injury of higher
than grade 1)
– Yes (Achilles
tendon rupture)
Immobilisation type Yes (plaster cast:
complete leg, circular
knee cast – ankle free,
foot, lower leg)
– – Yes (immobilising plaster
cast acquired < 1 month
previously)
Yes (plaster cast
extending above the
knee)
Yes (thigh
bandage)
– Yes (rigid
immobilisation
and/or above-
knee plaster cast)
Pneumonia Yes – – Yes (serious lung disease
including pneumonia,
diagnosed < 1 month
previously)
– – – No
Travel – – – – Yes [continuous travel of
≥ 3 hours (road, rail or
air travel) in the previous
4 weeks or needing to
travel while wearing
plaster cast]
– – No
Swollen legs – – – Yes (current) – – – No
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TABLE 14 Summary of predictor variables included in studies of RAMs, with comparison with the Delphi consensus exercise (continued )
Variable
RAM
L-TRiP(cast)32 Plymouth31 GEMNet17 Saragas et al.81 Haque et al.80
Giannadakis
et al.79
Eingartner
et al.78 Delphi
Sepsis – – – Yes (occurring < 1 month
previously)
– – – No
Central venous access – – – Yes – – – No
Antiphospholipid
antibodies
– – – Yes (positive lupus
anticoagulant, elevated
anticardiolipin antibodies)
– – – No
Multiple trauma – – – Yes (multiple trauma
occurring < 1 month
previously)
– – – No
CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HRT, hormone replacement therapy; MI, myocardial infarction.
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Summary of key findings
l Expert consensus on 13 variables most likely to predict VTE risk for outpatients with lower-limb injury
and temporary immobilisation has been established: eight generic VTE risk predictors (i.e. thrombophilia,
pregnancy/puerperium, active cancer, surgery in the preceding 3 months, prior VTE, exogenous oestrogen/
hormone therapy, lower-limb paralysis and superficial thrombophlebitis), two patient demographics
(i.e. age and BMI) and three variables specific to lower-limb immobilisation or injury (i.e. Achilles tendon
rupture, rigid immobilisation and above-knee cast).
l It was not possible to achieve expert consensus on the following seven variables: intravenous drug use,
significant injury in the preceding 3 months, significant medical comorbidity, preceding immobility,
comminuted injury, non-weight-bearing status and family history of VTE.
l Injury- and plaster-associated risk was proposed as a single ordinal variable based primarily on the
degree of calf pump immobilisation.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
A systematic review was undertaken to identify any existing studies on the cost-effectiveness of
thromboprophylaxis for lower-limb immobilisation due to injury.
Methods of reviewing cost-effectiveness
Identification of studies
Studies were identified by searching the following electronic databases and research registers:
l Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily, MEDLINE and Versions(R) (via OvidSP), 1946 to October 2017.
l EMBASE (via OvidSP), 1974 to October 2017.
l Cochrane Database of Systematic Reviews (via Wiley Online Library), 1996 to October 2017.
l Database of Abstracts of Review of Effects (via Wiley Online Library), 1995 to March 2015.
l HTA database (via Wiley Online), 1995 to October 2017.
l NHS EED (via Wiley Online Library), 1995 to March 2015.
For the MEDLINE and EMBASE searches, the aim was to maximise the specificity of the search in these
databases that do not target economic evaluations. In these searches, the keyword strategies developed
in the review of clinical effectiveness (see Chapter 3, Objective), which combined terms related to VTE
with terms related to lower-limb immobilisation, were used with sensitive economic evaluation, quality
of life and cost search filters91–93 aimed at restricting search results to economic and cost-related studies.
For the searches of HTA and NHS EED, terms for lower-limb immobilisation were not included, in order to
maximise sensitivity and find all economic evaluations relating to VTE. All resources were searched initially
from inception to October 2017 (or, in the case of discontinued sources such as NHS EED, the date at
which coverage ceased). Further details on the search strategy can be found in Appendix 9.
All identified citations from the electronic searches and other resources were imported into and managed
using EndNote bibliographic software.
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process by a single reviewer.
During the screening stage, all titles were examined for inclusion by the health economist and any citations
that clearly did not meet the inclusion criteria (e.g. non-human, unrelated to VTE) were excluded. During
the screening stage, abstracts were also examined if the paper could not be excluded based on the title
alone. During the eligibility stage, all full-text articles that could not be excluded based on title and abstract
were examined.
Studies were selected for inclusion on the basis of pre-determined inclusion and exclusion criteria.
The population, interventions and comparators were defined as per the clinical effectiveness review of
pharmacological thromboprophylaxis for preventing VTE (see Chapter 3, Inclusion and exclusion criteria).
In addition, the study population was restricted to patients treated in the UK NHS because estimates of
resource use and costs may not be transferable between different health-care settings. Criteria for the
study design and outcomes were specified to identify studies meeting the NICE reference case.94 In terms
of study design, the review was restricted to cost-effectiveness studies, thereby excluding cost-minimisation
studies. In terms of outcomes, the review was restricted to studies that measured benefits using QALYs because
the QALY has been defined by NICE as the reference case measure for benefit for UK cost-effectiveness
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studies94 and the NICE methods guide94 provides guidance on the range of cost-per-QALY values that can
be considered to represent good value for money within the UK NHS. Studies reporting alternative
outcomes, such as cost per VTE avoided, were therefore excluded. Cost-consequence studies and other
studies that reported data on costs, resource use or utility values in relevant populations were excluded
from the cost-effectiveness review but were examined for relevant data that might inform the modelled
estimates of cost-effectiveness (described in Independent economic assessment methods).
Results of cost-effectiveness review
The literature searches identified 1299 citations. Of these, no relevant published cost-effectiveness
studies were identified. A flow chart describing the process of identifying relevant literature can be found
in Figure 8. A total of three full-text articles were excluded as they did not meet all the prespecified
inclusion criteria.95–97 The articles were excluded for the following reasons: inappropriate study design
(not a cost-effectiveness analysis)96 and wrong target population (not isolated lower-limb injury requiring
temporary immobilisation).95,97 A full list of excluded studies with reasons for exclusion is presented in
Appendix 10. One study was identified that examined the costs of providing thromboprophylaxis following
lower-limb injuries but benefits were not assessed. This study was retained as a potential source of cost
inputs for the analysis described in Independent economic assessment methods.
Records identified through
database searching
(n = 1299)
Additional records identified
through other sources
(n = 0)
Full-text articles
(references) assessed
for eligibility
(n = 3)
Records screened by
title and abstract
(n = 1299)
Excluded by title
and abstract
(n = 1296)
Full-text articles included
(n = 0, studies) 
Full-text articles excluded,
with reasons
(n = 3)
• Population not isolated
   lower-limb injury
   requiring temporary
   immobilisation, n = 2
• Not a cost-effectiveness
   analysis, n = 1
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FIGURE 8 Study flow chart (adapted):37 cost-effectiveness review of pharmacological thromboprophylaxis for
preventing VTE in patients having lower-limb immobilisation due to injury. © 2009 Moher et al. This is an open-access
article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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Given the lack of published analyses in directly relevant populations, it was decided to retain papers
describing cost-effectiveness analyses in related populations for the purpose of identifying suitable model
inputs. Based on clinical advice, only those studies examining the cost-effectiveness of thromboprophylaxis
in patients having elective knee surgery were retained, as these patients are more likely to be generally fit
and well prior to surgery, do not have long periods of hospitalisation, will have some degree of reduced
mobility in the lower limb during their recovery from surgery and the impact of surgery may mimic, to
some extent, the trauma of lower-limb injury. Although two papers98,99 were identified that reported the
cost-effectiveness for thromboprophylaxis in patients having elective knee surgery, both corresponded
to the same study, namely main analysis99 and subgroup analysis98 of patients aged > 75 years or with
moderate renal impairment. Given that the parameter sources of interest did not vary between these two
citations, only the paper reporting the main analysis was retained.99 The parameters identified from this
paper are described in the next section.
Independent economic assessment methods
Given the lack of published analyses examining the cost-effectiveness of thromboprophylaxis in patients
having lower-limb immobilisation due to injury (see Systematic review of existing cost-effectiveness evidence),
a de novo economic evaluation was conducted using decision-analytic modelling.
Decision problem
The aim of the decision-analytic model was to estimate the incremental cost-effectiveness of different strategies
for thromboprophylaxis in patients with lower-limb injury requiring immobilisation. The thromboprophylaxis
strategies examined were based on treating all patients or treating patients in accordance with the application
of the RAMs identified in the review of RAMs described in Chapter 3, Review of risk assessment models for
predicting venous thromboembolic risk. Based on the estimates of sensitivity and specificity identified in the
review, it was decided to examine the L-TRiP(cast) tool, published by Nemeth et al.,32 using cut-off scores
ranging from 6 to 10. The Plymouth tool, published by Keenan et al.,31 and the GEMNet tool, published by
Roberts et al.,17 were not included in the economic analysis. The only available estimates of the sensitivity
and specificity for these RAMs, from an evaluation by Watson et al.,82 suggested that both of these tools
would be outperformed by the L-TRiP(cast) tool. The comparator considered in the economic analysis was
no thromboprophylaxis. The base-case economic analysis assumes that prophylaxis consists of LMWH being
given for the duration of lower-limb immobilisation (e.g. duration of casting or splinting).
Context
The model estimates lifetime costs and QALYs for the different thromboprophylaxis strategies and the
comparator of no thromboprophylaxis under a NHS and Personal Social Services perspective. Future costs
and benefits are discounted from their net present value at a rate of 3.5% per annum in accordance with
the NICE Guide to the Methods of Technology Appraisal.94 Costs are reported in Great British pounds,
based on 2017 prices. To achieve this, historical prices used as model inputs were inflated using the
hospital and community health services pay and prices index.100
Conceptual model
The clinical events that are expected to be affected by whether or not thromboprophylaxis is given to
patients with lower-limb immobilisation due to injury are as follows:
l bleeding events during the period of prophylaxis, including fatal bleeds, non-fatal intracranial bleeds,
other major bleeds and clinically relevant non-major bleeds
l VTE events, which includes distal and proximal DVT, both of which may be either symptomatic or
asymptomatic, and PE, which may be either fatal or non-fatal
l bleeding events during the treatment of symptomatic VTE with anticoagulants
l long-term complications of VTE, such as PTS and CTEPH
l long-term complications of bleeds, such as disability following non-fatal intracranial bleeds.
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It should be noted that, within the modelling framework, symptomatic DVTs include any DVTs causing
symptoms that result in the patient seeking medical care and any DVTs categorised as asymptomatic
would include those with minor symptoms that are not sufficient for the patient to seek medical care.
In the context of lower-limb injury and immobilisation, some DVTs may be categorised as asymptomatic in
this analysis despite symptoms being present if these symptoms are attributed to the injury and do not
prompt the patient to seek medical care.
Model structure
The model structure consists of a decision tree followed by a Markov model. The decision tree captures
outcomes related to prophylaxis and VTE events in the first 6 months. The Markov model is used to
extrapolate the QALY losses from fatal events and the costs and QALY losses from long-term complications
that develop or persist beyond 6 months. The model estimates outcomes for a cohort of identical patients
with average characteristics.
The decision tree captures the impact of alternative strategies on thromboprophylaxis rates, the impact of
thromboprophylaxis on VTE events (e.g. symptomatic/asymptomatic DVT and PE) and bleeding complications
related to either the initial thromboprophylaxis or anticoagulants used in the management of VTE in
symptomatic patients. Bleeding complications are split into fatal bleeds, non-fatal intracranial haemorrhage
(ICH) and other (i.e. non-fatal non-intracranial) major bleeds. The decision tree captures the first 6 months
after lower-limb injury as this is considered a sufficient time frame to capture both 6–8 weeks of
thromboprophylaxis during lower-limb immobilisation and 3 months of anticoagulant treatment for any
VTEs arising during lower-limb immobilisation. All costs and health effects related to major bleeds that are
non-fatal and non-intracranial are assumed to resolve within the 6-month timeframe of the decision tree
model. Any chronic complications of VTE are assumed not to be diagnosed until after the completion of
VTE treatment as it is difficult to distinguish PTS and CTEPH from acute symptoms during the first 3 months
after VTE. Therefore, PTS and CTEPH are assumed not to occur during the decision tree phase of the model.
The decision tree structure is shown in Figure 9. The key model assumptions were as follows:
l Bleeding events during immobilisation are possible in both those having thromboprophylaxis and those
having no thromboprophylaxis.
l Bleeds associated with thromboprophylaxis are assumed to occur before VTE associated with
immobilisation and both are assumed to occur within 12 weeks of the start of lower-limb
immobilisation.
l Patients who have major bleeding will stop thromboprophylaxis immediately, but the treatment effect
of thromboprophylaxis is assumed to be the same as for those who completed treatment, as patients
who bleed are assumed to be adequately anticoagulated.
l The risk of VTE is the same whether or not prophylaxis caused bleeding.
l All patients with symptomatic DVT receive accurate diagnosis and initiate treatment with anticoagulants
(3 months of either DOACs or phased anticoagulation).
l Asymptomatic DVTs are not detected and are not treated.
l All PEs are symptomatic and lead to detection and treatment with anticoagulants in all cases.
l Patients treated for symptomatic DVT and PE have a bleed risk associated with treatment, which is
assumed to occur during the 3-month treatment period (i.e. within 6 months of the start of lower-limb
immobilisation).
l Chronic complications of VTE (e.g. CTEPH following PE and PTS following DVT) are assumed to be
diagnosed at least 3 months after VTE and, therefore, occur after any bleeds associated with
VTE treatment.
l Deaths caused by PE occur before any bleeding associated with the treatment of PE.
l Risk of bleeding during treatment of VTE is independent of whether or not the patient bled
during prophylaxis.
l Risk of VTE, risk of bleeding and risk of PTS/CTEPH are not dependent on patient characteristics.
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AB
C
D
Choice of
prophylaxis
strategy
Alternative prophylaxis strategy
e.g. prophylaxis for all, prophylaxis
for none, prophylaxis at different
L-TRIP(cast) cut-offs
e.g. prophylaxis according
to L-TRIP(cast) score > 9
Prophylaxis
No prophylaxis
No major bleed
Major bleed
Fatal bleed
Non-fatal bleed
Intracranial bleed
Other major bleed
No VTE
Asymptomatic DVT
Symptomatic DVT
PE
Fatal PE
Distal
Distal
Proximal
Proximal
Fatal bleed
Non-fatal bleed
Intracranial bleed
Other major bleed
Major bleed
No major bleed
Non-fatal PE
Branches repeated as per node C
Branches repeated as per node D
Branches repeated as per node D
Branches repeated as per node B but with risk of VTE decreased and risk of bleeding increased due to prophylaxis
Branches repeated as per node A but with specificity and sensitivity as per alternative prophylaxis strategy
FIGURE 9 Decision tree structure.
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A key structural assumption within the model is the use of a cohort modelling approach that assumes that
all patients have identical characteristics based on the average characteristics of those having lower-limb
immobilisation due to injury. Depending on the RAMs used, the likelihood of receiving prophylaxis may be
dependent on patient characteristics, leading to the treated and untreated populations having different
characteristics, which is not captured in a cohort model. Based on clinical advice, it was expected that age
would be the only relevant patient characteristic that would predict different outcomes. A scenario analysis
was conducted to explore whether or not patient heterogeneity would affect the conclusions by varying
the age of the cohort. Based on this, it was concluded that the cohort-level modelling approach was
adequate and would not introduce significant bias.
Clinically relevant non-major bleeding (CRNMB), which is any non-major bleeding that results in contact
with a health-care professional, was not expected to be a significant driver of cost-effectiveness. It was
therefore excluded from the base-case analysis, but the impact of this assumption was explored in a
scenario analysis. As CRNMB has no long-term implications, it was not modelled using a separate branch
in the decision tree. Instead, it was included in a scenario analysis by applying a simple one-off cost for
consultation to a proportion of the population having thromboprophylaxis.
Outcomes related specifically to surgical site wounds, such as wound infection and wound breakdown,
were excluded from the model as there is substantial uncertainty as to whether or not thromboprophylaxis
influences wound healing. Furthermore, only a small proportion of the lower-limb immobilisation
population would have surgical intervention or open fractures. This is supported by data from the largest
RCT to date,59 in which only 12% of participants across both arms had surgery and the rate of infections
was similar across arms (12/719 for treatment vs. 14/716 for control).
The aim of the Markov model is to capture QALY losses due to fatal PEs or fatal bleeds and the costs and
QALY losses associated with chronic complications following VTE events (e.g. PTS or CTEPH) or bleeds
(e.g. disability following ICH). At 6 months, patients enter one of eight Markov states: (1) well, (2) dead,
(3) post-ICH, (4) asymptomatic proximal DVT, (5) asymptomatic distal DVT, (6) symptomatic proximal DVT,
(7) symptomatic distal DVT or (8) PE. The Markov model is then used to estimate the number of patients
from the DVT and PE states who develop either PTS or CTEPH, respectively, and the long-term survival in
each health state. Separate DVT states were required to capture differences in PTS risk depending on
whether the DVT was proximal or distal and whether it was symptomatic and treated or was asymptomatic
and, therefore, remained undiagnosed and untreated. The prevalence of PTS and CTEPH is captured by
having separate health states for patients with these long-term complications. All patients with PTS are
combined in a single health state, as costs, utilities and survival are not expected to be affected by whether
or not PTS occurred following proximal or distal DVT. The PTS state is not split into different severity levels
as the utility estimates are based on the average across severity levels and the costs are not expected to
differ by severity. Separate Markov states were required for medically and surgically managed CTEPH as
the type of management affects life expectancy, costs and utilities in patients with CTEPH. The health
states are shown in Figure 10.
The Markov model has one 6-month cycle, to extrapolate the decision tree outcomes to the end of the
first year, followed by annual cycles thereafter. All-cause mortality during the first year is assumed to occur
at 6 months (i.e. between the end of the decision tree and the start of the Markov model) and then
mid-way through each annual cycle thereafter. The CTEPH and post-ICH health states have state-specific
mortality risks, whereas the other states experience general population mortality rates. Average costs
and QALYs across each model cycle were calculated by applying a half-cycle correction.
ASSESSMENT OF COST-EFFECTIVENESS
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Assumptions related to the Markov phase of the model are as follows:
l All symptomatic DVTs are associated with a risk of PTS but the rate is allowed to differ depending on
whether the DVT is distal or proximal and whether it is symptomatic and treated or asymptomatic
and untreated.
l There is no risk of PTS for PE.
l CTEPH is possible only after PE.
l Further outcomes (i.e. VTE, CTEPH and PTS) are not modelled for those who experience ICH, as lifetime
cost and QALYs will be determined predominantly by disability related to the ICH.
l All-cause mortality is applied to all Markov states with state-specific mortality rates possible for patients
who have experienced ICH or who have CTEPH that is either medically or surgically managed.
l Recurrent VTE is not modelled as it is not likely to be related to the initial provoked VTE and, therefore,
would occur equally regardless of whether or not thromboprophylaxis was given during immobilisation.
Data sources
Identification of data sources
A summary of the model parameters and data sources used to populate the model are provided in Table 15,
with the exception of utility values, which are provided in Treatment-related utility decrement. The number
of patients receiving thromboprophylaxis under the various treatment strategies is estimated by combining
data on sensitivity and specificity, from the systematic review of RAMs (see Chapter 3, Review of risk
assessment models for predicting venous thromboembolic risk), with data on the risk in untreated patients,
from the review of RCTs comparing thromboprophylaxis with no thromboprophylaxis (see Chapter 3, Review
of pharmacological thromboprophylaxis for preventing venous thromboembolism). Parameters relating to the
PTS following DVT
Asymptomatic distal
DVT (no PTS)
Asymptomatic
proximal
DVT (no PTS)
Symptomatic distal
DVT (no PTS)
Symptomatic 
proximal
DVT (no PTS)
Dead
Post ICH
Survived PE (CTEPH
medically managed)
Survived PE (CTEPH
surgically managed)
Survived PE
(no CTEPH)
Well (no VTE
or bleed
complications)
FIGURE 10 Markov model structure.
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TABLE 15 Summary of clinical and cost parameters
Parameter description Mean value 95% CIa Source Notes
Clinical parameters
Sensitivity of decision tools See Chapter 3, Narrative data synthesis
L-TRiP(cast) score of
≥ 6 98.4% Assumed fixed
≥ 7 95.3% Assumed fixed
≥ 8 92.6% Assumed fixed
≥ 9 80.8% Assumed fixed
≥ 10 65.1% Assumed fixed
Specificity of decision tools See Chapter 3, Narrative data synthesis
L-TRiP(cast) score of
≥ 6 14.2% Assumed fixed
≥ 7 26.2% Assumed fixed
≥ 8 39.7% Assumed fixed
≥ 9 60.8% Assumed fixed
≥ 10 72.2% Assumed fixed
Probabilities of VTE in patients having
lower-limb immobilisation without
thromboprophylaxis
Systematic review of thromboprophylaxis
effectiveness
Average proportion across 12 RCTs
(see Table 16)
PE 0.4% 0.2% to 0.7%
Symptomatic DVT 0.9% 0.5% to 1.3%
Asymptomatic DVT 7.1% 6.0% to 8.1%
Proportion of asymptomatic DVTs that are distal 83.9% 73.3% to 92.2% Systematic review of thromboprophylaxis
effectiveness
Average proportion across six RCTs
(see Table 16)
Proportion of symptomatic DVTs that are distal 50% 26.5% to 73.4% Systematic review of thromboprophylaxis
effectiveness
Based on a single RCT that focused
exclusively on symptomatic DVTs
(see Table 16)
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Parameter description Mean value 95% CIa Source Notes
Effectiveness of prophylaxis: OR for VTE 0.52 0.37 to 0.71 Systematic review of decision tools for
identifying patients at risk of VTE
OR for LMWH vs. placebo for all VTE
based on random-effects Bayesian NMA
Risk of major bleed with no prophylaxis 1.89 per 1000
person-years
1.86 to 1.92 per
1000 patient years
Hippisley-Cox and Coupland101 Age-standardised incidence across whole
cohort used to derive the QBleed101
risk score:
l 1.34 per 1000 person-years for GI
bleed
l 0.55 per 1000 person-years for ICH
Bleed risk for prophylaxis vs. no prophylaxis: HR 1.64 0.98 to 2.75 Pooled analysis of bleed risks across all VTE
prophylaxis studies in NICE CG9224
Data presented in CG92 reanalysed on
log-odds scale using random-effects
Bayesian meta-analysis
Proportion of major bleeds during lower-limb
immobilisation that are fatal (with and without
prophylaxis)
21.0% 17.0% to 25.0% l Case fatality rate of ICH bleeds taken
from Fang et al.102
l Case fatality rate of GI bleeds taken
from Button et al.103
l Proportion of bleeds that are GI and
ICH are based on Hippisley-Cox and
Coupland101
Average fatality across GI and ICH
bleeds with case fatality rates of 10%
(95% CI 9.7% to 10.4%) and 49%
(95%CI 37% to 60%), respectively
Proportion of non-fatal major bleeds during
lower-limb immobilisation that are ICH
(with and without prophylaxis)
19.0% 15.4% to 22.2% Fang et al.,102 Button et al.103 and
Hippisley-Cox and Coupland101
Estimated based on incidence and case
fatality rates for GI and ICH bleeds
Risk of bleeding during 3-month anticoagulant
treatment for VTE
0.9% 0.2% to 2.0% Kooiman et al.104 6-month incidence pooled across
patients with HAS-BLED score of 0 or 1
Proportion of major bleeds during VTE
treatment that are fatal
25.0% 21.0% to 28.0% Nieto et al.105 Based on case fatality rates for major
bleeds within RIETE (Nieto et al.)105
Proportion of non-fatal major bleeds during VTE
treatment that are ICH
9.0% 6.5% to 11.9% Nieto et al.105 Based on proportion of major non-fatal
bleeds within RIETE that were ICH
(Nieto et al.)105
All-cause (non-VTE-related) mortality Varies by age N/A ONS lifetables106 Risk applied each year is based on
current age and is not adjusted to
account for contribution of VTE to
population mortality
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TABLE 15 Summary of clinical and cost parameters (continued )
Parameter description Mean value 95% CIa Source Notes
SMR for patients surviving ICH, compared with
general population
Ranges for SMRs not
stated so ± 20% on
the logged scale is
assumed
Fogelholm et al.107 Assumed no increased mortality risk
after 6 years
Year 1 after ICH 4.5
Years 2 to 6 after ICH 2.2
Probability of PE being fatal 2.9% 2.5% to 3.3% Maestre et al.108 l Data from RIETE
l Case fatality rate of clinically overt
PE in outpatients
Cumulative risk of PTS for treated symptomatic
DVT at 3 years
Hach-Wunderle et al.109 (TULIPA PLUS
registry)
Cumulative incidence at 3 years based
on the TULIPA PLUS registry.
Distribution of risk across years 1 to 3
based on van Dongen et al.110 Zero risk
assumed from year 4 onwards
Proximal 32.4% 22.1% to 43.6%
Distal 15.6% 7.9% to 25.3%
Cumulative risk of PTS for untreated
asymptomatic DVT at 3 years
Hach-Wunderle et al.109 and van Dongen
et al.110
l For proximal DVT, the data for
symptomatic DVT were uplifted
using the OR from van Dongen
et al.110 for the impact of inadequate
anticoagulation on PTS risk: OR 2.71
(95% CI 1.44 to 5.1)
l Assumed no increased risk for
asymptomatic distal DVT
Proximal 56.5% 29.0% to 79.8%
Distal 15.6% Fixed relative to
symptomatic
Risk of CTEPH per annum applied in the first
2 years after PE
1.6% 1.0% to 2.2% Ende-Verhaar et al.111 l 3.2% (95% CI 2.0% to 4.4%) at
2 years based on the incidence in
those surviving the initial treatment
period of 3–6 months
l Assumed no risk beyond 2 years,
based on Pengo et al.112
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Parameter description Mean value 95% CIa Source Notes
Proportion of CTEPH treated surgically 59.5% 55.8% to 63.2% Delcroix et al.113
Mortality for CTEPH
Medically treated Exponential survival
curve with mean
hazard of 0.1168
SE of mean hazard
0.0123
Original data from Delcroix et al.113 but
curves taken from Goodacre et al.114
l Medically treated patients have a
death risk of 11% per annum
(fixed over time)
l If the death hazard falls below
general population values, then
general population values apply
Surgically treated Log-normal survival
curve with mean
5.081 and SD of
3.343
l SE of mean 0.574
l SE of SD 0.399
Original data from Delcroix et al.113 but
curves taken from Goodacre et al.114
l Surgically treated patients have a
risk that declines over time (6% in
year 1 declining to 1.5% at year 5,
1% at year 10 and 0.8% at year 15)
l If the death hazard falls below
general population values, then
general population values apply
Cost parameters
Application of RAM to patient £8.83 Fixed Curtis and Burns100 Cost for 5 minutes of hospital
consultant time
Prophylaxis: 6 weeks of LMWH (dalteparin),
including costs of initiating treatment and
district nurse administration for 4% of patients
£224.64 £197 to £267 l Administration costs based on
Menakaya et al.115
l Drug costs based on Drug Tariff21
l Costs from Menakaya et al.115
updated to current prices using
inflation indices from Curtis and
Burns100
l Dalteparin is the lowest-cost
formulation of LMWH based on
2018 Drug Tariff prices21
l See Table 18 for a more detailed
costing breakdown
Treatment of symptomatic proximal DVT £687.69 £660 to £715 NHS reference costs116
Drug Tariff21
Clinical expert discussion regarding the
likelihood of resource use, combined
with NHS reference cost data116 for
health-care contacts and Drug Tariff21
costs for treatments (see Table 19 for a
more detailed costing breakdown)
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TABLE 15 Summary of clinical and cost parameters (continued )
Parameter description Mean value 95% CIa Source Notes
Treatment of symptomatic distal DVT £559.62 £536 to £584 NHS reference costs116
Drug Tariff21
Clinical expert discussion regarding the
likelihood of resource use, combined
with NHS reference cost data116 for
health-care contacts and Drug Tariff21
costs for treatments (see Table 19 for
more detailed costing breakdown)
Treatment of non-fatal PE £1788.44 £1995 to £2168 NHS reference costs116
Drug Tariff21
Clinical expert discussion regarding the
likelihood of resource use, combined
with NHS reference cost data116 for
health-care contacts and Drug Tariff21
costs for treatments (see Table 19 for
more detailed costing breakdown)
Fatal PE £1498.14 £1430 to £1571 NHS reference costs116 As per non-fatal bleed, minus drug
therapy for PE
Fatal bleed £1802.48 £322 to £3283 Luengo-Fernandez et al.117 l Costs of fatal haemorrhagic stroke
from OXVASC subgroup with
atrial fibrillation
l Updated to current prices using
inflation indices100
Non-fatal, non-ICH bleed £1197.88 £1118 to £1288 NHS reference costs 2015/16116 Weighted average of reference costs
for GI bleed (HRG codes FZ38G – FZ38P)
Post non-fatal ICH: first 90 days £21,255.00 £16,814 to £26,217 Luengo-Fernandez et al.117 Weighted average of costs for non-fatal
haemorrhagic strokes
Uplifted to current prices using inflation
indices100
Post non-fatal ICH: post acute (beyond 90 days)
costs per annum
£8013.00 £5300 to £11,271 Luengo-Fernandez et al.117 l Average costs across all stroke types
(haemorrhagic not reported
separately)
l Includes GP and ED costs and
long-term care cost
l Updated to current prices using
inflation indices100
A
S
S
E
S
S
M
E
N
T
O
F
C
O
S
T
-E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
6
6
Parameter description Mean value 95% CIa Source Notes
PTS cost per annum: year 1
(mild/moderate/severe)
£308 in year 1 £294 to £323 NHS reference costs 2015/16116 One first and one follow-up vascular
surgery outpatient appointment
Weighted average of consultant-led
and non-consultant-led outpatient
appointments for non-admitted
face-to-face first attendance (WF01B)
and follow-up (WF01A) for vascular
surgery (service code 107)
PTS cost per annum: year 2
(mild/moderate/severe)
£74 in each
subsequent year
Fixed Curtis and Burns100 Two GP surgery consultations with
qualification costs including direct-care
staff costs at £37 per appointment
CTEPH cost per annum
Medically managed £17,942 each year Fixed NICE CG9224 l Cost in CG92 was £1219 per
4 weeks in 2008/09 prices.24
This was updated to 2016/17
prices using inflation indices100
l Assume treatment is lifelong
Surgically managed £9890 in year 1 and
zero in year 2
onwards
£9471 to £10,370 NHS reference costs 2015/16116 l Average of DZ02H, DZ02J and
DZ02K ‘complex thoracic
procedures’ relating to procedure
code L041
l ‘Pulmonary thromboendodartectomy’
for elective inpatients including excess
bed-days
l In addition, 29% of surgically
treated patients require medical
bridging therapy for 4.6 months
(average cost £1992)
CG, clinical guideline; GI, gastrointestinal; GP, general practitioner; HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international
normalised ratio, Elderly, Drugs/alcohol concomitantly; HR, hazard ratio; HRG, Healthcare Resource Group; N/A, not applicable; ONS, Office for National Statistics; OXVASC, Oxford Vascular
Study; RIETE, Computerized Registry of Patients with Venous Thromboembolism; SE, standard error; SMR, standardised mortality ratio; TULIPA PLUS, Thrombosis and Pulmonary Embolism in
Out-Patients – plus; VKA, vitamin K antagonist.
a Except where stated otherwise (e.g. SD or SE).
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relative risk (RR) of VTE events in patients receiving thromboprophylaxis compared with those not receiving
thromboprophylaxis have been taken from the review of clinical effectiveness of thromboprophylaxis to
prevent VTE in lower-limb immobilisation. For all other parameters, data were obtained by reviewing the
data sources used in published cost-effectiveness analyses and other published sources. As no relevant
models were identified that were specific to the population having lower-limb immobilisation, the search
for parameter sources was broadened to models in related populations or indications. This search focused,
first, on models used to inform NICE guidance on anticoagulants to prevent and treat VTE as the models used
to inform any existing NICE guidance were considered highly likely to contain data relevant to the UK context
and the NICE reference case, and have been critically scrutinised by independent academic groups. Second,
the additional studies identified in the literature review for the related population of patients having elective
knee surgery were used (as discussed in Results of cost-effectiveness review). Finally, ad hoc searches were
conducted using the reference lists of recently published reviews to identify any relevant sources not
identified during the review of published models and clinical experts were consulted to see if any key data
sources known to them had been missed. This included any sources used in relevant models known to the
authors. The published cost-effectiveness analyses identified as potential sources of model inputs are
summarised in Appendix 11.
Characteristics of population having lower-limb immobilisation
The Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trial by van Adrichem et al.59
was selected as being representative of the population having lower-limb immobilisation due to injury
who are at risk of thrombosis. This was selected as it is a recent, large RCT conducted exclusively in Europe
(the Netherlands) and the inclusion and exclusion criteria were not too restrictive; patients with a prior
history of VTE were excluded but those with cancer or family history of DVT were not excluded. The starting
age in the model was set to be 46 years of age and 51.5% of the starting population were male.
Risk of venous thromboembolism and types of venous thromboembolism
The risk of VTE was based on data taken from the systematic review of clinical effectiveness for LMWH
versus control (see Chapter 3, Review of pharmacological thromboprophylaxis for preventing venous
thromboembolism). The rate of any form of VTE (i.e. PE, symptomatic DVT or asymptomatic DVT) was 8.39%
across the 12 studies23,49–56,58–60 reporting data for control (i.e. placebo, aspirin, no thromboprophylaxis). The
risk of PE, including those that experienced PE with DVT, was 0.43%. Therefore, the risk of DVT without PE
was 7.96%. Only nine studies23,49–52,54,56,58,60 reported outcomes for both symptomatic and asymptomatic
DVT. From these studies, it was estimated that 11.4% of DVT are symptomatic (16/140), giving an absolute
incidence of 0.91% for symptomatic DVT and 7.05% for asymptomatic DVT in patients having lower-limb
immobilisation without thromboprophylaxis. These are slightly higher than the raw figures (Table 16) as
three studies53,55,59 did not report outcome data for both symptomatic and asymptomatic DVT but did report
data for all VTE and PE. These estimates effectively assume the same split of symptomatic and asymptomatic
DVT for the three studies with missing data to achieve the total VTE rate observed across all 12 studies. For
asymptomatic DVT, only six studies23,50–52,58,60 reported outcomes for both distal and proximal asymptomatic
DVT. From these six studies, it was estimated that 16% (9/56) of asymptomatic DVTs are proximal (and,
therefore, 84% are distal). The data on the location of symptomatic DVTs (distal or proximal) were very
sparse, with only 46 events reported across all trial arms and many studies not reporting the location. It was
possible to extract data on the location of symptomatic DVTs for four studies54,57–59 included in the review,
covering a total of 34 events across all trials arms. The proportion of symptomatic DVTs that were proximal
varied from 14% to 100% across these four studies, with a median estimate of 36%. The POT-CAST trial59
was the only one of these four studies that focused exclusively on symptomatic VTE. The other three
studies54,57,58 screened patients for asymptomatic DVTs as well as recording the number of DVTs that were
symptomatic. There is a risk that the process of screening patients for asymptomatic DVTs may lead to
patients attributing symptoms to screening-detected DVTs that may otherwise not have been sufficiently
symptomatic to result in the patient presenting with symptoms in routine care. For this reason, it was
decided to use the POT-CAST trial59 as the single source of estimates for the proportion of symptomatic
DVTs that are proximal, as no routine screening was used in this trial to detect asymptomatic DVTs. As this
single study provided a low number of events, it was decided to pool the data across trial arms. This resulted
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
in 50% of the 16 symptomatic DVTs being proximal. Given that these data were based on a single study
and a small number of events, two extreme scenarios were examined, assuming that either 0% or 100% of
symptomatic DVTs are proximal, to see if the overall conclusions were sensitive to uncertainty around this
parameter.
All-cause mortality
It was not considered necessary to model males and females separately as the risks of VTE during
lower-limb immobilisation were not expected to vary according to sex. However, life-expectancy is
dependent on sex and, consequently, any QALY gains from deaths prevented would be dependent on
sex. For this reason, a weighted mortality risk was applied, based on the proportion of males (51.5%)
in the POT-CAST trial,59 using data on the risk of death for males and females by age obtained from
lifetables. The weighting across males and females was allowed to vary over the course of the model to
allow for the fact that lower mortality risks in females leads to a slight increase in the proportion of people
alive who are female over time.
Case fatality rate for pulmonary embolism
None of the studies included in the review of clinical effectiveness reported any fatal PEs. Given that
14 PEs were reported within the 13 studies23,49–60 included in the review, this suggests that the rate of
fatality due to PE is < 7% in the population having lower-limb immobilisation due to injury. The research
team looked for alternative data sources on the case fatality rate of PE. Data were identified from the
Computerized Registry of Patients with Venous Thromboembolism (RIETE) (an extensive data registry of
consecutive patients with VTE), which found that the rate of all-cause mortality at 30 days had fallen over
time from 6.6% in 2001–05 to 4.9% in 2010–13 (reported by Jiménez et al.118). However, some of this
mortality may not be related to PE. When looking at only PE-related mortality, the rate at 30 days was
1.8%. Another analysis of RIETE, by Maestre et al.,108 found that rates of fatal PE at 90 days were lower
for outpatients than inpatients. They found that of 7591 outpatients with clinically overt PE, 219 (2.9%)
had fatal PE at 90 days; this was lower than the 4.1% (119/2870) rate with clinically overt PE having a
fatal PE in the inpatient population. Given that patients having lower-limb immobilisation due to injury
would generally be managed as outpatients, this suggests that a lower risk may be seen in this population.
TABLE 16 Data from the systematic review on clinical effectiveness used to inform VTE event rates
Event type n with event N at risk
Rate based on
studies (%) Number of studies
Data applied
in model (%)
Any VTE 196 2336 8.39 1223,49–56,58–60 8.39
PE risk 10 2336 0.43 1223,49–56,58–60 0.43
DVT without PEa 186 2336 7.96 1223,49–56,58–60
Asymptomatic DVT 124 1466 8.58 923,49–52,54,56,58,60 7.05b
Symptomatic DVT 16 1466 1.11 923,49–52,54,56,58,60 0.91b
Asymptomatic proximal DVT 9 1055 0.85 623,50–52,58,60 1.13c
Asymptomatic distal DVT 47 1055 4.45 623,50–52,58,60 5.59c
Symptomatic proximal DVT 8 1435 0.56 159 0.45d
Symptomatic distal DVT 8 1435 0.56 159 0.45d
a Based on the difference between the two rows above.
b Estimated using the total rate of DVT without PE from 12 studies and proportion that are symptomatic from six studies.
c Estimated using the total that are asymptomatic from nine studies and proportion that are proximal from six studies.
d Estimated from the total that are symptomatic from nine studies and proportion that are symptomatic from the
POT-CAST trial59 (50%) that focused exclusively on symptomatic VTE events.
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The Emergency Medicine Pulmonary Embolism in the Real World Registry (EMPEROR) cohort study
(reported by Pollack et al.119), which recruited patients with PE from EDs in the USA, reported a 30-day
all-cause mortality rate of 5.4% for patients with confirmed PE, but the rate of mortality was only 1.1%
when restricted to PE-related in-hospital mortality. These data seem reasonably consistent with the 30-day
data from RIETE.
It was decided to apply the case fatality rate for outpatients from the RIETE study (2.9%) in the model,
as patients having lower-limb immobilisation would be managed as outpatients and there was a slight
increase from 30 days to 90 days, which is captured in the analysis by Maestre et al.108 but not in the other
two analyses, which were limited to 30 days.
Combining the incidence and case fatality rate for PE, it is estimated that one fatal PE per 8097 patients
having lower-limb immobilisation without thromboprophylaxis would be expected, which is consistent
with there being no fatal PEs observed in the studies included in the systematic review for treatment
effectiveness.
Effectiveness of thromboprophylaxis on prevention of venous thromboembolism during
lower-limb immobilisation
We applied the OR for LMWH versus control for the outcome of any VTE estimated from the NMA to all
forms of VTE within the model. Although the NMA provides estimates of clinical effect that are specific to
different types of VTE (i.e. symptomatic DVT, asymptomatic DVT and PE) the estimates for these specific VTE
types are more uncertain as they are based on fewer events. The pooled effect for the OR (0.52, 95% CrI
0.37 to 0.71) was converted to a RR and applied to the baseline risk within the model.
For the sensitivity analyses examining thromboprophylaxis using alternative drug classes, it was assumed
that DOACs would have the same effectiveness as LMWH, as no studies examining the effectiveness
of DOACs in this population were included in the systematic review. For the analysis assuming that
fondaparinux is used, the OR for fondaparinux versus control from the NMA was applied (0.13, 95% CrI
0.05 to 0.30). In both cases, the same adverse effects profile for LMWH, DOACs and fondaparinux were
implicitly assumed, as the only adverse event included in the model was bleeding and it was assumed that
all prophylaxis had the same impact on bleeding rates.
Risk of bleeding during lower-limb immobilisation
There is a risk of major bleeding within the general population regardless of whether or not they receive
treatment with anticoagulants. A cohort study (reported by Hippisley-Cox and Coupland101), conducted
in a large primary care population using data from 4.4 million patients with 16.4 million person-years of
follow-up, estimated an age-standardised incidence rate of 1.34 (95% CI 1.32 to 1.36) per 1000 person-years
for upper GI bleeding and 0.55 (95% CI 0.54 to 0.56) per 1000 person-years for intracranial bleeds for
patients not taking anticoagulants. Given that the study cohort was patients aged 21–99 years registered with
a general practice and that the only relevant exclusion criteria appears to be existing anticoagulated patients,
this study was considered to be reflective of the risk of GI bleeds and ICH in the general population at risk of
lower-limb injury who are not currently taking anticoagulants. The baseline characteristics of patients not
taking anticoagulants in the study by Hippisley-Cox and Coupland101 were compared with the characteristics
of those in the comparator arm of the POT-CAST trial59 (Table 17). Although Hippisley-Cox and Coupland101
did not present a mean age, a weighted mean age was calculated using the distribution across age bands
and the mid-point ages for each band: this was found to be 40 years (with a range of 36–45 years when
using the lower and upper limits of the age bands), which is lower than the mean age of 46 years from the
POT-CAST trial.59 The proportion of non-smokers was slightly lower in the POT-CAST trial and the proportion
of patients with previous cancer was slightly higher.
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To see if the rates of major bleeding in the RCTs included in the clinical effectiveness review were similar,
data on the rates of major bleeding (see Appendix 3) were combined with data on the number of
person-years people were at risk of bleeding within each study. It was assumed that the period at risk was
the period of cast immobilisation, unless the study explicitly reported a longer duration of follow-up. The
number of person-years at risk could be estimated for only 11 of the 13 studies.23,49–56,59,60 One study used
an active control group,57 whereas another did not explicitly report the duration of follow-up.23 There was
only one episode of major bleeding across 447 person-years, giving an incidence of major bleeding of two
per 1000 person-years. This appears to be relatively consistent with the estimates for ICH and GI bleeds
combined from the cohort reported by Hippisley-Cox and Coupland.101 Therefore, it was decided to use the
age-standardised estimates from the cohort reported by Hippisley-Cox and Coupland101 within the model.
Thromboprophylaxis would be expected to increase the risk of a major bleed but the very small number of
major bleeding events in the systematic review meant that the estimate of the risk of major bleeding due
to thromboprophylaxis in people with lower-limb immobilisation was very uncertain (OR 1.45, 95% CrI
0.08 to 32.17). Although the baseline risk of bleeding will vary between patient groups, there is no strong
reason to believe that the relative effect of thromboprophylaxis will vary. Therefore, data from the NICE
clinical guideline (CG) on reducing the risk of VTE (NICE CG92)24 was used, which pooled all indications
into a single meta-analysis.24 These data were reanalysed to use a random-effects approach. In this
meta-analysis, the median OR was found to be 1.643 (95% CrI 0.90 to 2.53). The OR was converted to a
RR and applied to the baseline risk within the model.
TABLE 17 Comparison of baseline characteristics reported by both QBleed (reported by Hippisley-Cox and
Coupland101) and the POT-CAST trial (reported by van Adrichem et al.59)
Characteristic QBleed (no anticoagulation)101 POT-CAST59
Male (%) 48.9 51.5
Age (years), mean (SD) NRa 46 (16)
Age group (years) (%)
21–24 54.6 NR
45–64 29.0 NR
65–74 8.5 NR
75–84 5.4 NR
≥ 85 2.5 NR
BMI (kg/m2), mean (SD) 26 (4.8) 26 (4.4)
Smoking status (%)
Non-smoker 55.9 46.5
Former smoker 18.7 26.8
Current smoker 21.7 26.8
Previous cancer (%) 2.7 4.3
NR, not reported.
a The mean age of 40 years was estimated using the mid-point ages for each age band and age 85 years for the
‘≥ 80 years’ band (range of mean 36–45 years, using upper and lower limits of age bands).
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The significance of major bleeding depends primarily on whether or not it is fatal; for non-fatal bleeds,
the significance depends on whether or not it is intracranial, as ICH has the potential to result in long-term
disability. Fang et al.102 examined death and disability following bleeds associated with warfarin (Coumadin®,
Bristol-Myers Squibb Company, New York City, NY, USA). These data were used to estimate the proportion
of major bleeding episodes that were fatal. Fang et al.102 found that 48.6% of patients having ICH died within
30 days, whereas only 5.1% of patients having non-intracranial bleeds died within 30 days.102 Although it is
acknowledged that bleeds associated with warfarin use may be more likely to result in fatalities than bleeds
in patients not having anticoagulation,120 it seemed reasonable to apply the case fatality rates from bleeds
associated with warfarin use in the model as these would be directly applicable to the additional cases of
bleeding associated with thromboprophylaxis. Any overestimation of mortality in those having bleeds not
related to anticoagulant use would be similar across arms and, therefore, would affect estimates of absolute
QALYs for each thromboprophylaxis strategy but not the incremental QALY gains when comparing
thromboprophylaxis strategies.
The case fatality rate for non-intracranial bleeds reported by Fang et al.102 was lower than the case fatality
rates observed for GI bleeds by Rockall et al.121 and Button et al.,103 but this may be because GI bleeds
have a greater mortality risk than other non-ICHs. Although Button et al.103 found that the case fatality
rate had fallen over time, the case fatality rate of 10% estimated by Button et al.103 appears to be
consistent with a 2015 report122 from the National Confidential Enquiry into Patient Outcome and Death,
based on data collected in 2013. As the data from QBleed101 related only to the incidence of ICH and GI
bleeds, the 10% risk of mortality from Button et al.103 was used instead of the 5% for extracranial bleeds
from Fang et al.102
In addition to the risk of ICH being fatal at the time of the bleed itself, there is an increased risk of death
in patients having ICH compared with population norms. Fogelholm et al.107 found that patients with
primary ICH who survived to 28 days had a standardised mortality rate that was 4.5-fold higher in the
first year and 2.2-fold higher in years 2–6 than that of age- and sex-matched controls. These figures
were applied as RRs to the all-cause mortality rates to increase the risk of mortality in those patients who
survived ICH. Although Fogelholm et al.107 reported a 10% reduction in mortality compared with general
population norms in years 7–16, no increased or decreased risk beyond 6 years was assumed as there was
doubt over the clinical plausibility of a reduced risk of death following ICH.
Risk of bleeding during anticoagulation treatment of venous thromboembolism
Several sources of data on bleeding risks during treatment of VTE were identified. These included the
RIETE105 and Prevention of thromboembolic events – European registry in venous thromboembolism (PREFER-
VTE)123 studies and a systematic review of RCTs and cohort studies by Carrier et al.124 In the review by Carrier
et al.,124 56 of the 69 studies included were RCTs, which the authors say are not generalisable to all patients
with VTE because those with additional comorbid conditions are often excluded from clinical trials. Carrier
et al.124 reported a rate of major bleeding for any VTE of 1.6% (95% CI 1.3% to 2.0%) at 3 months and a
rate of fatal bleeding of 0.2% (95% CI 0.1% to 0.3%). The case fatality rate for bleeding following any VTE
was 11.3%. RIETE reports a rate of major bleeding of 2.24% (95% CI 2.05% to 2.42%) at 3 months and a
rate of fatal major bleeding of 0.55% (95% CI 0.46% to 0.65%) giving a case fatality rate equivalent to
24.7%.105 This higher case fatality rate may be because of a higher rate of comorbidities in an unselected
cohort. In the PREFER-VTE cohort, the rate of major bleeds was 1.5% at 12 months but the rate of fatal
bleeds was not reported.123 In addition, the timing of the bleeds was not reported so it is unclear what the
rate of bleeding would have been during the treatment period. The data from PREFER-VTE were considered
to be more applicable to current UK practice than the data from RIETE as PREFER-VTE included only European
sites, included UK patients and recruited patients after the introduction of DOACs. However, it was noted
that only 56.7% of patients in the PREFER-VTE cohort had a low risk of bleeding at baseline [a HAS-BLED
(Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international
normalised ratio, Elderly, Drugs/alcohol concomitantly) score of 0 or 1].123 As thromboprophylaxis for lower-limb
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injury is likely to be limited to those with a low risk of bleeding, the research team looked for alternative
data sources. A study by Kooiman et al.104 estimated the incidence of major bleeding at 6 months for
patients having treatment for VTE stratified by HAS-BLED score. The combined incidence for patients with
a HAS-BLED score of 0 or 1 was 0.9% (3/335). Kooiman et al.104 did not report risks separately for PE and
DVT but Cohen et al.123 reported that, in PREFER-VTE, the rates of major bleeds were not significantly
different after PE and DVT, so the same rate of 0.9% has been applied to both DVT and PE. This seems
reasonable given that the same treatment is assumed in both groups.
Owing to the greater detail reported by RIETE, the breakdown of major bleeding events into fatal events,
non-fatal ICH and other non-fatal major bleeds was based on the event rates from RIETE.105 The analysis
of RIETE also found that symptomatic PE was not a significant predictor of whether a fatal bleed occurred
and the site of DVT was not a significant predictor unless the DVT was distal when the OR was 0.39
(95% CI 0.16 to 0.95). This lower rate may be as a result of less aggressive anticoagulation therapy or
another confounding factor not accounted for in the analysis. It was decided to apply the same rates of
fatal bleeding in all patients treated for VTE regardless of the VTE event type.
Clinically relevant non-major bleeding during prophylaxis
Clinically relevant non-major bleeding was not included in the base-case analysis as it has a low impact on
quality of life and would be likely to incur a relatively small cost compared with major bleeding. However,
to test whether or not the model was sensitive to this structural assumption, the cost of one ED attendance
was applied to those experiencing CRNMB. To estimate the rate of CRNMB, the ratio of CRNMB to major
bleeding (2.05) from Cohen et al.123 (PREFER-VTE) was applied to the rate of major bleeding for those
having prophylaxis to estimate the proportion of patients having CRNMB during prophylaxis. Owing to
the low rate of bleeding during prophylaxis, the cost of CRNMB was only £0.19 for each patient receiving
prophylaxis. Therefore, the exclusion of this cost from the base-case analysis is not expected to have
significantly biased the base-case results.
Risk of chronic thromboembolic pulmonary hypertension
The incidence of CTEPH following PE was based on a systematic review by Ende-Verhaar et al.,111 which
reported an overall incidence of CTEPH of 2.3% (95% CI 1.5% to 3.1%). The review111 also reported the
incidence separately for all patients with PE (0.56%, 95% CI 0.13% to 0.98%) and for those who survived
the initial 3- to 6-month treatment period for PE (3.2%, 95% CI 2.0% to 4.4%). The follow-up period in
the studies included in the review varied from 3 months to 8 years, with most reporting follow-up of
≈2 years. One study, by Pengo et al.,112 which followed patients prospectively for 10 years, found that no
cases occurred beyond 2 years, despite a median follow-up of 94 months. It is therefore assumed in the
model that all cases are diagnosed between 6 months and 2 years after PE. The rate of CTEPH for those
surviving the initial 3- to 6-month treatment period (3.2%) was considered to be the most relevant
estimate for the model as no diagnoses of CTEPH are assumed until patients complete their anticoagulant
treatment, and deaths during VTE and during anticoagulation are already accounted for in the decision
tree part of the model.
Mortality risks in patients with CTEPH were based on data from an international prospective registry
reported by Delcroix et al.113 A recent HTA report by Goodacre et al.114 used data from this registry to
estimate survival curves for patients having medical or surgical management of CTEPH. The same survival
curves were used in this model to estimate the hazard of death over time for patients diagnosed with
CTEPH. The proportion having surgical management in the registry was 60% and this was applied in the
model. Given that deaths related to PE occurring within 6 months of PE are already accounted for in the
model, all-cause mortality has been applied to those with PE in the first year regardless of whether or not
CTEPH occurs and the rate of mortality for those with CTEPH is applied from year 2 onwards. To ensure
that the risk of death in the CTEPH group was not artificially low compared with the risk of death in the
general population, general population mortality risks were applied whenever these were higher than the
risk in the CTEPH population, based on the survival curves.
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Risk of post-thrombotic syndromes
A review of epidemiological studies by Galanaud et al.125 describes how the incidence of PTS is dependent
on the scoring system used to diagnose PTS, the location and extent of the DVT (e.g. proximal vs. distal),
and the duration of time since DVT. Galanaud et al.125 also discuss how pre-existing chronic venous
insufficiency and the symptomatic versus asymptomatic nature of the DVT may also affect the risk of PTS.
The risk of PTS in patients with symptomatic DVT in the model was estimated from a prospective registry
[Thrombosis and Pulmonary Embolism in Out-Patients – plus (TULIPA-PLUS)], reported by Hach-Wunderle
et al.109 This source was chosen as the study design excluded patients with previous DVT or signs of PTS
prior to the index DVT. The incidence is reported separately for proximal and distal DVT and is stratified
into mild, moderate and severe PTS using a validated scoring system (Villalta scale), which is the scale
preferred by the International Society on Thrombosis and Haemostasis.126 The prevalence of symptomatic
PTS at 3 years was 24.4% for all DVTs, 32.4% for proximal DVT and 15.6% for distal DVT, with 70%
being mild, 24% being moderate and 6% being severe (average across both proximal and distal).109
One applicability issue related to this study was that patients received anticoagulation for a whole year,
which is longer than the period of anticoagulation assumed in the model. Therefore, the rates of PTS may
be underestimated if longer anticoagulation is protective of PTS. However, as it was not known if longer
anticoagulation was protective, and the risk of PTS in this study may reasonably be lower than other
estimates as a result of careful exclusion of PTS symptoms at the time of the index DVT, it was decided
that it was reasonable to apply the incidence from Hach-Wunderle et al.109 in the model given that the
incidence was in the range generally reported (20–50%).125
There are only limited data on the incidence of PTS in patients with asymptomatic DVT because these
patients are less likely to be followed up for a PTS diagnosis as their DVT is less likely to be diagnosed
outside a research setting. However, a study by Persson et al.127 examining PTS incidence in 83 patients
operated on for Achilles tendon rupture, which prospectively identified DVT using colour duplex scanning
3 and 6 weeks after surgery and assessed PTS (assessors were blinded to DVT diagnosis) 5 years post
operatively, reported a low rate of a PTS diagnosis (Villalta score of ≥ 5) of 8% (3/38) in the DVT group and
4% (2/45) in the no-DVT group. All of the diagnosed cases had a Villalta score of < 15 and were therefore
of mild to moderate severity. However, it should be noted that most of those patients with asymptomatic
DVT diagnosed post operatively received warfarin for 3 months and were advised to wear compression
stockings for 1 year. As a result, the rate of PTS in asymptomatic, undiagnosed and, therefore, untreated
DVT is unknown but is likely to be at least 8%. Furthermore, only three of the 38 DVTs were proximal,
making it difficult to estimate the rate of PTS in patients with asymptomatic proximal DVTs from this
study.127
A study by Schindler and Dalziel128 in a related population (those having total hip or knee arthroplasty)
found that four of 34 (11%) with asymptomatic distal DVT and three of eight (32.5%) with asymptomatic
proximal DVT developed PTS 15 to 24 months after surgery. In the knee arthroplasty subgroup (which is
considered to be more clinically relevant to those having lower-limb immobilisation), 28 patients had distal
DVT with one of these having clot propagation leading to proximal DVT. Four of these 28 patients (14.3%)
with DVT developed PTS, with one of these being the patient who had clot propagation. However, PTS
was also diagnosed in 5.3% of those patients without DVT. In this study,128 all those with proximal DVT
were treated with anticoagulants (i.e. 3 months of warfarin), whereas those with distal DVT received
3 months of aspirin. Therefore, the rate of PTS in untreated asymptomatic DVT following hip and knee
surgery remains unknown.
van Dongen et al.110 studied the relationship between inadequate anticoagulation with vitamin K antagonist
(VKA) and the risk of PTS with symptomatic proximal DVT and found that patients who spend > 50% of
their time beneath the international normalised ratio (INR) level of 2.0 are at a higher risk for PTS (OR 2.71,
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
95% CI 1.44 to 5.10). Based on this, one would expect a higher risk of PTS in patients with asymptomatic
proximal DVT that is untreated than in those with treated asymptomatic proximal DVT. Although van Dongen
et al.110 did not include untreated patients in their study, they reported a fourfold increase (OR 3.69, 95% CI
1.29 to 10.53) for those patients spending > 90% of their time outside the target INR range, which suggests
that the risks may be higher still in those patients not offered any anticoagulation.
The rate of PTS in patients with asymptomatic proximal DVTs reported by Schindler et al.128 (32.5%) was
similar to that reported in symptomatic proximal DVT by Hach-Wunderle et al.109 (32.4%). This suggests
that the risk of PTS is similar regardless of whether or not the proximal DVT is symptomatic, provided that
it is treated with anticoagulants. However, given that patients who are asymptomatic in the model will
not receive any anticoagulant treatment as they are not being proactively screened for asymptomatic DVT,
a higher rate for asymptomatic proximal DVT was applied using the OR reported by van Dongen et al.110
for good versus poor anticoagulation (OR 2.71 for those patients spending > 50% of their time outside the
target INR). This gave a rate of PTS of 56.5% for untreated asymptomatic proximal DVT. It is recognised
that the rate of PTS may be higher still for those receiving no anticoagulation at all, as discussed in the
previous paragraph, but this may be partially offset by asymptomatic DVTs being less extensive and,
therefore, less likely to cause PTS.
The rate of PTS in asymptomatic untreated distal DVT was set as equal to that for treated symptomatic
distal DVT, namely 15.6% as reported by Hach-Wunderle et al.109 Inflating this risk further by applying the
OR from van Dongen et al.110 did not seem appropriate, given that this would give a risk of 33.4% and the
clinical experts believed that the rate for untreated distal DVT should be lower than for treated proximal
DVT. Furthermore, it is noted that the rate from Hach-Wunderle et al.109 of 15.6% is nearly twice the
rate reported for treated asymptomatic distal DVT by Persson et al.,127 which would support not inflating
the rate further.
The timing of PTS within the model has been based on data reported by van Dongen et al.,110 who
reported the incidence of PTS at 0.5, 1, 2 and 4 years (Figure 11). The shape of the curve for incidence
over time was compared with that reported by Prandoni et al.129 and was found to be similar, although the
magnitude better matched the upper 95% CI of the estimates of incidence reported by Prandoni et al.129
The hazards based on the incidence reported by van Dongen et al.110 were scaled to match the rate
reported at 3 years by Hach-Wunderle et al.109 for symptomatic proximal and distal DVT. As van Dongen
et al.110 reported no further incidence beyond 4 years, no new incidence of PTS from 4 years was assumed.
The prevalence of PTS over time incorporated within the model is shown in Figure 12.
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Costs of prophylaxis
For thromboprophylaxis during lower-limb immobilisation, it was assumed that patients receive 6 weeks of
treatment using LMWH at the dose recommended for long-term treatment after hip or knee replacement.
In the base-case analysis, it was assumed that the lowest-cost formulation of LMWH would be used
(dalteparin), but the impact of treatment with either fondaparinux or dabigatran was explored in sensitivity
analyses as these represented the highest- and lowest-cost alternatives to LMWH. The dosages and drug
costs are summarised in Table 18.
Menakaya et al.115 estimated the costs of outpatient VTE prophylaxis for patients having lower-limb injuries
based on 388 patients receiving prophylaxis who were recruited from 7048 patients attending a fracture
clinic in England. The total cost for an average of 46 days of anticoagulant treatment was £107.54 for
the self-administration of LMWH, with £46 of this being the drug cost (the authors assumed £1 per day).
Therefore, the total cost of administration was £61.54. This covered clinical time for counselling and
taking blood samples (including a 5-day platelet count), pharmacy dispensing and initial administration.
For patients requiring district nurse administration (£23 per home visit), the average cost of administration
across the treatment course was £1096.54 but this was required in only 4% of cases, giving an average
cost of £102.94 across the cohort. Adjusting the number of doses from 46 to 42, which affects only the
district nurse administration costs, and updating this from 2011/12 to 2016/17 prices (Curtis and Burns100),
gives a total administration cost of £105.13. The total cost for the 6-week course of dalteparin, including
administration costs, was £223.70.
For the sensitivity analysis on fondaparinux, the same administration costs as those required for LMWH
were assumed. Patients initiating treatment with a DOAC were assumed to require one nurse-led telephone
consultation at 10 days. The range tested in sensitivity analysis for the whole course of treatment was
£84.23 for dabigatran to £355.66 for fondaparinux.
When assessing the cost-effectiveness of using RAMs to determine thromboprophylaxis, it is necessary to
include the cost of the time spent by the clinician to determine the individual’s risk score. It was assumed
that this would require 5 minutes of time by a hospital consultant, which was estimated to be £8.83 based
on an hourly cost of £106.100 This was applied to all patients in the RAM-based thromboprophylaxis
strategies but to none of the patients in the treat-all and treat-none strategies.
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TABLE 18 Drug costs for pharmacological prophylaxis of VTE in patients having lower-limb immobilisation
Drug Dosing and delivery21 Product and cost21 Cost per day (£)
Cost per course
(assuming 42 days
treatment) (£)
Administration
cost per course (£)
Total cost per
course (£)
Dalteparin 5000 units every 24 hours by
subcutaneous injection for
4–6 weeks
Dalteparin sodium 5000 units/0.2 ml solution
for injection: £28.23 for 10 pre-filled syringes
2.82 118.57 105.13 223.70
Exonaparin 40 mg every 24 hours by
subcutaneous injection for
4–6 weeks
Enoxaparin sodium 40mg/0.4 ml: £30.27 for
10 pre-filled syringes
3.03 127.13 105.13 232.26
Tinzaparin 4500 units every 24 hours by
subcutaneous injection for
4–6 weeks
Tinzaparin sodium 4500 units/0.45 ml solution
for injection: £35.63 for 10 pre-filled syringes
3.56 149.65 105.13 254.78
Fondaparinux 2.5 mg every 24 hours by
subcutaneous injection for
4–6 weeks
l Arixtra 2.5 mg/0.5 ml solution for injection:
£62.79 for 10 pre-filled syringes
l Fondaparinux 2.5 mg/0.5 ml solution for
injection: £59.65 for 10 pre-filled syringes
[Dr Reddy’s Laboratories (UK) Ltd,
Beverley, UK]
5.97 (assuming that
the lowest-cost
formulation was
prescribed)
250.53 105.13 355.66
Apixaban 2.5 mg orally twice daily Eliquis 2.5 mg tablets 1.90 79.80 12.83 92.63
Dabigatran 220 mg orally daily Pradaxa 110 mg capsules: £51.00 for
60 capsules (same cost per capsule for 10)
1.70 71.40 12.83 84.23
Rivaroxaban 10mg orally daily Xarelto 10 mg tablets: £54.00 for 30 tablets
(same cost per tablet for 10)
1.80 75.60 12.83 88.43
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Cost of treatment
Patients who have lower-limb immobilisation may later present with symptomatic DVT or PE, requiring
diagnosis and treatment. The costs of VTE have been estimated for three broad categories of costs: health-
care contacts, diagnostic costs and drug treatment costs. It was assumed that all patients presenting with
symptomatic VTE would require an ED assessment, but that a proportion would present first to a general
practitioner (GP) before attending an ED, and that only a proportion of those attending an ED would require
admission. It was assumed that those patients requiring admission would also be likely to require ambulance
transfer to the ED. The proportion of patients attending GPs prior to ED attendance and the proportion
requiring admission (Table 19) were based on clinical expert opinion. Discussions with clinical experts were
informed by the assumptions used in the model described in the 2017 draft update to the NICE guideline
on managing VTE130 and the assumptions used in relevant NICE single technology appraisals (STAs).131–139
Diagnostic tests that occur during the ED episode of care, such as electrocardiography monitoring and chest
radiography, are not costed separately. However, scans occurring later as outpatient activity were costed
separately as these diagnostic tests are ‘unbundled’ within the NHS reference cost data.116 Assumptions
regarding the use of diagnostic tests to assess patients with suspected DVT and PE were based on clinical
expert opinion. The main costs not covered within the ED episode of care are assumed to be leg vein
ultrasonography for patients with a suspected DVT and computerised tomography pulmonary angiography
(CTPA) or ventilation/perfusion scans for patients with a suspected PE. A minority of patients (20%) with
suspected PE are also assumed to require echocardiography. The diagnostic tests are summarised in Table 19.
It was assumed that all patients presenting with PE or symptomatic DVT (proximal or distal) would be treated
with anticoagulants.
Treatment for VTE was assumed to consist of 3 months of either a VKA (warfarin) or a DOAC. Patients
being treated with a VKA would also require initial anticoagulation with LMWH until adequate oral
anticoagulation is established. The proportion receiving DOACs versus VKA was informed by data from
the PREFER-VTE study,123 which found that 40% of patients in countries where DOACs had been launched
were receiving a DOAC as their initial treatment following DVT. The split between drugs in the LMWH
class was informed by assumptions used in a previous appraisal.140 The costs of administering treatment
with LMWH are based on the costs estimated by Menakaya et al.115 for initiating prophylaxis using LMWH
but with a reduction in district nurse administration based on the shorter duration of treatment (7 vs. 42 days).
Patients receiving VKA are assumed to require nine visits to an anticoagulation service in 3 months to monitor
their INR. Patients initiating treatment with a DOAC are assumed to require one nurse-led telephone
consultation at 10 days. All patients are assumed to require a consultant-led face-to-face visit at 3 months to
assess the need for ongoing treatment. The overall cost, including monitoring, when averaged across the
treatment strategies was £290.24 (Table 20).
The total cost for non-fatal PE was estimated to be £1788, which includes health-care contacts, diagnostic
costs and 3 months of drug treatment for VTE. Fatal PE was assumed to incur the same costs for health-care
contacts and diagnostics, but without the cost of VTE treatment, giving a cost of £1498. Symptomatic
proximal and distal DVTs had a total cost of £688 and £560, respectively, with the higher cost of proximal
DVTs driven by a greater likelihood of admission.
Cost of bleeding complications
A paper by Luengo-Fernandez et al.117 on the acute and long-term costs of care after stroke in patients with
atrial fibrillation (AF) was identified as a source of costs in those having ICH from the NICE appraisal of
edoxaban tosylate (Lixiana®; Daiichi Sankyo UK Ltd, Gerrards Cross, UK) for the treatment and secondary
prevention of DVT and/or PE.140 The paper117 provides estimates of acute (up to 90-day) and long-term costs
(average annual costs up to 5 years post stroke) using data from the Oxford Vascular Study (OXVASC), which
was a prospective study of 91,000 UK patients registered with general practices in Oxfordshire. The paper by
Luengo-Fernandez et al.117 reports costs for the subset of patients who experienced a stroke during the study
and who had a history of AF prior to that index stroke (n = 153). The mean age of patients in this subset was
80 years, with 26% of patients having previous stroke and 20% of patients having pre-morbid warfarin use.
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TABLE 19 Resource use and costs for patients presenting with PE and symptomatic DVT
Resource item
Proportion using resource (%)
Unit cost per
patient using this
resource (£) DescriptionNon-fatal PE
Symptomatic
proximal DVT
Symptomatic
distal DVT
Health-care contacts/admission
GP visit 20 50 50 37 Curtis and Burns,100 GP cost per surgery consultation with
qualification costs, including direct care staff costs
Ambulance transfer to ED 60 10 0 236 NHS Schedule of Reference Costs 2015–16.116 ‘See and treat and
convey’, code ASS02
ED visit leading to admission 60 10 0 228 NHS Schedule of Reference Costs 2015–16.116 VB05Z type 01
admitted (category 2 investigation with category 3 treatment)
ED visit without admission 40 90 100 196 NHS Schedule of Reference Costs 2015–16.116 VB05Z type 01
non-admitted (category 2 investigation with category 3 treatment)
Short stay admission for PE 60 0 0 1498 NHS Schedule of Reference Costs 2015–16.116 Weighted average
cost of non-elective inpatient (short and long stay with excess
bed-days) for ‘pulmonary embolus with interventions’, codes
DZ09 J to DZ09 N and DZ09P and DZ09Q
Short stay admission for DVT 0 10 0 1012 NHS Schedule of Reference Costs 2015–16.116 Weighted average
cost of non-elective inpatient (short and long stay with excess
bed-days) for ‘deep-vein thrombosis’, CC score 0 to ≥ 12, codes
YQ51 A to YQ51E
Critical care unit stay 10 0 0 1012 NHS Schedule of Reference Costs 2015–16.116 Weighted average
cost of adult critical care, 0 to 6 or more organs supported, codes
XC01Z to XC01Z
Subtotal for health-care contacts (£) 1365 342 214
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TABLE 19 Resource use and costs for patients presenting with PE and symptomatic DVT (continued )
Resource item
Proportion using resource (%)
Unit cost per
patient using this
resource (£) DescriptionNon-fatal PE
Symptomatic
proximal DVT
Symptomatic
distal DVT
Diagnostic costs
Risk assessment tool (Wells score) Included in an ED episode of care so not costed separately
D-dimer Included in an ED episode of care so not costed separately
ECG Included in an ED episode of care so not costed separately
Chest radiography
Proximal leg vein ultrasonography 0 100 100 55 RD40Z, outpatient ultrasound scan (duration of < 20 minutes),
without contrast, cost £55 [RD47Z may be more relevant for the
diagnosis of distal DVTs, but cost is similar (£58)]116
CTPA 90 0 0 102 RD21A, outpatient computerised tomography scan of one area,
with post contrast only, patients aged ≥ 19 years116
V/Q SPECT 5 0 0 261 RN08A, outpatient SPECT, patients aged ≥ 19 years116
V/Q planar 5 0 0 274 RN18A, outpatient lung ventilation or perfusion scan, patients
aged ≥ 19 years116
Echocardiography 20 0 0 72 RD51A, outpatient simple echocardiography116
Subtotal for unbundled
diagnostics (£)
133 55 55
Subtotal for drug treatment (£) 290 290 290 See Table 20
Total (£) 1788a 688 560
CC, complication or comorbidity; ECG, electrocardiography; SPECT, single-photon emission computed tomography; V/Q, ventilation/perfusion.
a Fatal PEs are assumed to incur diagnostic and inpatient costs but not VTE treatment costs (i.e. total cost of £1498).
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TABLE 20 Drug costs for treating DVT and PE
Drug Dosing and delivery Product and cost
Cost (£)
Percentage using
treatment
Drug, per
course
Monitoring/
administration
Apixaban Initially, 10 mg twice daily for 7 days, orally,
followed by 5 mg twice daily, orally, for the
remainder of the 3-month (91-day) treatment period
Apixaban, 5 mg: £53.20 for 56 tablets
(cost per tablet is the same for the
28-tablet pack size)
186.20 50.00a 20% (half of the 40%
using DOACs)
Rivaroxaban Initially, 15 mg twice daily for 21 days, to be taken
orally with food. This is followed by 20mg once
daily, to be taken orally with food for the remainder
of the 3-month (91-day) treatment period
Rivaroxaban, 20 mg: £50.40 for
28 tablets (cost per tablet is the same
for 15 mg tablets and larger and
smaller pack sizes)
201.60 50.00a 20% (half of the 40%
using DOACs)
Enoxaparin 1.5 mg/kg every 24 hours by subcutaneous injection
until adequate oral anticoagulation established
(7 days) (i.e. 120mg of enoxaparin if assuming
weight of 80 kg)
l Clexane Forte, 120 mg/0.8 ml
solution: £87.93 for 10 pre-filled
syringes, prescription-only medicine
l Assumed for other drugs
61.55 70.26b 30% (45% of heparin use)
Dalteparin 15,000 units (assuming body weight of 80 kg) once
daily until adequate oral anticoagulation established
(7 days)
Dalteparin sodium, 15,000 units/
0.6 ml solution: £42.34 for five
pre-filled syringes
59.28 70.26b 18% (35% of heparin use)
Tinzaparin 175 units/kg once daily until adequate oral
anticoagulation established (7 days) (i.e. 14,000
units if assuming body weight of 80 kg)
Innohep, 14,000 units/0.7 ml solution:
£83.30 for 10 pre-filled syringes
58.31 70.26b 6% (20% of heparin use)
Warfarin 5 mg twice daily orally for 3 months (91 days) Warfarin sodium, 5 mg (various
suppliers): £0.70 for 28 tablets
4.55 186.27c 60%
Average across those using
DOACs and those using
LMWH/VKA
116.35 173.89 Total: £290.24
HRG, Healthcare Resource Group.
a Based on one nurse-led telephone follow-up (WF01C) at 10 days and one consultant-led follow-up (WF01A) at 3 months to assess the need for ongoing treatment.116
b Based on the costs estimated by Menakaya et al.,115 with the number of district nurse administrations reduced to reflect the shorter duration of treatment (7 days vs. 6 weeks).
c Based on HRG costs for nine face-to-face visits at a non-consultant-led anticoagulation service over 3 months (WF01B for first attendance and WF01A for follow-up) plus a consultant-led
follow-up at 3 months to assess the need for ongoing treatment.116
Note
Costing assumes that packs of syringes and packets of tablets can be split between patients by the dispensing pharmacy.
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The costs were reported separately on the basis of disability level and whether the type of stroke was
ischaemic, haemorrhagic or not known. Only 17 of the 191 strokes experienced by the 153 patients were
haemorrhagic. The mean acute cost of fatal haemorrhagic strokes was £1592 (SD £1886; n = 8). This
mean cost was substantially lower than the average for all haemorrhagic strokes, which was £10,683
(SD £12,885; n = 17). Given that these estimates were based on a small number of patients, the estimates
for all stroke types were also considered. The cost of fatal strokes across all types was also lower, at £2680
(SD £2661; n = 40), than the average for all strokes (mean £10,413, SD £15,105; n = 191), suggesting
that fatal strokes do incur a lower acute cost than non-fatal strokes. The cost of fatal haemorrhagic strokes
was used in the base-case analysis for fatal intracranial bleeds. The cost was updated from 2008/9 prices
to 2016/17 prices (using Curtis and Burns100), giving an acute cost of £1802 over 3 months.
The paper by Luengo-Fernandez et al.117 also provided relevant data on the cost of non-fatal ICHs. The cost
of a non-fatal haemorrhagic stroke was estimated to range from £3401 to £24,234, depending on the
level of disability following the stroke. A weighted average cost for non-fatal haemorrhagic strokes of
£18,764 was calculated across the non-disabling, moderately disabling and totally disabling haemorrhagic
strokes. However, it was noted that these estimates were based on only nine non-fatal haemorrhagic
strokes. The equivalent average across all non-fatal strokes was £12,461. The higher cost for haemorrhagic
non-fatal strokes appeared reasonable given that haemorrhagic strokes appeared to result in higher than
average costs across all categories except fatal strokes. This is supported by data presented by Fernando
et al.,141 which show that patients with haemorrhagic stroke who are admitted to an intensive care unit
(ICU) incur higher costs than matched patients (matched for age, sex and comorbidity) admitted to an ICU
for other (non-ICH) reasons. Furthermore, ICHs associated with oral anticoagulant use were also found to
be significantly more costly than those not associated with oral anticoagulant use.141 The weighted average
cost for non-fatal haemorrhagic stroke from Luengo-Fernandez et al.117 was used in the base-case analysis
for the acute cost of non-fatal ICH. This cost was updated from 2008/9 prices to 2016/17 prices (using
Curtis and Burns100), giving non-fatal ICH a cost of £21,245 over 3 months.
It was noted that this cost for non-fatal ICH is significantly higher than the weighted average cost of stroke
based on NHS reference costs for non-elective long- and short-stay inpatients (including excess bed-days),
which was £3290 [average of reference costs116 for Healthcare Resource Group (HRG) codes AA35A to
AA35F]. However, the average NHS reference cost is similar to the cost reported by Luengo-Fernandez et al.117
for non-disabling stroke costs. This may reflect the fact that rehabilitation costs are reported separately in
NHS reference costs and these costs are between £332 and £402 per day for admitted rehabilitation. These
rehabilitation costs would have been included in the hospitalisation costs reported by Luengo-Fernandez
et al.117 and would be much higher for moderately and totally disabling strokes, which may explain the
higher costs in these groups than the NHS reference cost for admitted care in stroke patients, which excludes
rehabilitation.
The model also required post-acute costs (post 90 days) for patients having non-fatal ICH. Luengo-Fernandez
et al.117 estimated the post-acute costs per annum relative to the year before stroke (baseline). The total
post-acute costs were found to be non-significantly higher versus baseline costs at £804 (95% CI –£832 to
£2440). However, the GP and emergency care components were significantly higher at £98 (95% CI £27 to
£169) and £99 (95% CI £56 to £141), respectively. In addition, the paper separately reported long-term
residential care costs for patients not previously admitted to residential care. They reported that 18% of
strokes resulted in a new admission to long-term care (i.e. warden housing, residential care or nursing
home care), with an average annual cost of £6880 across all patients surviving the acute period (90 days).
Post-acute and long-term costs were not reported separately by stroke type (haemorrhagic vs. other) by
Luengo-Fernandez et al.117 The total costs of GP, emergency care and long-term care were averaged across
all stroke types and uplifted to current prices (using inflation indices from Curtis and Burns100) to give a total
cost per year for non-fatal ICH patients of £8013 in the post-acute (beyond 90 days) period. This was applied
in the Markov phase of the model to patients in the non-fatal ICH health state. It was also applied pro rata to
patients having non-fatal ICH more than 90 days before the end of the decision tree model.
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The cost of non-fatal extracranial bleeds was estimated using average inpatient costs for GI bleeds, based
on the approach taken in the NICE Technology Appraisal (TA) 354.140 A weighted average was taken
across bleeds requiring single, multiple or no intervention and across short- and long-stay non-elective
inpatients (including excess bed-days). This gave an average cost of £1198 based on 2015/16 reference
costs (HRG codes FZ38G to FZ38P).116
Cost of post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension
Several reviews of studies relating to PTS were examined to identify any cost papers cited.125,142–145 None
of the cost papers identified were specific to the UK NHS. Three examined costs from a US perspective
(Caprini et al.,146 MacDougall et al.147 and Olin et al.148), one examined costs from a Brazilian perspective
(Ramacciotti et al.149), one examined costs from a Swedish perspective (Bergqvist et al.150) and one
examined costs from a Canadian perspective (Guanella et al.151). Although the paper by Bergqvist et al.150
was from a European country, the data related to patients diagnosed between 1970 and 1985.
Several of the NICE STAs identified in Appendix 11 cited cost assumptions from Goodacre et al.152
One cited the US study by Caprini et al.146 and another cited costs from a 2001 abstract by Cohen et al.153
It was assumed in the model that management of PTS would involve one first and one follow-up vascular
surgery outpatient appointment in the first year after diagnosis and two follow-up GP appointments every
year thereafter. This was based on clinical expert advice regarding current management of PTS in the UK
and is consistent with the assumptions made by Goodacre et al.,152 which have been applied in several
previous NICE STAs.131,132,140,154
A review by Grosse et al.143 on the costs attributable to VTE in the USA identified one paper155 on the
cost burden of CTEPH. Kirson et al.155 compared costs for patients with CTEPH with those for controls
(matched for age, sex, employee status and geographical region) in a cohort of privately insured US patients.
They found that costs per month were US$2368 (p < 0.0001) higher in patients with CTEPH than in matched
controls, but they also found higher rates of comorbidities, suggesting that some of the differences may
not be directly attributable to CTEPH. Grosse et al.143 commented that CTEPH patients are far more likely to
have chronic heart failure or chronic pulmonary disease, and no risk-adjusted treatment cost estimates were
identified in their review.
The cost of CTEPH was based on the approach taken in technology appraisal (TA) number 354 (i.e. TA354)140
in which pulmonary endarterectomy costs were applied based on reference costs for complex thoracic
procedures. Updating this estimate by using current reference costs116 gave a cost of £7898. The Evidence
Review Group’s preferred assumption for TA354140 was to use the cost of drugs from CG92,24 which
estimated a cost of £1219 per 4 weeks, giving a cost of £17,942 per annum when uplifted to 2016/17
prices (using inflation indices from Curtis and Burns100). Data from Delcroix et al.113 were used to estimate
the proportion having surgical management and the proportion receiving medical management. The fact
that some surgical patients receive bridging therapy, as reported by Delcroix et al.,113 was taken into
account by allowing them 4.6 months of medical therapy based on the average time to surgery for these
patients. This increased the costs in the first year for patients having surgical management to £9890. It was
assumed that no further costs are incurred in year 2 and beyond for those having surgical management.
Summary of methods used to identify studies reporting utility values relevant to the model
The searches for the systematic review of published cost-effectiveness studies included a filter to identify
health-related quality of life (HRQoL) data. While sifting these studies, one study156 reporting HRQoL data in
patients with lower-limb immobilisation was identified; this study by Arverud et al.,156 reported EuroQol-5
Dimensions (EQ-5D)157 scores in patients who had an Achilles tendon rupture. The study reported mean
EQ-5D scores at 1 year for patients who did and patients who did not experience DVT following surgical
repair and immobilisation. The average EQ-5D score was lower in patients with DVT but the difference was
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not statistically significant (p = 0.6). A second study158 identified in the search reported the validation of
a disease-specific HRQoL measure, Deep Venous Thrombosis Quality of Life (DVTQoL), in patients with
DVT but this study reported only the correlation between the EQ-5D and the domains of the DVTQoL;
utility values based on EQ-5D scores could not be extracted. No other studies reporting preference-based
measures of utility in patients with lower-limb immobilisation were identified from the searches conducted
for the economic review.
One published study by Wolowacz et al.99 was identified from the literature review that examined the
cost-effectiveness of thromboprophylaxis for a similar, but not directly relevant, population (elective knee
replacement) as described in Results of cost-effectiveness review. This was supplemented by searches of
the NICE website to identify models developed to inform NICE TAs and CGs, as these models would be
expected to have a relevant setting and methodological approach and would not always be identified
through database searches. The cost-effectiveness analyses identified are summarised in Appendix 11.
In addition, ad hoc searches for systematic reviews of utilities for relevant model states (e.g. PTS) were
conducted using the Google Scholar search engine (Google Inc., Mountain View, CA, USA). This identified
a published systematic review of HRQoL studies for VTE and related complications by Lubberts et al.159
This review focused on studies with a minimum follow-up of 1 year in order to capture the long-term
impact of complications such as PTS and CTEPH. Only two of the studies included by Lubberts et al.159
reported a generic preference-based utility measure (EQ-5D). One of the two studies reporting EQ-5D was
conducted in patients with subclavian DVT and is therefore less applicable to this population. The other
study, by Haig et al.,160 reported EQ-5D scores for patients with and without PTS following DVT.
In addition, the systematic review by Lubberts et al.159 reports outcomes for 15 studies that used either
the Short Form questionnaire-36 items (SF-36)161 or the Short Form questionnaire-12 items (SF-12). Data
from these studies were meta-analysed to assess the difference in HRQoL between patients and members
of the general population matched by country, age and sex. Lubberts et al.159 report the meta-analysed
decrement in SF-36/SF-12 mental component summary (MCS) and physical component summary (PCS)
scores compared with general population norms (matched by country, age and sex) using the standardised
mean difference (SMD) as a common currency across studies. These meta-analyses by Lubberts et al.159 do
not provide a preference-based utility measure that can be used directly in the model, but their outcomes
are summarised below as they provide evidence as to whether or not each VTE-related outcome has an
important impact on long-term HRQoL based on more than a single study. They are therefore useful in
interpreting the utility estimates from individual studies identified from existing cost-effectiveness models.
Although Lubberts et al.159 included only studies reporting outcomes more than 1 year after VTE, they also
listed nine studies158,162–169 that were excluded for reporting outcomes at shorter follow-up points. Of these,
one study by Hogg et al.163 reported useful data (see Appendix 12); the remaining eight studies did not
report utility values for relevant health states.158,162,164–169
One additional HRQoL study170 was identified from ad hoc searches; Roberts et al.170 examined the
predictors of HRQoL for patients following DVT using the SF-36. This is also discussed below as it provides
useful additional information on PTS as a determinant of HRQoL.
The sources of utility data identified from both the published models listed in Appendix 11 and the
systematic review by Lubberts et al.159 are summarised in Appendix 12.
Utility values in pulmonary embolism
Lubberts et al.159 report that PE is associated with a significant reduction in SF-36 PCS score (SMD –0.30,
95% CI –0.45 to –0.14) but not SF-36 MCS score (SMD 0.14, 95% CI –0.01 to 0.30), relative to general
population norms at time periods of > 1 year based on an analysis of two studies.171,172 This suggests that
PE has an important long-term impact on patients. Three studies173–175 reported EQ-5D outcomes for
patients with PE, although two of these studies173,174 were published only in abstract form and the other
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study175 used Danish rather than UK population norms. One study used an alternative generic preference-
based measure, the Short Form questionnaire-6 Dimensions (SF-6D).163 In addition, two studies176,177
reported utility values for PE measured directly using either standard gamble or time trade-off (TTO). Data
from the study abstract by Cohen et al.173 were reported in additional detail in the company submission for
TA354140,178 (Figure 13).
The data from Cohen et al.153 were selected for use in the model because these were measured using the
EQ-5D, were sourced from a large registry database (PREFER-VTE) including patients recruited in the UK
and the paper included estimates of the change in utility over time (see Figure 13). The data reported by
Cohen et al.173 demonstrated that utility values varied depending on the time since PE, with utility values
appearing to stabilise at between 3 and 6 months. The average utility in patients with PE during the
6 months following PE was calculated using the data from Cohen et al.173 This was compared with the
utility value at 6 months in patients with DVT (who do not have a long-term utility decrement according
to the review Lubberts et al.159) to calculate the utility multiplier for PE, which was then applied to the age
appropriate utility for patients without PE. A linear change in utility between the points measured was
assumed, giving an average utility of 0.775 over the 6 months after PE, which is a 9% decrement relative
to utility at 6 months post DVT. Given that there was some evidence of a reduction in HRQoL for patients
with PE found by Lubberts et al.159 at 1 year, it was decided to use the 6-month utility decrement for PE
relative to DVT, when no long-term reduction was found, to estimate the long-term utility reduction for
patients following PE. This gave a 5% reduction in utility beyond 6 months for a patient surviving PE
beyond 6 months. Tavoly et al.175 reported mean EQ-5D values of 0.8 in patients post PE versus 0.86 in
age- and sex-matched general population controls, suggesting a 7% reduction in utility despite a median
time since diagnosis of 3.8 years. This supports the assumption that there are some ongoing post-PE
symptoms beyond 6 months.
Utility values in deep-vein thrombosis
The data sources for utility values in DVT were similar to those identified for PE, except that the study
by Tavoly et al.175 was not relevant because it examined only patients with PE. However, a similar study
by Utne et al.179 examining DVT outcomes from the same hospital registry was identified instead. One
additional study by Arverud et al.156 examining DVT versus no DVT after lower-limb immobilisation due to
injury was also identified. This study found that DVT identified by screening (colour duplex sonography)
2 weeks post operatively was a non-statistically significant predictor of worse EQ-5D scores (0.918 vs.
0.906; p = 0.604). This may be expected given that the DVTs were detected by screening and, therefore,
may have been asymptomatic. Utne et al.179 found that EQ-5D score was statistically significantly lower
for patients with DVT compared with age- and sex-matched buddy controls. However, these patients
were recruited any time after DVT, and a significant proportion had PTS, so the reduction compared with
controls may have been partly due to PTS symptoms, which are likely to be persistent beyond 6 months.
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FIGURE 13 Data from Cohen et al.,173 as reported in the company submission for TA354.140,178
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In the first 6 months of the model, the data from Cohen et al.173 were used to estimate the average
utility, which was compared with the utility at 6 months. This gave a utility decrement of 4%, on average,
during the first 6 months after DVT. Beyond 6 months, no utility decrement for patients without PTS was
assumed, as the systematic review by Lubberts et al.159 reported that there was no statistically significant
difference in SF-36 PCS and MCS scores for DVT at time periods of > 1 year based on an analysis of nine
studies.172,180–187 Utne et al.179 did not find a statistically significant difference in the odds of having
impaired HRQoL, measured by EQ-5D, depending on whether the DVT was proximal or distal. In the
absence of any other data on the difference in HRQoL impact of proximal versus distal DVT, the same
utility loss was assumed during the first 6 months for symptomatic proximal DVT and symptomatic
distal DVT.
Utility values in post-thrombotic syndrome
Lubberts et al.159 reported that patients with PTS had significantly lower MCS and PCS scores than matched
population norms (SMD for MCS score –0.27, 95% CI –0.43 to –0.11; SMD for PCS score –0.89, 95% CI
–1.21 to –0.57), based on an analysis of seven studies.180–182,184–186,188 Five studies reported utility values
for patients with PTS,160,177,189–191 with two studies160,189 reporting EQ-5D scores and three studies177,190,191
using direct measures of utility such as standard gamble or TTO. The data reported by Haig et al.160 and
Enden et al.189 were the 2-year and 5-year follow-up points from the catheter-directed thrombolysis versus
standard treatment for acute iliofemoral deep vein thrombosis (CaVenT) study that compared catheter-
directed thrombolysis (with 24 months of compression stockings) against standard treatment (6 months of
anticoagulant and 24 months of compression stockings) for patients with high proximal DVT. The CaVenT
study189 found no difference in EQ-5D scores between treatment arms at 6 months, 2 years or 5 years, but
did find a statistically significant difference in HRQoL between those with PTS (n = 92) and those without
PTS (n = 97) at 24 months and 5 years. At 6 months, the mean EQ-5D scores were lower for those with PTS
but the difference was not statistically significant (p = 0.062).
The decrement measured at 2 years in the CaVenT study189 was applied to all patients with PTS in the
Markov phase of the model. It was decided not to model a change in HRQoL for patients with PTS over
time as some HRQoL decrement is likely to be present from the time of diagnosis of PTS (i.e. 6 months
after DVT) and the HRQoL impact of PTS appears to remain apparent at 5 years. Therefore, a 10%
decrement was applied based on the 24-month data from Enden et al.189
Supportive evidence is provided in the study by Roberts et al.,170 which reported that patients without PTS
recovered their SF-36 PCS scores from below population norms by 6 months, whereas those with mild or
moderate/severe PTS did not experience a similar recovery. This study170 also reported that the location of
DVT (i.e. proximal or distal) was not an independent predictor of HRQoL, with only sex, comorbidities and
PTS being significant predictors in the multivariate analysis.
As the CaVenT study189 reported the average utility decrement across all PTS, without stratifying by PTS
severity, this value was applied in the model for all patients with PTS. This may overestimate the utility
decrement if patients in the CaVenT study had more severe PTS than would be seen in the modelled
population and severity was a predictor of utility decrement. However, in the study by Roberts et al.,170 the
coefficients for mild versus no PTS and for moderate/severe versus no PTS were similar in the regressions for
SF-36 PCS and MCS scores, suggesting that both mild and moderate/severe PTS had similar implications for
HRQoL. Furthermore, the review by Lubberts et al.159 shows that the 5-year estimates from the CaVenT study
reported by Haig et al.160 are fairly consistent with the average across the 10 studies160,180–182,184–186,188,192,193
that reported outcomes for the disease-specific measure of HRQoL Venous Insufficiency Epidemiological and
Economic Study – Quality of life (VEINES-QoL). A sensitivity analysis was conducted to see if halving the utility
decrement for PTS had a significant impact on the model results. A sensitivity analysis was also conducted
using the data from Lenert and Soetikno190 and estimating a weighted average utility across severe and mild/
moderate PTS using the data from Hach-Wunderle et al.109 to estimate the proportion of PTS that is severe
(6%). This gave an average utility decrement of 2% rather than the 10% assumed in the base-case analysis.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
Utility values in chronic thromboembolic pulmonary hypertension
Only one study included in the review by Lubberts et al.159 reported outcomes for CTEPH, and this reported
statistically significantly lower MCS (SMD –0.31, 95% CI –0.54 to –0.08) and PCS scores (SMD –1.72, 95% CI
–1.95 to –1.48) than matched population norms. Six studies were identified as providing information on
preference-based measures of HRQoL in patients with CTEPH. Three of these studies reported data based
on the EQ-5D,194–196 a fourth reported data from an alternative generic preference-based measure, the
SF-6D197 and a fifth reported data from a condition-specific preference-based measure, the Cambridge
Pulmonary Hypertension Outcome Review (CAMPHOR).198 Finally, one study reported values based on a
standard gamble.199 Only one of the papers reported values specifically for patients with CTEPH195 but this
paper was restricted to those with resistant/recurrent or inoperable CTEPH (i.e. those in whom pulmonary
endarterectomy had failed or was not possible). The paper by Ara and Brazier194 reported data for ‘other
heart problems’ (i.e. not heart attack/angina). The study by Keogh et al.197 only included patients with
idiopathic pulmonary arterial hypertension (PAH) or PAH related to connective tissue disease. Two studies,
by Olschewski et al.196 and Meads et al.,198 included patients with CTEPH and other forms of PAH but
Meads et al.198 reported utility outcomes separately for those with CTEPH. Meads et al.198 also reported a
statistically significant difference in utility between CTEPH and those with PAH associated with connective
tissue disorder. There was some inconsistency in the estimates provided by Ghofrani et al.195 and Meads
et al.,198 with higher baseline scores in the population with inoperable/recurrent resistant CTEPH (0.66 for
placebo arm) in Ghofrani et al.195 than in the CTEPH subgroup reported by Meads et al.198 (0.56). This may
be because patients accepted into trials have slightly better general health than those receiving treatment in
general practice. It was decided to use the data from Meads et al.198 in the model; this was calculated based
on the difference between the average utility for patients with CTEPH (0.56) and the average utility for
those with New York Heart Association (NYHA) class 1 (0.89), who would be expected to have minimal
HRQoL impact. This gave a multiplier of 0.63 or, equivalently, a 37% decrement relative to patients who are
well. The decrement was applied for a patient’s lifetime for those who were medically managed but only
applied for the first year for those being surgically managed, who had the decrement for PE applied
thereafter.
Utility values following intracranial haemorrhage
Of the 10 studies177,190,194,200–206 reporting utility values for stroke patients, six studies 194,200–204 measured
utility using the EQ-5D. Another four studies177,190,205,206 reported utility values using a direct standard
gamble or TTO measure, but these were disregarded as generic measures of HRQoL are preferred by
NICE.94 The values based on the EQ-5D ranged from 0.31 (as reported by Pickard et al.)203 to 0.70 (as
reported by Lunde et al.).202 Luengo-Fernandez et al.201 reported that the decrement ranged from 0.22 at
1 month to 0.09 at 5 years. Studies that reported multiple time points found that the absolute utility value
increased and the decrement versus controls decreased over time. The study with the longest follow-up201
found that utility values were relatively stable from 6 months to 5 years post stroke. The data from the
5-year follow-up of the OXVASC study201 were chosen for application in the model as this was the largest
sample of stroke patients, the population was selected from the UK, the duration of follow-up allowed
time since stroke to be accounted for, and a comparison was made against general population norms.
A decrement of 0.22 was assumed in the decision tree part of the model where time since stroke was
< 6 months and a decrement of 0.09 was assumed in the long-term part of the model.
Utility values for major non-intracranial haemorrhage bleeds
For major non-ICH bleeds, no studies were identified that measured utility using the EQ-5D or another
generic preference-based measure. Two studies176,206 reported values using the standard gamble and a
third used TTO.177 Two of the studies that recruited at least some patients with VTE reported a utility value
of 0.65,176,177 whereas the study in patients with AF reported a much higher value of 0.841.206 The study
by Locadia et al.177 (median 0.65, interquartile range 0.49 to 0.86) was considered to be the most relevant
as it used TTO, which is the same method used to generate utility vales for the EQ-5D, and it explicitly
included patients with experience of major bleeding episodes during VKA treatment in addition to some
patients with VTE. However, using the data from Locadia et al.177 directly would have resulted in a lower
utility value for non-ICH bleeds than for ICH, which would not have had face validity. As the study by
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Locadia et al.177 showed similar valuations for the PE and GI bleed health states, and these states were
ranked as equivalent, it was decided to use the data for PE from Cohen et al.173 in the model as the
longer-term data provided by Cohen et al.173 allows the utility multiplier to be calculated relative to a
patient who has recovered from VTE (i.e. relative to a patient 6 months after a DVT). The utility multiplier
was, therefore, estimated to be 0.80 (0.68/0.84). As major non-ICH bleeds are not expected to lead to
long-term disability, the utility multiplier for major bleeding was applied for 28 days.
Treatment-related utility decrement
Given that thromboprophylaxis involves giving patients treatment even though they may not go on to
experience a VTE event without treatment, it is important to include in the model the possibility that
treatment itself is associated with harm.
Several sources of data were identified for the decrement associated with prophylaxis and treatment of
VTE. Six studies reported the utility decrement for warfarin or other VKAs. Four of these studies177,205–207
used a direct measure of utility (e.g. TTO or standard gamble) and two of these studies173,208 measured
utility using the EQ-5D. The study by Monz et al.208 examined HRQoL in a subset of the Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, which was a randomised comparison of
dabigatran and warfarin in patients with AF. Therefore, it was unable to measure the utility impact of
warfarin alone. However, it did report that there was no statistically significant difference in HRQoL based
on treatment type (DOAC vs. warfarin) and the utility scores observed were similar to age-comparable
population norms. Cohen et al.173 reported EQ-5D data by treatment type (heparin only, heparin/VKA,
DOAC) from the PREFER-VTE registry. However, it was not clear whether or not patients receiving heparin
alone in the PREFER-VTE registry would have different characteristics from those receiving other forms of
treatment for VTE, in which case the difference in utility between heparin and other VTE treatments may
have been confounded by patient characteristics and their influence on clinicians’ choice of anticoagulant.
Only two studies173,207 provided data on the disutility associated with heparin. Given the potential bias
described above for Cohen et al.,173 it was decided to use the data provided by Marchetti et al.;207 in this
study, a TTO exercise was used in 48 patients attending an anticoagulation clinic who had experience of
LMWH. The trade-off was based on clinical vignettes for hypothetical patients receiving LMWH. The
average number of days they were willing to trade was 2.7 days over a 1-year time frame. Therefore,
a mean decrement of 0.007 was applied during thromboprophylaxis.
Four studies provided directly elicited measures of utility for warfarin therapy. Two were in patients with
AF.205,206 Marchetti et al.207 was the only study conducted exclusively in patients with a history of VTE.
Half of the patients recruited by Marchetti et al.207 had previous experience of receiving warfarin. All of the
patients in the study reported by Locadia et al.177 had been treated previously with a VKA, but not all had
previous VTE. The utility decrement for VKA versus no VKA was 4% for Locadia et al.177 (0.92 vs. 0.96)
based on median estimates of utility for both states, whereas it was 1% for Marchetti et al.207 based on a
willingness to trade 4 of 365 days of full health to avoid warfarin. The estimate from Marchetti et al.207 is
similar to the estimates from Gage et al.205 in patients with AF, whereas the estimate from Locadia et al.177
is close to the estimate from Robinson et al.206 It was decided to use the data from Marchetti et al.207 to
provide an estimate consistent with the methodology used to estimate the utility decrement for LMWH.
In the sensitivity values exploring the use of DOACs as prophylaxis, no utility decrement has been assumed,
as DOACs are taken orally and do not require frequent blood tests to monitor INR levels. In the sensitivity
analysis exploring the use of fondaparinux as prophylaxis, the same utility decrement as for LMWH was
assumed as both treatments are given by subcutaneous injection.
The utility values applied in the model are summarised in Tables 21 and 22.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Timing and duration of utility decrements applied in the decision tree
To calculate the QALYs gained by patients having different paths through the decision tree, it is necessary
to make some assumptions regarding the timing of events, as these are not explicitly modelled in a
decision tree. The following assumptions were made when estimating QALYs in the decision tree:
l Baseline utilities using general population utility values for the starting age are applied to those not
having treatment and not having any clinical events (e.g. VTE, bleeds).
l Bleeds during lower-limb immobilisation are assumed to occur halfway through the immobilisation
period, which is assumed to last 8 weeks (56 days), namely bleeds occur at 28 days.
l VTEs occurring during lower-limb immobilisation are assumed to be diagnosed at the end of
immobilisation (i.e. at 56 days) and utility decrements for PE and DVT are applied from diagnosis until
the end of the decision tree period.
l Bleeds occurring during treatment for VTE are assumed to occur at 13, 32 and 12 days post diagnosis
of VTE for fatal, ICH and other major bleeds, respectively (based on data from RIETE, reported by
Nieto et al.105).
TABLE 21 Utility values included in the decision tree model
Health state value
Absolute
utility
value Range Source Notes
Well/asymptomatic
DVT without
prophylaxis
0.879 0.878 to 0.882 Ara and Brazier194 Population mean utility values based on
person (average for male and females)
with starting age of 46 years
Symptomatic
proximal or distal DVT
0.848 0.846 to 0.850 Cohen et al.173 (using
additional detail reported
in TA354,140 Daiichi
Sankyo company
submission, table B78178)
5% reduction relative to well patients
based on comparison of average utility
over 6 months for DVT (0.819) vs. utility
at 6 months (0.850) for patients with DVT
Non-fatal PE 0.80 0.780 to 0.825 Cohen et al.173 (using
additional detail reported
in TA354,140 Daiichi
Sankyo company
submission, table B78178)
9% reduction relative to well patients
based on comparison of average utility
over 6 months (0.775) for PE vs. utility at
6 months (0.850) for patients with DVT
Non-fatal ICH 0.66 0.616 to 0.701 Luengo-Fernandez
2013201
Absolute decrement of 0.22 measured at
1 month
Non-fatal non-ICH
bleed
0.69 0.652 to 0.688 Cohen et al.173 l Assumed same utility decrement for PE
and GI bleeds at 1 month
l 21% reduction based on utility for
PE at 1 month (0.67) versus utility
for DVT at 6 months (0.85) from
Cohen et al.173
Prophylaxis: absolute
decrement applied to
utility values of well/
asymptomatic DVT
0.007 0.000 to 0.050 Marchetti et al.207 Patients willing to trade average of
2.7 days per year to avoid treatment with
LMWH
Treatment: absolute
decrement applied to
utility values for
non-fatal PE or
symptomatic DVT
0.011 0.000 to 0.081 Marchetti et al.207 Patients willing to trade average of
4 days per year to avoid treatment with
warfarin
Fatal PE 0 NA Assumption
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l Disutilities for ICH are applied lifelong, but separate disutilties are applied in decision tree and Markov
phases of the model (i.e. before and after 6 months post lower-limb immobilisation).
l Disutility of GI bleeding is assumed to last a maximum of 28 days.
l Disutility of prophylaxis applies for the duration of prophylaxis (6 weeks) and is therefore less in those
stopping early because of major bleeding.
l Disutility of treatment for VTE applies for the duration of treatment (3 months) and is therefore less in
those stopping early because of major bleeding.
The following assumptions were made when estimating QALYs in the Markov model:
l Utility values for patents without any long-term sequelae (e.g. ICH, CTEPH, PTS) are taken from general
population values and decrease as patients age in the model.
l All other utility values are applied as multipliers, such that the absolute utility value decreases for all
patients as a result of ageing.
l Utility decrements continue in the Markov model for the remainder of a patient’s lifetime for PE but not
for DVT, for which patients are assumed to return to general population utility values at 6 months.
l Patients with CTEPH who are treated medically have a lifelong utility decrement, whereas those treated
surgically return after 1 year to the same utility as those surviving PE without CTEPH.
l Patients with PTS have the same utility decrement from diagnosis to death.
l Patients with ICH have the same utility decrement from 6 months (i.e. the start of Markov model)
to death.
TABLE 22 Utility multipliers applied in the Markov model to the absolute utility value for well patients
Health state(s)
Utility
multiplier
relative
to well Range Source Notes
PE survivor without
CTEPH and PE
survivor > 1 year after
surgery for CTEPH
0.95 0.927 to 0.978 Cohen et al.173 5% reduction relative to well patients
based on comparison of average utility
at 6 months for patients with PE (0.81)
vs. utility at 6 months (0.85) for patients
with DVT
Any DVT without PTS 1 N/A Assumption Supported by Lubberts et al.’s159
systematic review finding no significant
HRQoL decrement in nine long-term
studies based on SF-36 outcomes
Non-fatal ICH 0.89 0.810 to 0.955 Luengo-Fernandez et al.201 Multiplier calculated based on absolute
decrement of 0.09 at 5 years (utility
values stable from 6 months to 5 years)
relative to absolute utility for well state of
0.88 from general population values
PTS 0.90 0.855 to 0.944 Enden et al.189 Multiplier calculated based on absolute
decrement of 0.09 relative to absolute
utility for well state of 0.86
CTEPH: first year for
surgically managed
and every year for
medically managed
0.63 0.579 to 0.690 Meads et al.198 Multiplier calculated based on
comparison of utility for CTEPH (0.56) vs.
utility for NYHA class I (0.89)
Dead 0 Assumption
N/A, not applicable; NYHA, New York Heart Association.
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Methods used to quantify decision uncertainty
A probabilistic sensitivity analysis (PSA) was used to estimate the impact of parameter uncertainty on
the estimates of costs and QALYs. For each input parameter, a probability distribution was assigned that
reflected the degree of uncertainty surrounding the mid-point parameter estimate and we sampled from
the distribution 10,000 times. This number of runs was deemed sufficient because it ensured that the
coefficient of variation was < 2% for both incremental costs and incremental QALYs. In general, utility
values, which must be < 1, and probabilities, which are bounded by 0 and 1, were sampled from beta
distributions, and costs, which must be > £0, were sampled from gamma distributions. Uncertainty
surrounding the ORs for efficacy (all VTE events) and adverse events (major bleeds) were captured using
the convergence diagnostics and output analysis (CODA) samples from the NMA. When parameters were
calculated from regression equations, multivariate normal sampling was used to incorporate the covariance
between the regression parameters. The estimates of sensitivity and specificity were fixed within the PSA
as the uncertainty around these parameters was not reported by Nemeth et al.32 Table 39 in Appendix 13
presents the distributions for each parameter included in the PSA. For each of the 10,000 sets of
parameter inputs, the costs and QALYs of each thromboprophylaxis strategy were re-estimated.
The 10,000 PSA estimates of costs and QALYs were used to estimate the mean costs and QALYs for each
thromboprophylaxis strategy. From this, the incremental net monetary benefit (INMB) was estimated when
using a willingness-to-pay threshold of £20,000 or £30,000 per QALY, which is the range of thresholds
used by NICE when assessing value for money in the context of the UK NHS.94 The strategy with the
maximum INMB at a given threshold is considered to have the optimal cost-effectiveness. The INMB was
used to calculate the optimal thromboprophylaxis strategy at both of these thresholds and the proportion
of times, within the 10,000 PSA samples, that each strategy is optimal across a range of thresholds was
estimated in order to generate the cost-effectiveness acceptability curve (CEAC).
The global expected value of perfect information (EVPI) was estimated, which tells a decision-maker the
value of reducing all current decision uncertainty associated with the parameters included in the PSA.
This was estimated across all the complete set of possible thromboprophylaxis strategies. The parameter
EVPI analysis was also used to assess the importance of each individual parameter in generating uncertainty
around the optimal strategy. The Sheffield Accelerated Value of Information (SAVI) tool was used to
calculate parameter EVPI.209
It should be noted that a PSA and an EVPI analysis can capture only uncertainty related to parameters
included in the PSA and will not capture any uncertainty associated with structural assumptions or the
choice of data inputs used to estimate parameter uncertainty. These uncertainties are quantified instead
using deterministic sensitivity analyses, in which a range of alternative parameter inputs and assumptions
are explored within the model to see whether or not the conclusions are robust under these changes.
Results of the de novo economic evaluation
Clinical outcomes predicted by the model
The symptomatic adverse clinical outcomes predicted by the model at 6 months (based on mid-point
parameter values) are summarised in Figures 14 and 15. As patients may have more than one adverse
outcome during the 6-month time period of the decision tree model, patients are summarised on the basis
of the worst outcome experienced, such that those recorded as having non-fatal PE or symptomatic DVT
are those who did not also have fatal bleed, fatal PE or ICH. In Figure 14 it can be seen that prophylaxis
for all is the strategy that minimises the total number of symptomatic adverse outcomes at 6 months.
The numbers of the most serious adverse clinical outcomes (e.g. fatal bleeds, fatal PEs or ICHs) are similar
across the prophylaxis strategies and the differences are too small to see based on Figure 14. Figure 15
focuses solely on these serious adverse clinical outcomes and shows that giving prophylaxis based on a
L-TRiP(cast) score of ≥ 9 minimises the total number of these outcomes, although the rate is very low
(≈1 in 4000) and shows little variation between strategies.
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It should be noted that major bleeds that are non-fatal and not ICHs are assumed to resolve within 6 months
and are, therefore, not included in Figure 14. The number of major bleeding outcomes is summarised in
Figure 16, which shows that the total number of major bleeds, including fatal and non-fatal ICHs, increased
from 4.03 per 10,000 having lower-limb immobilisation when no prophylaxis is given to 5.38 per 10,000
when prophylaxis is given to all. Giving prophylaxis to all patients with lower-limb immobilisation, therefore,
results in fewer than two additional cases of major bleeding per 10,000 patients receiving prophylaxis.
The increase in major bleeding is smaller than would be expected based solely on the RR of 1.64 for bleeding
with prophylaxis versus bleeding without prophylaxis, because prophylaxis prevents VTE, thereby lowering
the rate of bleeding experienced during VTE treatment.
The adverse clinical outcomes predicted by the model at 5 years (based on mid-point parameter values)
are summarised in Figure 17. Only those outcomes resulting in long-term morbidity are included;
therefore, patients who experience DVTs without any subsequent PTS are not included in the adverse
clinical outcomes shown. It can be seen that the number of people surviving to 5 years is fairly similar
across all the thromboprophylaxis strategies. The strategy of thromboprophylaxis for all results in the
smallest number of people surviving with CTEPH, PTS or ongoing morbidity due to previous ICH or PE.
The numbers surviving with either ongoing morbidity due to ICH or CTEPH following PE are relatively
small, at ≈1 per 10,000 patients for each outcome.
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FIGURE 14 Symptomatic clinical outcomes predicted at 6 months for 10,000 patients having lower-limb
immobilisation due to injury.
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FIGURE 15 Serious adverse clinical outcomes predicted at 6 months for 10,000 patients having lower-limb
immobilisation due to injury.
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Cost-effectiveness of thromboprophylaxis for all compared with thromboprophylaxis
for none
Figure 18 shows the estimates of incremental costs and QALYs for the comparison of thromboprophylaxis
for all with thromboprophylaxis for none for 10,000 PSA samples. The mean incremental costs and QALYs
from the 10,000 PSA samples are shown as an × on the cost-effectiveness plane. The mean QALY gain is
0.015, but it can be seen that there is a wide spread of incremental QALY estimates, with 95% of the
incremental QALYs falling in the range of 0.004 to 0.029 but with some PSA samples (0.53%) having a
negative QALY gain. The mean incremental cost is £203 with 95% of the PSA estimates falling in the
range £172–245. The incremental cost-effectiveness ratio (ICER) for thromboprophylaxis for all compared
with thromboprophylaxis for none based on the mean costs and QALYs is £13,524. Therefore, if a
decision-maker is willing to pay £20,000 per QALY, it would be cost-effective to give thromboprophylaxis
to all patients with lower-limb immobilisation due to injury if this was the only alternative to giving
thromboprophylaxis to none. However, it can be seen that a significant proportion of the PSA estimates
fall above the £20,000 per QALY threshold; therefore, there is a 24% probability that thromboprophylaxis
for all is not cost-effective.
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FIGURE 17 Adverse clinical outcomes predicted at 5 years for 10,000 patients having lower-limb immobilisation due
to injury.
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FIGURE 16 Major bleeding predicted at 6 months for 10,000 patients having lower-limb immobilisation due
to injury.
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Cost-effectiveness of using a risk assessment model to determine thromboprophylaxis
The results of all of the thromboprophylaxis strategies considered in the model (based on the mean outputs
of the PSA for 10,000 samples) are summarised in Table 23 and Figure 19. It can be seen in Figure 19 that,
generally, the QALYs increase as the proportion receiving prophylaxis increases across the decision tools, with
the QALY gains becoming more marginal as the proportion receiving prophylaxis increases. Furthermore, it can
be seen in Figure 19 that L-TRiP(cast)-7 is extendedly dominated, as the ICER to move from L-TRiP(cast)-8 to
L-TRiP(cast)-6 would be lower than the ICER to move from L-TRiP(cast)-8 to L-TRiP(cast)-7, but more QALYs are
gained by L-TRiP(cast)-6. However, it should be noted that the point for L-TRiP(cast)-7 is close to falling on the
cost-effectiveness frontier [i.e. on the line between L-TRiP(cast)-8 and L-TRiP(cast)-6]. The incremental analysis
for the remaining non-dominated strategies is shown in Table 24. The optimal strategy would be L-TRiP(cast)-9
if the decision-maker values QALYs at £20,000 and L-TRiP(cast)-8 if the decision-maker values QALYs at
£30,000.
Optimal balance of sensitivity and specificity for a risk assessment model
From the base-case results, it can be seen that as we move from higher to lower thresholds of the L-TRiP(cast)
score, the QALYs gained increase as the sensitivity of the risk assessment tool increases but the cost increases
as the specificity decreases. The ROC curve for the L-TRiP(cast) score provided by Nemeth et al.32 allows us to
explore where the optimal balance of sensitivity and specificity lies when assuming that it lies somewhere on
the ROC curve provided by L-TRiP(cast). To do this, a linear regression on the logit scale was fitted to the points
on the ROC plane from L-TRiP(cast)-6 to L-TRiP(cast)-10 (intercept = –1.5256, gradient = 0.8098, R2 = 0.9926).
The sensitivity and specificity values were then varied between the L-TRiP(cast)-9 and L-TRiP(cast)-8 points
of the curve to maximise the INMB using the deterministic model that uses mid-point parameter estimates.
It was identified that, when valuing a QALY at £20,000, the INMB is maximised for a sensitivity of 84% and
a specificity of 55%, resulting in 48% of patients being treated. When valuing a QALY at £30,000, the INMB
is maximised for a sensitivity of 89% and a specificity of 46%, resulting in 57% of patients being treated.
Therefore, even when using an optimised balance between sensitivity and specificity on the ROC curve
predicted by the data from Nemeth et al.,32 between 43% and 52% of patients would not receive
thromboprophylaxis. The incremental costs and QALYs for these optimal points are shown in Figure 20.
It can be seen from this that the optimal points on the ROC curve are actually extendedly dominated by the
points for LTRiP(cast)-9 and LTRiP(cast)-8. This is because the ROC curve predicted by the linear regression
on the logit scale passes below the data points for LTRiP(cast) scores of 9 and 8.
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FIGURE 18 Cost-effectiveness plane for the comparison of thromboprophylaxis for all vs. thromboprophylaxis
for none.
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TABLE 23 Base-case results (mean from 10,000 PSA samples) in order of the percentage receiving prophylaxis
Prophylaxis strategy
% receiving
prophylaxis Sensitivity Specificity
Absolute
costs (£)
Absolute
QALYs
Cost vs. no
prophylaxis (£)
QALYs vs. no
prophylaxis
ICER vs.
prophylaxis
for none (£)
INMB vs.
prophylaxis
for none, at
£20,000 per
QALY (£)a
INMB vs.
prophylaxis
for none, at
£30,000 per
QALY (£)a
Prophylaxis for none 0 0 1 65.37 16.6198 N/A N/A N/A N/A N/A
L-TRiP(cast)-10 31 0.651 0.722 128.11 16.6301 62.73 0.0103 6085 143.44 246.53
L-TRiP(cast)-9 43 0.808 0.608 150.96 16.6326 85.58 0.0127 6724 168.96 296.23
L-TRiP(cast)-8 63 0.926 0.397 194.41 16.6342 129.04 0.0144 8984 158.24 301.88
L-TRiP(cast)-7 76 0.953 0.262 222.55 16.6345 157.17 0.0146 10,755 135.10 281.23
L-TRiP(cast)-6 87 0.984 0.142 247.51 16.6348 182.14 0.0150 12,183 116.87 266.38
Prophylaxis for all 100 1 0 268.35 16.6348 202.98 0.0150 13,524 97.20 247.29
N/A, not applicable.
a INMB at £20,000 per QALY and INMB at £30,000 per QALY are the INMBs when valuing a QALY at £20,000 and £30,000 per QALY, respectively.
Note
Bold text indicates the optimal strategy.
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TABLE 24 Incremental analysis for interventions sitting on the cost-effectiveness frontiera
Absolute
costs (£) Absolute QALYs
Cost vs. previous
row (£)
QALY vs. previous
row
ICER vs. previous
row (£)
No prophylaxis 65.37 16.6198 N/A N/A N/A
L-TRiP(cast)-10 128.11 16.6301 62.73 0.01031 6085
L-TRiP(cast)-9 150.96 16.6326 22.85 0.00242 9448
L-TRiP(cast)-8 194.41 16.6342 43.46 0.00164 26,550
L-TRiP(cast)-6 247.51 16.6348 53.09 0.00059 90,554
Prophylaxis for all 268.35 16.6348 20.84 0.00006 357,026
N/A, not applicable.
a L-TRiP(cast)-7 does not fall on the cost-effectiveness frontier as it is extendedly dominated.
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Uncertainty surrounding base-case results
Figure 21 shows the cost-effectiveness plane for L-TRiP(cast)-9 (the optimal strategy when valuing QALYs
at £20,000) versus no prophylaxis. It can be seen that there is considerable uncertainty in the size of the
QALY gain but there is a low chance of the optimal strategy resulting in QALY losses, compared with
no prophylaxis, with 95% of the incremental QALYs falling in the range of 0.005 to 0.024. In terms of
costs savings, 95% of the incremental costs fell in the range of £69 to £107, suggesting that the optimal
strategy is unlikely to result in cost savings compared with no prophylaxis. This is expected, as prophylaxis
results in definite costs to those receiving it but the benefits of preventing VTE are small and uncertain
when averaged over the whole population receiving prophylaxis. Similar distributions of incremental costs
and QALYs were seen for the other L-TRiP(cast) cut-off scores, with all predicting additional costs and
additional QALYs and a mean ICER of < £20,000 relative to a strategy of no prophylaxis.
Figure 22 is the CEAC, which shows the probability that each strategy is optimal when varying the amount
that the decision-maker is willing to pay for a QALY. It can be seen that L-TRiP(cast)-9 has the highest
probability (66.8%) of being optimal when valuing a QALY at £20,000, which is consistent with the results in
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Table 24. L-TRiP(cast)-8 has a slightly higher probability of being optimal when valuing a QALY at £30,000,
but there is also a high probability of L-TRiP(cast)-9 remaining optimal. This makes sense given that the
ICER for L-TRiP(cast)-8 versus L-TRiP(cast)-9 is only just under £30,000 per QALY. It can also be seen that
L-TRiP(cast)-7 always has a low probability of being optimal regardless of what the decision-maker is willing
to pay and that the decision-maker would need to be willing to pay more than £100,000 per QALY before
prophylaxis for all is the optimal strategy. This is interesting because if the risk-stratifying decision tools had
not been included in the analysis, then prophylaxis for all would have been cost-effective compared with
prophylaxis for none. This demonstrates the potential value of using decision tools to target prophylaxis in a
cost-effective manner instead of focusing on evaluating all or nothing prophylaxis options.
To demonstrate the impact of different strategies on a health service, L-TRiP(cast)-9 can be compared with a
strategy of using prophylaxis for all across the English NHS. In Chapter 1, Description of the health problem,
it was estimated that 70,000 people per year across the English NHS experience temporary lower-limb
immobilisation due to injury as an outpatient. Using the mean outputs from the PSA, it is found that
prophylaxis for all would result in an additional 0.0023 QALYs per person, but for an additional cost of
£117.40 per person when compared with L-TRiP(cast)-9. Applied to the 70,000 annual population for the
English NHS, the cost saving that could be achieved by giving prophylaxis to only those with a L-TRiP(cast)
score of ≥ 9 would be £8.2M pounds and the QALYs lost would be 160. Conversely, if the impact of giving
prophylaxis to patients at a L-TRiP(cast) score of 9 compared with treatment for none is considered, it is
found that the additional cost to the NHS is £6.0M, with QALY gains of 891 for a population of 70,000
patients having lower-limb immobilisation. One-tenth of this additional cost to the NHS is the upfront cost
of performing risk assessment in all patients with lower-limb immobilisation following injury to identify
those requiring prophylaxis.
Value to the decision maker of reducing uncertainty in the estimates of
cost-effectiveness
The global EVPI was estimated, which tells a decision-maker the value of reducing all current decision
uncertainty associated with the PSA parameters. It was found that the overall EVPI was £4.12 per patient
treated, suggesting that although treating patients at the L-TRiP(cast)-9 cut-off score would be expected
to achieve an INMB of £168.96 per patient compared with no prophylaxis, based on current information,
only 2.4% more INMB could be achieved with perfect information. This suggests that the value of
reducing the decision uncertainty further is low on a per-patient basis. However, if the EVPI is estimated
over 5 years, assuming that 70,000 patients have lower-limb immobilisation due to injury every year, then
the overall discounted population EVPI is £1.3M.
Parameter EVPI analysis was also used to assess the importance of each individual parameter in generating
uncertainty around the optimal strategy. Based on this, the most important parameters for decision
uncertainty were the utility value for PTS, the efficacy of thromboprophylaxis in reducing VTE, the probability
of PTS for patients with distal DVT and the utility decrement associated with taking prophylaxis. This suggests
that the main factors driving uncertainty in the model are the efficacy and disutility of receiving prophylaxis,
and the long-term complications of PTS. The incidence of PTS in patients with distal DVT is particularly
important probably because asymptomatic DVT is more common than symptomatic DVT and the majority
of asymptomatic DVTs are expected to be distal in this population. However, the magnitude of the overall
EVPI suggests that a large-scale RCT comparing thromboprophylaxis with no thromboprophylaxis would be
unlikely to be cost-effective.
It should be noted that EVPI analysis can capture only uncertainty related to parameters included in the
PSA and will not capture any uncertainty associated with structural assumptions or the choice of data
inputs used to estimate parameter uncertainty. These uncertainties are quantified instead using
deterministic sensitivity analyses.
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Important factors driving the cost-effectiveness estimates identified during model validation were:
l incidence, long-term costs and utility decrement for PTS
l baseline risks of VTE and the proportion of DVTs that are distal
l costs and efficacy of prophylaxis and prophylaxis-related disutility.
These have been explored in deterministic sensitivity analyses by examining changes in the outputs of the
deterministic model (the values produced when assuming mid-point parameter inputs) when changing one
or more selected parameter inputs.
Scenario analyses and threshold analyses
The results of the individual scenario analyses are summarised in Table 25 by reporting the optimal
thromboprophylaxis strategy when valuing a QALY at £20,000 and £30,000 for each scenario.
Whether or not the age of the cohort being offered prophylaxis would alter the conclusions was examined,
as it is likely that those receiving prophylaxis under the various decision tools would be older than the mean
age of the whole group who have lower-limb immobilisation due to injury. It was found that increasing the
mean starting age of the whole cohort to 70 years increased the ICERs but L-TRiP(cast)-9 remained optimal
at £20,000 and L-TRiP(cast)-8 remained optimal at £30,000 with an ICER of £29,555 versus L-TRiP(cast)-9.
This suggests that the decision to use a cohort approach based on average age is unlikely to have over- or
underestimated prophylaxis benefits sufficiently to alter the key conclusions regarding the optimal strategy.
A threshold analysis was conducted to see how much the mid-point estimates of efficacy for LMWH in
preventing VTE would need to change to alter the optimal prophylaxis strategies. It was found that a
decrease in the hazard ratio (HR) (improvement in efficacy) from 0.54 to 0.44 would make L-TRiP(cast)-8
the optimal strategy at both £20,000 and £30,000 per QALY, whereas an increase in the HR (decrease in
efficacy) to 0.60 would make L-TRiP(cast)-9 optimal at both £20,000 and £30,000 per QALY. An increase
in the HR to 0.76 would be required for L-TRiP(cast)-9 to no longer be optimal at £20,000 per QALY.
An increase in the HR to 0.84 would be required for treatment for none to be the optimal strategy at
£20,000 per QALY.
It was examined whether or not the conclusions would differ if all patients were assumed to receive either
fondaparinux or DOACs instead of LMWH for prophylaxis. For this, no difference in adverse event rates
was assumed across the different prophylaxis options. Costs were assumed to vary in each case as per
the costing analysis in Table 18. For DOACs, equivalent efficacy to LMWH was assumed and no utility
decrement for DOACs was assumed because they are taken orally. For fondaparinux, the efficacy estimates
from the NMA for fondaparinux versus control (OR 0.1, 95% predictive interval 0.05 to 0.3, from the
random effects analysis) were used and the same utility decrement as applied for LMWH was assumed
because both drugs are given by subcutaneous injection. Using DOACs shifted the optimal strategy when
valuing a QALY at £20,000 from L-TRiP(cast)-9 to L-TRiP(cast)-8 and shifted the optimal strategy when
valuing a QALY at £30,000 to treat all. Using fondaparinux resulted in the ICER for L-TRiP(cast)-8 versus
L-TRiP(cast)-9 falling under £20,000 per QALY but L-TRiP(cast)-8 remained optimal when valuing a QALY at
£30,000. It should be noted that these two scenarios are fairly crude and do not fully explore differences
between the different drug classes in terms of adverse events. Furthermore, in the case of DOACs the
analysis is based on an assumption of equivalent efficacy. The intention here was to explore whether or
not the optimal cut-off point for providing thromboprophylaxis would differ when using a different drug
class, rather than determining the optimal drug class to use for thromboprophylaxis.
In addition to a lack of precision in the estimates of utility decrement associated with PTS, there were
differences in the estimates provided by different papers. The data from Lenert and Soetikno190 were used,
which had lower decrements for PTS and showed that the optimal strategy when willing to pay £20,000
per QALY became L-TRiP(cast)-10, with L-TRiP(cast)-9 having an ICER of just under £30,000 in this scenario.
This suggests that there is considerable decision uncertainty associated with the choice of utility data for PTS.
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TABLE 25 Deterministic sensitivity analyses
Scenario description Base-case parameter value Alternative parameter value
Optimal strategy
when valuing a
QALY at £20,000
Optimal strategy
when valuing a
QALY at £30,000
Base case N/A N/A L-TRiP(cast)-9 L-TRiP(cast)-8
High starting age 46 years 70 years L-TRiP(cast)-9 L-TRiP(cast)-8
Low starting age 46 years 20 years L-TRiP(cast)-9 L-TRiP(cast)-8
DOACS used for prophylaxis LMWH with cost of £223.70 and utility
decrement of 0.007 and an OR for
preventing VTE of 0.52
DOACs with cost of £84.23 and no utility
decrement and an OR for preventing VTE
of 0.52
L-TRiP(cast)-8 Prophylaxis for all
Fondaparinux used for prophylaxis LMWH with cost of £223.70 and utility
decrement of 0.007, and an OR for
preventing VTE of 0.52
Fondaparinux with cost of £355.66 and
utility decrement of 0.007 and an OR for
preventing VTE of 0.13
L-TRiP(cast)-8 L-TRiP(cast)-8
Double utility decrement for LMWH Utility decrement of 0.007 Utility decrement of 0.015 L-TRiP(cast)-9 L-TRiP(cast)-8
Cost of patients with CRNMB attending ED £0 (costs of CRNMB excluded in base-case
analysis)
£196 per patient having CRNMB L-TRiP(cast)-9 L-TRiP(cast)-8
Discounting 3.5% costs and 3.5% QALYs 1.5% costs and 1.5% QALYs L-TRiP(cast)-8 L-TRiP(cast)-8
Discounting 3.5% costs and 3.5% QALYs 3.5% cost and 1.5% QALYs L-TRiP(cast)-8 L-TRiP(cast)-8
Utility decrement of PTS based on data from
Lenert and Soetikno190
10% utility decrement for PTS vs. no PTS 2% utility decrement for PTS vs. no PTS L-TRiP(cast)-10 L-TRiP(cast)-9
Costs of PTS based on US estimates by
Caprini et al.146
l Year 1: £308
l Year 2: £74
l Year 1: £1022
l Year 2: £423
L-TRiP(cast)-9 L-TRiP(cast)-8
Time to complete risk assessment scoring tool 5 minutes of consultant time 20 minutes of consultant time L-TRiP(cast)-9 L-TRiP(cast)-8
Risk of PTS in patients with asymptomatic
distal DVT
15.6% at 3 years None L-TRiP(cast)-9 L-TRiP(cast)-9
Risk of PTS in patients with asymptomatic
proximal DVT
56.4% at 3 years (inflated vs. symptomatic
as untreated)
Same as symptomatic proximal DVT:
32.4% at 3 years
L-TRiP(cast)-9 L-TRiP(cast)-8
Higher risk of bleeding without prophylaxis 0.03% in 8 weeks Five times base-case value, namely 0.15%
in 8 weeks
L-TRiP(cast)-9 L-TRiP(cast)-8
Higher risk of bleeding without prophylaxis 0.03% in 8 weeks 10 times base-case value, namely 0.29%
in 8 weeks
L-TRiP(cast)-9 L-TRiP(cast)-9
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Scenario description Base-case parameter value Alternative parameter value
Optimal strategy
when valuing a
QALY at £20,000
Optimal strategy
when valuing a
QALY at £30,000
Proportion of symptomatic DVTs that
are distal
50% distal 0% distal (all proximal) L-TRiP(cast)-9 L-TRiP(cast)-8
Proportion of symptomatic DVTs that
are distal
50% distal 100% distal (none proximal) L-TRiP(cast)-9 L-TRiP(cast)-8
Proportion of asymptomatic DVTs that
are distal
84% distal 0% distal (all proximal) L-TRiP(cast)-8 L-TRiP(cast)-8
Proportion of asymptomatic DVTs that
are distal
84% distal 100% distal (none proximal) L-TRiP(cast)-9 L-TRiP(cast)-9
Increased VTE baseline risk 8.39% total VTE with 1.34% symptomatic
DVT or PE
Three times baseline, namely 25% total
VTE with 4.01% symptomatic DVT or PE
L-TRiP(cast)-6 Prophylaxis for all
Decreased VTE baseline risk 8.39% total VTE with 1.34% symptomatic
DVT or PE
One-third of baseline, namely 2.8% total
VTE risk with 0.45% symptomatic DVT
or PE
Prophylaxis for
none
L-TRiP(cast)-10
N/A, not applicable.
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An assumption was made regarding the resource use associated with management of PTS based on clinical
expert advice. A costing study from the USA146 reported higher costs, possibly related to more aggressive
management of PTS. Whether or not using these higher cost estimates changed the conclusions was tested;
it was found that the optimal strategies did not change, suggesting that the costs of managing PTS are not
an important source of decision uncertainty.
It should also be noted that the PSA does not incorporate any uncertainty related to the estimates of
sensitivity and specificity. Therefore, a scenario analysis was conducted in which, for each strategy, the
specificity was fixed and the sensitivity was reduced so that it fell half-way between the observed value and
the line on the ROC curve, which represents a tool that is no better than random selection. The alternative
points are shown in Figure 23. The approximate AUC for the alternative points is 0.62, which is in the lower
range of the CI for the AUC for the L-TRiP(cast) score is the plaster cast subgroup of the derivation cohort
(AUC mean 0.76, 95% CI 0.66 to 0.86).32 A similar AUC was achieved when L-TRiP(cast) score was validated
in a subgroup of patients having plaster cast in the THE-VTE study (0.77, 95% CI 0.58 to 0.96) but a much
better AUC was achieved when it was validated in the Milan study (0.95, 95% CI 0.91 to 0.99).32 It can be
seen in Figure 24 that, in this scenario assuming a lower AUC, the ICER for moving from each L-TRiP(cast)
cut-off score to the next is fairly constant, such that the gains in QALYs when increasing the numbers treated
are fairly proportional to the gains in cost across all L-TRiP(cast) cut-off scores. In this scenario, treatment for
all is the optimal strategy when valuing a QALY at either £20,000 or £30,000. This tells us that the shape
of the ROC curve is important in determining whether or not risk assessment tools can be used to target
treatments more cost-effectively. If the tool used is less efficient at identifying the patients at risk, as indicated
by a lower AUC, then a strategy of treating all patients would be most cost-effective. It was examined how
much the sensitivity and specificity values could change before the RAM based thromboprophylaxis became
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FIGURE 24 Cost-effectiveness plane when assuming that L-TRiP(cast) performs less well than observed by Nemeth
et al.32 (AUC of 0.62 instead).
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extendedly dominated by treatment for all (i.e. when the ICER vs. no treatment was the same for both).
It was found that for a specificity of 55%, the sensitivity would need to fall to 49% before thromboprophylaxis
using a RAM became extendedly dominated by thromboprophylaxis for all. However, the absolute QALY gains
would be 42% lower than the optimal point on the ROC curve and the costs would be only 16% lower.
Given that the use of a decision tool would result in clinical time being spent for every patient who has
lower-limb immobilisation, it was important to evaluate whether or not the assumption regarding the time
taken for risk assessment was associated with significant decision uncertainty. The time taken was changed
from 5 minutes to 20 minutes and it was found that this had an impact on the ICER only for L-TRiP(cast)-10
versus no prophylaxis; as this remained < £20,000, L-TRiP(cast)-9 remained optimal.
Whether or not the exclusion of costs related to CRNMB had an important impact on the model
conclusions was examined and it was found that the optimal strategies did not change when assuming
that all patients with CRNMB attended ED for assessment.
It was initially planned to have a zero rate of PTS in patients with asymptomatic distal DVT based on
clinical expectations that the rate of PTS would be low in this group. Given that we had identified that
PTS following distal DVT was an important driver of uncertainty in the model, a scenario analysis was
conducted with a zero rate of PTS for asymptomatic distal DVT. Under this assumption, L-TRiP(cast)-9
was still the optimal strategy when willing to pay £20,000 per QALY but L-TRiP(cast)-8 had an ICER of
> £50,000 compared with L-TRiP(cast)-9. In addition, under this scenario, prophylaxis for all had an ICER
of £26,962 versus prophylaxis for none. This is because the marginal gains of preventing VTE are smaller
when PTS risk is limited to the minority with proximal DVTs or symptomatic distal DVTs.
There was some uncertainty regarding the rate of PTS in asymptomatic proximal DVT that remains
undetected and untreated, as most of the studies that identified asymptomatic proximal DVT treated
patients. It was examined whether or not the conclusions varied if assuming the same rate of PTS as
observed in symptomatic proximal DVT but it was found that the optimal strategies were unchanged.
The estimates of the proportion of symptomatic DVTs that are proximal were based on 16 DVTs reported
in a single study.59 To determine if this factor was an important driver of cost-effectiveness, the proportion
was varied from 0% to 100%; it was found that this had no impact on the optimal strategy when valuing
a QALY at either £20,000 or £30,000.
Similarly, as the estimates of the proportion of asymptomatic DVTs that are distal was based on a small
number of events, an extreme analysis was conducted to see if varying the proportion from 0% to 100% had
a large impact on the conclusions. It was found that, when assuming that all asymptomatic DVTs are distal,
the optimal strategy was L-TRiP(cast)-9 when valuing a QALY at either £20,000 or £30,000. Conversely, when
assuming that all asymptomatic DVTs are proximal, the optimal strategy was L-TRiP(cast)-8 when using a
willing-to-pay threshold of either £20,000 or £30,000 per QALY.
Given that the major risk of adverse effects to patients is the risk of a bleed following prophylaxis, a threshold
analysis was conducted to see how much higher the bleed risk in the general population would need to be
to change the optimal strategy. It was found that L-TRiP(cast)-9 was optimal at £20,000 per QALY until the
bleed risk reached 30 times that assumed in the base-case analysis. However, a sixfold increase in bleed risk
in the population was required to make L-TRiP(cast)-8 have an ICER of > £30,000 per QALY. Furthermore,
when the bleed risk is 15-fold higher than assumed in the base-case analysis, the treat-all strategy is no
longer cost-effective relative to the treat-none strategy at a threshold of £20,000 per QALY.
The risk of VTE without prophylaxis was increased and decreased threefold; it was found that this had a
significant impact on the optimal strategy, with a threefold increase resulting in treating all being the
optimal strategy when valuing a QALY at £30,000, and a threefold decrease resulting in treat none being
optimal when valuing a QALY at £20,000. For a strategy of treat all to result in fewer QALYs gained than
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lost, namely for there to be a net harm to patients, the VTE risk would need to be < 9% of its base-case
value, suggesting that baseline risks would need to be substantially lower than thought before prophylaxis
would be at risk of doing more harm than good to a patient’s health. However, at this level of risk, none
of the prophylaxis strategies would be cost-effective.
Summary of key findings
l The benefits of thromboprophylaxis in terms of reducing VTE outweigh the harms in terms of increased
bleeding risk in the modelled population.
l Thromboprophylaxis for all has an ICER of £13,524 compared with thromboprophylaxis for none.
l When considering whether or not the cost-effectiveness of thromboprophylaxis can be improved by
using a RAM to target thromboprophylaxis, the optimal strategy would be to use the L-TRiP(cast) score
with a threshold score of 9 if the £20,000-per-QALY threshold is used and with a threshold score of 8 if
the £30,000-per-QALY threshold is used.
l An optimal RAM would be expected to operate with a sensitivity of 84–89% and specificity of 46–55%,
assuming the ROC curve for the L-TRiP(cast) score reflects the typical trade-off between sensitivity and
specificity in risk assessment.
ASSESSMENT OF COST-EFFECTIVENESS
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness reviews
Pharmacological thromboprophylaxis for preventing venous thromboembolism
In the meta-analysis, it was found that thromboprophylaxis with LMWH reduced any VTE (OR 0.52, 95% CrI
0.37 to 0.71), clinically detected DVT (OR 0.40, 95% CrI 0.12 to 0.99) and PE (OR 0.17, 95% CrI 0.01 to
0.88) compared with no thromboprophylaxis. The effect of LMWH thromboprophylaxis varied between
different VTE outcomes but all estimates were consistent with an approximate halving of risk. The number
of deaths and bleeding events were too small to draw reliable conclusions. Thromboprophylaxis with
fondaparinux also reduced any VTE (OR 0.13, 95% CrI 0.05 to 0.30) and clinically detected DVT (OR 0.10,
95% CrI 0.01 to 0.94) compared with no thromboprophylaxis, but the effect on PE was inconclusive (OR
0.47, 95% CrI 0.01 to 9.54). Event rates for symptomatic DVT and PE were generally low across the studies,
so an approximate halving of risk may result in a small absolute risk reduction. Network meta-regression did
not identify evidence of effect modification associated with population characteristics, type of injury, type of
immobilisation or duration of treatment. There was evidence of difference in the effect of different types of
LMWH used, with certoparin having the highest probability of the greatest effect on any VTE, but this was
based on findings from one study.52
Individual risk factors associated with venous thromboembolism risk
In the systematic review, it was found that only older age was consistently associated with increased risk of
VTE across the included studies. Four studies53,60,70,71 showed that higher BMI was associated with increased
risk and six studies11,50,52,53,69,70 show associations between injury type and risk of VTE. All studies were
deemed to be at moderate23,50,52,53,60,68,71 or serious9,11,64–67,69,70 risk of bias overall following structured quality
assessment. The use of individual risk factors to predict VTE risk in people with lower-limb immobilisation
due to injury is, therefore, based on limited and weak evidence.
Risk assessment models for prediction of venous thromboembolism risk
The systematic review identified a number of RAMs but only two studies32,82 (both case–control design)
provided estimates of sensitivity and specificity for three of the RAMs. The L-TRiP(cast) score32 using a
threshold score of 8 (sensitivity 92.6%, specificity 39.7%) or 9 (sensitivity 80.8%, specificity 60.8%) may
have appropriate accuracy for use in practice but these estimates are subject to considerable uncertainty.
Expert consensus study
The Delphi study resulted in agreement that the following were potentially useful predictors of VTE in
lower-limb immobilisation due to injury: age, BMI of > 30 kg/m2, active cancer, pregnancy/puerperium,
thrombophilia, prior VTE, surgery in the previous 3 months, exogenous oestrogen, lower-limb paralysis,
superficial thrombophlebitis, Achilles tendon rupture, above-knee plaster cast and rigid immobilisation in
a cast (as opposed to removable immobilisation). Most of the predictors agreed by the experts were not
supported by evidence in the systematic review. Therefore, it appears that experts are willing to draw
on evidence from other patient groups, pathophysiological knowledge and their clinical experience to
identify predictors of VTE.
Most of the agreed predictors were included in one or more of the RAMs, presumably reflecting the role
of clinical expertise in developing most of the RAMs. However, the expert group were unable to reach
consensus on many potential predictors, including many variables that were included in one or more
RAMs. The differences between RAMs are likely to reflect differences in expert opinion, which may, in
turn, reflect the lack of available evidence for VTE predictors in lower-limb immobilisation due to injury.
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Economic evaluation
Decision-analytic modelling compared thromboprophylaxis for all people with lower-limb immobilisation
due to injury with thromboprophylaxis for none and risk-based approaches [i.e. the L-TRIP(cast) score was
used to select higher-risk patients for thromboprophylaxis]. Effectiveness analysis suggested that the rate
of serious adverse outcomes (ICH or death from VTE or bleeding) would be very low regardless of the
approach used (around 1 in 4000). Rates of symptomatic DVT and non-fatal PE would be higher
(around 22 to 41 per 10,000 and 49 to 91 per 10,000, respectively) and varied across the strategies.
The total number of major bleeds, including fatal and non-fatal ICHs, ranged from 4.03 per 10,000 with
no thromboprophylaxis (reflecting baseline population rates and bleeding as a result of treatment of
subsequent VTE) to 5.38 per 10,000 when thromboprophylaxis is given to all. The higher rates of VTE
events compared with bleeding events meant that overall quality-adjusted life expectancy increased
in accordance with the proportion of the population receiving thromboprophylaxis with each strategy.
It therefore appears that the benefits of thromboprophylaxis in terms of reducing VTE outweigh the harms
in terms of increased bleeding risk in the modelled population.
Cost-effectiveness analysis comparing thromboprophylaxis for all with thromboprophylaxis for none showed
that thromboprophylaxis for all gained a mean of 0.0147 QALYs at a mean cost of £204 per patient, with
an ICER of £13,524. This suggests that, if no acceptable RAM is available, then thromboprophylaxis for all
would be cost-effective according to NICE thresholds, but there was some uncertainty in this estimate, with
a 24% probability that thromboprophylaxis for all is not cost-effective at the £20,000-per-QALY threshold.
Cost-effectiveness analysis comparing thromboprophylaxis for all, thromboprophylaxis according to varying
thresholds of the L-TRiP(cast) score and thromboprophylaxis for none showed that the optimal strategy
would use the L-TRiP(cast) score with a threshold of 9 if the £20,000-per-QALY threshold is used and
with a threshold of 8 if the £30,000-per-QALY threshold is used. Analyses to determine the optimal
trade-off between sensitivity and specificity suggested that INMB is maximised when sensitivity is 84% and
specificity is 55% when the £20,000-per-QALY threshold is used, or when sensitivity is 89% and specificity
is 46% when the £30,000-per-QALY threshold is used. An optimal RAM would therefore be expected to
operate with a sensitivity of 84–89% and a specificity of 46–55%, assuming that the ROC curve of the
L-TRiP(cast) score is typical of RAMs.
The EVPI analysis suggested that the most important parameters for decision uncertainty were the
utility value for PTS, the effectiveness of thromboprophylaxis in reducing VTE, the probability of PTS for
patients with distal DVT and the utility decrement associated with taking thromboprophylaxis. The value
of reducing the decision uncertainty further was low on a per-patient basis. However, the uncertainty
surrounding estimates of RAM accuracy in the PSA could not be appropriately reflected. As noted in the
review of RAMs, these estimates are based on very weak and limited data, and are therefore likely to be
subject to substantial uncertainty.
Strengths and limitations of the assessment
Clinical effectiveness review
Pharmacological thromboprophylaxis for preventing venous thromboembolism
The meta-analysis synthesised data from 6857 participants in 13 randomised trials that were judged to have
a low risk of bias or some concerns only for most quality criteria. This represents a large, methodological
robust data set across a variety of settings that allows us to draw generalisable conclusions. Reasonably
precise estimates of the effect of thromboprophylaxis compared with control could be produced for most
outcomes. Statistical power was more limited for uncommon outcomes, such as PE, but even here it was
possible to generate an estimate that suggested a statistically significant effect. It was also possible to
undertake a NMA to compare across three alternatives: (1) LMWH, (2) fondaparinux and (3) no
thromboprophylaxis.
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A recent Cochrane meta-analysis by Zee et al.18 reported data from eight trials,49,51–56,59 including
3680 participants, that compared thromboprophylaxis with no treatment or placebo. They found that
LMWH was associated with a significantly reduced risk of any DVT (OR 0.45, 95% CI 0.33 to 0.61) and
symptomatic VTE (OR 0.40, 95% CI 0.21 to 0.76) but not PE (OR 0.50, 95% CI 0.17 to 1.47). Zee et al.18
excluded four trials that were included in this analysis (Goel et al.,50 Selby et al.,58 Gehling et al.23 and
Samama et al.57), and one additional trial was published after their updated meta-analysis (Zheng et al.60).
Two of the trials were excluded because they focused on operatively treated fractures rather than
immobilisation (Goel et al.50 and Selby et al.58), one because the comparator was aspirin (Gehling et al.23)
and one because the intervention was fondaparinux rather than LMWH (Samama et al.57). The inclusion of
these trials has ensured that this analysis is more comprehensive and provides more precise estimates of
effectiveness, but at the expense of greater heterogeneity.
This analysis was inevitably limited by the primary data. The variety of settings and patient groups may be a
strength in terms of increasing generalisability; there was evidence of heterogeneity of effect for many of the
outcomes, suggesting that effects may differ between populations. Three trials23,52,53 were judged as having
a high risk of bias on the basis of outcome ascertainment being potentially subject to bias in an open-label
trial. One trial that administered aspirin to the control group was included on the basis that NICE guidelines
on VTE1,24 do not consider aspirin or other antiplatelet agents to be appropriate for VTE prophylaxis and
aspirin is not indicated as a treatment for VTE prophylaxis in lower-limb immobilisation.21,25,26 If aspirin has
a significant prophylactic effect, then this trial may underestimate the effect of thromboprophylaxis.
The primary studies had a number of selection criteria that limit the ability to apply the findings to certain
populations. Patients at a high risk of VTE (such as those with active cancer, thrombophilia, previous VTE
or pregnancy/puerperium) and those with an increased risk of bleeding were often excluded. The studies
generally included patients with rigid immobilisation rather than those with a degree of movement or a
removable cast or splint, so the findings may be applicable only to those with full immobilisation.
The analysis included a substantial number of participants but the event rates for some outcomes were very
low. As a consequence, it was not possible to produce reliable estimates of the effect of thromboprophylaxis
on major bleeding or death. The low rate of bleeding provides some reassurance that thromboprophylaxis is
not causing a clinically important rate of serious adverse outcome in this population but this may not be
applicable to patients at a higher risk of bleeding.
Individual risk factors associated with venous thromboembolism risk
This is the first systematic review conducted to look directly at individual risk factors increasing the risk
of VTE in patients with lower-limb injury immobilised in plaster, discharged to an outpatient setting. This is
an important distinction, as the population of interest differs markedly from generic thrombosis data sets;
patients with lower-limb injury tend to be younger, more active and devoid of comorbidity than those
presenting with unprovoked or cancer-associated thrombosis. Previous work has attempted to address a
similar issue in patients undergoing elective foot and ankle surgery.72,73,81 We consider this to be a different
population because of the absence of acute blunt trauma causing local vessel/endothelial injury, expert
postoperative immobilisation and often bespoke immobilisation regimes.
The review was undertaken in accordance with guidelines published by the Centre for Reviews and
Dissemination75 and the protocol was registered with the PROSPERO register.38 Clinical experts were
involved throughout as checkers and to assess the validity and applicability of research during the project.
Descriptive statistics were reported to provide plain insight into the limited evidence base applicable to the
subject matter and the scientific concerns regarding validity of the data.
The review was limited by a lack of studies specifically examining risk prediction in lower-limb immobilisation
due to injury. Therefore, studies, such as RCTs, that were designed for another purpose but reported risk
predictors in their analyses were included. The studies of risk prediction were a combination of prospective
cohorts and retrospective health database registries. Both have significant limitations. Retrospective studies
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of health database registries may have large numbers but may be limited by poor data quality and failure
to accurately ascertain outcomes. Prospective cohorts may have better-quality data but lack statistical
power because of smaller numbers. The included studies demonstrated high levels of heterogeneity,
so a meta-analysis could not be undertaken.
Several studies included patients receiving operative intervention and short inpatient stays. Following the
introduction of NICE guidance on thromboprophylaxis to reduce the risk of hospital-acquired thrombosis,
it is reasonable to assume that, in a modern health-care environment, all these patients would receive
some form of routine thromboprophylaxis.24 For this reason, inclusion of these patients could lead to false
reassurance regarding low incidence of VTE. However, patients with a short inpatient stay (< 5 days) were
considered to fit within the scope of interest; these patients often remain temporarily immobilised for a
period of 4–8 weeks in total, and debate persists about the role of thromboprophylaxis that is similar to
debate around patients discharged directly from the ED.
All the studies within the review were classed as being at moderate or severe risk of bias. Therefore,
any conclusions regarding the influence of risk factors on the subsequent development of VTE drawn are
based on weak evidence and have the potential to be inaccurate.
Risk assessment models for prediction of venous thromboembolism risk
This review had strengths of following recognised guidance, prospective registration, a clear protocol and
drawing on appropriate clinical and reviewing expertise. It was anticipated that the data would not allow
meta-analysis; therefore, descriptive analyses only were planned.
A previous review by Watson et al.82 identified two of the RAMS included in this review (Keenan et al.31
and Roberts et al.17), along with three generic RAMs that could be applied to people with lower-limb
immobilisation due to injury.210–212 Watson et al.’s82 review then undertook primary analysis of these two
RAMs to estimate sensitivity and specificity for predicting VTE. This review included these data and a
number of other studies32,78–81 but only the study of Nemeth et al.32 provided estimates of sensitivity and
specificity.
The review is, therefore, limited by the paucity of data. Furthermore, case–control designs are known to be
associated with a risk of bias,213 so sensitivity and specificity may have been overestimated. The study by
Watson et al.82 was relatively small (21 cases and 21 controls), so estimates of sensitivity and specificity are
imprecise. The study by Nemeth et al.32 involved validation using two data sets but each only contained a
small number of patients with lower-limb immobilisation (32 cases, 7 controls, and 143 cases, 8 controls,
respectively).
Expert consensus study
The Delphi study involved a wide range of experts from emergency medicine, orthopaedics and haematology,
and used recognised techniques to attempt to achieve consensus without supressing divergent views. There
were acceptable levels of participation and the experts seemed to understand and engage with the process.
Expert consensus is considered to represent weak evidence and is usually sought only when (as in the
case of VTE risk prediction in lower-limb immobilisation) other forms of evidence are weak or absent. It is
hoped that experts will draw on weak evidence appropriately and combine it with clinical experience and
pathophysiological understanding. However, experts may be subject to a number of cognitive biases that
may influence their judgement. For example, the availability heuristic may lead experts to place undue
emphasis on a risk predictor if they have seen a case in which a patient with that characteristic developed
VTE after lower-limb immobilisation.
The Delphi process achieved consensus on 13 predictors but failed to achieve consensus on many more.
This is perhaps unsurprising in the light of the limited evidence base relevant to the population of interest.
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It could be argued that achieving consensus on 13 predictors reflects undue certainty in the light of the
limited evidence to support these judgements.
Economic evaluation
A key strength of the de novo economic analysis is that it is able to synthesise the evidence on both
benefits and harms to assess the overall impact of different thromboprophylaxis strategies in people having
lower-limb immobilisation. Therefore, it was possible to explore the trade-off between preventing VTE
and the adverse effects associated with prophylaxis, including the direct impact of subcutaneous injections
of anticoagulants on patient quality of life. The estimates of clinical effectiveness were based on the
systematic review and meta-analysis and the decision uncertainty associated with the uncertainty in the
estimates of clinical effectiveness was captured in the model. The availability of the ROC curve for the
L-TRiP(cast) score allowed us to explore what the optimal sensitivity and specificity might be for a tool to
identify patients needing thromboprophylaxis when assuming that any future tool would have similar
characteristics to L-TRiP(cast).
The main limitation of the economic analysis was that it was not possible to incorporate the uncertainty
in the sensitivity and specificity estimates for the RAMs within the PSA as these were not reported.
A scenario analysis was conducted, which suggested that the cost-effectiveness of using a RAM to guide
thromboprophylaxis is dependent on the performance characteristics of the RAM, but it was not possible
to quantify the decision uncertainty associated with the RAMs currently available.
Another potential limitation of the economic analysis is that a cohort modelling approach was used, which
estimates outcomes based on average patient characteristics and, therefore, does not allow for heterogeneity
in patient outcomes on the basis of patient characteristics. However, whether or not variation in outcomes
on the basis of age would significantly alter the conclusions of the model was explored; it was found that the
optimal thromboprophylaxis strategy was not sensitive to variations in age.
The estimate of the incidence of major bleeds during thromboprophylaxis was based solely on the incidence
of GI bleeds and ICHs; therefore, this may have underestimated the impact on costs and QALYs of major
bleeds at other sites. In addition, CRNMBs were excluded from the model. However, the sensitivity analyses
suggest that neither of these factors is likely to have significantly biased the results, as incorporating costs
for CRNMBs and increasing the risk of bleeding during thromboprophylaxis fivefold did not alter the main
conclusions.
Another potential limitation is that many of the data sources quantifying the impact of VTE on patients,
such as the incidence and quality-of-life impact of post-thrombotic syndrome following DVT, were not
specific to patients having lower-limb immobilisation. Therefore, the benefits of thromboprophylaxis in this
population may have been overestimated if the risks of complications following DVT are lower in patients
having lower-limb immobilisation than in other groups at risk of VTE.
Uncertainties
The main uncertainty identified in the analysis related to the prognostic accuracy of RAMs. The estimates
were based on very weak data but suggested that L-TRiP(cast) score, using a threshold score of 8 or 9,
would be an optimal strategy. However, this conclusion holds only if the prognostic accuracy of L-TRiP(cast)
is confirmed. More precise and accurate estimates of the prognostic accuracy of RAMs are required but this
may be difficult to achieve if higher-risk patients receive thromboprophylaxis as standard care.
Most of the effectiveness data for thromboprophylaxis relate to LMWH, with a smaller number relating to
fondaparinux. LMWH is administered by injection, thereby incurring additional costs and inconvenience for
patients. DOACs are taken orally and, therefore, do not incur these additional costs and inconvenience.
However, no studies evaluating the effectiveness of DOACs as thromboprophylaxis for lower-limb
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immobilisation were found. DOACs have been used for thromboprophylaxis in other conditions and have
been shown to be generally as safe and effective as LMWH.214–216 On this basis, a secondary economic
analysis was undertaken, assuming that DOACs were as effective as LMWH and could be delivered at
lower cost and with less inconvenience. This suggested that at the £30,000-per-QALY threshold, DOACs
would be cost-effective in a thromboprophylaxis-for-all strategy, even compared with an optimal RAM.
The obvious uncertainty affecting this conclusion is whether or not it can be assumed that DOACs are at
least as effective and safe as LMWH.
The value-of-information analysis showed that the most important parameters for decision uncertainty
were the utility value for PTS, the effectiveness of thromboprophylaxis in reducing VTE, the probability
of PTS for patients with distal DVT and the utility decrement associated with taking prophylaxis. The
importance of uncertainty around PTS is consistent with the observation from the modelling that the
benefit of thromboprophylaxis lies in avoiding long-term complications rather than avoiding short-term
adverse outcomes. The utility decrement associated with taking prophylaxis is relevant to the potential
role of DOACs discussed in the paragraph above, because most of the decreased utility is assumed to be
as a result of the need to administer LMWH by injection.
The primary studies for the review of effectiveness, and, by implication, the economic model, excluded a
number of important patient groups. Patients at a high risk of VTE, because of active cancer, previous VTE,
pregnancy/puerperium or thrombophilia, were excluded but, as they have a higher risk of VTE, these
patients are even more likely to benefit from thromboprophylaxis. Patients with an increased risk of bleeding
were also excluded; these represent a more difficult group with regard to guiding recommendations. The
model assumed a low risk of bleeding so, clearly, the findings of modelling analysis cannot be applied to
this group. It may be possible to develop the model to provide estimates of overall effectiveness if bleeding
risk is higher, but increased bleeding risk is often associated with conditions that also increase the risk of
VTE. It is, therefore, unlikely that general recommendations can be made for those with an increased risk of
bleeding and decisions will have to be made on an individual case-by-case basis.
The primary studies for the review of effectiveness were also generally limited to patients with full, rigid
immobilisation and did not include those with more limited immobilisation, such as splints that allow a
degree of movement and removable splints or casts. There are pathophysiological reasons for expecting
the VTE risk to be lower for these patients and the benefit of thromboprophylaxis to be consequently
lower or even negligible. However, current evidence is insufficient to determine whether or not this is the
case and what, if any, role there may be for thromboprophylaxis.
Patient and public involvement
The patient and public involvement (PPI) representatives were involved in a number of elements of the
study and met regularly with the project team to discuss the interpretation and implications of the
emerging findings. The PPI representatives identified the following issues at these meetings:
l The risks and benefits of thromboprophylaxis need to be explained to patients in clear and comprehensible
terms so that they can participate in decision-making. It would be helpful to provide this information in
written form, along with information about the symptoms of VTE and what to do if they have concerns.
l It was considered acceptable to provide thromboprophylaxis in accordance with the patient’s risk of
VTE. It may be acceptable for patients to be involved in assessing their risk of VTE but this should be
done in consultation with a health professional.
l If a risk-based approach was used and a patient was assessed as not requiring thromboprophylaxis on
the basis of lack of cost-effectiveness when the risk is low, then they should be informed of the possible
benefit of thromboprophylaxis in case they wish to arrange their own treatment.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
l Use of LMWH for thromboprophylaxis has clear disadvantages related to the inconvenience and
discomfort of injections. Oral treatment would be much more acceptable but the risks of DOACs need to
be explained to patients, specifically the lack of a means of reversing DOACs in the event of bleeding.
The lack of research into the use of DOACs as thromboprophylaxis for lower-limb immobilisation was
also a concern.
l If the risk of adverse outcome is low (i.e. < 1 in 100), then patients may not think the benefit of
thromboprophylaxis is worth the inconvenience and discomfort of LMWH.
l An implementation study of risk-based thromboprophylaxis, potentially involving comparison of
different approaches, would be acceptable provided it was justified on the basis of current practice
being variable and the need to identify best practice.
Assessment of factors relevant to the NHS and other parties
Current NICE guidance1 recommends that clinicians consider pharmacological VTE prophylaxis with LMWH
or fondaparinux for people with lower-limb immobilisation whose risk of VTE outweighs their risk of bleeding.
This analysis suggests that the risk of VTE outweighs the risk of bleeding for any patient who does not have
risk factors for bleeding. The review for the NICE guidance1 did not identify any relevant economic evidence
and only considered the unit costs for different agents (LMWH and fondaparinux). This economic analysis
showed that thromboprophylaxis with LMWH is cost-effective compared with no thromboprophylaxis and a
risk-based strategy is potentially optimal, when valuing a QALY at £20,000 to £30,000. The NICE guidance1
also recommends that clinicians assess all patients to identify the risk of VTE and bleeding, but does not
identify or recommend any specific RAM for lower-limb immobilisation. This analysis suggests that the
L-TRiP(cast) score with a threshold score of 8 or 9 could have appropriate prognostic accuracy for
cost-effective risk stratification in lower-limb immobilisation but the available estimates of prognostic
accuracy are very uncertain.
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Chapter 6 Conclusions
Implications for service provision
The meta-analysis of effectiveness suggested that thromboprophylaxis in lower-limb immobilisation due to
injury approximately halves the risk of any VTE and is associated with reductions in the risks of symptomatic
DVT and PE. However, the evidence is limited to LMWH and fondaparinux, so it is unclear whether or not
the findings can be extrapolated to DOACs. This in an important consideration as the absolute risks of
clinically relevant VTE are low and patients may not be willing to submit to the inconvenience of parenteral
treatment to reduce a relatively small risk.
The economic analysis suggested that thromboprophylaxis is effective and cost-effective compared with
no thromboprophylaxis, so it would be reasonable to offer thromboprophylaxis to patients undergoing
lower-limb immobilisation due to injury. This is based on the potential for thromboprophylaxis to reduce
the risk of DVT and PE, with their long-term sequelae, rather than any meaningful reduction in the risk of
mortality. The economic analysis also suggested that risk-based thromboprophylaxis using a RAM with a
sensitivity of 84–89% and specificity of 46–55% is, potentially, the most cost-effective approach. This is
similar to the prognostic accuracy of the L-TRiP(cast) score using a threshold score of 8 or 9, although
estimates of sensitivity and specificity are very uncertain.
The cost-effectiveness of using an appropriate RAM is based on (1) reducing the number of people
requiring thromboprophylaxis (and thus costs) compared with thromboprophylaxis for all, with only a small
reduction in effectiveness and (2) increasing the number of VTE events prevented (and this effectiveness)
compared with no thromboprophylaxis, with only a small increase in costs. Assuming universal acceptance
by patients, a risk-based strategy, as outlined in the previous paragraph, would cost the English NHS £6M
per year and gain 891 QALYs compared with no thromboprophylaxis. Compared with this, providing
thromboprophylaxis for all would cost an additional £8.2M per year and gain an additional 160 QALYs.
These estimates are not intended to be precise figures, as strategies are unlikely to be implemented
perfectly and patients may decline treatment, but they provide an indication of the potential implications
of different strategies for service provision.
The PPI representatives highlighted the importance of patient involvement in decision-making and the
need for clear and comprehensible information to be provided. This has important implications for service
provision. To participate in shared decision-making, patients need to understand that the risk of clinically
important VTE is relatively low but that it can be reduced by thromboprophylaxis. The effectiveness of
thromboprophylaxis relies on the benefits of reducing DVT and PE (and their sequelae), outweighing a
small increase in the risk of bleeding, but VTE events may still occur despite thromboprophylaxis. The risks
of death from VTE or bleeding after immobilisation due to injury are very small regardless of the treatment
strategy, and thromboprophylaxis is unlikely to have any significant impact on the risk of death.
Suggested research priorities
This analysis suggested that risk-based thromboprophylaxis using a RAM with sensitivity of 84–89% and
specificity of 46–55% would be the most cost-effective strategy. However, the current evidence base for
RAMs is very limited and estimates of sensitivity and specificity are subject to substantial uncertainty.
Improving the evidence base for RAMs is therefore a key priority.
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Ideally, a large prognostic cohort study of people experiencing lower-limb immobilisation due to injury
would be undertaken to estimate the prognostic accuracy of existing RAMs for VTE and possibly derive a
new RAM. However, the evidence of effectiveness and cost-effectiveness provided by this analysis suggests
that thromboprophylaxis should be offered to patients in this cohort, or at least those considered as being
at a higher risk. Administration of thromboprophylaxis would be expected to reduce the risk of VTE and
thus lead to underestimation of the prognostic accuracy of RAMs. Furthermore, the VTE events that were
prevented by thromboprophylaxis would be precisely those that we would want a RAM to predict.
A large cohort study could still provide useful information if it is used to evaluate implementation rather
than accuracy. It could determine the proportion of the cohort receiving thromboprophylaxis with different
RAMs or different thresholds for treatment. It could be used to determine whether or not the low rate of
bleeding events is confirmed in practice and, if risk-based thromboprophylaxis were provided, it could be
used to determine whether or not the low rate of VTE events is confirmed in low-risk patients who do not
receive treatment.
Direct oral anticoagulants could provide the benefits of thromboprophylaxis without the costs, inconvenience
and discomfort of injections, which the PPI representatives identified as a potential barrier to patient
acceptance. However, all the evidence of effectiveness in this review related to LMWH or fondaparinux.
Ideally, an appropriately powered RCT comparing thromboprophylaxis of DOACs with LMWH would provide
evidence of equivalent effectiveness, but such a trial may be prohibitively expensive, especially if it were felt
that evidence of effectiveness of DOAC for other indications could be reasonably extrapolated to lower-limb
immobilisation.
The most important parameters for decision uncertainty in the value-of-information analysis were related to
the efficacy and disutility of receiving prophylaxis, and the long-term complications of PTS, so estimating
these parameters should be a priority for future research. The disutility of receiving LMWH injections or oral
DOACs could be investigated as part of a cohort study or trial of different types of thromboprophylaxis.
The uncertainty around the long-terms effects of PTS mainly relate to subclinical DVT rather than clinically
detected and treated DVT, so research to reduce uncertainty around the incidence and disutility of PTS
would need to involve long-term follow-up or a retrospective observational study of people following
lower-limb immobilisation due to injury.
It is currently unclear whether or not people with limited lower-limb immobilisation (such as splints that allow
some movement or removable splints or casts) carry similar risks of VTE to those with full immobilisation.
A cohort study of this population, perhaps undertaken alongside a cohort study evaluating risk-based
thromboprophylaxis, could determine the risk of VTE and identify risk predictors.
All of these research suggestions would require large numbers of participants to generate meaningful
results. There are plenty of eligible participants presenting to the NHS but an efficient research design
would be required, using standardised collection of predictor variables and routine data sources for
outcomes, to ensure that any study was not prohibitively expensive.
Finally, the PPI representatives identified the need for patients to receive clear and comprehensible
communication of the risks and benefits of thromboprophylaxis, including written materials. Research
is required to develop information for patients and ways of communicating benefits and risks.
CONCLUSIONS
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Appendix 1 Literature search strategies for the
review of pharmacological thromboprophylaxis for
preventing venous thromboembolism
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R)
Platform or provider used: Ovid SP.
Date range searched: 1946 to April 2017.
Date searched: April 2017.
Search strategy
1. thrombosis/ or exp venous thrombosis/
2. Venous Thromboembolism/ or Thromboembolism/
3. exp Pulmonary Embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. Splints/
11. Braces/
12. exp Casts, Surgical/
13. immobili*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
14. brace*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
15. splint*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
16. plaster*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
17. cast.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. exp Heparin, Low-Molecular-Weight/
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21. (heparin* or LMWH or nadroparin* or fraxiparin* or enoxaparin or Clexane or klexane or lovenox or
dalteparin or Fragmin or ardeparin or normiflo or tinzaparin or logiparin or Innohep or certoparin or
sandoparin or reviparin or clivarin* or danaproid or danaparoid or bemiparin or bioparin or Alphaparin
or Troparin).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
22. (antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or embolex or monoembolex or Mono-
embolex or parnaparin* or “rd 11885” or tedelparin or Kabi-2165 or Kabi 2165).mp. [mp=title,
abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary concept word, unique
identifier, synonyms]
23. (emt-966 or emt-967 or pk-10169 or pk10169).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms]
24. (cy-216 or cy216 or seleparin* or tedegliparin or seleparin* or tedegliparin* or tedelparin or Boxol or
Liquemine).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
25. fr-860.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
26. (wy90493 or wy-90493).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms]
27. (kb-101 or kb101 or lomoparan or orgaran).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
28. (parnaparin or fluxum or lohepa or lowhepa or “op 2123” or parvoparin).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
29. (AVE5026 or M118 or RO-14).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms]
30. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. (Rivaroxaban or xarelto or Apixaban or eliquis or Edoxaban or lixiana or Dabigatran or pradaxa or
prazaxa or Praxibind or idaricuzimab).mp.
32. (novel oral anticoagulant* or novel oral anti-coagulant* or (new adj3 (anticoagulant* or
anti-coagulant*))).mp.
33. (direct oral anticoagulant* or direct oral anti-coagulant*).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms]
34. (NOAC* or DOAC*).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms]
35. exp Aspirin/
36. (acetylsalicylic acid* or aspirin).mp.
37. 31 or 32 or 33 or 34 or 35 or 36
38. 7 and 19 and 30
39. limit 38 to yr=“2013 -Current”
40. 7 and 19 and 37
41. 39 or 40
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Cochrane Database of Systematic Reviews, Cochrane Central Register of
Controlled Trials, Database of Abstracts of Review of Effects, Health
Technology Assessment Database and NHS Economic Evaluation
Database
Platform or provider used: Wiley Online Library.
Date range searched: 1898 to April 2017.
Date searched: April 2017.
Search strategy
#1 MeSH descriptor: [Thrombosis] explode all trees
#2 MeSH descriptor: [Venous Thrombosis] explode all trees
#3 MeSH descriptor: [Thromboembolism] explode all trees
#4 MeSH descriptor: [Venous Thromboembolism] explode all trees
#5 MeSH descriptor: [Pulmonary Embolism] explode all trees
#6 (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or
thrombos* or embol*):ti,ab,kw (Word variations have been searched)
#7 ((vein* or ven*) near/7 thromb*):ti,ab,kw
#8 (PE or DVT or VTE):ti,ab,kw
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 MeSH descriptor: [Immobilization] explode all trees
#11 MeSH descriptor: [Mobility Limitation] explode all trees
#12 MeSH descriptor: [Splints] explode all trees
#13 MeSH descriptor: [Braces] explode all trees
#14 MeSH descriptor: [Casts, Surgical] explode all trees
#15 (immobili* or brace* or splint* or plaster* or cast):ti,ab,kw
#16 ((leg* or tibia* or fibula* or ankle*) and (fracture* or surg*) and complication*):ti,ab,kw
#17 #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Heparin, Low-Molecular-Weight] explode all trees
#19 (heparin* or LMWH or nadroparin* or fraxiparin* or enoxaparin or Clexane or klexane or lovenox
or dalteparin or Fragmin or ardeparin or normiflo or tinzaparin or logiparin or Innohep or certoparin or
sandoparin or reviparin or clivarin* or danaproid or danaparoid or bemiparin or bioparin or Alphaparin
or Troparin):ti,ab,kw
#20 (antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or embolex or monoembolex or
Mono-embolex or parnaparin* or “rd 11885” or tedelparin or Kabi-2165 or Kabi 2165):ti,ab,kw
#21 (emt-966 or emt-967 or pk-10169 or pk10169):ti,ab,kw
#22 fr-860:ti,ab,kw
#23 (wy90493 or wy-90493 or kb-101 or kb101 or lomoparan or orgaran or parnaparin or fluxum or
lohepa or lowhepa or “op 2123” or parvoparin or AVE5026 or M118 or RO-14):ti,ab,kw
#24 #18 or #19 or #20 or #21 or #22 or #23
#25 #9 and #17 and #24 Publication Year from 2013 to 2017
#26 MeSH descriptor: [Anticoagulants] explode all trees
#27 (Rivaroxaban or xarelto or Apixaban or eliquis or Edoxaban or lixiana or Dabigatran or pradaxa or
prazaxa or praxibind or idaricuzimab):ti,ab,kw
#28 (novel oral anticoagulant* or novel oral anti-coagulant* or (new near/3 (anticoagulant* or
anti-coagulant*))):ti,ab,kw
#29 (direct oral anticoagulant* or direct oral anti-coagulant*):ti,ab,kw
#30 (NOAC* or DOAC*):ti,ab,kw
#31 MeSH descriptor: [Aspirin] explode all trees
#32 (acetylsalicylic acid* or aspirin):ti,ab,kw
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#33 #26 or #27 or #28 or #29 or #30 or #31 or #32
#34 #9 and #17 and #33
#35 #25 or #34
EMBASE
Platform or provider used: Ovid SP.
Date range searched: 1974 to April 2017.
Date searched: April 2017.
Search strategy
1. thrombosis/ or exp vein thrombosis/ or deep vein thrombosis/
2. Venous Thromboembolism/ or Thromboembolism/
3. exp lung embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. Splints/
11. Braces/
12. exp Casts, Surgical/
13. immobili*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
14. brace*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
15. splint*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
16. plaster*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
17. cast.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
20. exp Heparin, Low-Molecular-Weight/
21. (heparin* or LMWH or nadroparin* or fraxiparin* or enoxaparin or Clexane or klexane or lovenox or
dalteparin or Fragmin or ardeparin or normiflo or tinzaparin or logiparin or Innohep or certoparin or
sandoparin or reviparin or clivarin* or danaproid or danaparoid or bemiparin or bioparin or Alphaparin
or Troparin).mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
22. (antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or embolex or monoembolex or Mono-
embolex or parnaparin* or “rd 11885” or tedelparin or Kabi-2165 or Kabi 2165).mp. [mp=title,
abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword, floating subheading word]
23. (emt-966 or emt-967 or pk-10169 or pk10169).mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word]
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24. (cy-216 or cy216 or seleparin* or tedegliparin or seleparin* or tedegliparin* or tedelparin or Boxol or
Liquemine).mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
25. fr-860.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
26. (wy90493 or wy-90493).mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
27. (kb-101 or kb101 or lomoparan or orgaran).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word]
28. (parnaparin or fluxum or lohepa or lowhepa or “op 2123” or parvoparin).mp. [mp=title, abstract,
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword, floating subheading word]
29. (AVE5026 or M118 or RO-14).mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
30. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. (Rivaroxaban or xarelto or Apixaban or eliquis or Edoxaban or lixiana or Dabigatran or pradaxa or
prazaxa or Praxibind or idaricuzimab).mp.
32. (novel oral anticoagulant* or novel oral anti-coagulant* or (new adj3 (anticoagulant* or
anti-coagulant*))).mp.
33. (direct oral anticoagulant* or direct oral anti-coagulant*).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword,
floating subheading word]
34. (NOAC* or DOAC*).mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
35. acetylsalicylic acid/
36. (acetylsalicylic acid* or aspirin).mp.
37. 31 or 32 or 33 or 34 or 35 or 36
38. 7 and 19 and 30
39. limit 38 to yr=“2013 -Current”
40. 7 and 19 and 37
41. 39 or 40
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Appendix 2 Excluded studies: review of
pharmacological thromboprophylaxis for preventing
venous thromboembolism
TABLE 26 Excluded studies with rationale: review of pharmacological thromboprophylaxis for preventing VTE
Number Authors, year Reason for exclusion
1 Blackwell et al.,218 2017 Not a randomised or controlled clinical trial
2 Braithwaite et al.,22 2016 Not a randomised or controlled clinical trial
3 Calder et al.,219 2016 Systematic review
4 Chapelle et al.,220 2014 Systematic review
5 Doggrell et al.,221 2003 Review (non-systematic)
6 Ettema et al.,36 2008 Systematic review
7 Griffiths et al.,222 2012 Not a randomised or controlled clinical trial
8 Haque and Davies,223 2015 Not a randomised or controlled clinical trial
9 Hickey et al.,224 2016 Systematic review
10 Kaye et al.,225 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
11 Kock et al.,226 1993 Duplicate of included full-text study: Kock et al.52
12 Little,227 2016 Commentary
13 López-Reyes et al.,217 2015 Not a randomised or controlled clinical trial (letter to the editor)
14 Mangwani et al.,228 2015 Systematic review
15 Menakaya et al.,229 2013 Not a randomised or controlled clinical trial
16 Metz et al.,230 2009 Systematic review
17 Ramos et al.,231 2008 Systematic review
18 Samama et al.,232 2014 Duplicate of an included full-text study: Samama et al.,57 2013
19 Samama et al.,233 2013
(abstract)
Abstract of an included full-text study: Samama et al.,57 2013
20 Samama et al.,234 2013 Subgroup results of an included full-text study: Samama et al.,57 2013
21 Spannagel and Kujath,235 1993 Duplicate of included full text study: Kujath et al.,53 1993
22 Testroote et al.,15 2014 Systematic review
23 Walenga et al.,236 2014 Substudy of an included full-text study (Lassen et al.,56 2002) – focus on
biomarker evaluation
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Appendix 3 Summary of trials included in the
base-case network meta-analysis of pharmacological
thromboprophylaxis for preventing venous
thromboembolism
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TABLE 27 Summary of outcomes: any VTE and clinically relevant DVT
Authors, year Comparison
Any VTE Clinically relevant DVT (i.e. symptomatic or proximal/extensive)
LMWH Fondaparinux Control LMWH Fondaparinux Control
Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
a
n (%) Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
b
n (%)
Goel et al.,50 2009 LMWH vs. placebo 11 127 (8.7) – – 14 111 (12.6) 0 127 (0.0) – – 0 111 (0.0)
Jørgensen et al.,51 2002 LMWH vs. no treatment 10 99 (10.1) – – 18 106 (17.0) 0 99 (0.0) – – 1 106 (0.9)
Kock et al.,52 1995 LMWH vs. no treatment 0 176 (0) – – 7 163 (4.3) 0 176 (0.0) – – 5 163 (3.1)
Kujath et al.,53 1993 LMWH vs. no treatment 6 126 (4.8) – – 21 127 (16.5) – – – – – –
Lapidus et al.,55 2007 LMWH vs. placebo 18 49 (36.7) – – 19 47 (40.4) 1 49 (2.0) – – 3 47 (6.4)
Lapidus et al.,54 2007 LMWH vs. placebo 24 117 (20.5) – – 34 109 (31.2) 2 117 (1.7) – – 6 109 (5.5)
Lassen et al.,56 2002 LMWH vs. placebo 17 183 (9.3) – – 35 188 (18.6) – – – – – –
Selby et al.,58 2015 LMWH vs. placebo 4 130 (3.1) – – 4 128 (3.1) 2 130 (1.5) – – 2 128 (1.6)
van Adrichem et al.,59 2017 LMWH vs. no treatment 10 719 (1.4) – – 13 716 (1.8) 7 719 (1.0) – – 9 716 (1.3)
Zheng et al.,60 2016 LMWH vs. placebo 6 411 (1.5) – – 13 403 (3.2) 1 411 (0.2) – – 6 403 (1.5)
Gehling et al.,23 1998 LMWH vs. aspirin 9 143 (6.3) – – 7 144 (4.9) 2 143 (1.4) – – 1 144 (0.7)
Bruntink et al.,49 2017 LMWH vs. fondaparinux
vs. no treatment
2 92 (2.2) 1 92 (1.1) 11 94 (11.7) – – – – – –
Samama et al.,57 2013 LMWH vs. fondaparinux 49 622 (7.9) 14 621 (2.3) – – 10 622 (1.6) 6 621 (1.0) – –
a Median incidence in control group, 12.2%.
b Median incidence in control group, 1.5%.
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TABLE 28 Summary of outcomes: clinically detected DVT and asymptomatic DVT (all)
Authors, year Comparison
Clinically detected DVT (i.e. symptomatic) Asymptomatic DVT (all)
LMWH Fondaparinux Control LMWH Fondaparinux Control
Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
a
n (%) Events, n
Total,
b
n (%) Events, n
Total,
n (%) Events, n
Total,
b
n (%)
Goel et al.,50 2009 LMWH vs. placebo 0 127 (0.0) – – 0 111 (0.0) 11 127 (8.7) – – 14 111 (12.6)
Jørgensen et al.,51 2002 LMWH vs. no treatment 0 99 (0.0) – – 0 106 (0.0) 10 99 (10.1) – – 18 106 (17.0)
Kock et al.,52 1995 LMWH vs. no treatment 0 176 (0.0) – – 4 163 (2.5) 0 176 (0.0) – – 3 163 (1.8)
Kujath et al.,53 1993 LMWH vs. no treatment – – – – – – – – – – – –
Lapidus et al.,55 2007 LMWH vs. placebo – – – – – – – – – – – –
Lapidus et al.,54 2007 LMWH vs. placebo 2 117 (1.7) – – 6 109 (5.5) 22 117 (18.8) – – 28 109 (25.7)
Lassen et al.,56 2002 LMWH vs. placebo 0 183 (0.0) – – 4 188 (2.1) 17 183 (9.3) – – 31 188 (16.5)
Selby et al.,58 2015 LMWH vs. placebo 1 130 (0.8) – – 1 128 (0.8) 3 130 (2.3) – 2 128 (1.6)
van Adrichem et al.,59 2017 LMWH vs. no treatment 7 719 (1.0) – – 9 716 (1.3) – – – – – –
Zheng et al.,60 2016 LMWH vs. placebo 0 411 (0.0) – – 0 403 (0.0) 6 411 (1.5) – – 13 403 (3.2)
Gehling et al.,23 1998 LMWH vs. aspirin 2 143 (1.4) – – 1 144 (0.7) 7 143 (4.9) – – 6 144 (4.2)
Bruntink et al.,49 2017 LMWH vs. fondaparinux
vs. no treatment
0 92 (0.0) 0 92 (0.0) 0 94 (0.0) 2 92 (2.2) 1 92 (1.1) 9 94 (9.6)
Samama et al.,57 2013 LMWH vs. fondaparinux 7 622 (1.1) 2 621 (0.3) – – 42 622 (6.8) 11 621 (1.8) – –
a Median incidence in control group, 0.7%.
b Median incidence in control group, 6.9%.
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TABLE 29 Summary of outcomes: asymptomatic proximal and distal DVT
Authors, year Comparison
Asymptomatic DVT (proximal) Asymptomatic DVT (distal)
LMWH Fondaparinux Control LMWH Fondaparinux Control
Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
a
n (%) Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
b
n (%)
Goel et al.,50 2009 LMWH vs. placebo 0 127 (0.0) – – 0 111 (0.0) 11 127 (8.7) – – 14 111 (12.6)
Jørgensen et al.,51 2002 LMWH vs. no treatment 0 99 (0.0) – – 1 106 (0.9) 10 99 (10.1) – – 17 106 (16.0)
Kock et al.,52 1995 LMWH vs. no treatment 0 176 (0.0) – – 1 163 (0.6) 0 176 (0.0) – – 2 163 (1.2)
Kujath et al.,53 1993 LMWH vs. no treatment – – – – – – – – – – – –
Lapidus et al.,55 2007 LMWH vs. placebo 1 49 (2.0) – – 3 47 (6.4) – – – – – –
Lapidus et al.,54 2007 LMWH vs. placebo – – – – – – – – – – – –
Lassen et al.,56 2002 LMWH vs. placebo – – – – – 14 183 (7.7) – – 21 188 (11.2)
Selby et al.,58 2015 LMWH vs. placebo 1 130 (0.8) – – 1 128 (0.8) 2 130 (1.5) – – 1 128 (0.8)
van Adrichem et al.,59 2017 LMWH vs. no treatment – – – – – – – – – – – –
Zheng et al.,60 2016 LMWH vs. placebo 1 411 (0.2) – – 6 403 (1.5) 5 411 (1.2) – – 7 403 (1.7)
Gehling et al.,23 1998 LMWH vs. aspirin 0 143 (0.0) – – 0 144 (0.0) 7 143 (4.9) – – 6 144 (4.2)
Bruntink et al.,49 2017 LMWH vs. fondaparinux
vs. no treatment
– – – – – – – – – – – –
Samama et al.,57 2013 LMWH vs. fondaparinux 3 585 (0.5) 4 582 (0.7) – – 39 585 (6.7) 7 582 (1.2) – –
a Median incidence in control group, 0.7%.
b Median incidence in control group, 3.0%.
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TABLE 30 Summary of outcomes: PE and major bleeding
Authors, year Comparison
PE Major bleeding
LMWH Fondaparinux Control LMWH Fondaparinux Control
Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
a
n (%) Events, n
Total,
n (%) Events, n
Total,
n (%) Events, n
Total,
b
n (%)
Goel et al.,50 2009 LMWH vs. placebo 0 127 (0.0) – – 0 111 (0.0) 0 127 (0.0) – – 0 111 (0.0)
Jørgensen et al.,51 2002 LMWH vs. no treatment 0 99 (0.0) – – 0 106 (0.0) 0 99 (0.0) – – 0 106 (0.0)
Kock et al.,52 1995 LMWH vs. no treatment 0 176 (0.0) – – 0 163 (0.0) 0 176 (0.0) – – 0 163 (0.0)
Kujath et al.,53 1993 LMWH vs. no treatment 0 126 (0.0) – – 0 127 (0.0) 0 126 (0.0) – – 0 127 (0.0)
Lapidus et al.,55 2007 LMWH vs. placebo 0 49 (0.0) – – 0 47 (0.0) 0 49 (0.0) – – 0 47 (0.0)
Lapidus et al.,54 2007 LMWH vs. placebo 0 117 (0.0) – – 0 109 (0.0) 0 117 (0.0) – – 0 109 (0.0)
Lassen et al.,56 2002 LMWH vs. placebo 0 183 (0.0) – – 2 188 (1.1) 2 217 (0.9) – – 1 221 (0.5)
Selby et al.,58 2015 LMWH vs. placebo 0 130 (0.0) – – 1 128 (0.8) 0 134 (0.0) – – 0 131 (0.0)
van Adrichem et al.,59 2017 LMWH vs. no treatment 4 719 (0.6) – – 5 716 (0.7) 0 719 (0.0) – – 0 716 (0.0)
Zheng et al.,60 2016 LMWH vs. placebo 0 411 (0.0) – – 0 403 (0.0) 0 411 (0.0) – – 0 403 (0.0)
Gehling et al.,23 1998 LMWH vs. aspirin 0 143 (0.0) – – 0 144 (0.0) 0 143 (0.0) – – 0 144 (0.0)
Bruntink et al.,49 2017 LMWH vs. fondaparinux
vs. no treatment
0 92 (0.0) 0 92 (0.0) 2 94 (2.1) 0 92 (0.0) 0 92 (0.0) 0 94 (0.0)
Samama et al.,57 2013 LMWH vs. fondaparinux 0 622 (0.0) 2 621 (0.3) – – 0 670 (0.0) 1 674 (0.1) – –
a Median incidence in control group, 0%.
b Median incidence in control group, 0%.
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Appendix 4 Details of the network meta-regressions
The following potential treatment effect modifiers were assessed: (1) population characteristics (i.e.proportion that were male, baseline risk of VTE), (2) type of injury (i.e. fractures, Achilles tendon
rupture, other soft-tissue injury), (3) treatment of injury (surgical vs. conservative, above- vs. below-knee
immobilisation), (4) thromboprophylactic agent used and (5) duration of thromboprophylaxis.
For each outcome of interest, except for major bleeding, a network meta-regression of the potential treatment
effect modifiers 1–3 and 5 was performed separately for each covariate using an approach similar to that
described in Chapter 3,Methods of data synthesis and analysis. The analyses were performed by centring the
covariates at their mean values of the reference treatment (i.e. placebo, no treatment and aspirin) to improve
mixing of the Markov chain Monte Carlo chains. In each model, the regression parameter was given a normally
distributed prior distribution with mean 0 and variance 1000, that is N(0, 1000). Only Lassen et al.56 and
Samama et al.57 provided information about major bleeding. Consequently, a meta-regression of major
bleeding was not performed.
The analysis of the effect of the baseline risk of VTE was performed with respect to the true baseline rather
than the sample estimate of the baseline in order to avoid regression to the mean. Simultaneously assessing
the effect of three types of injury would have involved a model with two covariates to estimate in relatively
sparse data sets; in practice, only the effect of fractures versus other types of injury was assessed. The effect
of the management of the injury using a surgical or conservative approach, and the method of immobilisation
(i.e. whether above or below the knee), were assessed separately. Several studies (i.e. Kujath et al.,53 Samama
et al.,57 Selby et al.,58 van Adrichem et al.59 and Zheng et al.60) provided insufficient information to allow a
classification of whether the immobilisation was above or below the knee; these studies were excluded from
the meta-regression.
In a network meta-regression, three assumptions can be made about the interaction between a covariate
and each treatment effect: (1) independent – treatment-specific interaction terms for each pair of treatments,
(2) exchangeable – treatment-specific but related interaction terms and (3) identical interaction effects for all
treatments. Given the relative sparseness of the data, the analysis was performed by only assuming identical
interaction terms for all treatments.
The effect of the type of thromboprophylactic agent used (i.e. dalteparin, tinzaparin, certoparin nadroparin,
reviparin) was assessed using a separate NMA. Van Adrichem et al.59 allowed nadroparin or dalteparin to
be used in accordance with the preference of each hospital and no further information was provided as
to what was actually used. No information was available on the LMWH used in Zheng et al.60 Therefore,
Van Adrichem et al.59 and Zheng et al.60 were excluded from the analysis.
The unadjusted and covariate-adjusted models were compared using the deviance information criterion.
Models fitted to a particular data set that have lower deviance information criterion values provide the
best predictions. However, differences in deviance information criterion values of < 5 are generally not
important and the simpler model is generally preferred, irrespective of the estimated effect of individual
parameters. In addition, deviation information criterion values can only be compared for models applied
to the same data sets. Consequently, it is not possible to compare unadjusted and adjusted models with
respect to the effect of immobilisation above or below the knee, or the type of thromboprophylactic agent
used, because the analyses make use of data from different studies.
It was not possible to use data from all the studies in all the analyses. Gehling et al.23 and Goel et al.50 had
no asymptomatic DVT proximal events and, consequently, provided no information with which to estimate
treatment effects or the effects of potential treatment effect modifiers. Jørgensen et al.,51 Goel et al.,50
Bruntink et al.49 and Zheng et al.60 had no clinically detected DVT events and, consequently, provided no
information with which to estimate treatment effects or the effects of potential treatment effect modifiers.
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Goel et al.50 had no clinically relevant DVT events and, consequently, provided no information with which
to estimate treatment effects or the effects of potential treatment effect modifiers. Only Lassen et al.,56
Samama et al.,57 Selby et al.,58 Bruntink et al.49 and van Adrichem et al.59 had PEs; all other studies
provided no information with which to estimate treatment effects or the effects of potential treatment
effect modifiers.
Table 31 shows the results of the network meta-regression for all potential effect modifiers except
thromboprophylactic agent used. Results according to the proportion of patients with immobilisation
below the knee should be treated with caution as the model is fitted to a subset of the data and it is not
possible to compare the fit of this model with that of the unadjusted model. The adjusted deviance
information criterion suggested that no covariate improved the model fits.
TABLE 31 Network metaregression for all potential effect modifiers except thromboprophylactic agent used
Covariate No treatmenta Adjusted DIC
Regression parameter
coefficient (95% CI)
Any VTE (unadjusted DIC = 157.6)
Proportion male 56 159.1 0.007 (–0.029 to 0.043)
Baseline VTE (%; logit) 0.10 (–2.214) 159.5 –0.024 (–0.358 to 0.299)
Type of injury: proportion fractures 68 158.9 0.003 (–0.007 to 0.015)
Treatment of injury: proportion surgery 63 153.6 0.009 (0.002 to 0.018)
Treatment of injury: proportion below knee 91 N/A –0.001 (–0.043 to 0.041)
Duration of thromboprophylaxis (days) 28 159.2 0.005 (–0.021 to 0.033)
Asymptomatic DVT (all) (unadjusted DIC = 113.9)
Proportion male 54 115.8 –0.005 (–0.064 to 0.053)
Baseline VTE (%; logit) 0.12 (–2.039) 172.1 –0.003 (–0.452 to 0.445)
Type of injury: proportion fractures 85 114.6 0.015 (–0.011 to 0.050)
Treatment of injury: proportion surgery 71 112.1 0.012 (–0.000 to 0.026)
Treatment of injury: proportion below knee 90 N/A –0.005 (–0.045 to 0.034)
Duration of thromboprophylaxis (days) 27 115.6 –0.005 (–0.035 to 0.025)
Asymptomatic DVT (distal) (unadjusted DIC = 84.4)
Proportion male 56 85.6 –0.040 (–0.153 to 0.059)
Baseline VTE (%; logit) 0.10 (–2.249) 128.8 –0.172 (–0.879 to 0.510)
Type of injury: proportion fractures 81 84.7 0.022 (–0.011 to 0.070)
Treatment of injury: proportion surgery 77 85.1 0.013 (–0.009 to 0.044)
Treatment of injury: proportion below knee 85 N/A –0.003 (–0.057 to 0.050)
Duration of thromboprophylaxis (days) 23 86.2 –0.005 (–0.045 to 0.038)
Asymptomatic DVT (proximal) (unadjusted DIC = 44.8)
Proportion male 60 46.6 –0.018 (–0.205 to 0.148)
Baseline VTE (%; logit) 0.11 (–2.141) 89.3 –0.060 (–1.467 to 1.123)
Type of injury: proportion fractures 69 46.5 0.003 (–0.032 to 0.045)
Treatment of injury: proportion surgery 84 43.9 0.900 (0.045 to 2.650)
Treatment of injury: proportion below knee 87 N/A 1.289 (–0.128 to 4.068)
Duration of thromboprophylaxis (days) 23 46.5 –0.007 (–0.146 to 0.111)
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Table 32 shows the results according to the type of thromboprophylactic agent used. These findings
should be treated with caution as the model is fitted to a subset of the data and it is not possible to
compare the fit of this model with the original model. In the case of an asymptomatic DVT (distal)
outcome, the study by Samama et al.57 is not connected; consequently, it is not possible to estimate
the effects of nadroparin or fondaparinux on an asymptomatic DVT (distal) outcome. In the case of an
asymptomatic DVT (proximal segment) outcome, the study by Samama et al.57 is not connected and the
Gehling et al.23 study had no events; consequently, it is not possible to estimate the effects of nadroparin,
reviparin or fondaparinux on an asymptomatic DVT (proximal segment) outcome. In the case of a clinically
detected (symptomatic) outcome, Jørgensen et al.51 and Bruntink et al.49 had no events and provide no
information about relative treatment effect; in addition, the study by Samama et al.57 is connected in the
network only via the nadroparin and fondaparinux arms of the study by Bruntink et al.49 Consequently,
it is not possible to estimate the effect of nadroparin, tinzaparin or fondaparinux on a clinically detected
(symptomatic) outcome. In the case of a clinically relevant DVT outcome, the study by Samama et al.57 is
not connected; consequently, it is not possible to estimate the effects of nadroparin or fondaparinux on a
clinically relevant DVT outcome.
TABLE 31 Network metaregression for all potential effect modifiers except thromboprophylactic agent used
(continued )
Covariate No treatmenta Adjusted DIC
Regression parameter
coefficient (95% CI)
Clinically detected (DVT) (unadjusted DIC = 64.4)
Proportion male 53 63.8 –0.209 (–0.685 to 0.056)
Baseline VTE (%; logit) 0.10 (–2.229) 127.0 –0.514 (–1.505 to 0.303)
Type of injury: proportion fractures 85 62.6 0.080 (0.003 to 0.267)
Treatment of injury: proportion surgery 65 64.9 0.007 (–0.017 to 0.041)
Treatment of injury: proportion below knee 90 N/A 1.247 (0.101 to 4.133)
Duration of thromboprophylaxis (days) 28 65.5 –0.018 (–0.119 to 0.076)
Clinically relevant (DVT) (unadjusted DIC = 80.9)
Proportion male 58 81.0 –0.062 (–0.176 to 0.029)
Baseline VTE (%; logit) 0.10 (–2.229) 137.3 –0.267 (–0.983 to 0.377)
Type of injury: proportion fractures 75 81.1 0.017 (–0.008 to 0.052)
Treatment of injury: proportion surgery 77 82.1 0.002 (–0.017 to 0.027)
Treatment of injury: proportion below knee 88 N/A 2.056 (0.128 to 7.393)
Duration of thromboprophylaxis (days) 27 82.2 0.010 (–0.063 to 0.082)
PE (unadjusted DIC = 38.2)
Proportion male 56 37.7 0.308 (–0.269 to 1.062)
Baseline VTE (%; logit) 0.09 (–2.277) 104.2 –15.190 (–36.670 to –3.094)
Type of injury: proportion fractures 74 38.3 –0.058 (–0.309 to 0.191)
Treatment of injury: proportion surgery 63 38.8 –0.057 (–0.263 to 0.028)
Treatment of injury: proportion below knee 91 N/A 0.060 (–0.212 to 0.488)
Duration of thromboprophylaxis (days) 28 38.9 0.060 (–0.212 to 0.488)
DIC, deviance information criterion; N/A, not applicable – analysis based on a subset of studies.
a Value used to centre the meta-regression.
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TABLE 32 Random-effects NMA of different pharmacological thromboprophylaxis interventions vs. no
thromboprophylaxis
OR (95% CrI) OR (95% PrI)
Probability of
being the best
Clinically detected DVT (symptomatic)
Dalteparin 0.38 (0.05 to 2.60) 0.38 (0.03 to 5.28) 0.01
Tinzaparin NE NE NE
Certoparin 7.2 × 10–10 (3.6 × 10–31 to 0.09) 7.0 × 10–10 (3.5 × 10–31 to 0.11) 0.98
Nadroparin NE NE NE
Reviparin 0.35 (0.03 to 2.71) 0.35 (0.02 to 4.99) 0.01
Fondaparinux NE NE NE
None – – 0.00
Asymptomatic DVT (proximal segment)
Dalteparin 0.43 (0.04 to 3.26) 0.42 (0.03 to 5.23) 0.00
Tinzaparin 6.4 × 10–10 (1.0 × 10–29 to 0.66) 6.1 × 10–10 (1.0 × 10–29 to 0.69) 0.51
Certoparin 5.8 × 10–10 (1.5 × 10–32 to 0.59) 5.8 × 10–10 (1.5 × 10–32 to 0.65) 0.49
Nadroparin NE NE NE
Reviparin NE NE NE
Fondaparinux NE NE NE
None – – 0.01
Asymptomatic DVT (distal)
Dalteparin 0.79 (0.25 to 3.13) 0.79 (0.15 to 5.36) 0.00
Tinzaparin 0.58 (0.13 to 2.48) 0.58 (0.08 to 3.96) 0.01
Certoparin 1.4 × 10–10 (2.5 × 10–30 to 0.20) 1.5 × 10–10 (2.6 × 10–30 to 0.22) 0.99
Nadroparin NE NE NE
Reviparin 0.81 (0.29 to 2.41) 0.80 (0.16 to 4.40) 0.00
Fondaparinux NE NE NE
None – – 0.00
Asymptomatic DVT (all)
Dalteparin 0.72 (0.35 to 1.59) 0.72 (0.23 to 2.54) 0.00
Tinzaparin 0.54 (0.16 to 1.84) 0.54 (0.11 to 2.54) 0.00
Certoparin 3.5 × 10–10 (4.7 × 10–31 to 0.13) 3.5 × 10–10 (4.6 × 10–31 to 0.13) 0.96
Nadroparin 0.23 (0.04 to 1.06) 0.23 (0.03 to 1.31) 0.00
Reviparin 0.66 (0.29 to 1.70) 0.66 (0.20 to 2.63) 0.00
Fondaparinux 0.06 (0.01 to 0.33) 0.06 (0.01 to 0.40) 0.04
None – – 0.00
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TABLE 32 Random-effects NMA of different pharmacological thromboprophylaxis interventions vs. no
thromboprophylaxis (continued )
OR (95% CrI) OR (95% PrI)
Probability of
being the best
PE
Deltaparin 4.2 × 10–10 (9.0 × 10–31 to 0.43) 4.2 × 10–10 (9.3 × 10–31 to 0.47) 0.27
Tinzaparin NE NE NE
Certoparin NE NE NE
Nadroparin 2.8 × 10–13 (8.8 × 10–28 to 1.6 × 10–3) 2.7 × 10–13 (8.7 × 10–28 to 1.9 × 10–3) 0.48
Reviparin 6.5 × 10–10 (1.6 × 10–27 to 0.26) 6.4 × 10–10 (1.4 × 10–27 to 0.28) 0.25
Fondaparinux 1.6 × 10–6 (5.9 × 10–15 to 62) 1.6 × 10–6 (5.3 × 10–15 to 0.70) 0.00
None – – 0.01
Major bleeding
Deltaparin NE NE NE
Tinzaparin NE NE NE
Certoparin NE NE NE
Nadroparin NE NE NE
Reviparin NE NE NE
Fondaparinux NE NE NE
None – – NE
Clinically relevant DVT
Deltaparin 0.40 (0.10 to 1.46) 0.40 (0.06 to 2.52) 0.00
Tinzaparin 3.4 × 10–10 (7.5 × 10–32 to 0.67) 3.3 × 10–10 (7.0 × 10–32 to 0.70) 0.46
Certoparin 1.3 × 10–11 (1.9 × 10–31 to 0.05) 1.3 × 10–11 (1.8 × 10–31 to 0.06) 0.54
Nadroparin NE NE NE
Reviparin 2.35 (0.14 to 92.18) 2.35 (0.11 to 112.10) 0.00
Fondaparinux 0.23 (0.03 to 1.36) 0.23 (0.02 to 2.11) 0.00
None – – 0.01
Any VTE
Dalteparin 0.69 (0.40 to 1.23) 0.68 (0.27 to 1.83) 0.00
Tinzaparin 0.54 (0.17 to 1.61) 0.54 (0.13 to 2.95) 0.00
Certoparin 8.5 × 10–12 (9.9 × 10–29 to 0.02) 8.6 × 10–12 (9.8 × 10–29 to 0.02) 0.99
Nadroparin 0.22 (0.08 to 0.54) 0.22 (0.06 to 0.69) 0.00
Reviparin 0.63 (0.31 to 1.42) 0.62 (0.23 to 1.97) 0.00
Fondaparinux 0.06 (0.02 to 0.19) 0.06 (0.01 to 0.24) 0.01
None – – 0.00
NE, not estimable; PrI, predictive interval.
DOI: 10.3310/hta23630 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 63
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
There was evidence to suggest that there were differences in the effects based on the type of thromboprophylactic
agent used, including between the different types of LMWH, with certoparin having the highest probability of
the greatest effect on any VTE. However, this is based on the effect of certoparin being used in one study (Kock
et al.),52 so it is not possible to draw any reliable conclusions.
The meta-regression used in this assessment was a between-study comparison and lacked information with
which to estimate parameters compared with a within-study comparison using patient data. In addition,
comparisons between treatments involving zero events within a study provide no information about the
relative treatment effect or the relationship between a potential treatment effect modifier and treatment
effect. The between-study meta-regression has the potential to suffer from an ecological fallacy, such that
the estimate of the relationship between a potential treatment effect modifier and treatment effect in a
between-study comparison may be qualitatively different from the relationship between the treatment effect
modifier and treatment effect within studies. Potential treatment effect modifiers were assessed separately,
whereas they could be affecting treatment effect simultaneously; there is insufficient information with which
to estimate potential treatment effect modifiers simultaneously. An adjusted model that is indistinguishable
from an unadjusted model may reflect a lack of evidence rather than a lack of a relationship between
potential treatment effect modifier and treatment. Estimates of the regression parameter should be
interpreted with caution when they indicate evidence of a relationship between a potential treatment
effect modifier and treatment but the adjusted model is indistinguishable from the unadjusted model.
There was insufficient evidence to suggest that any of the potential treatment effect modifiers defined in
the protocol affected the treatment effect.
There was evidence to suggest that there were differences in the effects based on the type of thromboprophylactic
agent used, including between the different types of LMWH.
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Appendix 5 Literature search strategies for the
review of individual risk factors associated with
venous thromboembolism risk and risk assessment
models for prediction of venous thromboembolism
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R)
Platform or provider used: Ovid SP.
Date range searched: 1946 to May 2017.
Date searched: May 2017.
Search strategy
1. thrombosis/ or exp venous thrombosis/
2. Venous Thromboembolism/ or Thromboembolism/
3. exp Pulmonary Embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. Splints/
11. Braces/
12. exp Casts, Surgical/
13. immobili*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
14. brace*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
15. splint*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
16. plaster*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
17. cast.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 7 and 19
21. predict:.mp. or scor:.tw. or observ:.mp.
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22. (validation or validate).tw.
23. predict:.tw. or validat:.mp. or develop.tw.
24. 21 or 22 or 23
25. (risk assess* or risk predict* or risk stratif*).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
26. exp *Risk/ or exp Models, Statistical/ or exp Risk Assessment/ or *Postoperative Complications/ or risk
model*.mp. or *Risk Factors/
27. 24 or 25 or 26
28. (Risk model* or prognostic model* or prediction model* or predictive model* or risk assessment
model* or prediction score* or algorithm* or matrix or matrices or assessment tool* or prediction
rule* or decision rule* or risk score*).mp.
29. 27 or 28
30. 20 and 29
Cochrane Database of Systematic Reviews, Cochrane Central Register of
Controlled Trials, Database of Abstracts of Review of Effects, Health
Technology Assessment Database and NHS Economic Evaluation
Database
Platform or provider used: Wiley Online Library.
Date range searched: 1898 to May 2017.
Date searched: May 2017.
Search strategy
#1 MeSH descriptor: [Thrombosis] explode all trees
#2 MeSH descriptor: [Venous Thrombosis] explode all trees
#3 MeSH descriptor: [Venous Thromboembolism] explode all trees
#4 MeSH descriptor: [Pulmonary Embolism] explode all trees
#5 (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*):ti,ab,kw
#6 ((vein* or ven*) and thromb*):ti,ab,kw
#7 (PE or DVT or VTE):ti,ab,kw
#8 MeSH descriptor: [Immobilization] explode all trees
#9 MeSH descriptor: [Mobility Limitation] explode all trees
#10 MeSH descriptor: [Splints] explode all trees
#11 MeSH descriptor: [Braces] explode all trees
#12 MeSH descriptor: [Casts, Surgical] explode all trees
#13 immobili* or brace* or splint* or plaster* or cast*:ti,ab,kw (Word variations have been searched)
#14 ((leg* or tibia* or ankle* or fibula*) and (fracture* or surg*) and complicat*):ti,ab,kw
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7
#16 #8 or #9 or #10 or #11 or #12 or #13 or #14
#17 #15 and #16
#18 MeSH descriptor: [Risk] explode all trees
#19 MeSH descriptor: [Models, Statistical] explode all trees
#20 MeSH descriptor: [Risk Assessment] explode all trees
#21 MeSH descriptor: [Postoperative Complications] explode all trees
#22 MeSH descriptor: [Risk Factors] explode all trees
#23 (risk and (assess* or predict* or model* or stratif*)):ti,ab,kw
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#24 (predict* or scor* or observ* or validat* or develop* or Risk model* or prognostic model* or
prediction model* or predictive model* or risk assessment model* or prediction score* or algorithm* or
matrix or matrices or assessment tool* or prediction rule* or decision rule* or risk score*):ti,ab,kw
#25 #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #17 and #25
EMBASE
Platform or provider used: Ovid SP.
Date range searched: 1974 to May 2017.
Date searched: May 2017.
Search strategy
1. thrombosis prevention/ or exp thrombosis/ or exp deep vein thrombosis/ or exp vein thrombosis/ or leg
thrombosis/ or lower extremity deep vein thrombosis/
2. exp thromboembolism/ or exp venous thromboembolism/
3. exp lung embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. exp splint/
11. exp brace/
12. exp plaster cast/
13. immobili*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
14. brace*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
15. splint*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
16. plaster*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
17. cast.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 7 and 19
21. predict:.mp. or scor:.tw. or observ:.mp.
22. (validation or validate).tw.
23. predict:.tw. or validat:.mp. or develop.tw.
24. 21 or 22 or 23
25. (risk assess* or risk predict* or risk stratif*).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word]
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26. (Risk model* or prognostic model* or prediction model* or predictive model* or risk assessment
model* or prediction score* or algorithm* or matrix or matrices or assessment tool* or prediction
rule* or decision rule* or risk score*).mp.
27. statistical model/
28. exp *risk factor/
29. exp *postoperative complication/
30. exp *risk/
31. exp risk assessment/
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. 24 or 32
34. 20 and 33
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Appendix 6 Excluded studies: review of individual
risk factors associated with venous thromboembolism
risk
TABLE 33 Excluded studies with rationale: review of individual risk factors associated with VTE risk
Authors, year Reason for exclusion
Ajwani et al.,237 2016 No data or analysis of risk factors associated with VTE
Batra et al.,238 2006 No data or analysis of risk factors associated with VTE
Bertoletti et al.,239 2011 No data or analysis of risk factors associated with VTE
Caprini,240 2011 Narrative review
Caprini et al.,210 2001 Population: not isolated lower-limb injury requiring temporary immobilisation
Cirlincione et al.,241 2001 Narrative review
Decramer et al.,242 2008 No data or analysis of risk factors associated with VTE
Department of Health and Social
Care,211 2010
No data or analysis of risk factors associated with VTE
Douna,243 2008 Commentary
Dyall et al.,244 2012 (abstract) No data or analysis of risk factors associated with VTE
Eingartner et al.,78 1995 No data or analysis of risk factors associated with VTE
Engbers et al.,245 2013 No data or analysis of risk factors associated with VTE
Fall et al.,246 2014 No data or analysis of risk factors associated with VTE
Felcher et al.,247 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
Fleischer et al.,248 2015 No data or analysis of risk factors associated with VTE
Gearhart et al.,249 2000 Population: not isolated lower-limb injury requiring temporary immobilisation
Giannadakis et al.,79 2000 No data or analysis of risk factors associated with VTE
Haque et al.,80 2016 No data or analysis of risk factors associated with VTE
Healy et al.,250 2010 No data or analysis of risk factors associated with VTE
Jiang et al.,251 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Kocialkowski et al.,252 2016 No data or analysis of risk factors associated with VTE
Lawall et al.,253 2011 Population: not isolated lower-limb injury requiring temporary immobilisation
Lim et al.,254 2016 Population: not isolated lower-limb injury requiring temporary immobilisation
Mangwani et al.,228 2015 Systematic review
Micheli,255 1975 No data or analysis of risk factors associated with VTE
Mizel et al.,73 1998 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Nemeth et al.,32 2015 RAM (including data on risk factors) developed using a generic thrombosis cohort
rather than a subgroup of patients with temporary lower-limb immobilisation.
However, based on regression coefficients in a clinical logistic regression model,
a RAM was developed for individuals with a plaster cast of the lower extremity
Nemeth et al.,256 2013 (abstract) Abstract of an excluded full-text study: Nemeth et al.32
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TABLE 33 Excluded studies with rationale: review of individual risk factors associated with VTE risk (continued )
Authors, year Reason for exclusion
Nesheiwat and Sergi,257 1996 No data or analysis of risk factors associated with VTE
Nilsson-Helander et al.,12 2009 No data or analysis of risk factors associated with VTE
Nokes,31 2010 No data or analysis of risk factors associated with VTE
Nygaard et al.,212 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
Park et al.,258 2016 Population: not isolated lower-limb injury requiring temporary immobilisation
Park et al.,259 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Parsonage,260 2009 Narrative review
Persson and Wredmark,261 1979 No data or analysis of risk factors associated with VTE
Randelli et al.,262 2013 No data or analysis of risk factors associated with VTE
Roberts et al.,17 2013 No data or analysis of risk factors associated with VTE
Rogers et al.,263 2012 Population: not isolated lower-limb injury requiring temporary immobilisation
Samama,264 2000 Population: not isolated lower-limb injury requiring temporary immobilisation
Saragas et al.,81 2017 No data or analysis of risk factors associated with VTE
Saragas et al.,72 2014 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Selby et al.,58 2015 No data or analysis of risk factors associated with VTE (authors reported that a low
event rate precluded any subsequent analysis of predictors for VTE)
Simon et al.,265 1982 Population: not isolated lower-limb injury requiring temporary immobilisation
Slaybaugh et al.,266 2003 Review
Solis and Saxby,267 2002 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Spannagel and Kujath,235 1993 No data or analysis of risk factors associated with VTE
Spencer et al.,268 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Spyropoulos,269 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Spyropoulos et al.,270 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
(elective surgical population)
Stockport NHS Trust
Foundation,33 2013
No data or analysis of risk factors associated with VTE
Tan et al.,271 2016 Systematic review
Testroote et al.,15 2014 Systematic review
Toure,272 2014 Population: not isolated lower-limb injury requiring temporary immobilisation
True and Williamson,273 2014 No data or analysis of risk factors associated with VTE
van Adrichem et al.,274 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
van Adrichem et al.,275 2013
(abstract)
Abstract of included full-text study: van Adrichem et al.70
Vollans et al.,276 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Wang et al.,277 2015 Not available
Watson et al.,82 2016 No data or analysis of risk factors associated with VTE
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Appendix 7 Excluded studies: review of risk
assessment models for prediction of venous
thromboembolism risk
TABLE 34 Excluded studies with rationale: review of RAMs for prediction of VTE risk
Authors, year Reason for exclusion
Ajwani et al.,237 2016 No outcome evaluation of RAM
Batra et al.,238 2006 No prognostic model/RAM
Bertoletti et al.,239 2011 No prognostic model/RAM (letter to the editor)
Caprini,240 2011 Narrative review
Caprini et al.,210 2001 Generic RAM (no outcome evaluation)
Cirlincione et al.,241 2001 Narrative review
Decramer et al.,242 2008 No prognostic model/RAM
Department of Health and Social Care,211
2010
Generic RAM (no outcome evaluation)
Douna,243 2008 Commentary
Dyall et al.,244 2012 (abstract) No prognostic model/RAM
Engbers et al.,245 2013 No prognostic model/RAM
Fall et al.,246 2014 No prognostic model/RAM
Felcher et al.,247 2009 Population: not isolated lower-limb injury requiring temporary immobilisation
Fleischer et al.,248 2015 No outcome evaluation of RAM
Gearhart et al.,249 2000 Population: not isolated lower-limb injury requiring temporary immobilisation
Gehling et al.,23 1998 No prognostic model/RAM
Goel et al.,50 2009 No prognostic model/RAM
Hanslow et al.,64 2006 No prognostic model/RAM
Healy et al.,250 2010 No prognostic model/RAM (letter to the editor)
Ho and Omari,65 2017 No prognostic model/RAM
Jameson et al.,66 2014 No prognostic model/RAM
Jiang et al.,251 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Kocialkowski et al.,252 2016 No outcome evaluation of RAM
Kock et al.,52 1995 No prognostic model/RAM
Kujath et al.,53 1993 No prognostic model/RAM
Lawall et al.,253 2011 Population: not isolated lower-limb injury requiring temporary immobilisation
Lim et al.,254 2016 Population: not isolated lower-limb injury requiring temporary immobilisation
Makhdom et al.,9 2013 No prognostic model/RAM
Manafi Rasi et al.,67 2013 No prognostic model/RAM
Mangwani et al.,228 2015 Systematic review
Meek and Tong,11 2012 No prognostic model/RAM
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TABLE 34 Excluded studies with rationale: review of RAMs for prediction of VTE risk (continued )
Authors, year Reason for exclusion
Micheli,255 1975 No prognostic model/RAM
Mizel et al.,73 1998 No prognostic model/RAM
Nemeth et al.,256 2013 (abstract) Abstract of an included full-text study: Nemeth et al.32
Nesheiwat and Sergi,257 1996 No prognostic model/RAM
Nilsson-Helander et al.,12 2009 No prognostic model/RAM
Nokes,31 2010 No outcome evaluation of RAM
Nygaard et al.,212 2009 Generic RAM (no outcome evaluation)
Park et al.,258 2016 Population: not isolated lower-limb injury requiring temporary immobilisation
Park et al.,259 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Parsonage,260 2009 Narrative review
Patel et al.,68 2012 No prognostic model/RAM
Persson and Wredmark,261 1979 No prognostic model/RAM
Randelli et al.,262 2013 No prognostic model/RAM
Riou et al.,69 2007 No prognostic model/RAM
Roberts et al.,17 2013 No outcome evaluation of RAM
Rogers et al.,263 2012 Population: not isolated lower-limb injury requiring temporary immobilisation
Samama,264 2000 Population: not isolated lower-limb injury requiring temporary immobilisation
Saragas et al.,72 2014 No prognostic model/RAM
Selby et al.,58 2015 No prognostic model/RAM
Simon et al.,265 1982 Population: not isolated lower-limb injury requiring temporary immobilisation
Slaybaugh et al.,266 2003 Review
Solis and Saxby,267 2002 No prognostic model/RAM
Spannagel and Kujath,235 1993 No prognostic model/RAM
Spencer et al.,268 2009 No prognostic model/RAM
Spyropoulos,269 2009 No prognostic model/RAM
Spyropoulos et al.,270 2009 No prognostic model/RAM
Stockport NHS Trust Foundation,33 2013 No outcome evaluation of RAM
Tan et al.,271 2016 Systematic review
Testroote et al.,15 2014 Systematic review
Toure,272 2014 Population: not isolated lower-limb injury requiring temporary immobilisation
True and Williamson,273 2014 No prognostic model/RAM
van Adrichem et al.,70 2014 No prognostic model/RAM
van Adrichem et al.,274 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
van Adrichem et al.,275 2013 (abstract) No prognostic model/RAM
Vollans et al.,276 2015 Population: not isolated lower-limb injury requiring temporary immobilisation
Wahlsten et al.,71 2015 No prognostic model/RAM
Wang et al.,277 2015 Not available
Zheng et al.,60 2016 No prognostic model/RAM
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Appendix 8 Delphi panel
TABLE 35 List of Delphi participants and clinical scope of practice
Participant number Initials Specialty Title/scope of practice
1 MC Orthopaedic surgery Professor
2 VL Orthopaedic surgery Advanced nurse practitioner
3 XG Orthopaedic surgery Consultant
4 JK Orthopaedic surgery Consultant
5 DJ Orthopaedic surgery Consultant
6 RS Orthopaedic surgery Consultant
7 SG Emergency medicine Professor
8 DH Emergency medicine Professor
9 RB Emergency medicine Professor
10 GJ Emergency medicine Consultant
11 JC Emergency medicine Consultant
12 CR Emergency medicine Consultant
13 JS Emergency medicine Professor
14 JT Thrombosis and haemostasis Consultant
15 BH Thrombosis and haemostasis Professor
16 KdW Thrombosis and haemostasis Assistant professor
17 TN Thrombosis and haemostasis Consultant
18 HW Thrombosis and haemostasis Consultant
19 RT-D Thrombosis and haemostasis Consultant
20 RM Thrombosis and haemostasis Consultant
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Appendix 9 Literature search strategies for
review of economic studies
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R)
Platform or provider used: Ovid SP.
Date range searched: 1946 to October 2017.
Date searched: October 2017.
Search strategy
1. thrombosis/ or exp venous thrombosis/
2. Venous Thromboembolism/ or Thromboembolism/
3. exp Pulmonary Embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. Splints/
11. Braces/
12. exp Casts, Surgical/
13. immobili*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
14. brace*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
15. splint*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
16. plaster*.mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
17. cast.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. exp “costs and cost analysis”/ or costs.tw. or cost effective:.tw.
21. (cost: or cost benefit analys: or health care costs).mp.
22. Economics/
23. exp “costs and cost analysis”/
24. Economics, Dental/
25. exp economics, hospital/
DOI: 10.3310/hta23630 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 63
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
26. Economics, Medical/
27. Economics, Nursing/
28. Economics, Pharmaceutical/
29. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic
$).ti,ab.
30. (expenditure$ not energy).ti,ab.
31. value for money.ti,ab.
32. budget$.ti,ab.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. ((energy or oxygen) adj cost).ti,ab.
35. (metabolic adj cost).ti,ab.
36. ((energy or oxygen) adj expenditure).ti,ab.
37. 34 or 35 or 36
38. 33 not 37
39. letter.pt.
40. editorial.pt.
41. historical article.pt.
42. or/39-41
43. 38 not 42
44. exp animals/ not humans/
45. 43 not 44
46. bmj.jn.
47. “cochrane database of systematic reviews”.jn.
48. health technology assessment winchester england.jn.
49. or/46-48
50. 45 not 49
51. “Value of Life”/
52. Quality of Life/
53. quality of life.ti,kf.
54. ((instrument or instruments) adj3 quality of life).ab.
55. Quality-Adjusted Life Years/
56. quality adjusted life.ti,ab,kf.
57. (qaly* or qald* or qale* or qtime* or life year or life years).ti,ab,kf.
58. disability adjusted life.ti,ab,kf.
59. daly*.ti,ab,kf.
60. (sf36 or sf 36 or short form 36 or shortform 36 or short form36 or shortform36 or sf thirtysix or
sfthirtysix or sfthirty six or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix
or short form thirty six).ti,ab,kf.
61. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six or
shortform6 or short form6).ti,ab,kf.
62. (sf8 or sf 8 or sf eight or sfeight or shortform 8 or shortform 8 or shortform8 or short form8 or
shortform eight or short form eight).ti,ab,kf.
63. (sf12 or sf 12 or short form 12 or shortform 12 or short form12 or shortform12 or sf twelve or
sftwelve or shortform twelve or short form twelve).ti,ab,kf.
64. (sf16 or sf 16 or short form 16 or shortform 16 or short form16 or shortform16 or sf sixteen or
sfsixteen or shortform sixteen or short form sixteen).ti,ab,kf.
65. (sf20 or sf 20 or short form 20 or shortform 20 or short form20 or shortform20 or sf twenty or
sftwenty or shortform twenty or short form twenty).ti,ab,kf.
66. (hql or hqol or h qol or hrqol or hr qol).ti,ab,kf.
67. (hye or hyes).ti,ab,kf.
68. (health* adj2 year* adj2 equivalent*).ti,ab,kf.
69. (pqol or qls).ti,ab,kf.
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70. (quality of wellbeing or quality of well being or index of wellbeing or index of well being or qwb).ti,
ab,kf.
71. nottingham health profile*.ti,ab,kf.
72. sickness impact profile.ti,ab,kf.
73. exp health status indicators/
74. (health adj3 (utilit* or status)).ti,ab,kf.
75. (utilit* adj3 (valu* or measur* or health or life or estimat* or elicit* or disease or score* or weight)).ti,
ab,kf.
76. (preference* adj3 (valu* or measur* or health or life or estimat* or elicit* or disease or score* or
instrument or instruments)).ti,ab,kf.
77. disutilit*.ti,ab,kf.
78. rosser.ti,ab,kf.
79. willingness to pay.ti,ab,kf.
80. standard gamble*.ti,ab,kf.
81. (time trade off or time tradeoff).ti,ab,kf.
82. tto.ti,ab,kf.
83. (eq or euroqol or euro qol or eq5d or eq 5d or euroqual or euro qual).ti,ab,kf.
84. duke health profile.ti,ab,kf.
85. functional status questionnaire.ti,ab,kf.
86. dartmouth coop functional health assessment*.ti,ab,kf.
87. (hui or hui1 or hui2 or hui3).ti,ab,kf.
88. or/51-87
89. 20 or 21 or 50 or 88
90. 7 and 19 and 89
EMBASE
Platform or provider used: Ovid SP.
Date range searched: 1974 to October 2017.
Date searched: October 2017.
Search strategy
1. thrombosis prevention/ or exp thrombosis/ or exp deep vein thrombosis/ or exp vein thrombosis/ or leg
thrombosis/ or lower extremity deep vein thrombosis/
2. exp thromboembolism/ or exp venous thromboembolism/
3. exp lung embolism/
4. (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*).ti,ab,kw.
5. ((vein* or ven*) adj7 thromb*).ti,ab,kw.
6. (PE or DVT or VTE).ti,ab,kw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Immobilization/
9. exp Mobility Limitation/
10. exp splint/
11. exp brace/
12. exp plaster cast/
13. immobili*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
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14. brace*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
15. splint*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
16. plaster*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word]
17. cast.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word]
18. (leg* or tibia* or fibula* or ankle*).mp. and (fracture*.hw. or su.fs.) and co.fs.
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 7 and 19
21. cost effectiveness analysis.sh. or randomized.tw. or economic.tw.
22. (cost or costs).tw.
23. Economics/
24. Cost/
25. exp Health Economics/
26. Budget/
27. budget*.ti,ab,kw.
28. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or
pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or
finances or financed).ti,kw.
29. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or
pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or
finances or financed).ab. /freq=2
30. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kw.
31. (value adj2 (money or monetary)).ti,ab,kw.
32. Statistical Model/
33. economic model*.ab,kw.
34. Probability/
35. markov.ti,ab,kw.
36. monte carlo method/
37. monte carlo.ti,ab,kw.
38. Decision Theory/
39. Decision Tree/
40. (decision* adj2 (tree* or analy* or model*)).ti,ab,kw.
41. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
or 40
42. 21 or 22 or 41
43. 20 and 42
44. socioeconomics/
45. exp Quality of Life/
46. quality of life.ti,kw.
47. ((instrument or instruments) adj3 quality of life).ab.
48. Quality-Adjusted Life Year/
49. quality adjusted life.ti,ab,kw.
50. (qaly* or qald* or qale* or qtime* or life year or life years).ti,ab,kw.
51. disability adjusted life.ti,ab,kw.
52. daly*.ti,ab,kw.
53. (sf36 or sf 36 or short form 36 or shortform 36 or short form36 or shortform36 or sf thirtysix or
sfthirtysix or sfthirty six or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix
or short form thirty six).ti,ab,kw.
54. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six or
shortform6 or short form6).ti,ab,kw.
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55. (sf8 or sf 8 or sf eight or sfeight or shortform 8 or shortform 8 or shortform8 or short form8 or
shortform eight or short form eight).ti,ab,kw.
56. (sf12 or sf 12 or short form 12 or shortform 12 or short form12 or shortform12 or sf twelve or
sftwelve or shortform twelve or short form twelve).ti,ab,kw.
57. (sf16 or sf 16 or short form 16 or shortform 16 or short form16 or shortform16 or sf sixteen or
sfsixteen or shortform sixteen or short form sixteen).ti,ab,kw.
58. (sf20 or sf 20 or short form 20 or shortform 20 or short form20 or shortform20 or sf twenty or
sftwenty or shortform twenty or short form twenty).ti,ab,kw.
59. (hql or hqol or h qol or hrqol or hr qol).ti,ab,kw.
60. (hye or hyes).ti,ab,kw.
61. (health* adj2 year* adj2 equivalent*).ti,ab,kw.
62. (pqol or qls).ti,ab,kw.
63. (quality of wellbeing or quality of well being or index of wellbeing or index of well being or qwb).ti,
ab,kw.
64. nottingham health profile*.ti,ab,kw.
65. nottingham health profile/
66. sickness impact profile.ti,ab,kw.
67. sickness impact profile/
68. health status indicator/
69. (health adj3 (utilit* or status)).ti,ab,kw.
70. (utilit* adj3 (valu* or measur* or health or life or estimat* or elicit* or disease or score* or weight)).ti,
ab,kw.
71. (preference* adj3 (valu* or measur* or health or life or estimat* or elicit* or disease or score* or
instrument or instruments)).ti,ab,kw.
72. disutilit*.ti,ab,kw.
73. rosser.ti,ab,kw.
74. willingness to pay.ti,ab,kw.
75. standard gamble*.ti,ab,kw.
76. (time trade off or time tradeoff).ti,ab,kw.
77. tto.ti,ab,kw.
78. (hui or hui1 or hui2 or hui3).ti,ab,kw.
79. (eq or euroqol or euro qol or eq5d or eq 5d or euroqual or euro qual).ti,ab,kw.
80. duke health profile.ti,ab,kw.
81. functional status questionnaire.ti,ab,kw.
82. dartmouth coop functional health assessment*.ti,ab,kw.
83. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or
61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or
78 or 79 or 80 or 81 or 82
84. 21 or 22 or 41 or 83
85. 20 and 84
NHS Economic Evaluation Database, Health Technology Assessment
Database
Platform or provider used: The Cochrane Library.
Date range searched: inception to 2015.
Date searched: October 2017.
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Search strategy
ID Search
#1 MeSH descriptor: [Thrombosis] explode all trees
#2 MeSH descriptor: [Venous Thrombosis] explode all trees
#3 MeSH descriptor: [Venous Thromboembolism] explode all trees
#4 MeSH descriptor: [Pulmonary Embolism] explode all trees
#5 (thromboprophyla* or thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or
embol*):ti,ab,kw
#6 ((vein* or ven*) and thromb*):ti,ab,kw
#7 (PE or DVT or VTE):ti,ab,kw
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
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Appendix 10 Excluded studies: review of
cost-effectiveness evidence
TABLE 36 Reasons for exclusion at full text
Authors, year Reason for exclusion
Brasel et al.,95 1997 Population: patients hospitalised for ≥ 5 days
Lu et al.,96 2009 Design: not a cost-effectiveness analysis
Velmahos et al.,97 2000 Population: trauma population but not specific to lower-limb injury
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Appendix 11 Supplementary table
TABLE 37 List of existing models used to identify relevant parameters
Model identifier Population
Interventions and
comparators How found
TA354140 People with DVT and/or PE (treatment
and secondary prevention)
l Edoxaban tosylate
l LMWH/VKA
l Rivaroxaban
l Dabigatran
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA341133 People with DVT and/or PE (treatment
and secondary prevention)
l Apixaban
l LMWH/VKA
l Rivaroxaban
l LMWH/dabigatran
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA327132 People with DVT and/or PE (treatment
and secondary prevention)
(Subpopulation with cancer also
considered but not considered
relevant here)
l Dabigatran etexilate
l LMWH/VKA
l Rivaroxaban
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA261154 People with a confirmed symptomatic
DVT
l Rivaroxaban
l LMWH/VKA
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA245135 People having elective hip or knee
replacement surgery
l Apixaban Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA287131 People with an acute symptomatic PE l Rivaroxaban
l LMWH/VKA
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA157134 People having elective hip or knee
replacement surgery
l Dabagitran etexilate
l LMWH
l Fondaparinux
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
TA170136 People having elective hip or knee
replacement surgery
l Rivaroxaban
l LMWH
l Dabigatran etexilate
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
NICE CG9224 This guideline examined many
populations but the group having
elective knee surgery is the most
relevant (note: the NG89 is more
likely to include up-to-date sources)
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
NG89130 People having elective hip or knee
replacement surgery
Search of NICE website for models
that informed NICE guidance on
VTE prevention or treatment
Goodacre et al.,114
2017 (draft, not
final)
Women with suspected PE during
pregnancy
Alternative diagnostic
pathways
Known to authors
Simpson et al.,278
2009
People with VTE Thrombophilia testing
strategies
Known to authors
Goodacre et al.,152
2006
People with suspected DVT Alternative diagnostic
pathways
Known to authors
Wolowacz et al.,99
2009
People having total knee and hip
replacement surgery
Dabigatran etexilate Published study for related
population identified during
economic review
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Appendix 12 Sources of utility data
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TABLE 38 Studies reporting utility data relevant to the de novo model for thromboprophylaxis in lower-limb immobilisation
Authors, year Participants
HRQoL tool and
valuation method Health state(s) valued Utility estimate, mean (SD)a Cited by
Ara and
Brazier,194 2011
General population sample with
utilities reported according to
whether or not responders were
affected by particular conditions
(stroke and other heart
conditions reported here)
EQ-5D UK tariff l Stroke (n = 360) l 0.541 (95% CI 0.488 to 0.593) Goodacre et al.114
l Stroke with no other
conditions (n = 102)
l 0.672 (95% CI 0.649 to 0.694)
l No stroke l 0.828 (95% CI 0.804 to 0.851)
l CTEPH (other heart conditions) l 0.672 (95% CI 0.649 to 0.694)
l No CTEPH l 0.802 (95% CI 0.771 to 0.831)
Cohen et al.,173
2014 (abstract)
2790 patients with VTE taking
anticoagulants (1640 with DVT
and 1150 with PE at baseline;
443 with DVT and 280 with PE
at 6 months)
EQ-5D-5L l Heparin l 0.66 baseline
l 0.75 6 months
l NG89130
l TA354140 ERG report cites
more detailed values from
company submission table
B 78178
l Heparin/VKA l 0.70 baseline
l 0.84 6 months
l DOACs l 0.73 baseline
l 0.87 6 months
l All DVT l 0.71 baseline
l 0.85 6 months
l All PE l 0.67 baseline
l 0.81 6 months
Arverud et al.,156
2016
111 patients 1 year after surgery
and immobilisation for Achilles
tendon injury
EQ-5D (valuation set
not stated)
l No DVT after lower-limb
immobilisation
l DVT after lower-limb
immobilisation
l 0.918 (0.1)
l 0.906 (0.1)
Searches conducted for the
systematic review of published
cost-effectiveness studies (see
Chapter 4, Systematic review
of existing cost-effectiveness
evidence)
Enden et al.,189
2013 (same
study as Haig
et al.160)
189 with proximal DVT EQ-5D l PTS vs. no PTS at 24 months l Decrement of 0.09 (95% CI
0.03 to 0.15)
TA354140
l PTS vs. no PTS at 6 months l Decrement of 0.02 (95% CI
–0.08 to 0.28)
Gage et al.,205
1996
70 patients aged ≥ 50 years
with AF (community dwelling),
half of whom were taking
warfarin
TTO and standard
gamble
l Mild stroke
l Moderate stroke
l Major stroke
l Warfarin
l Aspirin
l 0.76
l 0.39
l 0.11
l 0.987
l 0.998
l TA341133
l TA245135,137
l Simpson et al.278
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Authors, year Participants
HRQoL tool and
valuation method Health state(s) valued Utility estimate, mean (SD)a Cited by
Ghofrani et al.,195
2013
259 people with CTEPH
(inoperable or persistent post
surgically)
EQ-5D (valuation set
not stated)
l Placebo at baseline
l Drug therapy at baseline
l Placebo, change at 16 weeks
l Drug, change at 16 weeks
l Difference
l 0.66 (0.25)
l 0.64 (0.24)
l –0.08 (0.34)
l 0.06 (0.28)
l 0.13 (0.06 to 0.21); p < 0.001
TA341133
Haig et al.,160
2016
176 patients with DVT
(mid-thigh level or higher)
EQ-5D l DVT
l DVT with PTS
l 0.88 (0.16)
l 0.71 (0.28)
l p < 0.001
Data as reported by Lubberts
et al.159
Hogg et al.,176
2013
215 thrombosis clinic patients
with a history of VTE (at any
time, i.e. 56% of patients were
diagnosed > 12 months
previously)
Standard gamble for
vignettes, not
patient’s own health
state
l DVT
Mean (IQR)
l 0.81 (0.55 to 0.94)
l TA341133
l TA354140
l TA327132
l PE l 0.75 (0.45 to 0.91)
l Minor ICH l 0.75 (0.55 to 0.92)
l GI bleed l 0.65 (0.15 to 0.86)
l Major ICH l 0.15 (0.00 to 0.65)
Hogg et al.,163
2014
44 patients with previous
experience of VTE (PE or
proximal DVT) within 12 months
of diagnosis
SF-6D (standard
gamble also
reported) l PE
Median (IQR)
l 0.68 (0.62 to 0.84)
Lubberts et al.’s159 systematic
review
l DVT l 0.64 (0.58 to 0.69)
Ingelgard et al.,279
2002
121 outpatients with DVT EQ-5D (tariff not
reported)
Patients with PE or DVT treated
with warfarin
0.08 decrement for both TA245135
Wolowacz et al.99
Keogh et al.,197
2006
177 patients with PAH
(idiopathic or related to
connective tissue disease,
i.e. not CTEPH)
SF-6D UK valuation
set
l WHO functional class 1
l Class 2
l Class 3
l Class 4
l 0.73 (0.09)
l 0.67 (0.10)
l 0.60 (0.10)
l 0.52 (0.09)
TA327132 (company compared
class 1 mean with HSE data to
calculate decrement of 0.1)
continued
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TABLE 38 Studies reporting utility data relevant to the de novo model for thromboprophylaxis in lower-limb immobilisation (continued )
Authors, year Participants
HRQoL tool and
valuation method Health state(s) valued Utility estimate, mean (SD)a Cited by
Lenert and
Soetikno,190 1997
30 healthy volunteers (all
female) and 30 physicians
(not selected by specialty)
Standard gamble l Mild PTS
l Severe PTS
l Stroke
l 0.98 (0.04)
l 0.93 (0.07)
l Median 0.60 (95% CI 0.02
to 1.00)
l TA157134
l TA170136
l TA245135
l TA261154
l TA287131
l TA327132
l TA341133
l TA354140
l Wolowacz et al.99
Lindgren et al.,200
2007
60 patients with mild to
moderate hypertension, of
whom 18 experienced a stroke
event during the study
EQ-5D UK tariff Stroke over 1 year Decrement of 0.145 (0.145)
(95% CI 0.059 to 0.249)
TA327132
Locadia et al.,177
2004
Patients with VTE on VKA
(n = 53), a bleeding episode
during VKA therapy (n = 23) or
PTS treated with VKA (n = 48)
TTO for clinical
vignettes
l No VKA
Median (IQR)
l 0.96 (0.82 to 1.00)
l NG89130 (GI bleeding
and stroke)
l TA341133 (stroke, PE,
DVT, GI)
l TA327132 (ERG cited)
l Goodacre et al.114
(PE and bleed)
l TA261154 (DVT, PE,
non-ICH, ICH)
l TA287131
l TA287 (as for TA261154)
l TA354140 (PTS)
l Own current health l 0.95 (0.81 to 1.00)
l VKA treatment l 0.92 (0.77 to 0.98)
l PTS l 0.82 (0.66 to 0.97)
l DVT l 0.84 (0.64 to 0.98)
l Muscular bleeding l 0.76 (0.59 to 0.95)
l GI bleeding l 0.65 (0.49 to 0.86)
l PE l 0.63 (0.36 to 0.86)
l Non-fatal haemorrhagic stroke l 0.33 (0.14 to 0.53)
Luengo-Fernandez
et al.,201 2013
1188 stroke and TIA patients
(748 stroke patients)
EQ-5D UK TTO tariff l Stroke at 1 month l 0.64 Follow-up of OXVASC cohort
reported by Rivero-Arias et al.204l Stroke vs. matched controls at
1 month
l –0.22 (95% CI –0.26 to –0.18)
l Stroke at 6 months stable from
6 months to 5 years
l 0.70
l Stroke vs. matched controls at
5 years
l –0.09 (95% CI –0.13 to –0.05)
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Authors, year Participants
HRQoL tool and
valuation method Health state(s) valued Utility estimate, mean (SD)a Cited by
Lunde,202 2013 345 stroke patients (6 months
post stroke)
EQ-5D UK TTO
valuation set
Post stroke 0.70 (0.30) (also reports values for
independent yes/no)
l NG89130 (stroke)
l TA354140
l 0.713 with 11% decrement
Marchetti et al.,207
2001
48 patients attending an
anticoagulation clinic with
experience of heparin and half
with experience of VKA
Direct TTO using
clinical vignettes
l Warfarin treatment l 0.989 (0.016)
l 0.92 to 1.00
l NG89130
l TA354,140 TA261,154
TA287,131 TA327132
l Heparin treatment l 0.993 (0.024)
l 0.94 to 1.00
Meads et al.,198
2008
308 patients with CTEPH CAMPHOR QoL,
which was valued
by 249 members of
the UK general
population using
TTO
CTEPH 0.56 (0.29) (ERG in TA327132
calculated disutility relative to
age-matched general population
as 0.22 = 0.78–0.56)
l TA327132
l TA261154 and TA287131
l TA354140
l NG89130
Monz et al.,208
2013
1435 patients having dabigatran
or warfarin during RE-LY study
(AF patients)
EQ-5D UK TTO tariff VKA treated
DOAC treated
No statistically significant
difference in HRQoL substudy as a
whole
TA327132
Olschewski
et al.,196 2002
203 patients with primary PAH
and CTEPH (n = 57) (NYHA
class III or IV)
EQ-5D index l Iloprost (Ventavis;® Bayer Plc,
Reading, UK) treated
l Placebo controls
Improved from 0.49 ± 0.28 to
0.58± 0.27 in drug treatment
group
Reference list of Keogh et al.197
O’Meara et al.,191
1994
36 patients > 50 years, of which
20 had no history of DVT
Standard gamble l Mild postphlebitic syndrome
l Severe postphlebitic syndrome
l CNS bleeding
l 0.995 (95% CI 0.990 to 1.00)
l 0.982 (95% CI 0.962 to 1.00)
l 0.290 (95% CI 0.127 to 0.453)
l CG9224
l Goodacre et al.152
l Simpson et al.278
l TA287131
Pickard et al.,203
2004
124 patients hospitalised
following ischaemic stroke
EQ-5D with UK TTO
tariff (HUI3 also
reported)
Ischaemic stroke at
l Baseline l 0.31 (0.38)
l TA287131
l TA341133
l 1 month l 0.55 (0.36)
l 3 months l 0.61 (0.30)
l 6 months l 0.62 (0.34)
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TABLE 38 Studies reporting utility data relevant to the de novo model for thromboprophylaxis in lower-limb immobilisation (continued )
Authors, year Participants
HRQoL tool and
valuation method Health state(s) valued Utility estimate, mean (SD)a Cited by
Rivero-Arias
et al.,204 2010
1293 stroke and TIA patients
(subset of the OXVASC data set)
EQ-5D UK TTO tariff Stroke and TIA (average over
2 years)
Stroke data points (n = 1359)
l 0.713 (0.287)
l 0.67 (0.30)
l TA287131
l TA261154
Robinson et al.,206
2001 (data from
abstract)
57 patients with AF Standard gamble l Warfarin (GP monitored)
l Warfarin (hospital monitored)
l Major bleed
l Mild stroke
l Severe stroke
l 0.948
l 0.941
l 0.841
l 0.641
l 0.189
l Wolowacz et al.99
l TA157134
l TA245135,137
l TA327132
Shafazand
et al.,199 2004
53 patients with pulmonary
hypertension (not specifically
CTEPH)
Standard gamble All participants’ current health 0.71 (95% CI 0.64 to 0.78) TA327132
Sullivan et al.,174
2011
2299 patients with VTE taking
secondary prophylaxis
EQ-5D UK valuation
set
l Recurrent DVT
l Recurrent PE
l CRNMB
l –0.17
l –0.06
l –0.03
(Relative to baseline)
l TA354140
l NG89130
Tavoly et al.,175
2016
213 patients with PE (median
3.8 years since diagnosis)
EQ-5D with Danish
tariff
l PE
l No PE (population norms)
l 0.80 (0.22)
l 0.86 (NR)
l p < 0.005
TA327132 (cites 2013 abstract
but data here from full paper)
l No PE (age- and sex-matched
controls)
l 0.82 (0.16)
Utne et al.,179
2016
254 patients with DVT during
previous 1 to 10 years
EQ-5D with Danish
tariff
l DVT
l No DVT (age- and sex-matched
controls)
l 0.79 (0.20)
l 0.91 (0.12)
Review by Ghanima et al.280
CAMPHOR, Cambridge Pulmonary Hypertension Outcome Review; CNS, central nervous system; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; ERG, Evidence Review Group;
HSE, Health Survey for England; HUI-3, Health Utilities Index – 3; IQR, interquartile range; NR, not reported; NYHA, New York Heart Association; RE-LY, Randomized Evaluation of Long-Term
Anticoagulation Therapy; TIA, transient ischaemic attack; WHO, World Health Organization.
a Unless otherwise stated.
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TABLE 39 Parameter sampling inputs
Parameter description Mid-point value Uncertainty measure Distribution Source
Probability of PE in those having
lower-limb immobilisation
0.4% 95% CI 0.2% to 0.7% Beta(10, 2326) Rates across placebo arms of 12 studies included in the systematic
review of clinical effectiveness (see Table 16)
Probability of DVT in those having
lower-limb immobilisation not having PE
8.0% 95% CI 6.9% to 9.1% Beta(186, 2140) Rates across placebo arms of 12 studies included in the systematic
review of clinical effectiveness (see Table 16)
Proportion of DVT that is symptomatic 11.4% 95% CI 6.7% to 17.2% Beta(16, 124) Rates across placebo arms of 9 studies included in the systematic
review of clinical effectiveness (see Table 16)
Proportion of asymptomatic DVTs that
are distal
83.9% 95% CI 73.3% to 92.2% Beta(47, 9) Rates across placebo arms of 6 studies included in the systematic
review of clinical effectiveness (see Table 16)
Proportion of symptomatic DVTs that are
distal
50% 95% CI 26.5% to 73.4% Beta(8, 8) Rates across placebo arms of a single study (see Table 16)
Effectiveness of prophylaxis: OR for VTE 0.52 95% CI 0.37 to 0.71 Not applicable Systematic review of decision tools for identifying patients at risk
of VTE. CODA samples from NMA used directly to characterise
uncertainty around OR (see Methods used to quantify decision
uncertainty)
Risk of major GI bleed with no
prophylaxis (per 1000 person-years)
1.34 95% CI 1.32 to 1.36 Norm(1.34, 0.010) Hippisley-Cox et al.101
Risk of ICH with no prophylaxis
(per 1000 person-years)
0.55 95% CI 0.54 to 0.56 Norm(0.56, 0.005) Hippisley-Cox et al.101
Bleed risk for prophylaxis vs. none: OR
(OR is converted to RR using baseline
risks for no prophylaxis)
1.64 95% CI 0.90 to 2.53 Not applicable Pooled analysis of bleed risks across all VTE prophylaxis studies in
NICE CG92 re-analysed on log-odds scale using random-effects
Bayesian meta-analysis. CODA samples used directly to characterise
uncertainty around OR
Case fatality rate for GI bleeds 10.0% 95% CI 9.7% to 10.4% Beta(2452, 21,969) Case fatality rate of GI bleeds taken from Button et al.103
Case fatality rate for ICH 49.0% 95% CI 37% to 60% Beta(35, 37) Case fatality rate of ICH bleeds taken from Fang et al.102
Risk of bleeding during 3-month
anticoagulant treatment for VTE
0.9% 95% CI 0.2% to 2.0% Beta(3, 352) Kooiman et al.104
Proportion of major bleeds during VTE
treatment that are fatal
25.0% 95% CI 21% to 28% Beta(135, 411) Nieto et al.105
Proportion of non-fatal major bleeds
during VTE treatment that are ICH
9.0% 95% CI 6.5% to 11.9% Beta(37, 374) Nieto et al.105
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Parameter description Mid-point value Uncertainty measure Distribution Source
SMR for patients surviving ICH compared with general population
Year 1 after ICH 4.5 95% CI 3.7 to 5.5 Log(SMR) = norm(1.5,
0.1)
Fogelholm et al.107
CIs around SMR not reported, so have assumed ± 20% on the log scale
Years 2–6 after ICH 2.2 95% CI 1.8 to 2.7 Log(SMR) = norm(0.8,
0.1)
Probability of PE being fatal 2.9% 95% CI 2.5% to 3.3% Beta(219, 7372) Maestre et al.108
Cumulative risk of PTS for treated symptomatic DVT at 3 years
Proximal 32.4% 95% CI 22.1% to 43.6% Beta(23, 48) Hach-Wunderle et al.109
Distal 15.6% 95% CI 7.9% to 25.3% Beta(10, 54)
OR for PTS in asymptomatic untreated
proximal DVT vs. treated proximal DVT
2.71 95% CI 1.44 to 5.1 Log(OR) = norm(0.99,
0.32)
van Dongen et al.110
Incidence of CTEPH at 2 years (converted
to annual risk of 1.6%)
3.2% 95% CI 2.0% to 4.4% Beta(32, 967) Ende-Verhaar et al.,111 based on incidence in those surviving the initial
treatment period of 3–6 months
Proportion of CTEPH patients treated
surgically
59.5% 95% CI 55.8% to 63.2% Beta(404, 275) Delcroix et al.113
Proportion of those patients with CTEPH
who are surgically treated who also
received bridging medical care
30.0% 95% CI 24.6% to 33.5% Beta(117, 287) Delcroix et al.113
Mean hazard for exponential survival curve
in medically treated patients with CTEPH
0.1168 SE 0.0123 Norm(0.1168, 0.0123) Original data from Delcroix et al.113 but curves taken from
Goodacre et al.114
Mean and SD for log-normal survival
curve in surgically treated patients with
CTEPH
Mean 5.08
(SD 3.34)
l SE of mean 0.574
l SE of SD 0.399
Multivariate normal Original data from Delcroix et al.113 but curves taken from
Goodacre et al.114
Variance–covariance matrix
Mean log SD log
Mean 0.017708 –0.05572
SD –0.05572 0.230935
Ambulance transfer to ED £236 IQR £211–256, n = 11 Gamma(551, 0.43) l NHS reference costs116
l HRG code ASS02 ‘See and treat and convey’
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TABLE 39 Parameter sampling inputs (continued )
Parameter description Mid-point value Uncertainty measure Distribution Source
ED visit leading to admission £228 IQR £184–261, n = 139 Gamma(2210, 0.10) l NHS reference costs116
l HRG code: Type 01, leading to admission, VB05Z Emergency
Medicine, Category 2 Investigation with Category 3 Treatment
ED visit not leading to admission £196 IQR £165–220, n = 138 Gamma(3203, 0.06) l NHS reference costs116
l HRG code: Type 01, not leading to admission, VB05Z Emergency
Medicine, Category 2 Investigation with Category 3 Treatment
DVT admission: weighted average of following HRG costs
YQ51A £4632 IQR £2394–5794, n = 122 Gamma(42.4, 109) l NHS reference costs116
l Non-elective inpatient costs for HRG codes covering DVT,
with CC scores ranging from 0 to 12+YQ51B £2943 IQR £1595–3629, n = 130 Gamma(30.0, 98.3)
YQ51C £2406 IQR £1559–2773, n = 136 Gamma(41.5, 57.9)
YQ51D £1731 IQR £1267–1903, n = 141 Gamma(48.5, 35.7)
YQ51E £1453 IQR £1041–1574, n = 134 Gamma(35.7, 40.6)
PE admission: weighted average of following HRG costs
DZ09J £5903 IQR £3012–7602, n = 129 Gamma(45, 129) l NHS reference costs116
l Non-elective inpatient costs for HRG codes covering PE with and
without interventions, with CC scores from 0 to 12+DZ09K £3440 IQR £2116–4204, n = 137 Gamma(41, 84)
DZ09L £3795 IQR £2369–4741, n = 136 Gamma(48, 79)
DZ09M £2851 IQR £1997–3291, n = 142 Gamma(65, 44)
DZ09N £2276 IQR £1751–2507, n = 143 Gamma(92, 25)
DZ09P £1837 IQR £1473–2077, n = 144 Gamma(73, 25)
DZ09Q £1550 IQR £1270–1724, n = 141 Gamma(76, 20)
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Parameter description Mid-point value Uncertainty measure Distribution Source
Critical care: weighted average of HRG costs for codes
XC01Z £2588 n = 1 Fixed l NHS reference costs116
l HRG codes for Adult Critical Care for 0 to 6 organs supported
XC02Z £1682 IQR £1478–2014, n = 6 Gamma(107, 15.7)
XC03Z £1705 IQR £1419–1944, n = 11 Gamma(211, 8.1)
XC04Z £1581 IQR £1423–1781, n = 17 Gamma(605, 2.6)
XC05Z £1195 IQR £1133–1381, n = 21 Gamma(884, 1.4)
XC06Z £820 IQR £481–1001, n = 23 Gamma(104, 7.9)
XC07Z £521 IQR £188–868, n = 15 Gamma(16.0, 32.5)
Proximal leg vein ultrasonography £55 IQR £41–61, n = 149 Gamma(2135, 0.03) l NHS reference costs116
l RD40Z Outpatient Ultrasound Scan with duration of < 20 minutes,
without contrast
CTPA £102 IQR £71–135, n = 137 Gamma(635, 0.16) l NHS reference costs116
l RD21 A, Outpatient Computerised Tomography Scan of one area,
with post contrast only, ≥ 19 years
V/Q SPECT £261 IQR £118–337, n = 78 Gamma(202, 1.29) l NHS reference costs116
l RN08 A, Outpatient Single Photon Emission Computed
Tomography (SPECT), ≥ 19 years
V/Q planar £274 IQR £153–270, n = 106 Gamma(1045, 0.26) l NHS reference costs116
l RN18 A, Outpatient Lung Ventilation or Perfusion Scan, ≥ 19 years
Echocardiography £72 IQR £38–94, n = 47 Gamma(146, 0.50) l NHS reference costs116
l RD51 A, Outpatient Simple Echocardiogram, ≥ 19 years
Proportion receiving LMWH who need
district nurse administration
4% 95% CI 1.3% to 7.8% Beta(5, 123) Menakaya et al.229
Fatal bleed £1592 SD 1886, n = 8 Gamma(5.70, 279) Luengo-Fernandez et al.117 (cost before inflation)
Acute costs for non-fatal ICH (first 90 days) – weighted average of
Non-disabling non-fatal stroke £9903 SD 4510, n = 5 Gamma(24, 411) Luengo-Fernandez et al.117 (cost before inflation)
Moderately disabling non-fatal stroke £25,442 SD 9635, n = 3 Gamma(21, 1216)
Totally disabling non-fatal stroke £43,036 SD N/A, n = 1 Fixed
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TABLE 39 Parameter sampling inputs (continued )
Parameter description Mid-point value Uncertainty measure Distribution Source
Residential costs for non-fatal ICH
(first 90 days)
£6880 SD £15,600, n = 136 Gamma(26, 260) Luengo-Fernandez et al.117 (cost before inflation)
GP costs for non-fatal ICH (first 90 days) £98 95% CI £27 to £169 Norm(98, 36) Luengo-Fernandez et al.117 (cost before inflation)
Emergency care costs for non-fatal ICH
(first 90 days)
£99 95% CI £56 to £141 Norm (99, 22) Luengo-Fernandez et al.117 (cost before inflation)
Non-fatal non-ICH bleed (weighted average of HRG costs)
FZ38G £5369 IQR £3097–6235, n = 134 Gamma(63, 85) l NHS reference costs 2015/2016116
l HRG codes for GI bleed without interventions, with single
interventions and with multiple interventionsFZ38H £3172 IQR £2054–3876, n = 131 Gamma(35, 90)
FZ38J £3667 IQR £2100–4636, n = 135 Gamma(32, 115)
FZ38K £2630 IQR £1793–3153, n = 134 Gamma(39, 67)
FZ38L £2084 IQR £1655–£2332, n = 135 Gamma(72, 29)
FZ38M £2531 IQR £1646–3061, n = 136 Gamma(38, 66)
FZ38N £1882 IQR £1496–2051, n = 140 Gamma(94, 20)
FZ38P £1406 IQR £1161–1542, n = 142 Gamma(78, 18)
Anticoagulant service
Face-to-face follow-up, consultant led £37 IQR £21–41, n = 58 Norm(37, 3.7) with
minimum of zero
l NHS reference costs 2015/2016116
l Service code 324 – WF01A non-admitted
Face-to-face follow-up,
non-consultant led
£16 IQR £9–16, n = 46 Norm(16, 1.6) with
minimum of zero
l NHS reference costs 2015/2016116
l Service code 324 – WF01A non-admitted
First face-to-face attendance,
non-consultant led
£22 IQR £8–17, n = 40 Norm(22, 2.2) with
minimum of zero
l NHS reference costs 2015/2016116
l Service code 324 – WF01B non-admitted
Non-face-to-face follow-up,
non-consultant led
£13 IQR £5–7, n = 10 Norm(13, 1.3) with
minimum of zero
l NHS reference costs 2015/2016116
l Service code 324 – WF01C non-admitted
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Parameter description Mid-point value Uncertainty measure Distribution Source
Vascular surgery
First appointment face to face,
consultant led
£167 IQR £124–211, n = 112 Gamma(759, 0.22) l NHS reference costs 2015/2016116
l Service code 107 – WF01B non-admitted
Follow-up appointment face to face,
consultant led
£140 IQR £100–165, n = 111 Gamma(942, 0.15) l NHS reference costs 2015/2016116
l Service code 107 – WF01A non-admitted
First appointment face to face,
non-consultant led
£173 IQR £100–240, n = 48 Gamma(312, 1.39) l NHS reference costs 2015/2016116
l Service code 107 – WF01B non-admitted
Follow-up appointment face to face,
non-consultant led
£139 IQR £173–230, n = 55 Gamma(79, 1.76) l NHS reference costs 2015/2016116
l Service code 107 – WF01A non-admitted
Surgical management of CTEPH: average of following HRG costs
DZ02H £9871 IQR £7694–10,623,
n = 35
Gamma(723, 13.7) l NHS reference costs 2015/2016116
l HRG codes for Complex Thoracic Procedures, ≤ 19 years, with CC
score ranging from 0 to 6+
DZ02J £7772 IQR £6437–9086, n = 40 Gamma(627, 12.4)
DZ02K £6702 IQR £5048–7597, n = 46 Gamma(579, 11.6)
Utility decrement for stroke up to
6 months
–0.22 95% CI –0.26 to –0.18 Norm(–0.22, 0.02) Luengo-Fernandez et al.201
Utility decrement for stroke from
6 months
–0.09 95% CI –0.13 to –0.05 Norm(–0.09, 0.02) Luengo-Fernandez et al.201
Utility immediately after DVT 0.71 SD 0.26, n = 1640 Beta(3545, 1448) Cohen et al.173
Utility immediately after PE 0.67 SD 0.24, n = 1150 Beta(1663, 819) Cohen et al.173
Utility for DVT without PTS 0.86 95% CI 0.823 to 0.903 Beta(248, 40.3) Enden et al.189
Utility decrement for PTS vs. no PTS after
DVT
0.09 95% CI 0.03 to 0.15 Beta(7.78, 78.6) Enden et al.189
Utility for CTEPH 0.56 SD 0.29, n = 308 Beta(505, 397) Meads et al.198
Utility for NYHA class I 0.86 SD 0.17, n = 35 Beta(105, 12.9) Meads et al.198
Utility for LMWH 0.993 SD 0.016 Beta(27.5, 0.205) Marchetti et al.207
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TABLE 39 Parameter sampling inputs (continued )
Parameter description Mid-point value Uncertainty measure Distribution Source
Utility for warfarin 0.989 SD 0.024 Beta(17.6, 0.195) Marchetti et al.207
Utility regression for age-related decrement: coefficients for
Age –0.0001728 SE 0.0003737 Multivariate normal Ara and Brazier194
Variance–covariance matrix
Age Age × age Constant
Age 1.4 × 10–7
Age × age –1.5 × 10–9 1.6 × 10–11
Constant –2.80 × 10–6 2.8 × 10–8 6 × 10–5
Age × age –0.000034 SE 3.96 × 10–6
Constant 0.9584588 SE 0.0077431
CC, complications and comorbidities; CODA, convergence diagnostics and output analysis; CTPA, computerised tomography pulmonary angiography; IQR, interquartile range; N/A, not
applicable; NYHA, New York Heart Association; SE, standard error; SMR, standardised mortality ratio; SPECT, single-photon emission computed tomography; V/Q, ventilation/perfusion.
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